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Abstract
As keratin is the principle structure of the plantar stratum corneum, it has been 
postulated that changes in this protein, associated with non-enzymatic glycation, 
may contribute to abnormalities in the development of plantar callus in diabetes 
consequently leading to ulceration of plantar skin. The clinical appearance of the 
skin in the diabetic state has been described as being thicker and less flexible 
than non-diabetic skin, particularly in the hands.
A group of six Type II diabetic patients and six age and sex matched controls 
were initially selected for the verification of the methods of analysis to be used on 
a larger sample group.
Epidermal keratin extraction protocols were tested and their validity confirmed 
using immunoblot analyses.
The early glycation product, furosine and the advanced glycation end-products 
pentosidine and carboxymethyllysine were the glycation products chosen for 
quantification in plantar callus tissue. The quantification of furosine and 
pentosidine were successfully achieved using high performance liquid 
chromatography assays. The qualitative detection of CML was achieved using 
gas chromatography/ mass spectrometry (GC/MS).
In response to the lack of sensitivity of the GC/MS detection method for CML, 
polyclonal and monoclonal antibodies were developed. Screening of these 
antibodies identified a lack of specificity for CML detection and quantification.
In addition to the quantification of the glycation compounds in plantar epidermal 
tissues; the flexibility and thickness of the skin on three different sites on the feet 
were measured. The epidermal thickness was measured using high frequency 
ultrasound imaging and the mechanical properties of the epidermis were tested 
using vertical negative pressure methods.
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The selected group of Type II diabetic subjects (n=103), in the final clinical study, 
showed a statistically significant increase in levels of pentosidine in plantar callus 
specimens compared with the control group (n=87). The quantity of furosine and 
pentosidine measured in the callus samples did not correlate with those 
measured in blood serum. The HbA1c levels showed no association between 
glycation of plantar epidermal proteins and glycaemic control.
The echogeneic images captured by ultrasonography were thickest on the plantar 
metatarsal sites, followed by the medial longitudinal arch and finally the dorsal 
skin sites. The epidermal thickness in the PMA region was greater in diabetics in 
comparison to controls and an association with neuropathy was suggested.
Pedal skin exhibited viscoelastic properties. The magnitude of the elastic 
component, measured immediately after the negative displacing pressure was 
removed, was significantly greater in diabetic skin than controls on all three sites 
on the foot. Plantar diabetic skin was significantly less plastic than non-diabetic 
plantar skin.
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Foreword
This thesis incorporates the scientific disciplines of biochemistry, physics and 
clinical sciences, therefore the chapters have been organised according to their 
disciplines rather than the standard PhD format The arrangement of each 
experimental chapter includes a literature review of methods, followed by the 
experimental methods and results, finishing with a discussion of the findings. At 
the end of Chapters 4, 7 and 8, the data collected from the non-diabetic subjects 
were statistically analysed and discussed. The data from diabetic subjects was 
compared to the control data in Chapter 9. This chapter includes the volunteer 
recruitment process in detail. The final chapter discusses all the results.
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Chapter 1 Review of Literature
1.1 Introduction to Callus, Ulceration and the Diabetic Foot
Com and callus formation is a common occurrence affecting all age groups, 
particularly the elderly 11-71 and people with diabetes [8:91. In the case of diabetes, 
the development of callus is one of the most common problems associated with 
the fee tl101, and in such a high-risk group, is a warning sign for ulceration 111:121. 
Neuropathy, vascular insufficiency and trophic changes add to the risk 1131 The 
neuropathic ulcer is invariably associated with the presence of callus[13]. Infection 
often complicates ulceration, which can cause overwhelming tissue destruction 
and subsequent lower extremity amputation (LEA).
Clinical observational data suggest that there is variation in callus texture in the 
diabetic foot from dry to macerated, but invariably it is thick and bulky. Only one 
paper has described the plantar callus of diabetic individuals as being “unusually 
hard” I141. Since high vertical pressures and shear stresses imposed on the skin, 
encourage the development of callus it could be possible that formation of plantar 
diabetic callus is either a reaction to abnormal pressures or an abnormality of the 
specific area compromising the response to normal pressures. This poses the 
question - is there a connection between diabetes and the quality of the skin, in 
particular at the extremities?
Despite the increased awareness of the long-term diabetic complications, 
statistics for diabetic foot pathologies are still distressing. The prevalence of 
active foot ulceration varies around the world (Table 1.1), and is the most 
common cause of hospitalisation for diabetic patients in Western countries I15]. It 
is estimated that approximately 15% of people with diabetes, world-wide, will at 
some stage develop diabetic foot ulceration i12;16;171. in studies of causal pathways 
leading to LEA, foot ulcers precede approximately 84% of amputationsI12]. Lower 
extremity amputation in patients with diabetes is associated with high 
postoperative mortality and a high rate of secondary amputation, accumulating 
considerable health care costsI18].
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Published data on the distribution of the risk factors of ulceration and amputation, 
in the British population of people with diabetes alone, is lacking. The length of 
stay in hospital for patients with diabetes is almost twice that of the non-diabetic 
population and the risk of hospital mortality in diabetics is almost three times that 
of non-diabetics [19]. The costs for treating these complications account for 25% of 
the hospital costs of diabetes care, but the indirect costs can be much more [17], 
for example the fitting of artificial limbs costs approximately £8500 per patient.
Table 1.1. The prevalence and cost of diabetic foot ulceration worldwide.
UK USA Europe Africa
Prevalence of Active Foot Ulceration 4 -1 0 % 1% 1% 11%
Annual Hospital Amputations per Year £13.4 million £350 million Unknown Unknown
A health problem of this scale merits attention. Plantar callus in the diabetic 
population is of major importance. There is not a great volume of research 
devoted to the etiology of callus. As the development of the callus is a key 
component of the pathophysiology of ulceration in diabetic patients it is a good 
target for initiating an exploration for preventative measures. The purpose of this 
thesis is to understand better the mechanisms of the development of callus and 
to contribute to the growing body of knowledge on preventable complications in 
the diabetic foot. The public health benefits of this research may be realised in 
the accurate and early detection of people with diabetes at greatest risk of 
developing foot ulceration, so that resources may be appropriately directed to 
preventative health programs.
1.2 Diabetic Foot Pathologies
Of the many diabetic complications, some of the most unpleasant affect the lower 
extremities. The remarkable factors associated with the diabetic foot are 
neuropathy, macrovascular and microvascular disease [2Ql. These processes may 
occur exclusively or together in varying degrees, placing the patient at risk of 
ulceration, infection, gangrene and ultimately amputation (Fig. 1.1-1.4). With 
regards to foot ulceration, there is a complex interaction between these
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pathologies and other contributory factors, such as altered foot pressures; 
secondary to structural foot deformities and limited joint mobility[2il.
1.2.1 Peripheral Neuropathy
Diabetic peripheral neuropathy is described as the presence of signs and 
symptoms of peripheral nerve dysfunction excluding other causes 1221 and 
encompasses distal sensory motor polyneuropathy, autonomic neuropathy and 
mononeuropathy. Nerve damage of this kind occurs in up to 25% of people with 
diabetes mellitus 10 years post diagnosis and increases to 50% after 20 years 
duration of the diseaseI22:23]. Sensory polyneuropathy is the most common of the 
diabetic peripheral neuropathies, affecting 30% of diagnosed diabetic patients[22]. 
The clinical features of diabetic neuropathy are outlined in Table 1.2.
1.2.1.1 Peripheral Motor Neuropathy
The classic signs of peripheral motor neuropathy in the foot are a high medial 
longitudinal arch (pes cavus), and clawed or retracted lesser toes, with prominent 
metatarsal heads (Fig. 1.5 & 1.6). The clawing of the lesser toes is due to intrinsic 
muscle atrophy, as a result of the denervation of the muscles, leading to the 
excessive influence of the extensors. The foot becomes rigid and the shock 
absorption abilities diminish. This characteristic posture exposes the skin to high 
pressure points, particularly over the metatarsal heads, dorsal interphalangeal 
joints and the apices of the toes 1161 and increases the susceptibility of these 
areas to ulceration I12]. The vulnerability of the plantar metatarsal area is further 
compounded by the atrophy of the plantar metatarsal fat pad as well as its 
anterior displacement as a result of retraction of the lesser toes I23). The 
combination of insensitivity to pain, lack of proprioception and high pressures 
under the relatively exposed metatarsal heads, leads to callus and ulcer 
formation1241 (Fig. 1.7&1.8).
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Figure 1.1. Dry digital gangrene in a 
neuroischaemic foot.
Figure 1.2.Necrosis secondary to popliteal 
artery thrombosis.
Figure 1.3. Necrosis indicated by blue -  Figure 1.4. Ulceration, discharge and
black discolouration surrounded by necrosis in a neuroischaemic foot,
cellulitis and haemorrhage in a 
neuropathic foot.
Pictures taken - Managing the Diabetic Foott25]
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Table 1.2. Features of neuropathy
Motor Neuropathy Autonomic Neuropathy Sensory Neuropathy
Symptoms •  May be 
asymptomatic or 
severe
•  May accompany 
sensory
polyneuropathy, or 
manifest as a pure 
autonomic affect
1) Non-painful and 
asymptomatic, or
2) Paraesthesia of feet 
and occasionally 
hands, or
3) Shooting pains and 
burning sensation, 
pins and needles 
sensation, in the legs 
and feet, especially at 
night.
Signs Cranial nerve lesions
•  Double vision due to 
damage to nerves 
that supply the eye
•  facial nerve palsy
Isolated peripheral
lesions
•  lateral cutaneous 
nerve of the thigh
•  femoral, sciatic and 
peroneal nerves 
affected
Diabetic am yotrophy
•  proximal, painful, 
weakness and 
wasting of the leg 
and digital muscles
•  anterior compartment 
syndrome
•  loss of reflexes, but 
not loss of sensation
•  extensor plantar 
responses
•  decreased nerve 
conduction times
Cardiovascular
•  postural hypotension
•  vagal denervation of 
the heart, with high 
resting heart rates
• greater blood flow 
through superficial 
tissues, presenting in 
the foot as a warm 
and red
Gastrointestinal tract
•  diarrhoea
•  delayed gastric 
emptying
Sudom otor
•  facial and upper body 
sweating at meal 
times
•  loss of sweating in 
the feet
Endocrine effect
•  Impaired or upset 
renin, glucagon or 
catecholamine 
release
• Failure of metabolic 
response to 
hypoglycaemia
Im potence
•  May present as the 
earliest feature of 
autonomic 
neuropathy
•  Loss of vibration 
sense in feet
•  Loss of pain 
sensation in feet
•  Loss of thermal 
sensitivity in feet
•  Reduced or absent 
limb tendon reflexes
Outcomes • Mild to moderate 
reduction on pain 
sensation
•  Muscle weakness 
and denervation of 
intrinsic foot muscles, 
leading to pes cavus
Outcomes of chronic 
neuropathy 
(after 20 year +)
• Glove and stocking 
anaesthesia
•  Impaired joint 
position sense, 
contributing to 
Charcot joint 
formation
•  Sensory ataxia, 
impaired gait and 
positive Romberg's 
sign
•  Deep trophic 
ulceration
•  Bladder atony and 
impotence
(Adapted from Assessment of the Lower Limb l J.
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Figure 1.5. Clawed Toes (Secondary to pes 
cavus)
A fixed flexion deformity at the interphalangel joints.
Figure 1.6. Pes Cavus
The dorsum of the foot is domed due to a high 
medial longitudinal arch.
® Points commonly associated with callus formation and ulceration.
U
Figure 1.7. Ulceration over the dorsal 
aspect of the proximal interphalangeal 
joint of the third toe which is clawed
Pictures taken from - Managing the Diabetic Footp5]
Figure 1.8. Ulceration of the apex of 
the fourth toe with overlying callus.
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1.2.1.2 Peripheral Sensory Neuropathy
Neuropathic anaesthesia tends to follow a “glove and stocking” pattern affecting 
all modalities of sensation, although not necessarily to the same extent. Early 
signs of impending loss of sensation are feelings of vague numbness, 
paraesthesia, shooting pains, hyperaesthesia and atypical sensations such as 
burning pains. Acute neuropathy presenting early may improve with tight 
glycaemic control, but chronic longstanding changes are irreversible (Table 1.2).
1.2.1.3 Peripheral Autonomic Neuropathy
Autonomic dysfunction frequently coexists with sensory neuropathy and is 
characterised by reduced or absent perspiration along with increased blood flow. 
The resulting denervation of the sweat glands causes the skin to become dry and 
predisposes it to Assuring and callus formation l27]. The increase in blood flow 
occurs as a result of autonomic neuropathy of the vasomotor nerves to the foot 
causing the skin temperature to increase and the dorsal veins in the foot to 
become more prominent when the individual is supine. These changes are a 
result of arterio-venous (A-V) shunting that diverts blood away from the bones 
and the capillaries of the skin, causing Charcot foot collapse and skin atrophy 
respectively (Fig. 1.9-1.12).
1.2.2 Peripheral Ischaemia
In long-term diabetes mellitus, both micro- and macrovascular disease is evident, 
particularly in the periphery. These pathologies manifest as arteriosclerosis, 
atheroma and median calcification and involve arteries below the knee. There is 
little evidence to support the thinking that microcirculatory disease is the sole 
cause of diabetic foot ulceration [121. For instance, a thickening of the basement 
membrane surrounding muscle capillaries is a well established lesion in diabetes, 
but a similar lesion is not found in the capillaries of the skin I23]. The clinical signs 
of ischaemia are summarised in Table 1.3.
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Figure 1.9. The Charcot Foot
Bone and joint damage in the metatarsal-tarsal region leads to the 
rocker-bottom deformity in which there is displacement and 
subluxation of the tarsus downwards, and the medial convexity, 
which results from displacement of the talonavicular joint or from 
tarsometatarsal dislocation. Both are often associated with a bony 
prominence.
Figure 1.10. Ulceration over the bony Figure 1.11. Charcot foot showing a
prominence on the plantar surface of a rocker bottom deformity,
rocker bottom deformity
Points commonly associated callus formation and ulceration.
Figure 1.12. Distended veins over the dorsum of 
the foot and ankle in the neuropathic foot.
Pictures taken from - Managing the Diabetic Foot[25]
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1.2.3 Peripheral Neuro- ischasemia
Many patients with diabetes develop signs and symptoms of neuropathy and 
ischaemia. The coincidence of neuropathy places the foot at a greater risk of 
ulceration, as the normal warning symptoms of a compromised circulation, pain, 
is absent.
1.3 Hyperkeratosis and the Diabetic Foot
Hyperkeratosis is a thickening of the keratinised layers of the skin, in particular 
the stratum comeum (SC). In the foot it presents in the form of callus (a discreet 
area of thickened SC) or Heloma (a small area of callus containing a deep centre 
or nucleus of parakeratotic cells), which presses into the underlying skin. Callus 
presents in different ways in each different foot type in diabetes (Table 1.3 and 
Fig. 1.13 & 1,14).
It is known that the majority of people who suffer from corns and callus have 
increased forefoot loading[28:29]. The formation of callus is thought to be a normal 
protective response to trauma, partly due to abnormal anatomy and foot 
mechanics. If the mechanical trauma is removed, the skin will revert back to its 
normal structure. However, whilst this seems plausible, it has yet to be tested 
since the investigative methods for properly exploring this proposition have not 
yet been available.
An understanding of foot biomechanics will not answer all the questions, since 
lifestyle must also come into play through factors such as mobility, cadence, daily 
activities and footwear. The biochemical and clinical nature of callus tissue is 
discussed later.
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Tables 1.3. The four types of diabetic foot and the presentations of callus.
Clinical Signs and Symptoms Callus Presentation
Normal •  No noticeable changes but at 
risk of developing fungal, 
bacterial and viral infections.
•  Dry fissures around the heels 
occur in conjunction with 
dermatophyte infection.
Neuropathic • Warm, with bounding pulses.
•  Characterised by Charcot joints 
and deep trophic ulcers, with 
associated infection.
•  Cavoid type foot shape with 
clawing of the lesser toes and 
trigger first toes.
•  Prominent joints.
•  Prone to ulceration.
•  Skin is dry and prone to 
fissures.
•  Callus forms readily at areas of 
high pressures, particularly in 
cavoid and Charcot type foot.
Ischaemic •  Cold with thin, dry and atrophic 
skin.
•  Nail and hair growth is 
compromised.
•  Pulses are reduced or absent
•  Loss of muscle bulk in the 
lower limb.
•  Intermittent claudication and/or 
rest pain
•  Patchy dry gangrene and 
ulceration
•  Plantar callus is thin, glass -  
like and difficult to debride.
•  Painful Heloma Milte form 
within the dry and inelastic skin.
•  Hyperkeratotic skin lesions and 
thickened nails may be 
underlain by tissue breakdown.
Neuro-ischaemia •  Similar to the ischaemic foot 
and limb i.e. temperature, 
paucity of blood supply and 
ulceration.
•  Foot will be relatively pain free
•  Callus formation is similar to 
the neuropathic foot type.
(Note that the extrinsic factors such as poor footwear and activity levels also contribute to the build-up of callus.)
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<fc Figure 1.13. Plantar callus with extravasation
Figure 1.14. Dry skin with fissures on the 
periphery of the calcaneum
Taken from -  Managing the Diabetic Foot
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1.4 Diabetic Foot Ulceration
Diabetic ulcers result in the loss of full skin thickness with exposure of dermal 
and, potentially, subdermal tissues. There are both physiological and mechanical 
events leading to foot ulceration (Fig. 1.15).
The neuropathic ulcer is associated with an excessive build-up of hyperkeratotic 
tissue, around its periphery. In contrast, an ischaemic ulcer has minimal callus on 
and around it (Table 1.4 & Figs. 1.16-1.19).
Table 1.4. Comparison of neuropathic and ischaemic ulcers
Neuropathic Ischaemic
Pain free Excessively painful
Hyperkeratotic edges Slight Hyperkeratosis
May be macerated Usually dry unless infected
Occur on areas of pressure and shear Occur at extremities
Medium to large Initially small
Undermined walls Vertical walls
Yellow purulent slough Thick adherent slough
Copious discharge Seropurulent discharge
General/ local neuropathy Associated signs of ischaemia
Investigations into the aetiologies of plantar diabetic ulcers have, for many years, 
concentrated on pressure studies and limited interest has been directed to the 
formation of callus.
Non-enzymatic glycation (NEG) of the connective tissue collagen, abundant in 
dermal tissues and joint tendons, may influence the formation of diabetic ulcers. 
The process of glycation of collagen has an effect on the biomechanics of the 
tissue, mainly cross-linking of the collagen fibres, causing the reduction in the 
mobility of the tendons and skin of the foot. This leads to a lack of shock 
absorption during gait, both locally at high pressure points and generally 
throughout the foot. This is discussed in more detail in sections 1.24 onwards.
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A-V shunting
Reduced 
capillary blood 
flow
Micro/macro
scular
ISCHAEMIA
ULCER
CALLUS
COMPRESSION
<C— >
FRICTION
DERMIS
EPIDERMIS
TORSION Altered foot 
pressures
Limited Joint Mobility Small muscle atrophy and
muscle imbalance
Decreased 
pain and 
proprioception
ARTHROPATHY
Figure 1.15. Physiological and mechanical events 
ulceration
NEUROPATHY
leading to
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Figure 1.16. Callus over a neuropathic 
ulcer.
Figure 1.17. Neuropathic foot with plantar 
ulcer surrounded by callus.
Figure 1.18. Callus over and surrounding a 
plantar ulcer.
Figure 1.19. Neuro-ischaemic ulcer over the 
medial aspect of the 1st metatarsal-phalangeal 
joint.
Taken from -  Managing the Diabetic Foot1251
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1.5 Causes of Plantar Ulceration
The two prerequisites for the formation of diabetic plantar ulcers are 
neuropathy112:151 and elevated plantar pressures I30]. This is supported by the 
observation that neuropathic ulcers commonly form on the plantar aspect of the 
forefoot I231, the most common sites being the hallux and the 1st and 5th 
metatarsal heads. Limited mobility of the sub-talar joint (STJ) and 1st 
metatarsalphalangeal joint (MTPJ), is most prevalent in Type II diabetes121:311 and 
may influence plantar foot pressures. This might explain why Type II diabetics 
present with more plantar callus in these areas than Type I diabeticsI321.
Callus acts as a foreign body elevating plantar pressures furtherI11;33]. These 
data showed that callus was a better predictor of ulceration than foot pressure 
measurements. This is explained by two main schools of thought: firstly, callus 
may be a manifestation of long-term exposure to high pressure (from footwear) 
whereas foot pressure in many studies has been measured without shoes on; 
and secondly, the pressure required to produce callus may vary between 
individuals, but once it has formed it is at this point that the abnormal response to 
local pressures leads to ulceration. Finally, foot pressure systems measure only 
vertical pressure, but callus and ulceration develop in response to vertical and 
horizontal forces, and callus may represent a better measure of “total pressure”.
Although the argument that high pressure causes damage to tissues is logical, 
the evidence is conflicting. It has been shown that diabetic patients with 
neuropathy tend to have high plantar pressures compared to non-diabetic 
controls and diabetic patients without neuropathy [23] and the vertical dynamic 
plantar pressures are especially high in those patients with a history of plantar 
neuropathic ulcers l27]. However, there is also contradictory data that show 
plantar pressures not to be elevated in insensate feet[16].
There is argument about the threshold pressure above which it is likely that injury 
to the tissue will occur. Boulton et al (1983)1271 have suggested a value of 1 MPa 
(measured between the foot and the floor), but ulcers have been observed in 
patients with considerably lower plantar pressures ^  An example of a plantar
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pressure distribution in a patient who has experienced a plantar ulcer is shown in 
Figure 1.20a. A comparison of the location of the ulcer with the peak pressure 
plot provides convincing evidence of the association between ulceration and high 
pressure. In contrast, the pressure distribution in Fig. 1.20b is from a patient with 
higher pressures and similar loss of sensation, but this individual has not 
experienced a plantar ulcer. These examples emphasise not only the importance 
of a multifactorial approach to the evaluation of risk in the diabetic foot, but it also 
renders uncertain the use of direct pressure measurement as predictive tool for 
plantar ulceration.
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Figure 1.20a. (Left) Foot photograph from a patient with loss of protective sensation, hallux 
rigidus, and an ulcer (indicated by arrow) under the great toe.
(Right) Diagram depicting peak plantar pressure during late support phase of gait for the same 
patient. Contour intervals are 125kPa (taken from Sims DS et al 1988)[ 3l.
Figure 1.20b. (Left) Foot photograph from a patient with loss of protective sensation, marked 
equinus deformity, heavy callus formation (indicated by arrow), and absent history of ulceration. 
(Right) Diagram depicting peak plantar Dressures during late support phase of gait for the same 
patient (taken from Sims DS et al 1988) .
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1.6 Dermal Manifestations of Diabetes Mellitus
Diabetes is accompanied by widespread biochemical, morphological and 
functional abnormalities of connective tissues such collagen and elastin, reflected 
as reduced elastic recoil of lung tissue [35]; elastic fibre fraying in Type I and II 
diabetic skin and resistance to digestion of collagen in diaphragmatic tendons t361.
Virtually all people who suffer with diabetes develop skin manifestations at some 
stage of the disease progression. Some of the manifestations might be explained 
on the basis of the attachment of glucose to dermal collagen proteins, and the 
metabolism of this combination, collectively termed non-enzymatic glycation 
(NEG). The NEG of skin changes its structure, function and colour. The 
biochemistry of NEG, and its relation to skin proteins, will be discussed in more 
detail later.
1.6.1 Diabetic Hand Syndrome
Limited joint mobility affecting the small joints of the hands (cheiroarthropathy) of 
diabetic patients has been recognised for some time and presents in conjunction 
with thick, tight, waxy skin on the dorsum of the hands I37'411. This collection of 
pathologies have been attributed to neuropathy [42\  duration of diabetes I3714*44!, 
retinal microvascular disease1431 and NEG of tendon and skin collagenI36:451.
The earliest description of this phenomenon was the observation that insulin 
dependent diabetes mellitus (IDDM) was often complicated with painful stiff 
hands. Subsequently, Rosenbloom and Frias (1974) 1461 described three 
adolescent patients with long-standing IDDM, restricted joint mobility, thick tight 
waxy skin, growth impairment and maturational delay. This was substantiated 
further by similar observations in a larger cohort (n=309) of IDDM 1471 and NIDDM 
patients m . Others claimed that although there was a weak correlation between 
skin thickening and duration of diabetes, skin thickness did not correlate with 
cheiroarthropathyI39].
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1.6.2 Diabetic Thick Skin
Diabetic thick skin shows characteristic features different from those seen in 
sclerodermaI38;401. It presents as thickened and indurated skin at the extremities. 
The observation may range from clinically inapparent, but a measurable, increase 
in skin thickness unassociated with symptoms, to clinically apparent thickening of 
skin involving the fingers, hands and upper back region m .
Pulsed ultrasound techniques have demonstrated forearm skin to be thicker in 
diabetics in comparison to non-diabeticsI501. Contrary to the pattern seen in non­
diabetics, skin thickness in diabetics may increase with age. This may be 
associated with longer duration of diabetes. It is supported by evidence of the 
reduction in skin thickness following pump administration of insulin and tight 
control of blood sugar levelsI511.
As most studies have concentrated on upper extremity skin, it is not valid to 
conclude that diabetic skin is thickened at other sites. In the case of the lower 
extremities, the pathogenesis of this condition has been attributed to factors such 
as neuropathy 141A2\  duration of diabetes p7:43:441; and microvascular disease [47] 
and there are conflicting views about the effects of diabetes on skin thickness. 
Malik et al (1992) l52], found no significant difference in skin thickness on the 
extremities (dorsum of the foot) between diabetics and their non-diabetic 
counterparts. The inconsistency between studies is partly explained by the 
methods used for determining skin thickness, such as pinching the skin, giving a 
purely qualitative estimation [37]. Studies that have used ultrasound equipment, 
where an accurate measurement of thickness is achieved, have reported thicker 
skin in diabetics compared to non-diabetics I401. Using ultrasonography 
techniques, Huntley and Walter (1990)1401 were unable to confirm a correlation 
between skin thickness, glycaemic control or duration of the disease, on the 
thigh, forearm and dorsum of the foot. The greatest differences were found at the 
thigh and the least at the foot, suggesting that the increased skin thickness is not 
necessarily uniform in diabetics nor a universal occurrence in diabetes. No 
studies of this kind have been carried out on the plantar aspect of the foot of 
diabetics where the majority of neuropathic ulcers form. Only one published study
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has investigated plantar skin, in a small number of non-diabetic volunteers (n=9), 
using ultrasound imagingI531. It has only been assumed, therefore, that the skin of 
the lower extremities of diabetics is thicker.
Whether the change in capillary blood flow, increased NEG, polyol 
accumulation1541551 or other metabolic disorders are responsible for these findings 
has yet to be ascertained. All these observations establish joint contracture and 
waxy skin as complications of diabetes. Although they are multifactorial in origin, 
it is believed that the NEG of collagen plays an important role in the stiffening of 
connective tissues around the joints and the thickening of the skin A direct 
role of hyperglycaemia that relates to the increase in the NEG of proteins is 
impliedl45:51J.
1.6.3 Yellow Skin and Nails
Diabetic skin and nails often have a yellow hue1571 as a result of the accumulation 
of advanced glycation end-products (AGEs). The colour is best appreciated on 
the palmar and plantar sites because of the sparse competition with melanocytes 
in these areas (Fig. 1.21). All the nails are affected by the yellow colouration but it 
is most commonly seen on the distal edge of the nail of the hallux, as the protein 
turnover in this nail is very slow (more than one year). The level of AGEs in the 
nail plate have not been measured to date, but one study of the fingernails has 
demonstrated that diabetics have high levels of fructose-lysine (furosine), a 
marker of early glycation [58]. The yellow colouration of the skin and nails is seen 
in elderly non-diabetic people, NEG is part of the normal aging process. It is also 
noted in lymphatic odema from neoplasia of hypoplasia [59]. The significance of 
this observation in skin and nail tissue of diabetics is undetermined. One of the 
obvious questions is whether or not the yellow nails and skin can be used as a 
quantifiable indicator of the degree of NEG for other tissues of the body.
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COLLAGEN NEG KERATIN
Figure 1.21. Illustration of cheiroarthropathy and its relationship with keratin and collagen. All
photograph taken from reference [60]
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1.7 Skin
The skin is comprised of two layers, the dermis and the epidermis. The principle 
fibrous proteins of the dermis are elastin and collagen and those of the epidermis 
are collectively termed keratins (-65% of epidermal proteins)[611. There are many 
keratins and they vary in structure and function[62].
In the dermis the collagen and elastic fibres are laid down extracelluiariy but 
remain under the influence of fibroblasts. In contrast, keratin is laid down 
intracellularly and the keratinocytes (responsible for keratin synthesis) die in the 
terminal stages of the synthesis of keratin when the intermolecular cross-linkages 
are formed.
1.7.1 The Epidermis
The epidermis is made up of a keratinizing, multilayered (stratified), squamous 
epithelium. It is constantly being renewed, a protective adaptation, which 
compensates for wear and damage at the skin surface. This is most noticeable 
following injury and in some pathological states.
Although the basic organisation of the skin is the same throughout the body, the 
epidermis on the plantar aspect of the foot has several unique features I53], one 
being that it is considerably thicker than that on other parts of the body (1.4 and 
0.1mm, respectively), particularly the SC layer. This correlates with the larger 
size and number of stratum comeum cells in palmar and plantar skin in 
comparison to other sites of the bodyl631.
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1.7.2 The Structure and Function of the Epidermis
The epidermis is sub-divided into several distinct strata, each layer differing in 
the extent of cell differentiation (Fig. 1.22). It has five main functions: (1) 
protection against desiccation and external injury, such as chemical, thermal, 
microbial and photic stresses; (2) touch, pressure, pain and temperature 
sensation; (3) thermoregulation via insulation and via vasculature and 
evaporation of sweat. Hands, feet and ears act as heat exchangers; (4) metabolic 
functions including Vitamin D synthesis in the epidermis, storage of energy in the 
form of triglycerides in the dermis, and the skin as a whole has an immunological 
role particularly through the production of cytokines; and (5) it has a high 
coefficient of friction, which aids stability during locomotion.
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Stratum Corneum
This is the outer most layer of the skin, and is made 
up of flattened squames, where the cellular 
structures have been lost and the cell contents and 
membrane converted to keratin and phospholipids. 
Desmosomic connections are still visible, but the 
most superficial layers lose their adherence to one 
another and desquamate. The adherence cells are 
enmeshed within a complex of lipid waxes, sterols 
and other products of keratinocyte lysis.
The cells of this layer lie superficial to the stratum 
spinosum, and they no longer mitose. It is two to four 
cells thick, and acts as the junction between the 
clearly living deeper cells and clearly dead cells of the 
outer epidermis. The cytoplasm contains a population 
of basophilic granules of keratohyalin made from 
transformed cell organelles and lysosomes containing 
hydrolytic enzymes. True keratin does not develop in 
this layer, but the disulphide bone characteristic of 
keratin is seen in this layer.
Stratum Spinosum
This lies just superficial to the stratum basale. The cells at 
this point can still undergo maturation and produce highly 
specialised structures involved in the process of 
keratinisation. It is comprised if several layers of polyhedral 
cells
Stratum Basale
This is the deepest layer of the epidermis and lies at the 
dermoepidermal junction. It is made up of one layer of 
living columnar cells (except in pathological states when 
more layers are found). The cells undergo frequent mitosis 
and the daughter cells formed are called keratinocytes, the 
principal cell type of the epidermis. These proliferating cells 
maintain the cell population of the epidermis.
Epidermal Basem ent Mem brane
Stratum  Lucidum
This lies superficial to the stratum granulosum, and is 
only seen as a clear homogenous line in glaborous skin. 
The cells are very flat, arranged in lamellae.
Stratum Granulosum
The epidermal basement membrane (EBM) is a dynamic structure, 
undergoing constant remodelling, that forms a continuous interface 
between the epidermis and the dermis (the derm o- pidermal -  junction) 
and, as such it is thought to have a number of essential functions, 
including the support and attachment of epidermal cells, the regulation 
and nutritional transport between the dermis and the epidermis, and the 
control of epidermal development and organisation. The EBM appears 
to play an integral part in such physiological and pathological processes 
as wound healing, and blistering.
Figure 1.22. Schematic diagram illustrating the layers of the epidermis. 
Taken from reference [64].
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1.7.3 Keratinisation
As the basal keratinocytes migrate upwards through the layers of the epidermis, 
they undergo remarkable morphological, biochemical and functional changes 
during the process of terminal differentiation (Fig. 1.23). The keratinocyte cells 
become polyhedral in shape, and flatten as they enter the SC layer. Originally 
about 6 micrometres in width, the cell in the homy layer flattens to 30 
micrometres. The terminally differentiating cells lack a nucleus and are filled with 
keratin fibres. This process is called keratinisation [65]. This culminates in the 
formation of the SC layer, which provides a durable, pliable and effective barrier 
of tightly packed dead cells (modified keratinocytes called comeocytes).
When the cells reach the surface of the SC they are lost, a process called 
desquamation. The adhesion between the cells of the SC is influenced by 
intercellular lipid content l661, intercellular desquamin content 1671 and the 
intercellular proteolytic degradation of cohesive structure m . An alteration in the 
distribution of these substances has an effect on the desquamation process. The 
time it takes for a single basal cell to migrate through the epidermis and 
desquamate (the epidermal turnover time) is between 40 and 56 days I69,701. The 
time required for an individual cell to reach the surface, is greater for a thick SC. 
Epidermal turnover time of the SC on the forearm, back and thigh appears to 
decrease with ageI7il.
1.7.4 Hyperkeratosis
Hyperkeratosis is an excessive increase in the thickness of the SC (callus). It is a 
common feature of many chronic diseases such as lichen planus, psoriasis and 
chronic discoid lupus. In the case of hyperkeratosis on the foot, it is more of a 
response to mechanical trauma, resulting in the formation of callosities. Little is 
known about the persistence of callosities when the source of the mechanical 
trauma has been removed.
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Figure 1.23. Diagram illustrating the change in shape of keratinocytes during keratinisation. 
Picture taken from reference [72], 
m-melanocyte, L-Langerhans cell, M-Merkel cell
1.7.4.1 Hyperkeratosis and Mechanical Trauma
The SC shows locational variations both in structure and thickness, depending on 
the degree of mechanical trauma that the site is subjected to, for example the 
skin of the forearm is thinner than that on the sole of the foot. The skin, therefore, 
has an adaptive response to physical trauma. When callus plaques begin to form 
there is an alteration in the homeostatic mechanisms, which maintain normal 
epidermal thickness. Depending on the type and frequency of application, the 
epidermis responds to friction by either blistering (an acute response to friction) 
or by thickening (a chronic response). MacKenzie (1974)[73] attributed the chronic 
response to a decrease in the rate of desquamation as opposed to an increase in 
cell proliferation [66]. He suggested that friction induces an alteration in cell 
differentiation in the epidermis, leading to the formation of ‘hard’ keratins like that 
of hair and nails, that do not desquamate as readily as ‘soft keratins.
Springetts' model of callus formation (Fig. 1.24) suggests that tissues subjected 
to stress are stimulated to produce growth factors and inflammatory mediators 
[74]. These chemicals increase the transit time of epidermal cells resulting in the 
accumulation of immature cells, appearing in the form of callus at the surface of 
the skin.
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Callus tissue 
becomes more rigid, 
less able to dissipate 
mechanical stress 
and transmits load to
deeper structures
Keratinocyte immaturity on entering the 
stratum corneum
• Desmosomal degradation incomplete
• Enzymes involved in formation of cell 
envelope still active
• Abnormal lipid bilayer formation
• Squame surface very convoluted
Figure 1.24. A proposed model for callus formation 1741
Water gradient through 
skin becomes more 
marked and callus surface 
water content is lower than 
plantar skin 
a
Bulk of tissue irritates/ 
stresses keratinocytes 
causing release of cytokines 
by epidermal and dermal 
tissues
Stratum corneum thickness 
increases with time
Alteration in squame 
cohesion and rate of 
desquamation
Excess duration 
-and magnitude of 
mechanical stress
Release of cytokines 
by keratinocytes and 
perhaps other 
structures
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1.7.4.2 Stratum Corneum Cells and Mechanical Trauma
The cellular architecture of the SC is responsible for the major role it plays in the 
protective function of the epidermis. The SC cell surface is comprised of a series 
of projections and depressions, which complement those of adjacent cells I751, 
resulting in the strong cohesion between the cells of the SC which are arranged 
in tightly packed columns. The maintenance of this ordered stacking depends on 
the relatively slow rate of cell turnover. In the palmar and plantar regions this 
system is disrupted due to the high rate of cell proliferation I75]. The epidermis 
copes with this random stacking system by allowing faster surface clearance of 
cells and more massive SC[751.
A higher rate of cell proliferation results in cells moving much faster through the 
viable epidermis, and does not allow sufficient time for complete differentiation 
producing less dense comeocytes with a less ordered structure 1631 When 
subjected to physical trauma comeocytes become thicker than those of normal 
skin and a large numbers of cells are formed (Tables 1.5 & 1.6)I631.
Proliferation is controlled by negative feedback mediated by endogenous 
hormone-like mitotic inhibitors. When injury occurs, these substances are lost 
and proliferation takes place. These inhibitors are glycoproteins called chalones. 
The epidermal glycoproteins, termed chalones, control cell division and 
desquamation. This is an important safety mechanism. It does not, however, 
explain why epidermis varies in thickness from one body site to another.
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Table 1.5. Thickness of comeocytes at different sites on the human body^61
Site Mean Thickness (pm±SD)
Forehead 0.28±0.10
Axilla 0.22±0.05
Upper arm, lateral 0.28±0.03
Lower arm, ventral 0.23±0.05
Lower arm, dorsal 0.27±0.06
Paraumbilical region 0.29±0.05
Shoulder blade 0.23±0.07
Upper thigh 0.34±0.09
Lower leg 0.34±0.03
Palm 0.31±0.13
Sole 0.42±0.13
Table 1.6. The number of comeocytes counted at different sites on the human body [77]
Body area Mean Average % nucleated
Forehead 61,800 9.9
Axilla 104,000 2.3
Arm 152,500 0.7
Palm 96,400 2.6
Abdomen 134,000 0.4
Thigh 124,000 2.0
Heel 228,000 0.2
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1.8 Keratins
Proteins are macromolecules that execute, regulate and mediate most biological 
functions in the cell as well as in the intercellular matrix. Each different protein in 
the organism performs a different task. To ensure that these reactions are 
beneficial to the organism, the proteins need to be efficient and specific in their 
function. Structural changes within proteins cause incorrect folding, leading to a 
loss or a modification of their biological activities. A number of processes can 
lead to this type of behaviour, including the introduction of covalent modifications 
such as oxidation and glycation.
Keratins, are the main fibrous proteins of the epidermis and are one of the most 
abundant proteins in the human body. Their molecular weights range from 40-70 
kDa, implying approximately 350-550 amino acids per molecule [781. They occur 
primarily as extracellular, insoluble fibres, which account for the major part of the 
organic mass of the epidermis, hair and nails. They possess unique structural 
and functional properties depending on the inter- and intra-molecular cross- 
linking of the keratin fibrils.
1.8.1 The Structure of Keratins
Keratin proteins adopt two types of structural conformations: a-helical (in the skin 
of mammals) and (3-pleated (in the feathers of birds and the scales of reptiles).
1.8.1.1 Keratin Intermediate Filament Proteins
The intermediate filament proteins (IFs) are major components of the 
cytoskeleton (10-15nm in diameter) of most eukaryotic cells including 
keratinocytes, and they display considerable structural and functional 
heterogeneity. The other two major filament systems are actin microfilaments 
(MFs) (7-1 Onm in diameter), and microtubules (MTs) (25nm in diameter)I791. The 
IFs are the most dynamic of the three filament types. In particular, reversible 
dissociation-association of IF dimers can occur along the entire filament length 
and not just at the two ends as is with the other two filament types. The
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integrated network formed by the three filament systems is responsible for the 
mechanical integrity of the cell and is critically involved is such processes as cell 
division, motility and plasticity.
Epidermal keratinocytes contain an abundance of IF proteins, the correct 
formation of which is essential for normal differentiation. The filaments are 
synthesized in and retained by the inner living cell layers and eventually 
constitute the major component (up to 2/3 of the total mass) of the terminally 
differentiated SC. Keratins are the most diverse proteins and, unlike other IF 
proteins, are heteropolymers comprising of at least one Type I (acidic, pH range 
4.5-6) keratin and one Type II (neutral-basic, pH 6.5-8.5) keratin. To date, 16 
human Type I keratin IF proteins have been described, ranging in size from 40 to 
65 kDa and 13 larger Type II keratins (50-70 kDa).
1.8.1.1.1 The Primary Sequence of Keratin Intermediate Filaments
All IF proteins exhibit a characteristic ‘tripartite’ structure, which includes the a - 
helical central domain, the ‘rod’ (highly conserved in size 310-315 amino acid 
residues), and the non-helical ‘head’ (amino terminal) and ‘tail’ (carboxyl 
terminal) domains located at either end of the rod domain l79]. The characteristic 
features of the central rod domain reveals a pronounced heptad repeat (a-b-c-d- 
e-f-g)n, where portions a and d are occupied by apolar amino acid residues (e.g. 
Leu, lie, Met or Val) and the other positions are occupied by polar or charged 
residues. This gives rise to an alpha-helical twist in the polypeptide chain 
favouring the formation of a coiled-coil structure, and producing a characteristic 
pattern of charged and hydrophobic residue (Fig. 1.25 & 1.26). The coiled-coil 
structure defines the overall elongated shape of an IF dimer. The IF proteins 
have 4 coiled-coil domains (1A, 1B, 2A and 2B) which are separated by short 
linear regions or linker segments (L1, L12 and L2) (Fig. 1.27). The elementary 
unit of an IF is long (-47 nm) and thin (-2-3 nm) central rod-like dimer domain, 
which accounts for roughly 38 kDa in molecular weight terms. Thus, the smallest 
keratin (K19), which is only 40 kDa, possesses a rod domain with only a minimal 
amount of amino (N) and carboxy (C) terminal sequences.
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Figure 1.25. Coiled-coil parallel heterodimer formation.
Figure 1.26. The alpha helix secondary structure. Alpha helix with the hydrogen bonds holding 
the chain in a coil. There are 18 amino acids per five turns of the coil and there are always two 
amino acid groups distance between the hydrogen bonds.
Figure 1.27. Homologous regions of keratin intermediate filaments
It is these N- and C- terminal sequences that are responsible for the 
heterogeneity of the IF proteins in terms of size (2-32 kDa) and composition. 
Although the rod domain structure is highly conserved in Type I and II keratins, 
the terminal sequences (especially the C-termini) are often unique and have 
specialised primary and secondary structures which differ not only between types 
of IF proteins but between different keratins too.
1.8.1.1.2 Structure of the Elementary Intermediate Filament Dimer
Two dimers condense to form an anti-parallel staggered tetramer which in the 
case of keratins has two Type I and two Type II subunitsI801. These aggregate 
with other tetramic units to form and 8-chain unit and eventually a filament of 10- 
15nm diameter[81] (Fig. 1.28). An additional non-random periodic distribution of 
acidic and basic residues in the rod has been suggested to play a role in 
intermolecular ionic associations (Table 1.7). A series of zones alternating acidic 
and basic residues seem to repeat at ~9.5 residue intervals along the molecule, 
or 3 times every 28 residues [G2]. This charge periodicity may reflect the 
importance of electrostatic interactions in stabilising associations between coiled- 
coil dimers or higher ordered structures. The filaments form a lattice structure that 
has approximately 32 polypeptide chains in cross-section, which often aggregate 
together to form tonofilament bundles and run through the cellular cytoplasm 
terminating at the desmosomal complexes that rivet the adjacent keratinocytes 
together.
Scanning transmission electron microscopy shows the filaments to appear ‘fuzzy’ 
at the surface and the density falls off at the periphery. This indicates that the Inl­
and C-terminal sequences, which are extensive for the larger keratins, lie on the 
surface of the filament and protrude into the cytoplasm. Studies of epidermal 
keratins suggest that the termini are on the surface, as proteolytic modification 
and phosphorylation of intact filaments produces molecular alterations to the 
terminal sequences. As the IF proteins all differ in the nature of their terminal 
sequences, and these are accessible to the surrounding cellular environment, it 
appears that the function of individual IF proteins is dictated by the nature of 
these heterogenous terminal (‘surface’) structures.
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1.8.2 Mechanical Properties of Keratins
The mechanical properties of keratins are a function of the geometrical form and 
the intrinsic properties of the filament matrix. The combination of the linearly 
elastic, high modulus fibres, embedded in a viscoelastic low modulus matrix has 
a biological value in being able to distribute any applied stress evenly over the 
filaments, thus preventing the propagation of cracks or points of rupture. The a - 
helical structure in conjunction with the long length of the keratin filaments allows 
for bending and stretching. The keratin filament matrix is an aqueous 
environment with cysteinyl residues in a reduced form. In the final stages of 
synthesis the cysteinyl residues are oxidized in pairs to yield disulphide cross- 
linkages which stabilize the matrix (Table 1.7). When the keratin is eventually 
exposed to the environment, there is a reduction in water content, accompanied 
by shrinkage, and a profound change in the mechanical properties of the matrix 
causing it to become stiffer and brittle. Little is known about the proportion of 
matrix proteins in ‘soft’ keratins, therefore, it is difficult to determine their 
contribution to the mechanical properties of the epidermis.
Keratinocytes specialise in making keratins, but other proteins include involucrin, 
fillagrin and loricrin to mention but a few. These are matrix and cross-linking 
proteins which, like keratin IF proteins are expressed to a high level to provide 
structural integrity to tissues.
Table 1.7. The three main chemical bonds involved with the structure of keratins.
Disulphide Bonds Hydrogen Bonds Salt Bonds
Atoms involved - S - S -
(cysteine residues)
- NH & - C=0 C=0 negatively 
charged
- N -  H positively 
charged
Bond interaction 3 0 -1 0 0  cals/molecule 2 - 1 0  cals/molecule 1 0 - 2 0  cals/molecule
energies
Chemical Resistance to Can be ruptured by 6M Bonds cross -  link
characteristics digestion. 
Resistance to 
hydrolysis.
urea polypeptide
chains.
Difficult to rupture. 
Ruptured by 
alkalies -  but also 
rupture disulphide 
bonds.
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1.8.3 Keratin Expression in the Epidermis
It seems very likely that different keratins provide cells with subtly different 
properties of resistance and plasticity to equip them with the ability to resist the 
physical stresses of each particular body site. During normal keratinisation the 
expression of epidermal keratins alters during terminal differentiation. The basal 
cells of the epidermal proliferative compartment are composed largely of K5 and 
K14, providing crucial mechanical support within the basal region [82]. As cells 
become committed to terminal differentiation, they switch on two other keratin 
genes: K1 and K101621. Biochemical, immunological and in situ hybridisation data 
show that K5 and K14 are progressively down-regulated and that the filament 
system in the upper suprabasal cells not only increases in density but also 
changes in composition, as more K1-K10 appears. When the cells reach the 
upper granular layer, the filament system is composed almost entirely of K1 and 
K10. These filaments are then proteolytically modified, becoming smaller and 
more acidic as the organelles are removed and the dead comeocytes are formed. 
When the skin is damaged there is an over production of K6 and K16 at the 
expense of K1 and K10.
1.8.4 Keratin Expression in Plantar Epidermis
Although, K2 and K9 are generally minor components in the epidermis, they are 
abundant in palmar and plantar epidermis I831. The raised papillary ridges 
overlying the primary epidermal ridge take most of the compression stress on this 
skin. This is also the region where the palmo-plantar specific keratin K9 is most 
highly expressed [841, strongly suggesting that the function of K9 is to provide 
additional reinforcement in this stress-bearing epidermis ^  Keratins K6 and 
K16 are also constitutively expressed in palmar and plantar epidermis and are 
expressed in response to any wounding or perturbation of the epidermis such as 
hyperproliferationI85;861. The expression of K16 in the intervening secondary ridge 
zones may provide areas of plasticity and elasticity in between stiffer K9- 
expressing patches, as well as strengthening the epidermis [871 to prevent it from 
being tom apartI84].
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1.9 Advanced Glycation End Products and Diabetes
Glycation* is a complex, series of parallel and sequential non-enzymatic reactions 
of glucose, a-oxaldehydes and other saccharide derivatives with proteins, 
nucleotides and lipids, resulting in structural modifications of the proteins 
involved1871. Also known as the ‘Maillard reaction’, the process was first 
discovered in 1912 by the French food chemist L.C. Maillard who noted the 
browning of amino acids when heated with sugarm . Food chemists continued to 
work on the chemistry of the Maillard reaction, leading to the hypothesis that a 
similar reaction could also occur between other amino substances other than in 
foods1891 .It is the AGEs that form cross-links between proteins, having effects on 
their chemical and physical behaviour. AGEs have been proposed in hypotheses 
to explain a number of diabetic and age-related complications I901. Although the 
basic chemistry of the process was described more than ninety years ago, it is 
only in the last twenty years that extensive, clinical research in this area has 
taken place1911.
Alterations in the structural and functional properties of proteins as a result of 
AGE formation are implicated in key diabetic pathologies, in particular diabetic 
microvascular disease[92:93], neuropathy1941 and nephropathy[951, as well as being 
implicated in a wide range of other pathologies such as cartilage pathology, in 
rheumatoid arthritis I96]; amyloid plaques in Alzheimer's disease I9?1; and nephron 
structural change in end stage renal disease[98].
The pathophysiological changes that result from AGE accumulation, follow 3 
general mechanisms:
• Extracellular AGEs and matrix dysfunction -  The functional properties 
of several important matrix components are altered by AGE formation. The 
first matrix protein to be seen to undergo intermolecular covalent, bonds
* Protein glycosylation is the chemical addition of carbohydrate or giycosyl groups to peptides or proteins, to produce 
glycopeptides or glycoproteins. Giycosyl transferases are used in this biochemical reaction. Glycation is a less controlled 
reaction by which a sugar ketone or aldehyde group becomes attached to the free amino groups of proteins or amino 
acids without the assistance of an enzyme. This attachment occurs at the free amine group of lysine or arginine, which is 
not involved in the peptide bond.
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via AGEs, was collagen [991. AGE formation on collagen also covalently 
cross-links soluble plasma proteins such as low-density lipoproteins 11001 
and immunoglobulins. These trapped plasma proteins contribute to the 
characteristic nature of the narrowing of the vascular lumen in diabetes. 
The structure and function of intact vessels appear to be altered by these 
AGE-induced abnormalities in the extracellular matrixI1011.
• Cellular receptors for AGEs -  Monocytes and macrophages were the 
first cells on which the high affinity receptor for AGE was identified11011. As 
a response to receptor binding by AGE-proteins, the macrophages 
produce cytokines (IL-6, IGF-1 and TNF-alpha). These cytokines are 
produced at levels that have been shown to increase glomerular synthesis 
of Type IV collagen and to stimulate proliferation of arterial smooth muscle 
cells and macrophages i101;102i
• Intracellular glycation - Haemoglobin was the first protein for which 
intracellular NEG was demonstrated to reflect time-integrated glucose 
concentration. These modifications involved the Amadori product, not 
AGEs and alter the protein function in the target tissues. Intracellular AGE 
formation may also affect DNA function causing mutations and potential 
deleterious effects on gene expression.
Current understanding of how chronic hyperglycaemia leads to the 
pathophysiological features of diabetic complications is due, in part, to the better 
understanding of the role of AGEs. The chemical processes and pathways that 
ultimately lead to AGE formation have yet to be fully clarified. Not all AGEs have 
been isolated; those that have been characterised are heterogeneous in nature 
and have a tendency to be unstable during isolation. There is currently no 
universally accepted method of detecting AGEs, no internal standards or any 
internationally recognised standard unit of measurement. These inconstancies 
make the comparisons of results between different research groups difficult. 
Although the actions of AGEs are complex and not fully understood, the currently 
known AGEs produce the same chemical outcome.
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1.9.1 The Chemistry of Glycation -  The Formation and Structure of AGEs
1.9.1.1 The Hodge Pathway
The Hodge pathway represents the classic two-stage glycation reaction.
1.9.1.1.1 Stage 1 -  Formation of Amadori Products
Most studies of glycation reactions have investigated the modification of N- 
terminal amino groups in circulating and tissue proteins by the carbonyl groups of 
the free glucose11031. The range of extent of glycation is typically 0.1-1% of lysine 
and arginine residues in proteinsI1041. The first step is a concentration dependent
process 11051 involving the binding of glucose to a protein and the formation of
early glycation products (Schiffs base). A Schiffs base is an unstable and 
reversible product that exists mainly in the form of cyclic glycosylamine, for 
example fructoseamine. With time it either dissociates or undergoes a further 
reversible rearrangement, to form a Amadori or Heyns product, depending on 
whether the implicated sugar is an aldose or a ketose, respectively 11041. An 
example of an Amadori product is fructose-lysine or furosine (Fig. 1.29).
1.9.1.1.2 Stage 2 -  Formation of AGEs
The early glycation products follow complex degradation reactions such as 
dehydration, condensation and oxidation, to become AGEs [1061. Examples of 
known AGEs are pentosidine and A/6- (carboxymethyl)lysine (CML)11071 (Fig. 1.30 
& 1.31). Pentosidine and CML are termed glycoxidation products t108"111! as both 
glycation and free radical oxidation reactions are required for their formation from 
reducing sugars. Oxidation of polyunsaturated fatty acids may also lead to the 
formation of CML, suggesting the role of lipid oxidation AGE formation i112;113i.
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study.
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1.9.1.2 Alternative Pathways
1.9.1.2.1 The Wolff Pathway
Glucose may undergo auto-oxidation, prior to attachment to the substrate, 
catalysed by metal ions, producing reactive carbonyl precursors of AGEs (Fig. 
1.32). AGEs may, therefore, be formed early in the glycation process, making the 
term “advanced glycation end product” a misnomer, as with the Hodge pathway, 
glucose is rearranged to form an ene-diol radical ion under hyperglycaemic 
conditions11141. This radical ion then reduces molecular oxygen, to form a super­
oxide- anion: an oxidizing agent that can go on to oxidize peptides [1141. The 
products are reactive dicarbonyl species that can modify lysine residues to form 
AGEs 11141 and hydrogen peroxide. Therefore, autoxidative glycation generates 
free radicals, leading to the fragmentation of proteins, cross-linking and oxidation 
of associated lipids.
1.9.1.2.2 The Namiki Pathway
The Namiki pathway, involves the Schiff base undergoing a reverse aldol reaction 
followed by oxidative cleavage. Among the highly reactive products of the Namiki 
pathway are the reactive intermediate species (RIS) 3-deoxyglucasone (3-DG), 
glyoxal (GO) and methylglyoxal (MGO) P1:1151. They are thought to have a role
similar to that of classical AGEs in the development of old age and diabetic
complicationsI104].
Methylglyoxal can also be formed by non-oxidative mechanisms in anaerobic 
glycolysis and from oxidative decomposition of polyunsaturated fatty acids. In 
addition, MGO can be derived from fructose by fragmentation of triose phosphate 
(whose intracellular concentration is increased in diabetes mellitus) or the 
catabolism of ketone bodies and threonine [104]. Methylglyoxal is a physiological 
a-oxaldehyde that can bind to modify arginine, lysine and cysteine residues in 
proteins (Fig. 1.33). It is formed from glyceraldehydes-3-phosphate and 
dihydroacetone phosphate, metabolites of the Embden Meyerhof pathway that 
are generated from glucose or from fructose, a product of the polyol pathway.
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Methylglyoxal is usually inactivated by conversion to D-lactate by the glutathione 
-dependent glyoxalase pathway. However, glyoxalase activity is decreased and 
blood levels of MGO and D-lactate are increased in diabetes, suggesting 
deficiencies in glutathione metabolism in diabetes[126]. Glyoxal is a precursor of 
CML, and is also formed by the degradation of ascorbate (Vitamin C). Because of 
the disorders in ascorbate homeostasis in diabetes mellitus, ascorbate may be a 
major source of glycoxidation products in some tissues.
1.9.2 Conditions of Glycation
Contributory factors to the different rates of AGE accumulation apart from sugar 
concentration include environmental pH, temperature, accessibility of the lysine 
residues and the half-life of the protein11161. The resulting structures can possess 
chromophoric, fluorophoric and cross-linking properties.
In a clinical setting the key saccharides and saccharide derivatives, involved in 
glycation, are glucose and the reactive a-oxaldehydes - GO, MGO and 3-DG 
respectively. Consequently, in conditions of elevated blood sugar levels such as 
diabetic hyperglycemia, glycation rates are increased i117;118i. This results from 
the fact that AGE formation proceeds through RIS binding indiscriminately to 
amino groups present on diverse “bystanding” proteins I1191. In fact, AGE levels 
are increased as early as three months from the development of 
hyperglycaemia1941. The levels of AGEs do not return to normal once 
hyperglycaemia is corrected: instead the products accumulate over the lifetime of 
the tissueI1201.
1.9.3 Glycation Kinetics
The full process of glycation takes place over a period of weeks, and is therefore 
thought to affect mostly stable, long-lived proteins t91], such as the connective 
tissue matrix, basement membrane collagen, cartilage collagen, and 
myelinI119:121'1231. But, AGEs are also found in short-lived proteins as well, such 
as lipid constituents and nucleic acids - more apparent in diabetes and renal 
failure11191. Cellular proteins are less affected by AGEs, due to their high turnover
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and fairly short lives, while extra-cellular long-lived proteins are more severely 
affected l104]. Glycated, peptides of low molecular weights are considered more 
toxic than larger, heavier proteins. The reason for this is the ability of smaller 
fragments of glycated proteins to act as ‘second generation glycating agents’, 
and glycate other proteins at higher rate than glucose.
1.9.4 Alternative Reducing Agents
Glucose is a relatively slow glycating agent, in comparison to other reducing 
monosaccharides. The reactivity of the sugar increases as follows: e.g., 
glucose<mannose<galactose<xylose<fructose<arabinose<riboseI87].
Phosphorylated sugars are much more reactive than their unphosphorylated 
counterparts [124]. It follows, therefore, that sugars such as fructose and the 
intracellular glucose-6-phosphate are known to have a faster AGE formation rate, 
approximately ten times faster p1:125i. This is theoretically explained by fructose’s 
different, possibly preferable, pathway for the formation of the highly reactive a- 
oxoaldehydes. In addition, the fructose-protein early glycation product is a Heyns 
product (the parallel to Amadori Product), a significantly more reactive 
compound.
1.9.5 The Clinical Effects of AGEs
Animal models have shown that AGE concentrations increase within a few weeks 
after the animal is rendered diabetic and that this increase is systemic, occurring 
in the kidneys, skin and vascular tissue.
Human studies, such as the Diabetes Control and Complications Trial (1993), 
confirm that, patients with high blood glucose levels have a higher prevalence of 
diabetic complications. Glycated haemoglobin, sampled from diabetic patients is 
an indicator of glycaemic control and is the best studied Amadori product l126l  
AGEs are formed irreversibly and are expected to have longer half-lives than 
early glycation adducts. Given this expectation, the measurement of AGEs may 
reflect changes in glycaemic control, AGE formation and could therefore be
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diagnostic indicators of disease management, or risk indicators of development of 
disease. The importance of a risk indicator may depend on the type of AGE 
measured, since AGEs have different functional activities: some are protein 
cross-linkers, some are agonists at AGE receptors and some have no defined 
activity. AGE content (CML and pentosidine) of skin collagen has been shown to 
be a risk maker for microvascular complications of diabetes[105].
1.9.6 Receptors for AGEs (RAGE)
Prior to the discovery of AGE binding proteins, the main biological effects of 
AGEs were considered to be extracellular and related to cross-linking of long- 
lived proteins such as collagen [119]. Surface AGE receptors such as RAGE have 
been identified on a wide range of cells i127:128i the discovery of which raised the 
possibility that these receptors may modulate the biological effects of AGEs by 
activating the cellular expression of growth factors and cytokines. These 
receptors can be activated by a variety of AGEs, which can stimulate 
inappropriate cellular activity. For example, monocytes bearing RAGEs on their 
surface can be activated by chemotaxic signals and move towards sites of AGE 
accumulation where they penetrate the sub-endothelium and form foam cells, 
leading to the development of arteriosclerosis l1291. The binding of AGEs to 
receptors on endothelial cells also increases the generation of reactive oxygen 
species.
1.9.7 Exogenous Sources of AGEs
Tobacco smoke contains high concentrations of GO and MGO and other AGEs 
from the thermal combustion of saccharides These AGEs have been 
observed in coronary artery walls, providing further suggestive evidence of 
tobaccos contribution to cardiovascular disease.
Because of the heterogeneous nature of the AGEs, the lack of sensitive 
measurement techniques and the inability to measure the endogenous flux of 
glycation adducts, the contribution of food derived AGEs has been difficult to 
determinet130]. For example, the metabolic flux of MGO of a 70 kg human subject
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is estimated to be 8.4 mmol/day. This is the same amount as 24 kg of toast or 
1440 litres of coffee![131]. Normal dietry intake of MGO, therefore, may represent 
a minor contribution to the total body pool of this metabolite. The situation may be 
different in the case of CML, for example: rats have been fed CML -  rich diets 
and excreted it in urine without any reported ill effect. Normal dietry AGEs may be 
within limits but excess overwhelms the system.
The physiological significance of dietry a-oxaldehydes and glycation adducts 
depends on: the contribution to the dietry component makes to the total body 
pool of metabolite; the detoxification capacity of the host and the functional 
activity of the particular glycation adduct concerned.
Another suggested source or catalyst of AGE formation is sun l132]. Levels of 
AGEs in elastic fibres in the upper dermis are significantly higher in skin 
chronically exposed to sunlight. Ultraviolet light could stimulate oxidation by 
activating free-radical intermediates.
1.9.8 Physiological Defence against Glycation
There are 2 chief natural defense processes against glycation. Firstly, 
metabolism has evolved to use glucose as the most prevalent monosaccharide, a 
monosaccharide that has a relatively low reactivity towards glycation. Secondly, 
there is a risk of rapid formation of MGO ih Embden-Meherhof glycolysis, this is 
minimised by evolving glycolytic energetics to maintain very low steady state 
levels of triosephosphate and triosephosphate isomerase (Fig. 1.34).
Frutoseamine is the glycation adduct found in highest concentration in proteins 
and phospholipids. Since it may degrade to form reactive p,a-dicarbonyl 
precursors of AGEs, either directly or via the Schiffs base, the removal of 
fructoseamines from proteins may be a protective endogenous anti-glycation 
response.
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Figure 1.34. A schematic diagram illustrating Embden-Meherhof glycolysis
Inside cells, the impact of glycation is countered by the high turnover of cellular 
proteins, phopholipids and RNA, and mechanisms of DNA repair. Degradation of 
the extracellular AGE-modified proteins requires specific recognition by 
receptors, internalization of the AGE ligand-receptor complex and proteolytic 
processing of the AG E-ligand.
1.9.9 Cross-Link Formation
AGEs form covalent cross-links with adjacent protein strands. This cross-linking 
stiffens tissues, which were formally flexible and elastic. The process happens 
gradually, so that cross-links accumulate over the years on the longest lived 
proteins that do not get recycled very often. The clearest evidence of this is found 
in the extracellular collagen and elastin. In non-pathological states, collagen is 
involved in cross-linking, between the N and C terminal groups of each collagen 
strand. Abnormalities in collagen cross-linking lead to increased stiffness of the 
protein matrix and reduced digestibility of the proteins by enzymes t98:116:122i t 
seen in advanced aging and in diabetes i105:133i. The chemistry of AGE cross- 
linking involves the lysine and arginine residues of the protein I1341. The principle 
of cross-linking could be applied to keratin filaments in the epidermis. In addition, 
cross linking is thought to be the reason for the trapping of serum proteins, such 
as albumin, low density lipoprotein (LDL), and immunoglobulin G (IgG), causing 
luminal narrowing - a major feature in blood vessels in diabetes.
1.9.10 Inhibition of AGE Formation
The realization that the progression from the Amadori product to protein cross­
links requires slow rearrangement reactions, suggests possible pharmacological 
strategic interventions. In addition to the treatment of hyperglycaemia, there are 2 
routes for the inhibition of the Maillard reaction in vivo: (1) Trapping of reactive 
intermediates in non-enzymatic reactions between carbohydrates and proteins; 
and (2) Inhibiting the rate of formation of AGEs by the reduction of oxidative 
stress.
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1.9,10.1 Route 1
Therapeutic modalities include the development of compounds designed to break 
apart cross-linked macromolecules I135], AGE inhibitors, such as 
aminoguanidineI101:1361, aspirin i137-14°i arginine, arginine-lysine, tetracylcline, 
uboquinone, and RAGE blockers i141*143i.
Aminoguanidine (AG) is a hydrazine-like, small, nucleophilic compound that is 
thought to interact with Amadori-derived products, thereby blocking the formation 
of AGEs I1441. It is a potent and specific inhibitor of glucose mediated cross- 
linking in vivo I1011. The terminal amino group of the aminoguanidine reacts 
specifically with glucose derived reactive intermediates and prevents protein- 
protein or protein lipid cross-links from forming. Its activity is concentration 
dependentI145].
It is pharmacologically effective at plasma concentrations of less than 100 
pmol/L, while much higher doses are typically required for inhibition of the 
Maillard reaction in vitro. The main disadvantage of aminoguandine is that in low 
doses it also inhibits some enzymatic activity in the nitric oxide acid pathway, 
therefore affecting vascular toneI146]. There are questions related to the toxicity of 
aminoguanidine in high doses, which may compromise its use as therapy in 
humans. ALT-946 is a more potent compound with a limited effect on the nitric 
acid pathway, making it a preferable inhibitor particularly in kidney tissue [U7]. 
Pyridoxamine (PM) inhibits lipoxidative modification of proteins by trapping 
intermediates of the pathwayI148].
At present the development of these compounds is in its infancy, and the full 
medical benefits that may accrue from the use aminoguanidine-like compounds 
are under investigation by way of clinical trials.
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1.9.10.2 Route 2
Antioxidants like ascorbic acid, vitamin E, uric acid and glutathione are all 
decreased in diabetes. In particular, the glutathione levels are depressed both in 
the plasma of diabetic patients and at the edges of foot ulcersI14?I.
Exogenous vitamin C and E are reported to inhibit glycation l1501, although it is 
difficult to explain as the early stages of glycation do not involve oxidative 
reactions. Vitamin E inhibits glycation in vitro and vivo in a dose dependent 
mannerI151].
Because of the complex nature of the Maillard reaction and its role in the initiation 
of lipid peroxidation, it is unlikely that any single drug therapy will be sufficient to 
inhibit the formation of AGEs and the subsequent pathologies. However, any 
effort to decrease the oxidative stress is likely to be beneficial. In the holistic 
treatment of diabetes mellitus and age-related diseases, patients are frequently 
advised to stop smoking and to limit their alcohol intake.
1.9.11 Processes Related to Aging
There is a close relationship between glycation and three other metabolic 
processes: free radical damage, mitochondrial defects and calcium 
dyshomeostasis (Fig. 1.34). All four processes play crucial roles in cellular and 
organism senescence [1521. Other modifications besides that of glycation include 
carbamylation, racemization and deamination. This post-translational 
modifications result in altered stability of the protein and decreased 
digestibility11531. Aging is also associated with decreased protein synthesis - 70% 
of total protein synthesis may be reduced in aged animals.
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Figure 1.35. Diagrammatic presentation of the hypothesis of glycation aging
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1.9.12 Non-enzymatic Glycation and Collagen
Alterations in collagen synthesis and turnover in diabetes [45] are accompanied by 
structural and functional changes related to cross-linking [1251, such as decreased 
joint and skin mobility [37], impaired wound healing, decreased solubility [154;155i 
and increased resistance to enzymatic digestion (Table 1.8)
Table 1.8. Chemical and physical changes in collagen in diabetes.
Chemical_______  __Physical_________________
Increased glycation Increased browning
Increased pentosidine Increased fluorescence
Increased carboxymethylation Increased mechanical strength
Increased cross -  linking Increase thermal stability
Maturation of reducible cross -  links Decreased solubility and elasticity
Resistance to enzymatic digestion Resistance to denaturants.______
The rate of glycation may not be gradual as the tissue accumulates with time, but 
immediate, therefore the point at which tissues become glycated could be of 
significance. For example, it is interesting that older Type II diabetics do not have 
more glycated tendon collagen than their age matched controls f155;156i. 
Therefore, it could be possible that in the postmature collagen tendon there are a 
limited number of sites available for glycation and that these sites are occupied 
early during the course of hyperglycaemia. An alternative hypothesis could be 
that abnormal collagen is synthesized by diabetics and that this abnormality leads 
to changes that appear to represent accelerated aging. This is a feasible 
argument, insinuating that one or more properties of collagen are altered in ways 
that stimulate accelerated aging.
1.9.12.1 Skin Collagen and Glycation
Skin has collagen present in abundance and is the site for a number of age 
related changes. Both biochemical and biomechanical studies of diabetic palmar 
skin in vitro have revealed many pertinent findings l57]. Melting and associates 
(2000)[571 noted that in general the palmar skin from diabetics was brown/ yellow
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in colour and thicker than that from non-diabetics, with reduced pepsin digestion. 
There was also a higher concentration of fluorescent compounds in the diabetic 
skin samples than in the non-diabetic ones l57]. Vishwanath et al (1986) 11571 
duplicated these findings along with measuring increased skin collagen content in 
diabetics. These observations did not correlate with age, diabetes duration, 
severity of nephropathy, retinopathy, arterial stiffness, and joint stiffness in the 
hands although there was, a weak but positive correlation between blood HbA1c 
levelsI1571. Therefore, Amadori products alone cannot explain the pathogenesis of 
diabetic skin complications. Animal studies carried out on streptozotocin diabetic 
rats revealed similar findings, demonstrating an increase in skin collagen stiffness 
with an additional interesting observation of a reduction in collagen content with 
increase in duration of diabetesI158].
1.9.12.2 AGE Measurement in the Skin Collagen
In accordance with the concept that the quantification of AGEs could provide a 
tissue measure of the integrated glycaemia over several years and an estimate of 
the consequent risk of the development of the complications, several studies 
have investigated the relationship between AGE content in skin and diabetic 
complications [92]. Skin collagen levels of specific and non-specific AGEs 
(pentosidine and CML) were found to correlate positively with the duration of 
diabetes and to varying degrees with the severity of retinopathy and nephropathy 
in patients with Type I diabetes i9* 105!. in one study, intensive treatment of 
glycaemia in Type I diabetic subjects, over a period of 4 months, resulted in a 
decrease in skin collagen glycation but had no effect on the glycoxidation 
productsI1591. Similar results were observed in Type II diabetics followed over five 
years of therapyl1601. One study has been carried out on a larger cohort (n=216 
Type I diabetics) of diabetic individuals assessing all of these factors 
mentioned11451. In this study the relationship between long-term intensive control 
of glycaemia and indicators of skin collagen glycation (furosine), glycoxidation 
(pentosidine and CML), and cross-linking (add and pepsin solubility) were 
measured. The results showed that 5 years of intensive treatment was 
associated with lower furosine, pentosidine and CML levels and higher acid- 
soluble and pepsin-soluble collagen. Also the study revealed a correlation
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between secondary complications of diabetes and all of the full set of measured 
variables.
1.9.13 Epidermal Proteins and Glycation
Increased glycation of proteins of the plantar epidermis, as well as those of hair 
and nails i161_165i may contribute considerably to the stiffness and other changes 
seen in the skin of the hands and feet of diabetics. Delbridge et al (1985)11661 
showed that epidermal proteins from the plantar aspect of the foot undergo 
increased glycation, which relate to diabetic control and possible neuropathic 
ulceration. M£rov£ et al (1995)11671 confirmed these results and suggested that 
the glycation of proteins of the stratum comeum can serve as a variable for long 
term monitoring of glycaemia. M£rov3 also suggested that by monitoring the 
course of glycation in specific dermal tissues, one could predict the development 
of dermatological complications seen in diabetes. This study also established a 
good correlation between glycated proteins and age. These two studies 
demonstrate that the glycation of plantar stratum comeum proteins is subject to 
certain laws applicable to proteins of other tissues i.e. the glucose binds to the 
proteins at the same rate and follows a first order reaction with respect to the 
concentration of the glucose. Although Nozaki et al (1988) 11631 revealed some 
years earlier no significant correlation between increased glycation of SC proteins 
and the prevalence of cutaneous manifestations. None of these studies pursued 
what the effects of glycation on epidermal proteins would have on the 
biomechanical properties of the skin. Aspirin can block this glycation process, be 
it in relatively large doses, in SC tissue, which adds to the evidence that the 
process of glycation of keratins may follow the same pathways as that of 
glycation of other tissues in the body I1661.
1.9.13.1 Methods of Analysis of Glycated Epidermal Proteins
The first point of discussion, with regards to quantification techniques, is the 
assay procedure for NEG. Most studies on keratin-based tissues have used the 
TBA method of measurements of glycation f164:166i. The principle of this method is 
the reaction of 2-thiobarbituric acid and 5-hydroxymethylfurfuraldehyde (HMF)
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produced after the hydrolysis of glycated protein from oxalic acid. Therefore, 
various other substances with aldehyde groups may be measured 
simultaneously11681. Brevity seems to be an advantage of this method even though 
it is a semi-quantitative technique t164:160J. The furosine assay used for the 
measurement of NEG of nail and SC proteins i5* 1621, is superior to the 
thiobarbituric acid assay with respect to specificity, because furosine is the 
hydrolysed product of fructose-lysine linkages present only in glycated proteins. 
The measurement of furosine by high performance liquid chromatography 
(HPLC) had been described as specific and sensitivef16^ .
The second point of discussion is the relationship between furosine content in the 
epidermis and blood glucose levels. Sueki et al (1989) 11621 revealed a close 
correlation between HbA1c and furosine (%) of SC and nail. Glycation of many 
other proteins has been shown to be a function of the duration of exposure and 
concentration of glucose in the environment. Therefore, if the stratum comeum is 
turned over more rapidly than nail and hair tissue and collagen in the dermis, the 
opportunity for the former to become glycated will be diminished. The mean 
turnover time for the entire epidermis is estimated to be 40 days m . Therefore, 
the furosine value of the comeal layer of skin may reflect the blood glucose of the 
last 4-7 weeks similar to that reflected by HbA1c levels. Furosine values 
obtained from the free edge of the nail reflect the blood glucose of the previous 4 
months before. This could be amore valuable indicator for the evaluation of long­
term control of diabetic patients than is HbA1c. This suggests that the prolonged 
retention of the SC and nail may accelerate the formation AGEs. Although Paisey 
et al (1984) f164], found a significant correlation between the glycation of the 
proximal 4cm of hair and the simultaneously measured HbA1c value, there was a 
considerable scatter in the results. This scatter may be due, in part, to the 
variation in the rate of growth or the hair proteins being glycated in vivo with 
different dynamics than that of haemoglobin, an important factor when 
considering the dynamics of SC proteins.
Since glucose diffuses freely into epidermal cells, NEG of keratin formed during 
epidermal differentiation should, like all other proteins studied so far, be related to 
glucose levels over that period. From this information it is reasonable to propose
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that in skin conditions where the rate of cell turnover and desquamation is 
affected, there may be an effect on the accumulation of glycated proteins within 
that tissue site.
1.10 Summary
It is recognised that the aetiologies of callus formation in diabetes are complex, 
each of which would have to be considered separately before a clear-cut 
difference in any one factor can be demonstrated. Clearly, the literature shows 
that further investigations into diabetic plantar thick skin are needed. Glycation of 
proteins occurs in the diabetic population, but a direct connection between 
glycation of keratins and ulceration in diabetes has not been elucidated, though 
this relationship is implicated. It seems reasonable to hypothesise that alterations 
in the NEG of keratins may contribute to the changes in the biomechanical 
properties of the epidermis, therefore accelerating the development of callus. 
Thus, changes in keratin may be an additional factor contributing to ulceration in 
diabetics in whom all the factors are present. If such a relationship exists 
therapeutic options could be targeted at preventing this progression.
The practical clinical question is whether measurement of plantar keratin 
variables would yield additional useful information to that provided by HbA1 c, as 
the individual’s risk of developing ulcers. If a reliable epidermal keratin predictor 
emerges, it would identify subjects who are particularly in need of intensive 
glycaemic control or anticomplication therapy, and those at very low risk of 
complications could be spared the rigors and risks of intensive therapy of Type I 
diabetes.
This study aimed to measure the accumulation of the early glycation adduct, 
furosine, and the AGEs, pentosidine and CML, in plantar epidermal keratins, 
along with the measurement of plantar epidermal thickness and flexibility. The 
glycated proteins were quantified by the adaptation and development of existing 
analytical techniques, mainly HPLC, mass spectroscopy and immunoassays. 
Before collecting this data from a group of 190 volunteers (103 Types II diabetics 
and 87 non-diabetics), all the methods were tested for sensitivity and specificity.
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1.11 Hypotheses
The following hypotheses were tested:
1. There is an increase of glycation of plantar epidermal proteins in Type II 
diabetes.
2. There is a decrease in flexibility of pedal epidermis in Type II diabetes.
3. There is an increase in the thickness of pedal epidermis in Type II diabetes.
1.12 Statistical Analysis
All data analyses were preformed on a personal computer. Mathematical 
functions, graphical representation of data and curve fitting were all performed 
using Kaleidagraph™, for Windows, version 3.5 (Synergy Software (PCS Inc.)) 
and Microsoft® Excel 2000, version 5.0 (Microsoft Corporation). . Power tests 
were calculated using Sample Power™ (SPSS Inc.).
All statistical analyses were carried out by SPSS for Windows (SPSS Inc. 1989 -  
2001). The median, interquartile range, minimum and maximum values of the 
grouped data were illustrated by box plots. Values in the text were quoted as the 
arithmetic mean ± one standard deviation (mean ± SD). The standard deviation is 
a measure of the variability of the individual values around the mean in a data 
set. The distribution of the data was plotted as histograms and Q-Q plots. This 
was done for continuous outcomes inorder to see whether the data was normally 
distributed. This showed that the data had a skewed distribution, therefore 
standard parametric techniques were considered as being inappropriate when 
comparing outcomes between two groups. The Mann-Whitney test was used to 
test for the significance between the data sets. This is a non-parametric test that 
does not rely on the data following a normal distribution. It was decided apriori to 
use a 5% two-sided significance level to decide whether to reject the null 
hypothesis (p<0.05). When investigating the association between two continuous 
variables a non-parametric form of the correlation co-efficient was used, the 
Spearman correlation analysis.
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2.0 Chapter 2 -  Extraction and Purification of Keratin Proteins from 
Human Plantar Callus Samples
2.1 Review of Methods of Keratin Extraction and Identification from 
Epidermal Tissues
The process of normal keratinisation is characterised by a series of 
morphological and biological changes, as ceils progress from the germinative 
basal layer through to the outer comified layer [1691. One key change is the 
formation of disulphide bonds between keratin intermediate filaments during 
terminal differentiation, providing stability, strength and chemical inertness to the 
keratin fibres [651. The origins of these bonds lie in the free sulphydryl groups (-SH 
from cysteine) in the living layers of the epidermis, which gradually convert to 
disulphide bonds (-S-S-) in the SC (Fig. 2.1). The disulphide bonds are a 
characteristic feature of mature epidermal cells, rendering them relatively 
insoluble and resistant to keratinolytic agents [65:17° i .
SH oxidation S
♦ 2(H)
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Figure 2.1. Schematic diagram illustrating disulphide bond formation.
In view of the insolubility of keratin proteins, investigation have used degradative 
solvents (sodium hydroxide and methanoic acid), denaturants (aqueous urea and 
lithium bromide), reducing agents (G-mercaptoethanol) and surfactants (sodium 
dodecyl sulfate-SDS), to successfully extract proteins from epidermal ce ll[171].
Water in-soluble proteins from normal human epidermis can be sequentially 
extracted with increasing concentrations of urea [1701, and when the same tissues
i n
are incubated with additional SDS and G-mercaptoethanol more keratins are 
extracted. The procedure disrupts the cell membranes and releases the keratin 
filaments in the form of their constituent polypepetide subunits and offers 
quantitative extraction. In the case of human epidermis I78]> these subunits 
represent up to two thirds of the total dry weight mass of the epidermis. 
Yamauchi and associates (1976) 11721 also used a mixture of urea, G- 
mercaptoethanol and SDS to extract keratins from wool. They demonstrated that 
SDS is essential to produce a high yield of keratin proteins (40-50 wt%). They 
also demonstrated that above a temperature of 100°C and in alkaline conditions 
the keratins decompose. The ideal extraction conditions were a temperature 
between 50-70°C and a pH around 7 and 8. The same reagents and conditions 
have been used to extract keratins from human epidermal cells, including the 
SC™.
Baden et a l11731 confirmed that only trace amounts of keratins are extracted if 
SDS is not used and that G-mercaptoethanol is essential for the selective 
extraction of keratin firom tissues. For example, nails contain epidermal and hair 
keratin - with 50mM 2-mercaptoethanol, only epidermal types are extracted and 
hair keratins are extracted with 200nM 2-mercaptoethanol[1741. This adds to the 
suggestion that different keratins have different structural features despite their 
co-existence.
Once the aqueous solution of keratins is obtained, classic methods of protein 
identification and quantification can be employed. The proteins can be separated 
by one dimensional sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) giving protein bands of different molecular weights, identified by 
the use of known molecular weight markers. In order to identify the presence of 
specific keratins, immunoblot techniques can be employed using monoclonal 
antibodies. The specificity of these antibodies is crucial to the identification of 
keratins in the protein extract.
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2.1.1 Existing knowledge of Molecular Weights of Keratins after Protein 
Extraction
Gel electrophoresis and immunoblotting techniques demonstrate isoelectric 
variants of keratins, depicted as many bands covering a broad range of molecular 
weights [1751. This variation applies to cultured keratinocytes and human 
epidermal cells (Table 2.1) from different body sites and disease states (781.
Table 2.1. Molecular weights of keratins extracted from different keratinised tissue types
Tissue type Molecular weight (kDa) References
Cultured epidermal cells 1 0 -2 0 0 [78]
Keratinocytes 4 5 - 5 8 [78]
Human epidermis 4 0 - 7 0 [78]
Glycated human foreskin keratin 53 !1I 6i . ................... .
This apparent heterogeneity is due to post-translational modifications, such as 
phosphorylation l78]. The functional significance of these post-translational 
changes is uncertain but may play a role in modulating the interactions of the 
cytoskeleton with other intracellular structures. In view of the accumulating 
evidence that sugar moieties on proteins are involved in the intracellular 
adaptation of proteins, it is possible that glycated keratins are synthesised in the 
epidermis. One study shows that human keratinocytes (cultured from foreskin) 
synthesise a glycated keratin of mass 53 kDa [176]. Further investigations into this 
keratin have not been pursued.
2.1.2 Keratins Identified in the Stratum Comeum
Over 20 different human keratin polypeptides have been identified in various 
epithelia, hair and nails and are classified as members of an acidic subfamily 
(Type I) or a relatively basic subfamily (Type II). The co-existence of these two 
types of keratins in the filament correlate with specific phenotypic features of 
epithelial differentiation [170].
Normal human epidermis contains four major keratins (molecular masses 67, 58, 
56.5, and 50 kDa, corresponding to keratins K1, K5, K10/11, and K14,
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respectively), as well as lesser amounts of K2 (65 kDa) and K15 (50 kDa). The 
major keratin polypeptides are sequentially expressed during the course of 
epidermal differentiation. Keratin K5 (Type II) and keratin K14 (Type I) are co­
expressed in basal cells, whereas keratins K1 and K10/11 (types II and I, 
respectively) are synthesised in the suprabasal cells (Table 2.2). Using a 
combination of biological and immunological techniques, Woodcock-Mitchell et 
a /169] confirmed that a 50 kDa (K14 and K15) and a 58 kDa (K5) keratin were 
present in all living layers including the relatively undifferentiated basal cell layer, 
whereas a 56 kDa (K10/11) keratin and 65- 67 kDa (K2, K1 and K5) keratins 
were associated only with more differentiated cells above the basal layer. The 
latter keratins are therefore regarded as molecular markers of keratinisation 
(Table 2.3). In keeping with these concepts, studies of epidermal keratin 
polypeptide interactions in vitro have demonstrated that filaments reconstituted 
from keratins K5 and K14 form filaments similar to those seen in living (and 
dividing) basal cells, whereas reconstituted filaments containing keratins K1 and 
K10/11 have a propensity to aggregate, as occurs in formation of the SC.
Table 2.2. Predominant keratins present in the viable layers of normal human epidermis
Keratin Type of Keratin Molecular weight (kDa)
kT II 67
K5 II 58
K10/K11 I 56.5
K14 I 50
K2“ II 65
K15D I 50
Main keratin bands.
Keratins present in lesser amounts 
Sun and Green "IS/S1781.
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Table 2.3. The presence of specific keratins in different layers of the epidermis
Layer of 
epidermis
Keratin References
Basal layer K5
K14
K15
[78]
Suprabasal cells K1*
K10/11*
K5*
K14
K15
K2*
[169]
All living layers K14
K15
K5
* Molecular markers of keratinisation
2.2 Aims of this Thesis
• The extraction of keratin proteins, with minimal contamination by other 
proteins, in aqueous solution.
• Identification and quantification of keratins within the extracts.
• Comparisons between keratins extracted from diabetic and non-diabetic 
callus specimens.
2.3 Introduction
Three methods of extraction were employed to confirm previous findings and 
develop an efficient method of producing pure solution of keratins of a high yield. 
The first method involved sequential extraction using different concentrations of 
urea (in a Tris buffer). The second involved a series of sequential extractions 
using a Tris buffer, Tris and urea buffer and Tris, urea and IJ-mercaptoethanol 
buffer. The third method was an adaptation of methods 1 and 2 combined, 
resulting in a speedy and efficient extraction procedure. Each extract was 
examined by one-dimensional SDS-PAGE to ascertain the molecular weights of 
all proteins present in solution followed by, immunoblot (Western blot) analysis, 
using monoclonal and polyclonal antibodies to identify specific keratins.
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2.4 Method 1 -  Extraction and Identification of Keratins using Different 
Concentrations of Urea Solution
2.4.1 Reagents and Buffers
Buffer 3 
Buffer 4 
Urea solutions
Buffer 1 
Buffer 2
Tris/HCI (25 mM, pH 7.4), KCI (1.5M) in d.H20  (100 ml) 
EDTA (5 mM), EGTA (1 mM), Pepstatin A (5 pg/ml) and 
Antipain (10 pg/ml) in dH20  (50 ml)
Buffers 1 and 2 in a 1:1 ratio and Triton-X 100 (0.5 ml) 
Same as stock solution 3 but without Triton X-100 
2, 4, 6 and 9.5M urea in buffer 4.
Plantar callus samples taken from subject 6N (see Chapter 4, Table 4.2).
2.4.2 Extraction Procedure
The sample of human plantar callus (0.25 g) was minced using a blade to 1 to 
2mm3 and subjected to a series of sequential extractions in urea solutions of 
differing concentrations (2, 4, 6 and 9.5 M urea) and one direct extraction in 9.5M 
urea solution as follows. Buffer 3 (10 ml) was added to a callus sample, 
incubated over night and homogenized (30 min). The sample was centrifuged 
(4000 rpm, 15 min) at 4°C and the supernatant discarded. The pellet was washed 
with buffer 4, centrifuged as described above and the solvent discarded, leaving 
a solid pellet ready for lyophilising.
Direct extraction procedure - The dry pellet was incubated for 3h at room 
temperature (RT) in urea solution (4 ml, 9.5 M), followed by centrifuging (4000 
rpm, 15 min). The supernatant was removed and stored at +4°C and labelled -  
9.5M urea direct extract
Sequential extraction procedure - The remaining sample was incubated at 4°C in 
urea solution (2 ml, 2 M) for 3h, shaking occasionally. The sample was
All chemicals are bought from Sigma Chemicals, Poole, Dorset -  unless otherwise stated.
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centrifuged (4000 rpm, 15 min) and the supernatant stored in a glass vial 
(labelled 2 M urea sequential extract). This procedure was repeated on the 
remaining protein pellet using 4 M, 6 M and 9.5 M urea solutions (at room 
temperature). The extracts were stored in glass vials at +4°C. The protein content 
of each extract was measured using the Lowry protein assay (Appendix I).
2.4.3 Identification of Proteins in Extracts using One -  Dimensional SDS -  
PAGE and Immunoblot (Western Blot) Techniques.
The method protocols are described in full in Appendices II and III. In summary, 
samples containing 50 pg of proteins were heated at 100°C for 4 min in 150 pi of 
sample buffer. The upper stacking gel contained 5% acrylamide and the lower 
separating gel contained 12.5% acrylamide. The samples were run alongside 
markers of known molecular weight. All samples were treated with G- 
mercaptoethanol prior to separation. A constant current of 200 mV was applied to 
the gel slab (18 cm x 17 cm x 1.5 mm) for approximately 3 h until the dye front 
approached to within 1cm of the end. The gel was then stained in fresh 
Coomasie blue staining solution for 1-2 h and the stain removed by incubating 
the gel in destaining solution. A gel light transiiluminator and appropriate software 
were used to analyse the gel. The relative molecular weights of each protein 
band were calculated from the retardation factor compared to the standard 
protein mixture.
To better understand the polypeptides extracted at each urea concentration, 
unstained gels of the extracts were blotted onto nitrocellulose and then probed 
according to the Western ligand blot protocol described in Appendix III. Two 
monoclonal antibodies (AE1 and AE3,1mg/ ml concentration) and one polyclonal 
antibody (SIGMA antikeratin, 1/1000 concentration) against epidermal keratins 
were used to identify specific keratins. Anti-mouse/anti-guinea pig IgG 
horseradish peroxidase antibody (10 pi) was added to the blocking buffer (20 ml).
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2.4.4 Results
2.4.4.1 Protein concentration of keratin extracts
The table and graph below (Table 2.4 & Fig. 2.2) report the concentration of 
protein measured in each extract.
Table 2.4. Protein concentration of keratin extracts.
Extract Concentration of Protein 
(mg/ml)
9.5M urea direct extract 0.655
2M urea sequential extract 0.501
4M urea sequential extract 0.431
6M urea sequential extract 0.980
9.5M urea sequential extract 0.745
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Keratin Extracts
9.5M
Figure 2.2. Protein concentration of keratin extracts
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2.4.4.2 Detection of Keratin Proteins Extracted from different Urea
Solutions using One-Dimensional SDS-PAGE and Immunoblot
Analysis
200kDa
116.25kD
97.4k Da
66.2kDa
45 kDa
67kDa
65k Da
56kDa
50 kDa
1 Molecular weight markers
2 Keratin standard (Sigma)
3 Direct keratin extract using 9.5M urea solution
4 Sequential keratin extract using 2M urea solution
5 Sequential keratin extract using 4M urea solution
6 Sequential keratin extract using 6M urea solution
7 Sequential keratin extract using 9.5m urea solution
1 2 3 4 5 6 7
Figure 2.3. Direct and sequential keratin extracts from human plantar callus (method 1)
111 kDa
84 Oa
58! Da
45! Da
50kDa
26. 3kDa
s.58kDa-67kDa
67 kDa
65kDa
58 kDa
Figure 2.4. Western blot analysis 
using AE1 monoclonal anti-keratin 
antibody. *
Figure 2.5. Western blot analysis 
using AE3 monoclonal anti-keratin 
antibody. *
Figure 2.6. Western blot analysis 
using a polyclonal anti-keratin 
antibody. *
1 Keratin standard (Sigma)
2 Direct keratin extract using 9.5 M urea solution
3 Sequential keratin extract using 2 M urea solution
4 Sequential keratin extract using 4 M urea solution
5 Sequential keratin extract using 6 M urea solution
6 Sequential keratin extract using 9.5 M urea solution
The main bands are marked in, as the photographs do not show them clearly
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Coomassie Blue staining of the SDS-PAGE gels showed bands on the range of 
50-65 kDa (67, 65, 58, 56.5 and 50 kDa -  representing keratins K1, K2, K5, 
K10/11 and K14/15, respectively) in all 4 sequential extracts and the direct 
extract (Fig. 2.3). The 2 M urea extract contained relatively small amounts of 
numerous proteins, so that faint polypeptide bands were distributed over a 
molecular weight range of 50 -  70 kDa (Fig 2.3). In the 4 M urea extract the 
keratin bands were more pronounced. The majority of keratins were extracted by 
the 6 M urea solution, this was confirmed by the highest protein concentration 
measured by the Lowry protein assay (Table 2.2 & Fig.2.2). Although, one 
additional high molecular weight band (-85 kDa) was noticeable in the 6M 
extract, the keratin bands were dominant (Fig. 2.3-lane 6, Fig. 2.4-lane 5, Fig. 
2.5-lane 5). Higher molecular weight keratins are synthesised in progressively 
more differentiated cell layers, suggesting that the increase in molecular weight 
may be a signal for cell death, producing the stratum comeum I1771. The same 
reasoning can be applied to regions of diseased skin, for example in psoriasis the 
amount of keratin filament subunits of high molecular weight are substantially 
diminished in comparison to normal skin, with an increase in the amount of lower 
molecular weight subunitsI17il.
Keratins were identified by reacting the electroblots with monoclonal anti-keratin 
antibodies AE3 and AE1. AE3 antibodies bind to K1, K2 and K5 and AE1 
antibodies bind to keratins K10/ K11, K14 and K15 so that together the antibodies 
recognise all major epidermal proteins l1781. In the 9.5 M urea direct extract, AE1 
antibodies identify a light band at 50 kDa (K14 and K15) and the AE3 antibodies 
bond to K1, K2 and K5 (67, 65 and 58 kDa, respectively). Immunoblot analysis of 
the sequential extracts showed that all the major epidermal proteins were present 
in increasing amounts as the urea concentrations used for extraction increased 
(Fig. 2.4-2.6). The most prominent bands were noted from the 6 M urea extract.
The experiment was repeated twice using a range of concentrations of urea 
between 6 M and 9.5 M. The 7 M urea extracts had the same keratins as those 
found in the 6 M extracts but were of a higher concentration. The urea 
concentrations higher than 7M were less effective in extracting proteins.
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2.5 Method 2 -  Sequential Extraction of Keratins using different Extraction 
Buffers.
2.5.1 Introduction
This method involved sequential extraction of keratins using a Tris only buffer, a 
Tris and urea buffer, and a Tris, urea and reducing agent buffer. This experiment 
aims to confirm that reducing agents (G-mercaptoethanol) and denaturants 
(urea) work together to extract more keratin proteins from callus specimens, than 
denaturant on its own.
2.5.2 Reagents
Buffer 1 - Tris/HCI (20mM, pH 7.4), Buffer 2 - Tris/HCI (20mM, pH 7.4) 
containing urea (7M), Buffer 3-Tris/HCI (20mM) containing urea (7M) and 0- 
mercaptoethanol (0.1 M).
2.5.3 Method
The callus tissue (0.25 g) was minced using a scalpel to 1 to 2 mm3 pieces. The 
extraction procedure was carried out in 3 steps using the different buffers 
described. The callus was placed in a plastic vial, Buffer! (2 ml) was added and 
the mixture was homogenised (6000 rpm, 10 min) and incubated at room 
temperature for 16 h. The supernatant was decanted and stored at 4°C after 
centrifuging (13000 rpm, 15 min). The remaining callus sample was resuspended 
in Buffer 1 (2 ml) and homogenised (6000rpm, 10 min) and incubated at room 
temperature for another 16 h. The supernatant was decanted and stored at 4°C 
and the procedure was repeated for a third time. The extraction procedure was 
repeated using Buffer 2 (extracts collected every 16 h for 48 h) and again with 
Buffer 3 (extracts collected every 16 h for 88 h). The protein content of each 
extract was measured using the Lowry method of protein detection (Appendix I). 
All the extracts were examined by one-dimensional SDS-PAGE and immunoblot 
techniques.
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2.5.4 Results
2.5.4.1 Protein Concentration of each Extract
Tris buffer 
only
Tris & urea 
buffer
Tris, urea and IJ- 
mercaptoethanol buffer
Extract number
Figure 2.7. Graph illustrating the protein concentration of each extract
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2.5.4.2 Detection of Keratin Proteins from each Extract using One-
Dimensional SDS - PAGE and Immunoblot Analysis
63kDa
55k Da
10-44kDa«
1 Molecular weight marker
2 Keratin standard (SIGMA)
3 Tris/HCI buffer extract
4 Tris/HCI buffer extract
5 7M urea and Tris/HCI buffer extract
6 7M urea and Tris/HCI buffer extract
7 7M urea, Tris/HCI and p-mercaptoethanol buffer extract
8 7M urea, Tris/HCI and p-mercaptoethanol buffer extract
9 Keratin standard (SIGMA)
10 Molecular weight marker
1 2 3 4 5 6  7 8 9  10
Figure 2.8: Keratin extracts from human plantar callus (method 3)
Sigma
116kDa
84kDa
58 kDa
45k Da
26.6kDa
Figure 2.9: Western blot analysis using AE1, AE3 and Sigma anti-keratin antibodies.
1 Keratin standard [SIGMA]
2 Tris/HCI buffer extract
3 7M urea and Tris/HCI buffer extract
4 7M urea, Tris/HCI and p-mercaptoethanol buffer extract
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2.5.4.S Microscopic Examination of the Extracted Keratin Cells-The 
Effect of Reducing Agent on Human Stratum Comeum Cells
Photographs of the suspensions in 7 M urea and p-mercaptoethanol and urea 
alone were taken (Plate 2.1-2.3). The cells from the urea suspension alone were 
intact, whereas the cells from the reduced extract were macerated and appeared 
to have no cell structure.
Plate 2.1. Corneocytes extracted from human plantar callus using Tris/HCI buffer and 7 M urea 
only. Photograph taken from a light (phase) microscope. -----  Represents 25 pm
Plate 2.2 Corneocytes extracted from human plantar callus using Tris/HCI buffer and 7 M urea 
only. Photograph taken from a light (phase) microscope.
Plate 2.3 Corneocytes extracted from human plantar callus using Tris/HCI buffer, 7 M urea 
and p-mercaptoethanol. Photograph taken from a light (phase) microscope.
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2.5.5 Discussion
The identity of the patterns on the immunoblots showed that almost all keratins 
proteins were insoluble in Tris buffer (Fig. 2.8, lanes 2). The proteins from the 
other extracts were resolved into two major bands of molecular weight 55 and 63 
kDa. These proteins are in the same molecular weights as those described for 
the epidermal keratins in a number of mammalian species1781.
The SDS-PAGE gels (Fig. 2.8) showed the Tris buffer extract to have a number 
of non-keratin bands with a molecular weight range of 10 to 48kDa (presumably 
serum albumin). The urea extracts contained traces of keratins, as shown in the 
immunoblot (Fig. 2.9, lanes 3). The extracts containing urea and reducing agent 
contained all the epidermal keratins recognised by AE1 and AE3 antibodies (Fig. 
2.9, lanes 4). Other studies have produced similar gel patterns from samples 
taken from the SC on the forearm I78]. Sun and Green (1978) m  showed that Tris 
extracted cultured keratinocytes contained many water soluble proteins; but in 
contrast to the corresponding extract of SC, the urea fraction contained over 80% 
of the extracted keratins, the reducing agent being necessary for release a small 
proportion of the total protein. The reducing agent was essential for the extraction 
of significant amounts of protein, this is consistent with earlier observations [1731, 
and is supported by microscopic examination of the cells (Plates 2.1-2.3).
2.6 Method 3 -  Preparation of a Stable Aqueous Solution of Keratins using 
Denaturant (Urea), a Reducing Agent (6-mercaptoethanol) and 
Surfactant (SDS) as the Extraction Buffer
2.6.1 Introduction
The previous two methods confirm that for the successful extraction of epidermal 
keratins a combination of denaturant and reducing agent as the extraction buffer 
is needed. Yamauchi et al (1988)11791 recommended the addition of a surfactant 
(SDS) to prevent the reconstitution of keratin fibres post extraction. The following 
method was adapted from the Yamauchi method, using all three compounds for 
the direct extraction of keratins.
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2.6.2 Reagents
Urea (7M), Sodium dodecyl sulphate (SDS), p-mercaptoethanol, cellulose dialysis 
tubing (diameter 2.5cm diameter, molecular cut off of 8000-10.000D).
2.6.3 Method
A mixture of callus (0.25 g), urea (4.5 ml, 7 M), SDS (0.15 g) and p- 
mercaptoethanol the (0.375 ml) was placed in a sealed glass vial and dry heated 
for 12 h at 50°C°°. The mixture was filtered through a stainless steel mesh and the 
filtrate was dialyzed against degassed water until a clear, colourless solution 
remained in the dialysis tube. The aqueous solution was stored in a plastic vial at 
-70°C. The extract was analysed using one-dimensional SDS-PAGE and 
immunoblot techniques as described previously.
* As the keratin is not extracted in acidic pH (<5) and undergoes decomposition at alkaline pH, the aqueous phase was 
maintained at a neutral pH
2.6.4 Results
2.6.4.1 Detection of Keratin Proteins by One-Dimensional SDS-PAGE and
Immunoblot Analysis
200k Da
63kDa
15k Da
55 k Da
53kDa
40 k Da
Figure 2.10. Keratin extracts from human callus (method 2)
11l!kDa
84I Da
581 Da 5€kDa
45I Da
50 k Da
36.5k Da
26.6k Da
1 2 3
Figure 2.11. Western blot analysis using AE1, AE3 and Sigma keratin antibodies. 
(On separate blots -  brought together for comparison.)
1 Keratin extract immunoblot using AE1 primary antibody
2 Keratin extract immunoblot using AE3 primary antibody
3 Keratin extract immunoblot using Sigma primary antibody
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The protein bands were well defined, in comparison to the gels from previous 
experiments, where the bands appeared blurred. These streaks could have 
occurred as a result of the urea and SDS in the solution, causing the proteins to 
‘drag’ along the gel. Purification of the extracts using gel filtration made little 
difference to the clarity of the protein bands and had disadvantages, mainly that 
of dilution and loss of proteins during the procedure. It was therefore decided that 
desalting of the extracts would introduce too many errors. The prolonged, 
repeated dialysis of the extracts reduced the presence of contaminants.
The direct method of extraction using the key compounds-urea, SDS and G- 
mercaptoethanol produced solutions containing all the epidermal keratins 
recognised by monoclonal and polyclonal antibodies. The SDS-PAGE gels 
stained with Coomassie blue showed additional bands of molecular weight 40, 53 
and 63 kDa (Fig. 2.10). The 53 kDa protein, by virtue of its size, corresponds to 
glycated keratin I1761. However, it also corresponds to keratin K13, which is found 
in cultured keratinocytes but is a characteristic keratin of non-stratified epithelial 
cells.
This procedure was less time consuming than the first two methods and had the 
same outcomes with regards to specific keratin content. It was clear from the 
immunoblot analysis that the majority of the proteins in the solutions are keratins, 
with trace amounts of non-keratin proteins.
The reproducibility of the extraction procedure was confirmed by repeating the 
method on 14 randomly selected callus samples (Appendix IV). All the sample 
extracts showed the 2 main bands at molecular weights 55 and 63 kDa. The 
immunoblot analyses showed similar results to the immunoblots from section
2.6.4.1.
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2.7 Summary
It is evident from these results that the proteins of human plantar callus have 
varying degrees of solubility i.e. they are only partially soluble in the absence of 
reducing agents, even after excessive physical cell disruption, which suggests 
that a small proportion of the keratin chains are not cross-linked by disulphide 
bonds. However, for the successful extraction of all major epidermal keratins, 
cleavage of disulphide cross-links, by a reducing agent is needed.
The keratins are extracted via the following processes: 1) the microfibrilla of the 
cortical cells are loosened by the hydrogen bond breaking effect of urea and 
depolymerised by reduction (by p-mercaptoethanol) of the inter- and intra 
molecular S-S bonds (to -SH groups), and 2) the resulting reduced keratins are 
introduced into water forming large micelles with surfactant (SDS) molecules (Fig. 
2.12). Although no full explanation of the stability of the keratin solution can be 
given, it is speculated that the micelles are separated from each other by 
electrostatic repulsion, thereby retarding the aggregation of the protein molecules 
and oxidation of the nearby -SH groups, to form S-S bondsl172].
When observing the repeatability of the gel patterns between different individuals, 
although the same bands appeared on the gels, they differed in amounts from 
person to person (Appendix IV). However, duplicate samples from the same 
individual were identical. Baden et al (1978)11751 showed that in two individuals 
the electrophoretic pattern of keratin from normal epidermis was compared to that 
with seborrheic keratosis. Although the same major components were present 
there was a variation in the amounts. It is possible that the differences in the 
polypeptide composition of different body areas are responsible for the variations 
observed. Baden and associates were unable to test this further due to the lack 
of samples from different body areas from the same subject. Whether these 
differences in modalities actually reflect the changes in size as a result of some 
modification, such as the addition of carbohydrate component, has not been 
determined. Phosphorylation of the proteins is among the causes of the charged 
heterogeneity. Phosphorylation of keratinocytes in vitro can be readily achieved 
and analysed by using labeled 32P and 2-dimensional electrophoresis.
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Keratin polypeptide chain 1
Keratin polypeptide chain 2
ft - mercaptoethanol
  Intermolecular disulphide bonds
I Intramolecular disulphide bonds 
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Figure 2.12. Schematic diagram illustrating the actions of urea, SDS and ft-mercaptoethanol on
keratin proteins.
Urea
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Testing for glycation using a similar technique is less simple as all the sugars 
involved with glycation are organic themselves, therefore radioactive labeling 
would be an inappropriate technique.
Polyclonal probes on all the blots agreed with the monoclonal probes, suggesting 
the differences in keratin composition of the sequential extracts were not due to 
post-translational modifications. Therefore, it is unclear as to what causes the 
heterogeneity of keratin filaments.
The protein analyses of plantar callus samples revealed the presence of all the 
main keratins present in the living and comified layers of normal epidermis, with 
additional keratins unique to plantar specimens. As described in sections 1.8.3 & 
1.84, keratins K2, K9, K6, K16, K1 and K10 are the most prevalent keratins in 
palmar and plantar epidermis (Table 2.5). All the protein bands from the extracts 
in these experiments lie in the region of 40-70 kDa. Due to their close proximity, 
the resolution of the bands is not clear enough (e.g. K10 MW=56.5 and K6 
MW=56) to be able to identify lone keratins, but the presence of these keratins as 
a collective is clear. Future work would benefit from the isolation and 
quantification of specific keratins from plantar sites from different individuals, to 
assess whether these keratins are common in particular groups of people, for 
example diabetics or people who develop pathological callus. The keratins that 
would be of use to study are K1 and K10 (markers of keratinisation) and K6 and 
K16 (markers of proliferation in response to trauma), including analysis of their 
glycated states.
Despite attempts to alter the concentrations of protein solutions applied to the 
SDS-PAGE gels, the protein resolution was poor. Any concentration of solution 
below 50 pg produced poorly visible bands on the gels, which in turn did not 
transfer well onto the immunoblots. This problem of ‘smearing’ of the protein 
bands is a common problem, which has not yet been resolved by protein 
chemistsI611.
131
Table 2.5. Keratins common in plantar and palmar epidermis.
Keratin Type Observed molecular 
weight-kDa (SDS- 
PAGE human)
Distribution
K1 II 67 Co-expressed with 
K10 in the post­
mitotic differentiating 
cells of the epidermis
K10 I 56.5
K6 II 56 Occur in a number of 
complex epithelia, but 
there is as yet no 
obvious relationship 
between their 
expression and a 
particular program of 
terminal differentiation 
or epithelial function. 
Expression is strongly 
induced after acute 
challenge (e.g. injury), 
and in the context of 
diseases featuring 
aberrant epithelial 
differentiation.
K16 I 48 Co-expressed with 
keratin K6 in a 
number of complex 
epithelia. Expression 
is induced after acute 
injury.
K2 II 65 Expressed late in the 
differentiating 
process. It is not co­
expressed with a 
partner keratin
K9 I 64 Expressed in post­
mitotic differentiating 
layers of palmar and 
plantar epidermis. It is 
co-expressed with K1 
and is not present in 
normal interfollicular 
epidermis of trunk 
skin.
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All the keratins common to plantar epidermal tissues (K1, K10, K6, K16, K2, K9, 
molecular weight 48-64 kDa) were identified in the extracts generated from six 
diabetic and six non-diabetic plantar callus samples, and agreed with the work of 
other investigators I1801. The individual bands of protein varied in density of colour 
within each extract and between extracts. This would imply that the concentration 
of certain keratins differed. However, the extracts were comprised of different 
classes of keratins, which differ in sulphur content, and the Coomassie Blue stain 
is taken up by proteins high in sulphur content and less so in the low sulphur 
compounds I611. An improvement in the resolution of the keratin mixtures is only 
slightly achieved by running the protein mixture on a two-dimensional SDS-PAGE 
gel [611. Therefore, the calculations of the concentrations of keratins in the 
extracts, using SDS-PAGE gels, would have been unreliable, hence the use of 
the Lowry protein assay to quantify the concentration of the proteins in the 
extracts.
In addition to the keratin protein bands on the SDS-PAGE gels, there were two 
faint bands, in the 40 and 53 kDa regions that were not identified as being 
keratins by consequent immunoblot analysis. The 40 kDa protein occurred less 
frequently than the 53 kDa protein that was visible in all the samples and is a 
known glycated keratin l176]. The 40 kDa protein has been identified as a 
glycoprotein from human epidermis [671. Due to the unavoidable smearing of the 
protein bands of the gels, it could be possible that glycated proteins may be 
present amongst the identified keratin bands.
The collection of studies in this thesis concentrates on the extraction of plantar 
epidermal keratins as a group (using method 3), followed by the measurement of 
glycated adducts within this group. Chapter 9 describes the measurement of 
furosine, pentosidine and CML in the extracts of 103 diabetic and 87 non­
diabetic callus samples. The glycated protein content will be expressed in terms 
of AGE per mg of protein. The quantity of keratins will be measured by using the 
Lowry method of protein detection. The selective analysis of specific keratins is 
an area that should be addressed in the future.
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Chapter 3.0 Synthesis of AGE Standards -  Carboxymethyllysine (CML) and 
Pentosidine
3.1 Aims
• Synthesis of a high yield of pure CML and pentosidine.
There is currently no commercial source of CML and pentosidine.
3.2 Synthesis of CML
CML is an acid stable, colourless, non-UV active molecule (Fig. 3.1). Its 
formation requires oxidative conditions, and it can be formed from a broad range 
of reducing agents, including glucoseI18il.
In this chapter several different methods of CML synthesis are described. Each 
method produced different products. Only one produced pure CML of an 
adequate yield.
3.2.1 Method 1 -  The Synthesis of CML -  An Adaptation of the Snyder and 
Angelici (1973) Procedure11821
The procedure involves the reaction between iodoacetic acid and L-lysine (Fig.
3.2)
3.2.1.1 Reagents*
Iodoacetic acid (50 mM), L-lysine (50 mM), sodium hydroxide (5 M), HCI (6 M), 
ammonia (0.5 M), ethanol, Dowex 50W-X4 (100 -  200 mesh) cation exchange 
resin (NFL").
‘Unless otherwise indicated, reagents were the highest quality obtainable from Sigma or Aldrich 
Chemicals Co.
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Figure 3.1. Illustration of the glycation of proteins and the routes of formation of CML
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Figure 3.2. The reaction between iodoacetic and L-lysine.
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3.2.1.2 Method
Iodoacetic acid (50 mM) and L-lysine (50 mM) were separately adjusted to a pH 
of 11 with sodium hydroxide (NaOH). The iodoacetic acid was maintained at 0°C 
by placing the container in ice. The 2 solutions were stirred together at a 
temperature of 50°C and maintained at a pH of 11. After 90 min the pH remained 
at a steady pH of 11, without addition of NaOH, indicating that the reaction had 
ceased. At this point enough HCI (6M) was added to reduce the pH to 2. The 
solution was loaded onto a 2 x 80cm column of Dowex 50W-X4 (100-200 mesh) 
cation exchange resin in the H+ form and eluted with 160 ml water (one column 
volume) followed by ammonia (0.5 M).
The bulk of the CML was displaced from the column by ammonia. Fractions 
containing the CML had a pH between 2 and 4 (fractions 1-4). These were 
pooled and reduced in volume at 50°C under rotary evaporation until white 
crystals were visible. The addition of ethanol, equal to 3 times the solution 
volume, encouraged further precipitation. After filtering, the precipitate was 
washed with ethanol and dried under vacuum.
Characterisation of the products was accomplished by nuclear magnetic 
resonance (NMR) spectroscopy and gas chromatography/ mass spectroscopy 
(GC/MS).
3.2.1.3 Results
Approximately 2.5 mg of product was derivatised in preparation for GC/MS 
analysis (see Appendix V & VI for a full description of the derivatisation procedure 
and GC/MS conditions). CML was eluted at a retention time of ~35 min, along 
with several other peaks between 40 and 50min (Appendix VII, Fig. VII.ii) NMR 
spectroscopy confirmed the presence of CML with additional impurities, possibly 
CML salts (Appendix VII, Fig. Vll.i). Yield = 6.3 mg.
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The significant flaw in this method was the use of lysine without protection of the 
a-NH2 group, thus both the -NH2 groups were open to attack by acetic acid (Fig.
3.3). In theory, an alkaline pH during the reaction procedure makes the e-NH2 
more susceptible to the reaction with iodoacetic acid than the a-NH2. Therefore, 
the close monitoring of pH during the reaction is important. The presence of 
lysine and CML in the analytical spectra confirms that the reaction was not 
complete due to an insufficient amount of iodoacetic acid.
The next point of error was the inadequate separation of the mixture of lysine, 
CML and CML salts, using ion exchange chromatography (Fig. 3.4). Miyazawa 
(1980)11831 suggested ways of improving the separation by using water instead of 
ammonia as the eluent and passing the mixture through a shorter cation 
exchange column.
3.2.1.4 Conclusion
The experiment was repeated, bearing in mind the suggestions made by 
Miyizawa (1980) I183,f i.e. the reaction was allowed to continue until the mixture 
was positive to the ninhydrin test (confirming the completion of the reaction), 
followed by elution with water on a shorter cation-exchange column. With these 
corrections applied pure CML was still not harvested.
Although this method produced the desired product the difficulties in isolating 
pure CML were profound. The next attempt involved using lysine with a protected 
a-NH2 group as the starting material, with close monitoring of the pH of the 
reaction mixture. This attempt was a method proposed by Prof. Baynes, 
University of South Carolina.
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Figure 3.3. Schematic diagram illustrating the two possible points of acetylation of 
lysine by iodoacetic acid. This explains the relative speedy completion of the reaction, 
as 2 iodoacetic acid molecules are used for every one lysine molecule
NH4+-OOC C H  NH2
(CH2)4
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I
CH.
c o o n h 4+
Figure 3.4: Figure illustrating the suggested CML ammonium salt structure 
formed during cation exchange chromatography.
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3.2.2 Method 2 -  The Synthesis of CML -  Method provided Courtesy of 
Prof. Baynes (University of South Carolina, USA).
3.2.2.1 Reagents
Na-acetyl-lysine (75 mM), glyoxylic acid (75 mM), sodium cyanoborohydride 
(225mM), potassium phosphate buffer (0.2 M), sodium hydroxide (1 M), 
hydrochloric acid (1 M, 2 M and 6 M), Dowex-50 (NH+4 form).
3.2.2.2 Method
The reagents Na-acetyllysine, glyoxylic acid and sodium cyanoborohydride were 
mixed in a ratio of 1:1:3, respectively, in potassium phosphate buffer (0.2 M, pH
7.4), and incubated at room temperature for 24 hours in a screw cap glass vial 
(Fig. 3.5). The pH was checked at 1-2 hour intervals and re-adjusted to 7.4 with 
sodium hydroxide (1 M), as required. After 24 hours at room temperature, the 
solution was adjusted to pH 2 with HCI (6 M) in order to discharge the residual 
sodium cyanoborohydride. After the effervescence ceased (release of hydrogen 
gas), which took approximately 6 hours, the solution was dried by rotary 
evaporation. The resulting white, crystalline solid (labelled crude/protected CML) 
was dissolved in HCI (10 ml, 2 M) and heated for 2 hours at 50°C (to remove the 
acetyl group). Water (15 ml) was added to the mixture and lyophilised overnight 
to dryness.
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Figure 3.5. Illustration of the reaction between glyoxylic acid and Na-acetyllysine
producing CML
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The sample was dissolved in dH20  (50 ml) and the pH was adjusted to 7 using 
sodium hydroxide (1 M). The solution was applied to a 2 x 8 cm column of 
Dowex-50 in NH+4 form*. The CML eluted from the column in dH20  (1-2 column 
volumes). The eluent was lyophilised to dryness and the resulting white solid 
(labeled: pure CML) was analysed by NMR spectroscopy.
3.2.2.3 Results
The NMR spectra showed that most of the eCH2 (>80%) was still present in the 
non-carboxymethylated form (i.e. it is a doublet rather than a multiplet). The aCH 
move upfield due to the /V-acetyl group. No CML was present (Appendix VII, Fig. 
Vll.iii).
3.2.2.4 Conclusions
This experiment was repeated and produced the same results. Advice was 
sought from Prof. Thomalley and associates (Department of Biochemistry, 
University of Essex, UK) who suggested 3 adjustments to the existing method: 
(1) the use a-t-BOC-lysine as the starting amino acid, this is a better protecting 
group than the acetyl group; (2) reducing the molarity of the phosphate buffer 
from 1 M to 1 mM (this was discovered by one of the chemists at Essex 
University by chance) and (3) close monitoring of the pH of the reaction mixture 
at 7.4 through out the reaction, as changes in pH have a profound effect on the 
progression of the reaction.
Dowex-50 H* was cleaned by boOing for 30mins in 10 volumes of sodium hydroxide (1M), washed with dHzO, then 
deaned again by boiling for 30mins in 10 volumes of HCI (1M). The resin was washed with water unti near neutral and 
then placed in the column and washed wfch NaOH (1M) unti converted to N H \ form (pH of elution solution >10. The 
column was then washed with water until neutral and then used for the purification of CML.
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3.2.3 Method 3 -  The Synthesis of CML using a Method Recommended by 
Prof. Thomalley (Department of Biochemistry, University of Essex, 
UK).
3.2.3.1 Reagents
a-t-BOC-lysine, glyoxylic acid, sodium phosphate buffer, pH 7.4 (1 mM), sodium 
hydroxide (3 M), sodium cyanoborohydride (4 mM), hydrochloric acid (1 M and 
0.5M), trifluoracetic acid (TFA), methanol.
3.2.3.2 Method
Sodium phosphate buffer, pH 7.4 (1 mM, 40 ml), a-t-BOC-lysine (98.4 mg, 
0.4mmol) and glyoxylic acid monohydrate (148 mg, 2 mmol) were mixed together 
in a plastic vial and the pH adjusted to 7.4 with sodium hydroxide (5 M). Sodium 
cyanoborohydride (252 mg, 4 mmol) was added to the mixture and the pH of the 
solution was adjusted to 7.4 using hydrochloric acid (1 M). The reaction mixture 
was incubated at 37°C for 24 hours. During this time, the pH of the solution was 
monitored and maintained at 7.4 at the following incubation times: 15 min, 30 
min, 1 hour, 2 hours, 4 hours, 6 hours*.
After the 24 hours incubation period was complete the sample was placed in a 
round-bottomed flask and lyophilised over night, resulting in a dry, white, solid. 
The solid was reconstituted in 0.1% TFA in water (2 ml). The pH of the solution 
was immediately adjusted to pH 2 using HCI (1 M) whilst continuously stirring 
(monitoring every half hour). The solution was spin filtered using 0.2 pm cellulose 
acetate, microspin filter tubes (Alltech) for 5 min at 4000 rpm. The crude CML 
was then ready for preparative HPLC (Column:25 x 10mm Waters RCM, 
detection wavelength: 230 nm, mobile phase flow rate: 9.9 ml/min, mobile phase: 
0.1% TFA(aq)).
•
It was noted that the pH of the solution was high in the first hour of the reaction and by the 4 to 6 hours incubation time, 
the pH had stabilized to 7.4. Therefore, it is recommended to monitor the pH of the mixture over the first 2 hours of the 
reaction.
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A solution of a-t-BOC-lysine (5 m/gml) was injected into the system (RT: 10 min). 
The crude CML (0.5 ml) was injected into the system and one single broad peak 
was detected, spanning a retention time of approximately 9 to 11 mins. The 
remainder of the solution was injected into the system and the relevant fractions 
collected pooled together and lyophilised over night. A portion of the dried, white 
solid was submitted for NMR spectroscopy confirming the solid to be pure 
protected CML (Appendix VII, Fig. VII.iva).
The CML was deprotected by dissolving the crude CML in 0.5M HCI (0.1ml used 
for every 10mg of sample) and incubating overnight at room temperature. The 
sample was lyophilised and NMR, carbon and mass spectroscopy achieved 
confirmation of successful deprotection (Appendix VII, Fig. Vll.ivb-Vll.vi).
The NMR spectrum Vll.ivb shows 1:1 ratios of the p, y, 5, e, where p, y and 5 are 
1.4, 1.2 and 0.9 ppm. The CH2CO2 of the carboxymethyl group is at 2.5ppm in 
this spectrum. The loss of the tBOC signals are shown in Vll.ivb.
The pure CML was stored at -20°C. The total yield of pure CML was 39.3mg.
3.2.2.3 Conclusions
This method produced a pure batch of CML of a substantial yield and confirmed 
that the BOC protected lysine was more desirable than the acetyl protected 
lysine. The pure CML was used as the external standard for the identification of 
CML in human plantar callus (Chapter 5).
3.3 Synthesis of Pentosidine
Pentosidine is an acid stable, highly fluorescent AGE and cross-link, derived 
from one molecule of arginine, one of lysine and a pentose sugar (e.g. ribose) 
bridged in to an imidozo-pyridinium structure (Fig 3.6). Dyer et al (1991) 11101
144
have also described its formation from glucose, by a slower rate and probably 
through oxidation of glucose to arabinose. Since its formation from either glucose 
or ribose requires oxidation, pentosidine is both an AGE and a glycoxidation 
product11111.
It is present in small amounts in many long-lived human tissues, including skin 
collagen no8;iio;i84] ancj js a biological marker of protein glycoxidation. Due to its 
biochemical structure, pentosidine cannot be derivatised in preparation for 
GC/MS analysis. Detection and quantification is achieved by acid hydrolysis 
followed by fluorescent HPLC detection (Chapter 4).
Lysine -
HN
Arginine *
Figure 3.6. Structure of Pentosidine
3.3.1 Reagents
Sodium phosphate buffer (0.2 M, pH 9), sodium hydroxide (5 M), Na-acetyl-L- 
lysine, Na-acetyl-L-arginine, D-ribose, hydrochloric acid (6 M, 12 M), ninhydrin, 
Dowex AG5050W-X8 (200-400 mesh, H+ form).
3.3.2 Method
Na-acetyl-L-arginine (3.243 g, 15 mmol) and Na-acetyl-L-arginine (941 mg, 5 
mmol) were dissolved in 100 ml 0.2 M phosphate buffer, pH=9. The solution was 
heated in a water bath at 65°C for 48 hours under continuous stirring. During
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incubation, 10 portions (75 mg each) of D-ribose were periodically added to the 
reaction mixture (Fig. 3.7). After each addition of ribose, the pH was adjusted to 9 
using NaOH. The mixture was hydrolysed in four vacuum-sealed glass vials 
using HCI (30 ml, 12 M) at 110°C for 2 hours. The resulting solution was reduced 
under low pressure at 60°C and the dried brown residue was dissolved in dH20  
(20 ml) and applied to a chromatography column (16x120 mm), filled with cation 
exchange resin (Dowex 50W-X8) H+ form (flow rate: 1 ml/min, wavelength: 
254nm). The column was eluted with water (-250 ml) followed by HCI (400 ml,
2.6 M). Pentosidine was eluted with HCI (150 ml, 6 M) at a flow rate of 1 ml/min 
and fractions (10 ml) were collected and tested for the ninhydrin reaction. 
Ninhydrin positive fractions (5-16) were pooled and dried under reduced pressure 
at 60°C. The sample was then dissolved in dH20  (4 ml) and filtered through a 
syringe filter (0.2 pm). Of this solution, 200 pi portions were injected into the 
same preparative HPLC system as that used for the CML preparation in section
3.2.3.2. Pentosidine was eluted (RT: 4 min at wavelength 230 nm) from aqueous 
acetic acid (50 mM).
3.3.3 Results and Conclusions
Fractions were pooled together, lyophilized to dryness and pure pentosidine was 
identified by NMR spectroscopy (Appendix VII, Fig. Vll.v). The total yield of pure 
pentosidine was 22.5mg.
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4.0 CHAPTER 4 - Quantification of Furosine and Pentosidine in Human 
Plantar Callus using HPLC.
4.1 Introduction -  Measurement of Glucose, Early Glycation Adducts and 
AGEs
To date the measurement of AGEs has been confined to investigative 
laboratories. Currently there is no universally established method of detection of 
AGEs, units of measurement, nor any commercially available assay kits. This 
makes it hard to evaluate and compare results from different studies. Currently, 
the most common forms of detection of AGEs are HPLC, GC-MS, enzyme-linked 
immunosorbent assay (ELISA)11851 immunohistochemistry.
There are no reports to date on the correlation between the degree of glycation of 
plantar epidermal keratins and pedal skin complications in diabetes. Glucose in 
the epidermal cells, intercellular spaces, microcirculation of the skin, passive 
diffusion rate of the glucose and carbohydrate metabolism all contribute to the 
overall epidermal glucose concentration in diabetesI162].
With the discovery of glycation in foods I1861, and later in human tissues, the 
proteins that were extensively investigated were from blood plasmaI18?l, urine11881, 
skin collagen 11891 and dialysate proteins I190]. Studies on skin collagen directed 
further investigations into glycation of keratins in epidermis, nails and hair.
The most frequently used techniques for the determination of NEG of proteins in 
the 1980s were colorimetric methods, primarily the TBA assay 11211 . The 
technique was also used to measure the glycation of hair and epidermal 
keratins1161:163:1641. The key problem with this procedure was the high non-specific 
background absorbance, leading to a loss of sensitivity *1681. The use of the TBA 
reaction for the measurement of glycated haemoglobin and glycated serum 
proteins has largely been replaced by newer, more specific techniques tailored to 
the particular analyte and to the needs of the clinical laboratory. Keratinised 
tissues were investigated by adapting these methods, principally the detection of 
furosine i162;191if but no attempts to detect AGEs in these tissues were made.
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4.1.1 Reaction with TBA
The TBA method is one of the oldest chemical assays for glycated proteins [192]. It 
is a colorimetric procedure based on the formation of a chromogen upon the 
reaction between TBA and HMF. HMF is generated from the dehydration of 
hexose sugars by boiling in oxalic acidI1931.
The technique remains useful for the estimation of glycation of proteins [194]. Its 
advantages include simplicity, lack of the need for sophisticated equipment, and 
absence of interference by Schiff base intermediates. Its disadvantages include a 
low sensitivity due to a low yield of HMF and susceptibility of interference by free 
glucose, other sugars and glycoproteins I195]. Some of these problems can be 
partially avoided by modifications of the technique [1611, but avoidance of 
interference by glycoproteins cannot be completely achieved, making the TBA 
method more suitable for relative and not absolute measurements of glycated 
proteins. In this regard the method has been used successfully to demonstrate 
increased glycation of collagen11561 and keratin [1661.
4.1.2 Borohydride Reduction
Sodium borohydride or sodium cyanoborohydride will reduce the aldimine and 
ketoamine products of NEG, converting them to aminohexitols. The 
aminohexitols can then be identified with amino acid analysis[195]. Reduction with 
tritiated borohydride is often used to enhance sensitivity when the amounts of 
protein available for analysis are small. Simultaneous reduction of peptide bonds 
can limit specificity, but separation and identification of the tritiated aminohexitols 
by amino acid analysis or by affinity chromatography of the labeled borohydride- 
reduced peptides helps address this problem.
4.1.3 Amino Acid Analysis
Glycated amino acid derivatives in acid hydrolysates of proteins can be detected 
and measured by HPLC and modifications of conventional amino acid analysis. 
Since acid hydrolysis of the ketoamine produces some racemization at the
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second carbon atom, mannitol as well as glucitol derivatives are formed. Partial 
degradation further complicate identification of different amino acid derivatives.
4.1.4 Furosine Detection
Fructoseamine (1 amino-1-deoxyfructose) is the stable ketoamine derivative 
formed after the condensation of glucose with protein. Since non-enzymatic 
glycation largely involves s-amino groups of lysine, e-D-fructose-lysine is the 
principle fructoseamine formed. Acid hydrolysis of this compound leads to the 
formation furosine I168]. Furosine can be separated on HPLC and quantified by 
reference to furosine standard, allowing the development of a sensitive and 
specific method for the quantitative determination of the overall level of non- 
enzymatic glycation in proteins l168]. The method has been successfully applied 
for specific measurement of glycation of serum and tissue proteins, in which the 
only source of furosine is the glycated amino groups of lysine residuesI195J.
The disadvantages of the HPLC assay, with regards to routine clinical studies, 
are: the long assay time due to the use of the gradient elution; the high acidity of 
the sample which can damage the chromatographic injector and column and the 
use of very expensive furosine dedicated chromatographic columns I1871. The 
studies in this thesis succeed in adapting the protocols so as to overcome these 
hindrances.
Other analytical methods used for furosine quantification, in different biological 
samples, include ion-exchange chromatography with amino acid analysis and 
post-column ninhydrin derivatisation 1891 and gas-liquid chromatography[118]. The 
sensitivity, accuracy and precision of these methods differ and they are often time 
consuming, expensive and not sufficiently free of interference.
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4.1.5 HPLC Methods of Detection and Quantification of Furosine and 
Pentosidine
In order to be able to assay for glycation adducts, the polypeptide chain of the 
protein being analysed is split into smaller peptide subunits. Hydrolysis is 
successfully conducted by acid (HCI) or peptidases (Fig. 4.1). The peptidases are 
residue specific and will only hydrolyse peptide bonds where those residues 
occur. Therefore, by using specific proteolytic enzymes, predetermined fragments 
can be formed prior to analysis, specificity being the advantage of this method. 
Add hydrolysis is a well used method of analysis, resulting in the complete 
breakdown of the peptide chain into its constituent amino add residues. This 
method is widely used when preparing a protein for HPLC detection of furosine in 
human serum and keratin containing tissues i162;168:168:191!
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COOH
Complete hydrolysis 
(chemical) ,
Treated with 6N HCI for 24hrs under 
vacuum
Partial hydrolysis 
(enzymic)
Hydrolysis with residue specific
endopeptidase
All the amino acids in the chain can now be 
assayed for furosine but their sequence in the 
original chain cannot be identified
Figure 4.1. Schematic representation of the use of hydrolytic procedures in preparation for 
furosine HPLC analysis. The presence of a free amino group " ,  with which a reagent can react, 
enables the amino acid to be identified.
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4.1.5.2 HPLC Analysis of Acid Hydrolysates for Furosine
After the acid hydrolysis of the test protein has been carried out, a portion of the 
sample is dissolved in an appropriate buffer and injected into an HPLC system. 
Different laboratories have used different HPLC set-ups that have suited them 
and have provided an adequate resolution of the furosine peak (Table 4.1).
Table 4.1. Description of the variations of HPLC protocol for the identification and quantification of 
furosine.
Column
type
Column 
size [mm]
Particle 
size [pm]
Mobile 
phase 1
Mobile 
phase 2
Retention 
time for 
Furosine 
[min]
Reference
C i e 4x200 10 H 3 P O 4
(7mM)
H 3 P O 4
(5.6mM)
3 [195]6]
C8 4.6x200 unknown Acetic acid 
(0.4%
Acetic acid 
(0.4%) & 
KCI (0.27%)
28 [190; 196]7]
C -I8 4.6x200 unknown Sodium
acetate
(0.4%)
Acetonitrile
(6%)
13 [187]8]
C -I8 4x300 5 H3 PO4
(7mM)
Not used 4.6 [58]0]
C i 8 4.6x150 5 NaH3 P04
(50mM)
Not used 3.79 [162; 191 ]2]
Furosine was detected at absorption 280nm and the flow rate was 1ml/min.
The details in blue font indicate the protocols used for measuring furosine in keratinised tissues.
4.1.5.2 HPLC Analysis of Acid Hydrolysates for Pentosidine
Pentosidine has excitation-emission maxima at 335/385nm and is assayed by 
HPLC. Acid hydrolysates of human tissues have a pentosidine concentration 
ranging from 30-250 pmol/mg protein have been found in dura mater, skin, and 
glomerular basement membranes f108;197i.
Initial attempts to quantitate pentosidine in blood and other proteins have 
highlighted interference by fluorescent artifacts, generate during acid hydrolysis. 
This lead to a detailed study that achieved an accurate chromatographic method 
for quantification of low levels of pentosidine in blood and tissue proteins [198]. 
Pentosidine was determined by applying acid-hydrolysed samples (under hypoxic 
conditions) to HPLC. Borohydride reduction before acid hydrolysis had no
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significant effect on the accumulation of artifacts. Separations were made with a 
25x0.46cm 018 column (10um) column with a linear gradient program of 10- 
17% acetonitrile from 0 to 35min containing water and 0.1% heptafluorobutyric 
acid (HFBA). The eluent was monitored by fluorescent detection at an excitation- 
emission wavelength of 335/385nm (attenuation: 4, gain:x100). A similar method 
was used in this thesis.
According to Baynes and associates (Department of Chemistry and Biochemistry, 
University of South Carolina), reduction of the sample before acid hydrolysis 
prevents interference from products of decomposition, Amadori products and 
reactive AGEs on proteins. This step together with hydrolysis under nitrogen 
generally reduces the complexity of the chromatograms.
4.1.6 Summary
This chapter reports the development of an HPLC protocol for reliable furosine 
and pentosidine determination in human plantar epidermal tissues. The method 
for furosine detection involved the integration and adaptation of several methods 
previously developed to quantitate furosine in both food products and human 
tissues. The pentosidine assay also deviated slightly from the conventional 
protocol. Both methods were suited to the tissue being analysed and the 
laboratory set-up. The experiments concentrated on the reproducibility of the 
methods and compared the results from callus tissues and keratin extracts. It 
also challenged the method of acid hydrolysis of the proteins, suggesting that the 
glycation adducts may be lost during the process. An enzymatic hydrolysis 
method was tested to see whether there was less destruction of furosine and 
pentosidine in comparison to acid hydrolysis.
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4.2 Development of a Furosine and Pentosidine HPLC Assay for Human 
Plantar Keratin Proteins
4.2.1 Aims
• Measurement of inter- and intra-assay variation of furosine and 
pentosidine standards including day-to-day variance, recovery, stability 
and precision.
• To test that hydrolysis of tissues under hypoxic conditions is optimal for 
quantification.
• A comparison of furosine and pentosidine content from acid hydrolysed 
plantar callus tissue and keratin extracts.
• A comparison of furosine and pentosidine content from enzyme 
hydrolysed plantar callus tissue and keratin extracts.
• To determine the optimal hydrolysis time for keratins.
• To determine the recovery, stability and precision of the chosen method of 
analysis.
4.2.2 Sample Collection and Subject Details
Specimens of callus were obtained from a random sample of 6 diabetics 
attending the London Foot Hospital. The same number of control patients was 
taken as a random sample from the non-diabetic subjects attending the London 
Foot Hospital for chiropody treatment. These subjects did not suffer from any 
saccharide metabolism disorder. Each group comprised of males and females 
aged between 30 and 80yr. Both groups were age matched (Table 4.2). The 
callus specimens were taken from the plantar metatarsal area using a scalpel. 
Areas involved with sepsis and specimens contaminated with blood were 
avoided. Each specimen was stored at -70°C®.
Furosine assay by HPLC as been used to demonstrate an increase in glycated lysine over time with storage of serum 
samples at -20*C, perhaps due to the ongoing reaction between glucose and lysine e-amino groups in the frozen serum. 
Storage at -70°C eliminates this problem (Cohen 1996).
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Table 4.2. Details of the subjects used for the study
Identification 
of Normal 
Subjects
Age of 
Normal 
Subjects 
[years]
Identification 
of Diabetic 
Subjects
Type of 
Diabetes
Type of 
Therapy
Number of 
Years of 
Diagnosis
1 N 6 5 1 D II Insulin 3 0
2 N 5 5 2 D II Insulin 9
3 N 6 0 3  D o o II Insulin 1 0
4 N 5 5 4 D II Oral 1 3
5 N 7 8 5 D II Insulin 2 6
6 N 3 7 6 D  * II Insulin 3 2
oo Plantar callus was taken from the periphery of a long standing neuropathic ulcer. 
* Poorly controlled diabetes with continuous ulceration 
All subjects were male.
4.2.3 Inter- and Intra-Assay Variance of Furosine and Pentosidine Standard 
Measurement
4.2.3.1 Reagents
Furosine standard (Neosystem, Groupe SNPE, Strasbourg), pentosidine 
(synthesised in Chapter 3), trifluoracetic acid (TFA), HPLC grade water.
4.2.3.2 HPLC conditions
Table 4.3. HPLC conditions for furosine detection.
Mobile Phase 
Gradient
Time [min] %A %B
0 100 0
10 75 25
15 75 25
20 100 0
35 100 0
Automated injector system (Waters 712 WISP), pump system (Varian), UV monitor (Waters 486), 
software (Prostar, Varian), column (Hypersil C18 100mx4.6mm, particle size 7fj.m), mobile phase A (0.1% 
TFA in HPLC grade water), mobile phase B (0.1% TFA in HPLC grade acetonitrile), flow rate 1ml/min and 
absorbance 280nm.
Table 4.4. HPLC conditions for pentosidine detection.
Mobile Phase 
Gradient
Time [min] %A %B
0 100 0
5 90 10
10 90 10
15 100 0
25 100 0
Automated injector system (Waters 712 WISP), pump system (Varian), UV monitor (Waters 486), 
software (Prostar, Varian), column (Hypersil, BDS C18 250mmx4.6mm, particle size 5nm), mobile phase 
A (0.1% TFA in HPLC grade water), mobile phase B (0.1% TFA in HPLC grade acetonitrile), flow rate 
1ml/min, excitation wavelength: 335nm, emission wavelength: 385nm.
4.2.3.3 Methods
Each standard was dissolved in 0.1% TFA (aq) and a set of serial dilutions made 
up (furosine: 15.6, 7.8, 3.9 and 1.95 pg/ml; pentosidine: 200, 100, 50, 25 and
12.5 ng/ml) and stored at -80°C. These ranges were chosen as the furosine and 
pentosidine content in the test samples fell within these concentrations and lower 
concentrations produced poor chromatograms. To minimise variability in the 
results, through solvent evaporation, the vials were sealed before being placed in 
the HPLC machine.
4.2.3.4 Results
4.2.3.4.1 External Standard Curves
There was a linear relationship between standard peak area and varying 
concentrations of each standard (Fig. 4.2-4.5). Injections of all the dilutions of 
standard were carried out three times and on two different days to monitor inter- 
assay and day-to-day repeatability, respectively (Table 4.5).
Table 4.5. Day-to-day and interassay repeatability of HPLC standard injections (raw data in 
Appendix VIII, .Tables Vlll.i-Vlll.iv).
Furosine Pentosidine
Interassay RT [min] Mean 8.13 -8 .37 10.25-10.44
Standard deviation 0 .03 -0 .09 0.008-0.03
Standard error 0 .002-0 .04 0 .005-0.02
Day-to-day Mean 8 .19 -8 .35 10.28-10.39
repeatability RT [min] Standard deviation 0 .02 -0 .06 0.01 -0 .0 5
Standard error 0 .01 -0 .13 0.01 -0 .0 3
Peak area CV 
[counts]
<10 <10
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Standard curve of furosine analysed by HPLC. b. Chromatograms of furosine peaks (retention times 8.18.4 min) 
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Figure 4.4. Day one
a. Standard curve of pentosidine analysed by HPLC. Absorption peaks at ex: 335nm em: 385 nm
b. Chromatograms of pentosidine standard peaks (retention tknes 10.3-10.44min)
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Figure 4.5. Day two
a. Standard curve of pentosidine analysed by HPLC. Absorption peaks at ex: 335nm em: 385 nm
b. Chromatograms of pentosidine standard peaks (retention times 10.3-10.44min)
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4.2.4 Freeze-Thaw Study of Furosine and Pentosidine Standards
4.2.3.3 Aims
• To assess whether repeated freezing and thawing of standard solutions 
changes the quality of the chromatograms.
4.2.3.4 Methods
Aliquots (0.5 ml) of furosine and pentosidine standards (15.6 pg/ml and 200ng/ml, 
respectively) were respectively placed in plastic vials and thawed and refrozen for 
up to six cycles. The experiments were repeated twice and the mean peak area 
(counts x 103) was plotted against freeze-thaw cycle number (Figs. 4.6 & 4.7)
4.2.3.5 Results
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F re e ze -T h a w  Cycle
There was a decrease in peak area after the first 
freeze thaw cycle, from 191.7x103 to 
182.2x103counts. The area of this peak lies 
outside the 95% confidence limit interval of the 
mean (mean: 195.02x103, upper limit:
201.11x103, lower limit: 188.93x103). Raw data 
in Appendix VIII, Table VIII.v
Figure 4.6. The effect of successive freeze-thaw cycles on levels 
of furosine standard (0.0156 mg/ml)
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Freeze-Thaw Cycle
There was a decrease in peak area after the 
third freeze thaw cycle, from 80.0 x 103 to 66.1 x 
103 counts which continues to decrease in 
subsequent freeze/thaw cycles. The area of this 
peak lies within the 95% confidence limit interval 
of the mean (mean: 73.406, upper limit:
91.191x103, lower limit: 54.082x103). Raw Data 
in Appendix VIII Table VIII.vi
Figure 4.7. The effect of successive freeze-thaw cycles on levels 
of pentosidine standard (200 ng/ml)
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A similar observation was made when hydrolysates were freeze-thawed and 
assayed for furosine and pentosidine. Therefore, the repeated freeze-thawing of 
the standards was avoided when measuring of glycation adducts in tissue 
samples in future experiments (Chapter 9).
4.2.4 Acid Hydrolysis of Human Plantar Callus Samples under Hypoxic and 
Non-Hypoxic Conditions
4.2.4.1 Aims
• To assess the effects of oxygen, nitrogen and air during hydrolysis on the 
measurement of furosine and pentosidine in callus samples.
4.2.4.2 Reagents
Hydrochloric acid (6 M), trifluoracetic acid (TFA), ethanol, acetonitrile (HPLC 
grade)
4.2.4.3 Methods
Callus tissue (5 mg) was washed with absolute ethanol followed by water, 3 
times, cut into small pieces using a blade and placed in a glass vial. An aliquot of 
HCI (0.2 ml, 6 M) was added to the sample, flushed with nitrogen gas and sealed 
with a Teflon lined cap. The sample was heated for 18 h at 110°C, shaking 
occasionally to allow dispersion on the callus tissue in the solution. This was 
carried out on all the callus samples (1-6 diabetics and controls). The procedure 
was then repeated with oxygen and air in place of nitrogen to see if there is a 
difference in the amount of furosine and pentosidine measured. The hydrolysates 
were lyophilised over night to dryness and redissolved in TFA (200 pi, 0.1% 
aqueous). The solutions were filtered, if necessary, using a syringe filter (0.2 pm 
Millipore). The protein content of each hydrolysate was measured using the 
Lowry method of protein detection (Appendix I) and all samples were 
subsequently adjusted to a 1 mg/ml solution in preparation for HPLC analysis.
160
4.2.4.4 Results
There was a higher yield of furosine and pentosidine from samples hydrolised in 
the presence of nitrogen (Fig. 4.8 & 4.11). Therefore, all future hydrolysis 
procedures were carried out under hypoxic conditions. While there was no 
significant difference in furosine content between the diabetic and non-diabetic 
groups (Fig 4.9) there were greater inter-individual differences in furosine levels 
in diabetic callus compared to non-diabetic controls (diabetic mean furosine:
354.5 ± 268.6 ng/mg protein; non-diabetic mean furosine:224.6±75.3 ng/mg 
protein). However, in the case of pentosidine content (Fig. 4.12), the opposite 
was the case (diabetic mean pentosidine:153.9±106.6 ng/mg protein; non­
diabetic mean pentosidine: 325.5±172.8 ng/mg protein). The diabetic subjects, 
2D (55 yr) and 6D (37 yr), showed high levels of furosine in comparison to their 
matched controls (Fig. 4.10). The diabetic subject 6D, had relatively high levels of 
furosine, although, he was the youngest of the group (37 yr). Both of these 
subjects were the only patients with plantar ulcers (see Appendix VIII Tables 
Vlll.vii. & Vlll.viii).
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Figure 4.8. Box plot comparing the amount of furosine in 
diabetic and non-diabetic callus samples hydrolysed in the 
presence of nitrogen, oxygen and air.
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Figure 4.11. Box plot comparing the amount of pentosidine in 
diabetic and non-diabetic callus samples hydrolysed in the 
presence of nitrogen, oxygen and air.
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Figure 4.12. Data from diabetic and non-diabetic callus 
samples hydrolysed under hypoxic conditions
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4.2.5 Acid Hydrolysis of Human Plantar Epidermal Keratin Extracts
4.2.5.1 Aims
• To measure the furosine and pentosidine content in plantar keratin.
• To compare the amount of glycation adducts measured from callus and 
keratin hydrolysates.
4.2.5.2 Reagents
Hydrochloric acid (6 M), trifluoracetic acid (TFA), acetontrile (HPLC grade), 
keratin extracts from Chapter 2
4.2.5.3 Methods
Keratin extracts were lyophilised to dryness and approximately 0.2 mg was 
hydrolysed in HCI (200 pi, 6 M) as described in the previous section, under 
nitrogen gas. The hydrolysates were dissolved in 0.1% TFA (aq) and adjusted to 
a 1 mg/ml protein concentration in preparation for HPLC analysis.
4.2.5.4 Results
There was a higher yield of furosine from the keratin extracts, than that of callus 
tissue (Fig. 4.13) and a lower yield of pentosidine from extracts than callus (Fig.
4.14). As with the callus hydrolysates, there is no significant difference in furosine 
content between diabetic and non-diabetic keratin hydrolysates -  p=0.368 (Fig.
4.15). The pentosidine concentration was greater in diabetic keratin extracts than 
controls -  p=0.048 (Fig. 4.16). There were greater inter-individual differences in 
the amount of furosine measured from diabetic samples (diabetic mean furosine:
151.3 ± 354.1 ng/mg protein; non-diabetic mean furosine: 146.9 ± 300.8 ng/mg 
protein; diabetic mean pentosidine: 42. 3± 53.6 ng/mg protein; non-diabetic mean 
pentosidine: 10.7 ± 6.8 ng/mg protein).
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Figure 4.13. Graph illustrating the difference in furosine 
content between callus and keratin extracts hydrolysed in acid
Figure 4.14. Graph illustrating the difference in pentosidine 
content between callus and keratin extracts hydrolysed in acid
Diabetic keratin Normal keratin
Diabetic keratin exlracts Normal keratin exfacts
Figure 4.15. Graph illustrating the difference in furosine 
content between diabetic and normal keratin extracts
Figure 4.16. Graph illustrating the difference in 
pentosidine content between diabetic and normal keratin 
extracts
The results show that the nature of the tissue used for acid hydrolysis is relevant 
when measuring furosine and pentosidine. There is a significantly higher amount 
of furosine measured from keratin extracts than that of corresponding callus 
samples. A possible explanation for this is the keratin extraction procedure 
produces free polypeptide chains that are readily hydrolysed by acid, and in 
callus tissue the keratin filaments are tightly bound together by disulphide bonds, 
which are not adequately hydrolysed by HCI, and hence limiting the amount of
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free furosine and pentosidine in the hydrolysate. Alternatively, the glycation 
adducts could be destroyed during acid hydrolysis.
All the chromatograms of the callus hydrolysates show the presence of tyrosine 
in abundance, which suggests that there is a degree of successful hydrolysis of 
the protein chains. However, is possible that the acid may disrupt the glycated 
side chains of the amino acids. This may be the case for both the callus tissue 
samples and the keratin extracts. In view of this, the next investigation involved 
the hydrolysis of callus and keratin extracts using enzymes to see if a higher 
amount of furosine and pentosidine could be measured.
4.2.6 Enzyme Hydrolysis of Human Plantar Callus Samplesp
4.2.6.1 Aims
• To investigate if there is a difference between acid and enzyme hydrolysis 
on the amount of furosine and pentosidine measured.
4.2.7.2 Reagents
Pepsin, pronase E, aminopeptidase, hydrochloric acid, potassium phosphate (0.5 
M), potassium hydroxide
Samples
Callus samples (1 mg), keratin extracts (100 pg)
4.2.7.3 Methods
To each sample (callus 5 mg, keratin 200 pg) dH20  (25 pi), HCI (25 pi, 4 mM) 
and pepsin solution (5 pg/ml, 2 mg/ml in 20 mM HCI) were added and incubated 
at 37°C for 24 h. The samples were neutralised to 7.4 pH by adding potassium
p Dr N Ahmed. Department of Biochemistry, Essex University, has developed the protocol for enzymolysis. The procedure 
is unpublished. Dr Ahmed has kindly given permission for this method to be tested in this study.
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phosphate buffer (25 pi, 0.5 M, pH 7.4) and potassium hydroxide (5 pi, 260 mM). 
Pronase E (5 pi, 2 mg/ml in 10 mM potassium phosphate, pH 7.4) was added to 
each sample and incubated at 37°C for 24 h. Aminopeptidase solution (5 pi, 2 
mg/ml in 10 mM potassium phosphate, pH 7.4) was added and the samples were 
incubated for a further 48 h at 37°C. The hydrolysis was carried out under 
nitrogen gas. The resulting hydrolysates were centrifuged, before use to afford a 
clear solution. The samples were adjusted to 1 mg/ml protein concentrations.
4.2.7.4 Results
The acid hydrolysis of keratins produced the highest yield of furosine and 
pentosidine in comparison to enzyme hydrolysates of both callus and keratin 
extracts (Fig. 4.17 & 4.18). Therefore, the acid hydrolysis of keratin extracts was 
the standard procedure used in the future. The next stage involved refining the 
method for accuracy and efficiency.
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Figure 4.17. Graph comparing the furosine content of acid and 
enzyme hydrolysates.
Enzyme Hydrolysis Acid Hydrolysis
Figure 4.18. Graph comparing results from acid and enzyme 
hydrolysis of keratin extracts 166
4.2.8 Time Course Acid Hydrolysis of Callus and Keratin Extracts
4.2.8.3 Aims
• To find the optimal hydrolysis conditions for keratin extracts.
4.2.8.2 Methods
Keratin extracts were hydrolysed for different time periods (2, 4, 6, 18, 24 and 30 
h) and assayed for furosine and pentosidine content. The experiments were 
carried out in triplicate and the mean concentrations plotted in the graphs below.
4.2.8.3 Results
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Figure 4.19. Keratin extracts hydrolysed for different periods 
of time and assayed for furosine (see Appendix VIII Fig. Vlll.xi 
for data)
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Figure 4.20. Keratin extracts hydrolysed for different periods of 
time and assayed for pentosidine (see Appendix VIII Table Vlll.xi 
for data)
The optimum hydrolysis times for furosine and pentosidine assays were 6 and 
18h, respectively (Figs. 4.19 & 4.20). These conditions differ from those of 
optimal furosine detection in other tissues, such as urine, where the hydrolysis 
time is 24 h [188).
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4.2.9 Recovery, Stability and Precision of Assays using Acid Hydrolysates 
of Keratin Extracts
4.2.9.1 Methods
Threes keratin extracts were selected at random for the measurement of furosine 
and pentosidine recovery. Known amounts of standard were added (1, 0.1, 0.01 
and 0.001 mg/ml) to the keratin (0.2 mg) before acid hydroiysis and assayed for 
furosine and pentosidine. At the same time, furosine and pentosidine standards 
were hydrolysed without test samples and assayed. The experiments were 
carried out in triplicate and the mean percentage recovery of the glycation 
adducts were calculated.
The hydrolysates were stored at -70°C and a random selection of the samples 
assayed every month to assess for any deterioration in furosine and pentosidine 
content. The within run precision and day-to-day precision was assessed on all 
sample hydrolysates.
4.2.9.2 Results
4.2.9.2.1 Recovery
Table 4.6. Recovery of furosine from keratin extract hydrolysed in acid for 6h 
(data in Appendix VIII, Table VIII.xii).
Samples Mean % Recovery of 
Furosine
minus furosine
1 mg/ml furosine 79.97
0.1 mg/ml furosine 77.36
0.01 mg/ml furosine 76.60
0.001 mg/ml furosine 75.00
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Table 4.7. Recover of pentosidine from keratin extracts hydrolysed in acid for 18h 
(data in Appendix VIII, Table VIII.xiii).
Samples Mean % Recovery of
Pentosidine
minus pentosidine
1 mg/ml pentosidine 69.97
0.1 mg/ml pentosidine 57.36
0.01 mg/ml pentosidine 56.60
0.001 mg/ml pentosidine 45.00
4.2.9.2.2 Stability
All hydrolysates were stored at -70°C and showed no change in furosine and 
pentosidine content for up to three months. After a period of six months the 
samples had deteriorated.
4.2.9.2.3 Precision
The precision of furosine and pentosidine determination was carried out on all 
keratin hydrolysates. The within run precision and day-to-day repeatability of the 
measurement of furosine and pentosidine concentration was adequate (CV<10).
4.2.9.3 Discussion
This section was successful in completing the assay design for furosine and 
pentosidine detection. The results allowed the confident measurement of the 
glycation adducts in the 12 samples collected for this section and for the callus 
samples in the larger sample groups in Chapter 9.
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4.2.10 Acid Hydrolysis of Keratin Extracts
4.2.10.1 Aims
• Acid hydrolysis of keratin extracts 6 and 18 h and assayed furosine and 
pentosidine, respectively.
4.2.10.2 Methods
The keratin extracts (0.2 mg) from all the callus samples were hydrolysed in HCI 
(200 pi, 6 M), for 6 and 18 h. Evaporation and reconstitution in buffer was the 
same as described in previous methods. The protein concentrations of the 
hydrolysates were standardised to 1 mg/ml before injection into the HPLC 
systems.
4.2.10.3 Results
The concentration of furosine and pentosidine measured from the diabetic 
samples covered a wider range than non-diabetic samples (Table 4.7, Figs. 4.21 
& 4.22). A difference in the distribution of the glycation adducts between groups 
was suggested. This was tested further in Chapter 9, where more samples were 
assayed for furosine and pentosidine (103 diabetics and 87 non-diabetics) and 
statistically analysed.
Table 4.8. Comparison of furosine and pentosidine concentrations between diabetic and non-diabetic 
subjects (data in Appendix Vlll.xiv & VIII.xv).
Furosine Pentosidine
Diabetic Keratin Non-diabetic 
n = 6 Keratin
Diabetic Keratin Non-diabetic 
n = 6 Keratin
Concentration 1.69-240
n = 6
1.46-15.29 40.46-210.63
n = 6
2.56-156.10
range (Mg/mg
protein
Mean 48.4 5.2 104.7 39.6
±SD 94.3 5.8 75.9 60.7
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Diabetic Keratin Normal Keratin
Figure 4.21. Graph comparing the furosine content from 
diabetic and non-diabetic keratin extracts hydrolysed for 
6h in acid.
Diabetic Keratin Normal Keratin
Figure 4.22: Graph comparing the pentosidine content 
from diabetic and non-diabetic keratin extracts 
hydrolysed for 18h in acid.
4.3 Discussion
This chapter illustrated the problems associated with the accurate quantification 
of furosine, in particular, in callus tissue. Due to the biochemical nature of callus, 
it is probable that the keratin extraction procedure frees the polypeptide chains 
from their hydrogen and disulphide bonds, thus leaving the proteins exposed for 
hydrolysis. The next step involved the collection of more callus tissue samples 
from diabetics and non-diabetics to see if there is an association between 
increased glycation and diabetes (Chapter 9).
4.4 Measurement of Glycohaemoglobin (HbA1c) and Glycated Serum 
Proteins in the Blood of Non-Diabetic Subjects
4.4.1 Aims
• Record HbA1c levels from blood samples taken from volunteers.
• To measure glycated adducts in the serum of blood samples taken from 
volunteers.
• To compare the results with the glycation adducts measured in keratin 
proteins.
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4.4.2 Introduction
Recent advances in biochemical research have strengthened the argument in 
favour of “tight” control of diabetes as a means of preventing the long-term 
complications of the disease. The evidence in favour of this hypothesis is quite 
compelling, and it is reasonable to recommend good long-term control of 
diabetes to patients in an attempt to prevent the late complications I199]. Good 
long-term monitoring cannot be easily achieved without frequent home self­
monitoring of either blood or urine glucose. Home self-monitoring of blood 
glucose has become possible over the past 15 years and has made a major 
impact on the, management of diabetes.
Neuropathy and vascular disease, both likely contributory factors in the 
development of foot lesions, are two of the late complications of diabetes. An 
overall glycaemic control since diagnosis may be more relevant to the 
development of foot pathologies than recording the degree of current glycaemic 
controlI2001. There are also some theoretical reasons to recommend good blood 
glucose control in the presence of an acute foot lesion. Inadequate control 
probably interferes with white-cell function, which is important in combating 
infection. Also, wound healing might be impaired in the setting of very poor 
diabetes control, pertiaps because of the glycation of structural proteins.
4.4.2.1 The Chemistry of Glycohaemoglobin
In 1966 Holmquist and Schroeder 12011 demonstrated the presence of an N- 
terminal blocking group involving a Schiff base in haemoglobin Aic. By the 1970s 
it was confirmed that this blocking group was glucose, which is added non- 
enzymatically and then undergoes an Amadori rearrangement to form a stable 
ketoamine linkage to the valine residue. The aldimine intermediate is often 
referred to as labile HbAic and the rate of its reaction to the ketoamine is some 60 
times slower than the reverse reaction to glucose and haemoglobin. It is an 
indicator of glycaemia from the preceding 6-12 weeks, in comparison to 
advanced glycation, which reflects a process that can occur over a longer period 
of time. Haemoglobin glycated at other positions on the polypeptide subunit is
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referred to as non-Aic glycohaemoglobin or glycated haemoglobin. In the case of 
non-Aic haemoglobin the glucose is linked to an e-amino group or lysine 
residues in the a or p chains. The Aic and the non-Aic configurations together 
constitute the total glycohaemoglobin and their formation is increased in diabetic 
patients with ambient hyperglycaemia. The normal range of HbAic is 4%-6% of 
total haemoglobin.
Many methods are available to measure glycohaemoglobin species. In general 
these fall into two categories; tests such as ion exchange chromatography and 
electrophoresis, that rely on charge differences to separate the glucose-modified 
from the unmodified haemoglobin; and tests such as affinity chromatography, 
immunoassay and colorimetric procedures that exploit the presence of 
carbohydrate to distinguish glycohaemoglobin from non-glycated haemoglobin 
species. Each different test has its advantages and disadvantages and the costs 
are different per test. There is a reasonable correlation of values between 
methods but each laboratory should establish and stipulate the non-diabetic 
reference range for the method it has selected. It is worth noting that when the 
glycohaemoglobin is high, a change of 1% may reflect greater changes in 
glycaemia (in mg/dL) than it does in the lower ranges of glycohaemoglobin 
values.
Ion exchange chromatography is the most commonly employed method for the 
measurement of HbAic. This method relies on the change in charge of the 
haemoglobin molecules conferred by N-terminal modification with glucose. 
Haemoglobins glycated at the amino terminus of the p-chains elute from the 
cation-exchange resin ahead of the main HbAo peak, and are named according to 
the elution order as HbAia, HbAib and HbAic. Haemoglobin glycated at other sites 
than the p-chain amino terminus elute in the leading edge of the main HbAo 
peak. This portion may represent some 50% of the total glycated haemoglobin 
and may be measured by glycation specific methods such as the TBA method, or 
by boronate affinity chromatography.
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4.4.2.2 The Chemistry and Measurement of Non-Enzymatically 
Glycated Serum Proteins
Albumin and other serum proteins may be non-enzymatically glycated in vitro and 
in vivo. Chromatographic and colormetric measurement of these non- 
enzymatically glycated proteins shows that levels are approximately two to three 
times higher in diabetic than non-diabetic subjects. Because serum and plasma 
proteins have shorter half-lives than haemoglobin, glycated proteins are altered 
more rapidly than glycated haemoglobin in response to prolonged decreases or 
increases in blood glucose levels.
There are several techniques for demonstrating the presence and extent of 
glycation of serum proteins. Serum albumin can be separated 
chromatographically into glycated and non-glycated fractions, by application onto 
a carboxymethylcellulose column and elution with sodium acetate. The main 
drawback of this procedure is that it is laborious and time-consuming, involving 
chromatography on several columns and using multiple buffers. This inevitably 
limits its clinical application.
An alternative approach is to measure directly the amount of adducted glucose. 
This is achieved by the weak acid hydrolysis of the haemoglobin resulting in the 
release of HMF, which can be quantitated by a colour reaction with TBA. A 
similar technique has been applied to albumin, resulting in a strongly positive test 
with the glycated and not the non-glycated albumin. This method has a strong 
correlation with the chromatographic technique. The necessity to purify and then 
concentrate albumin also makes this technique laborious for routine clinic work.
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4.4.3 Method for the Measurement of HbA1c and Glycated Plasma Proteins 
used in this Study
4.4.3.1 Low Pressure Cation Exchange Chromatography for the 
Measurement of HbA1c
The Hb-GOLD analyser and associated reagent kit (Drew Scientific Ltd, Cumdria, 
UK) is an automated instrument intended for in vitro estimation of human 
glycated haemoglobin fractions. The reagent kit is capable of a range of assays 
including routine measurement of HbA1c in whole blood in the care of diabetes.
The Hb-GOLD analyser uses low pressure cation exchange chromatography in 
conjunction with gradient elution to separate human haemoglobin subtypes and 
variants from haemolysed blood. The separated haemoglobin fractions are 
monitored by means of absorption of light at 415nm. The chromatogram obtained 
is recorded and a software program performs the analysis of the chromatogram 
and generates a results report. This method of HbA1c measurement was used 
for this study. Samples were sent to the haematology department at the 
Whittington Hospital for analysis (Table 4.8).
Table 4.9. Ranges used for HbA1c levels using the Hb-GOLD analyser
Haematology Normal Ranges
Non Diabetic 3.6 -6 .0
Diabetic Well controlled <7.0
Average Control 7.0-10.0
Poor Control >10.0
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4.4.3.2 The Measurement of Glycated Serum Proteins using HPLC
4.4.3.2.1 Extraction of Plasma Proteins
Venous blood (5 ml) was collected in heparinised tubes and immediately 
centrifuged for 10 min at +4°C and 3000 rpm to allow for the serum to separate. 
Unless immediately analysed, the serum samples were stored at -70°C. An 
aliquot of serum (0.25 ml) was placed in a vial in ice. Trichloracetic acid (2.25 ml, 
6%w/v), that had been allowed to cool in ice for 15mins, was added to the sample 
and allowed to sit in the ice for 5min. A light yellow precipitate was formed as the 
trichloracetic acid was added. The mixture was centrifuged for 15min at +4°C and 
3000rpm, allowing the protein pellet to settle at the bottom of the vial.
4.4.3.2.2 Acid Hydrolysis of Plasma Proteins
The protein pellet was placed in a glass vial and HCI (200 pi, 6 M) was added. 
The vials were flushed with nitrogen gas for 5 min and sealed with Teflon® lined 
lids. The sample was then heated at 110°C for 24 h. Once the hydrolysis was 
complete dH20 (4 ml) was added to the sample, mixed thoroughly and passed 
through a syringe filter (0.2 pm, Millipore). The sample was lyophilised over night 
and then reconstituted in 0.1% TFA (aq) to a concentration of 1 mg/ml protein 
content in preparation for injection into the HPLC system for the detection of 
furosine and pentosidine. The HPLC conditions were the same as those used for 
the detection of furosine and pentosidine in keratin extract hydrolysates in section 
4.2.3.2.
4.5 Statistical Analysis of Data Collected from Non-Diabetic Keratin 
Extracts and Serum Proteins
This section concentrates on the data collected from the non-diabetic group. A 
full explanation of the recruitment of patients is described in detail in Chapter 9, 
along with the comparison of data between the diabetic and non-diabetic groups.
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4.5.1 Distribution of the Ages
Table 4.10. Information regarding non-diabetic subjects.
Total
Number
Mean Age 
[yrs]
Number 
of Males
Mean Age 
of Males 
[yrs]
Age 
Range 
of Males 
[yrs]
Number
of
Females
Mean Age 
of Females 
[yrs]
Age 
Range of 
Females 
[yrs]
87 57.0±10.9 38 55.6 ±6.8 4 3 -69 49 58.1 ± 13.1 35-81
Fig. 4.23 illustrates the distribution of the age data. A histogram and Q-Q plot of 
the different ages confirms a normal distribution. The distributions of the furosine 
and pentosidine data collected from keratin extracts and serum of non-diabetic 
individuals were all skewed, therefore non-parametric statistical tests were used 
(see Appendix IX for distribution plots).
3 5 .0  4 0 .0  4 5 .0  5 0 .0  5 5 .0  6 0  0  6 5 .0  7 0 .0  7 5 .0  8 0  0
Normal Q -Q Plot
V
>CO
Zs
Age [yrs] Observed Value
Figure 4.23. Histogram and Q-Q plot illustrating the distribution of ages in a group of 87 non­
diabetic subjects
4.5.2 Data Analysis
Samples of callus and venous blood were collected at the same time from all the 
volunteers so that a comparison of the furosine and the pentosidine content from 
both types of proteins could be made. As the process of glycation, and the 
accumulation of AGEs increases with age in many human tissues, a comparison 
of the quantities of glycated keratin adducts with age was conducted.
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Age group <65 years n=67
Median: 495.5 ng/mg of protein.
Interquartile range: 1114.6 ng/mg of protein. 
Minimum: 0. ng/mg of protein 
Maximum: 6331.6 ng/mg of protein
Age group >65 years n=20
Median: 376.1 ng/mg of protein.
Interquartile range: 660.2 ng/mg of protein. 
Minimum: 0.0 ng/mg of protein 
Maximum: 4443.0 ng/mg of protein
Mann-Whitney Test
p = 0 .8 8 8
« Q5 jes»
Figure 4.24. The relationship between age and furosine measured in plantar keratin extracts.
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Age group <65 years n=67
Median: 8.8 ng/mg of protein.
Interquartile range: 45.9 ng/mg of protein. 
Minimum: 0.0 ng/mg of protein 
Maximum: 485.4 ng/mg of protein
Age group >65 years n=20
Median: 20.5 ng/mg of protein. 
Interquartile range: 76.7 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 324.4 ng/mg of protein
Mann-Whitney Test
p=0.416
Figure 4.25. The relationship between age and pentosidine measured in plantar keratin extracts.
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Furosine in Keratin Extracts
Median: 471.1 ng/mg of protein 
Interquartile range: 903.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 6331.6 ng/mg of protein
Furosine in Blood Serum
Median: 122.7 ng/mg of protein 
Interquartile range: 110.2 ng/mg of protein 
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Figure 4.26. The relationship between the concentration of furosine in keratin extracts and serum 
proteins.
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Concentration of pentosidine in blood serum [ng/mg of protein]
Spearman’s Correlation
r=0.136
Pentosidine in Keratin Extracts
Median: 10.5 ng/mg of protein 
Interquartile range: 54.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 485.4 ng/mg of protein
Pentosidine in Blood Serum
Median: 25.6 ng/mg of protein 
Interquartile range: 134.5 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 1569.4 ng/mg of protein
Mann-Whitney Test
p = 0 . 4 3 7
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Figure 4.27. The relationship between the concentration of pentosidine in keratin extracts and serum 
proteins.
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Furosine in Keratin Extracts
Median: 471.2 ng/mg of protein 
Interquartile range: 903.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 6331.6 ng/mg of protein
Pensosidine in Keratin Extracts
Median: 10.6 ng/mg of protein 
Interquartile range: 54.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 485.4 ng/mg of protein
Mann-Whitney Test
p=0.001
Figure 4.28. The relationship between the concentration of furosine and pentosidine in keratin extracts.
4.5.4 Discussion
The first point of discussion is the measurement of the amount of glycation 
adducts present in the plantar callus protein extracts. The HPLC methods of 
detection of both furosine and pentosidine in this study have been specific, 
sensitive and reproducible. Several research groups i162;163;191i have 
demonstrated the HPLC quantitative analysis furosine in plantar callus tissue. In 
these studies the quantity of furosine was expressed as a percentage of the 
tyrosine present in the acid hydrolysates, therefore a comparison between this 
data and previous studies was not possible. The measurement of pentosidine 
had to be in the same units as the furosine, but tyrosine was not visible on the 
fluorescence chromatograms of the pentosidine assays. Therefore, the
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concentrations of the glycation adducts were expressed as ng/mg of protein, 
using external standard curves. As the assays were carried out over a prolonged 
period of time, quality control measures were put into place to ensure that the 
standard curves did not deviate from assay to assay. The assays for furosine and 
pentosidine in these series of experiments were accurate and reproducible.
The second point was the relationship between furosine and pentosidine in the 
keratin extracts, and the age of the subjects. There was no correlation between 
furosine (r=0.21) and pentosidine (r=0.04) in keratin and the ages of the subjects. 
Although the median and range of furosine and pentosidine concentrations was 
higher in the older age group than that of the younger group, the difference 
between the groups was not statistically significant (furosine: p=0.888, n=87, 
pentosidine: p=0.416, n=87).
The relationship between the glycation adducts in keratin and in the blood serum 
from the same subjects was tested. There was no correlation between furosine 
and pentosidine in keratin extracts and furosine and pentosidine measured in 
blood serum (furosine: r=0.084, pentosidine r=0.136). There is a wider 
interquartile range of concentration readings for furosine in keratin extracts (903.1 
ng/mg of protein) than the concentration found in the blood serum samples 
(110.2 ng/mg of protein). The opposite was the case for the pentosidine in keratin 
(54.1 ng/mg of protein) and in the blood serum (134.5 ng/mg of protein).
There was no correlation between the HbA1c levels and furosine (r=0.145) and 
pentosidine (r=-0.105) in the keratin extracts.
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5.0 Chapter 5 - The Detection of CML using GC-MS.
5.1 Methods of Measuring CML
The two main methods of detection of CML (UV inactive) are GC-MS i117:118:188i 
and HPLC, after derivatisation with o-phthaldialdehyde (OPA) p021. These 
methods have their advantages, but GC-MS is the most common technique used 
for CML detection
5.1.1 Carboxymethyllysine Assay by HPLC with Post-Column Detection
Post-column detection of CML using OPA involves a sequential dual column 
system or a single column systeml1961. Samples are injected into a C-18 reverse- 
phase column and the fractions containing CML are collected, dried and 
reinjected into a different C-18 column for clear CML detection. Although the 
method is very sensitive, it is time consuming and the high sensitivity of the 
procedure makes it prone to interference by contaminants.
5.1.2 GC-MS Assay for the Detection of CML
Gas chromatography-mass spectroscopy is a technique often used for the 
detection of CML and furosine in protein hydrolysates. It comprises of two 
techniques: gas chromatography (used to separate the components of a mixture 
of compounds) and mass spectroscopy (used to characterise each individual 
component). The principle of GC-MS is based on the production and analysis of 
ions formed from neutral compounds, a process known as fragmentation. The 
resulting spectra present the masses of each ion in the form of a mass: charge 
ratio (m/z), therefore giving information about the mass of the ion, although not its 
exact structure. The advantage of the MS system is that only a trace amount (a 
few nanograms) of test sample is required for successful identification, however, 
the sample is not recoverable.
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In order for a compound to be suitable for GC-MS analysis it must be volatile to 
allow for breakdown and rearrangement in the gaseous state. Proteins and 
peptides need to be reacted with compounds that render them more volatile prior 
to GC-MS analysis. In the case of CML, this process of derivatisation 
conventionally involves acylation at the unprotected N-terminus and esterification 
of the carboxylic acid functional groups (Fig. 5.1).
CF
Acylation
Esterification CF.CH.
m/z=424
Figure 5.1: The chemical structure of CML after esterification by methanolic 
acid and acylation by trifluoracetic acid (TFAA)
5.1.3 Summary
Before the test samples of plantar epidermal keratins were analysed for CML 
content, a series of experiments were carried out to test the GC-MS method of 
analysis for efficiency using a pure synthetic CML standard. The suitability of the 
derivatisation procedure was also tested, with regards to the acylation procedure 
and the use of a suitable injection solvent was also investigated.
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5.2 Carboxymethyllysine as a GC-MS Analyte
5.2.1 Aims
• To validate the sample derivatisation procedure prior to GC-MS.
• To detect CML from acid and enzyme hydrolysates using GC-MS.
• To quantify the presence of CML in plantar epidermal keratins.
5.2.2 Reagents
Methanolic acid (0.5 M), dichloromethane, TFAA, methanol, lysine, CML 
(synthesised in Chapter 3).
5.2.3 Experiment 1 -  GC-MS Spectrum of Pure CML
5.2.3.1 Aims
• To produce a mass spectrum of pure synthetic CML that compares to spectra 
in previous literature.
5.2.3.2 Methods
Pure CML (1 mg) was placed in a glass vial and methanolic acid (0.5 ml, 0.5 M) 
was added and heated for 1 h at 70°C. The acid was removed by rotary 
evaporation and dichloromethane (0.5 ml) was added and mixed. Trifluoracetic 
anhydride (1 ml) was added to the solution and mixed and the reaction mixture 
was allowed to stand at room temperature for 1 h. All solvent was removed under 
rotary evaporation, until the sample was dry. The samples were dissolved in 100 
pi of dichloromethane, mixed thoroughly and 1 pi of the solution was injected into 
the GC-MS system (see Appendix VI for the GC-MS equipment conditions). 
Different concentrations of the derivatised CML were injected into the system, 
until a clear, peak was achieved.
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S.2.3.3 Results
The chromatogram for pure CML had one major peak at the retention time of -34 
min (Fig. 5.2). The mass spectrum of this peak (Fig. 5.3) compares well to the 
spectra seen in previous literature in this field (Fig 5.4). The ion m/z 392 
confirmed the detection of CML. This m/z value was chosen because it provides 
good reproducibility and sensitivity11171, although the molecular ion for CML is m/z 
424 (Fig. 5.1).
There were two additional small peaks noted at the paling end of the main CML 
peak (Fig. 5.2). These peaks suggest that a small portion of the CML has a 
slightly different stereochemistry. In view of these results, the CML spectrum was 
compared with a spectrum of lysine in the next experiment.
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Figure 5.2. Chromatogram of synthesised CML
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Figure 5.3. Mass spectrum at 34 min of synthesised CML
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Figure 5.4. Mass spectrum of synthesised CML taken from reference [203]
5.2.4 Experiment 2 -  A Comparison of Lysine and Synthetic CML Mass 
Spectra
5.2.4.1 Aims
• To assess whether there are fragments that are common to both lysine and 
CML.
• To differentiate between lysine and CML spectra.
5.2.4.2 Methods
The amino acid lysine and pure CML were derivatised according to the protocol 
described in section 5.2.3.2 and injected into the mass spectrometer.
5.2.4.3 Results
The ion m/z 320 is used to identify lysine I11?l. There are fragments that are 
common to both lysine and CML spectra: m/z 126, 180, 251, and 293 (Figs. 5.6- 
5.8). These fragments are common to lysine and lysine based compounds. The 
chromatogram of lysine had a major peak at 22 min with 2 minor peaks at the 
paling end of the peak (Fig. 5.5). This was similar to the CML chromatogram, 
suggesting that the stereochemical changes observed in CML originates from 
lysine at an early stage of synthesis, and probably not as a result of deterioration 
of CML with time. This concept was tested in the next experiment.
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Figure 5.5. Chromatogram of lysine
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Figure 5.6: Mass spectrum of lysine at 22 min
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5.2.4.4 Fragmentation Patterns of CML and Lysine
The fragments used to identify CML and lysine are illustrated in Figs. 5.7 and 5.8, 
respectively.
c — CH NH
CH,
I
N  C ^
%
\ CF,
I \ FCH, 3
m/z=424
\ CH,
-CH3OH m/z=22
Q  C =  C NH C
CF,
tCH,)4
N  C
\
CH, CFs
m/z=292
\
CH,
Figure 5.7. Main fragments of CML
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Figure 5.8. Main fragments of lysine
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5.2.5 Experiment 3 -  The Stability of Synthetic CML
5.2.5.1 Aims
• To assess whether CML deteriorates with time.
« To assess whether CML deteriorates during the acid hydrolysis procedure
5.2.5.2 Methods
A sample of CML was derivatised according to the protocol described in section
5.2.3.2 and injected into the GC-MS system. The sample was stored in methanol 
at +4°C and after a period of 2 months was rederivatised and injected into the 
system. The mass spectrum was compared to that of the fresh CML sample.
A known amount of CML (40 pg) was added to a known amount of keratin extract 
(1 mg). Another vial containing pure CML alone (40 pg) was prepared. Both 
mixtures were then hydrolysed in HCI (200 pi, 6M) under nitrogen for 18 h at 
110°C and the resulting hydrolysates were lyophilised to dryness. The 
hydrolysates were derivatised and injected into the system according to the 
protocol.
5.2.5.3 Results
The chromatograms of fresh CML and 2 month old CML were identical.
The chromatograms of CML alone and CML plus keratin were also identical. This 
confirms that CML is relatively stable with time and is not damaged during acid 
hydrolysis.
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5.2.6 Experiment 4 -  Testing the Efficiency of Acylation as part of the 
Derivatisation Procedure
5.2.6.1 Aims
• To identify the optimal incubation time for the acylation procedure using 
TFAA.
5.2.6.2 Methods
Three aliquots of keratin hydrolysate (0.3 mg) were incubated with TFAA for 20, 
40 and 60 min, respectively. The remainder of the derivatisation procedure was 
carried out as previously described and injected into the GC-MS system. CML 
was isolated from the spectra and the abundance of the key fragments were 
compared.
5.2.6.3 Results
The abundance of the CML fragments increased as the incubation time increased 
(Fig. 5.9). The 60 min incubation time for the acylation procedure produced 
chromatograms with the greatest abundance of CML fragments. This agrees with 
the incubation times used by Dunn et a /(1989)I1171.
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Figure 5.9. The abundance of CML fragments following different incubation times with TFAA
5.2.7 Experiment 5 -  Testing the Suitability of the Solvent used for 
Injection into the GC-MS System
5.2.7.1 Aims
• To compare the effect of two different injection solvents on the quality of the 
mass spectra of CML.
5.2.7.2 Methods
Two separate samples of CML were derivatised according to the existing 
protocol. One sample was dissolved in dichloromethane and another in a mixture 
of methanol and dichloromethane (ratio-1:2) prior to injection into the system.
5.2.7.3 Results
The two spectra were different from each other (Figs. 5.10-5.11). The peak 
obtained from the dichloromethane injection solvent was a sharp, well-resolved
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peak (RT=33.7 min), akin to spectra observed in the previous experiments. The 
mixture of methanol and dichloromethane produced a poor CML peak, with an 
additional peak at 43.1 min. The peak was considerably smaller, than that 
produced when dichloromethane alone was used, suggesting poor delivery of the 
test compound and possible destruction of CML. The peak is relatively broad, 
with the methanol solvent, indicating that methanol is a slower carrier of CML 
than dichloromethane. It is clear from looking at the quality of the 
chromatograms, that dichloromethane was a suitable delivery solvent for the 
analysis of CML.
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Figure 5.10. Chromatogram of CML injected with dichloromethane
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Figure 5.11: Chromatogram of CML injected with dichloromethane: methanol (2:1)
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5.3 Detection of CML in Human Plantar Epidermal Keratin Hydrolysates
5.3.1 Aims
• To detect the presence of CML in diabetic and non-diabetic plantar epidermal 
keratin samples.
• To investigate whether the conditions of hydrolysis influence the detection of 
CML within keratin samples.
5.3.2 The Detection of CML in Acid Hydrolysates of Callus and Keratin 
Extracts
5.3.2.1 Aims
• To assess if there is a difference in the detection of CML between callus 
tissue and keratin extracts.
5.3.2.2 Methods
A set of 6 diabetic and 6 non-diabetic callus and keratin extracts was selected 
randomly from 100 samples. Equal amounts of the samples (callus-5 mg, keratin- 
0.2 mg) were hydrolysed in acid as described in Chapter 4. Hydrolysis was 
carried out in the presence of sodium borohydride solution, to prevent the 
formation of artifactual CML, and derivatised according to the protocol, prior to 
injection into the GC-MS system. An aliquot of pure CML standard was also 
injected into the system to obtain a reference retention time for CML. The 
investigator was not told what the samples were to prevent any bias.
5.3.2.3 Results
The retention time for the standard CML was approximately 32 min. All the 
samples showed no trace of CML. The same results were also produced when 
the samples were hydrolysed without borohydride reduction.
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These results suggest that the GC-MS method is not sensitive enough to detect 
small amounts of CML in the samples. They also suggest the possibility that acid 
hydrolysis may destroy any CML present in the samples. However, the acid 
hydrolysis of the synthetic CML does not have a destructive effect. Therefore, the 
next step involved the analysis of enzyme hydrolysates.
5.3.3 The Detection of CML in Enzyme Hydroiysates of Extracted Keratins
5.3.3.1 Aims
• To detect the presence of CML in diabetic and non-diabetic keratin 
samples hydrolysed by enzymes.
5.3.3.2 Methods
Two samples of callus and two of keratin extracts were hydrolysed using 
enzymes, according to the methods described in Chapter 4 and injected into the 
GC-MS system. The investigator did not know what the samples were until after 
all the spectra were collected.
5.3.3.3 Results
All four hydroiysates showed traces of CML, but the chromatograms presented 
with poor peaks, making quantification difficult (Figs. 5.12-5.15). Although the 
peaks were not quantifiable, the method could be used for a qualitative 
investigation of the samples. As the presence of the AGE, CML has never been 
detected in plantar keratin tissues, it was pertinent to test this. Therefore, 12 
keratin samples (6 diabetic and 6 non-diabetic) were hydrolysed using the same 
procedure and given to another investigator to carry out the GC-MS procedure. 
CML was not detected in all the samples, even though two of the samples were 
used earlier on by the first investigator, where CML was detected.
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Figure 5.12. a. Chromatogram of an enzyme hydrolysate of non-diabetic callus sample,
b. Mass spectrum of CML peak at -33 min
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Figure 5.13: a. Chromatogram of an enzyme hydrolysate of non-diabetic keratin extract,
b. Mass spectrum of CML peak at -34 min
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Figure 5.14. a. Chromatogram of an enzyme hydrolysate of a diabetic callus sample,
b. Mass spectrum of CML peak at -32 min
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Figure 5.15: a. Chromatogram of an enzyme hydrolysate of a diabetic keratin extract,
b. Mass spectrum of CML peak at ~32min
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After prolonged close monitoring of both the investigator conducting the 
derivatisation and injection procedures, an error could not be identified, although 
there was no anomaly when both investigators processed synthetic CML. 
Therefore, although the method was shown to be successful for repeated 
identification of synthetic CML, it was not sufficient for detecting CML in the test 
samples, as it was susceptible to inter-investigator error or chemical instability.
5.4 Discussion
The ultimate aim of these series of studies was to develop an efficient and 
accurate technique for the quantification of CML in plantar epidermal keratin 
proteins, so that the hypothesis that CML levels are higher in diabetics than non­
diabetics could be tested.
The outcomes of these experiments have shown that CML was not reliably 
detected from hydrolysates of plantar keratin proteins. The method of CML 
detection was tested and refined using synthetic CML, which concurred with 
previous work in this area 11191 . These results suggest 2 possible outcomes: 
firstly, there was no CML present in the samples, and secondly, the amount of 
CML in the tissue samples was too small for detection by this method, i.e. the 
GC-MS method of detection lacks sensitivity. It would be logical to presume that 
the former reason is unlikely to be the case, as both furosine and pentosidine 
were detected in the same samples. Pentosidine and CML are glycoxidation 
products and therefore it is correct to presume that they both form under 
oxidative conditions within proteins. However, the origins of these AGEs are 
different, pentosidine is formed from cross-links between lysine and arginine 
residues and CML forms by utilising lysine from proteins and lipids. The question 
of the speed with which these AGEs form is also put forward, especially in 
epidermal proteins, as the skin has a relatively short turnover time in comparison 
to other tissues. Therefore, further investigations into the lipid-sugar interactions 
and general protein kinetics of epidermal tissues are needed.
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If, however, CML is present in the samples, the options of using more sensitive 
methods of detection need to be considered. This study has shown the GC-MS 
method to be a qualitative one, which has been reflected by other investigators 
[H7;ii8] jt kggp usec| pure|y for detection, not quantification, of CML in 
blood and collagen and little attention has been paid to the nature of the CML 
mass spectrum and its fragmentation patterns. This study has been helpful in 
understanding the spectrum of CML and hence improving our understanding of 
its structure. A full understanding of the chemistry of the compound is essential 
before any quantification is attempted. This is still unknown due to its possible 
heterogeneous nature in tissues. A more specific method would be helpful to 
identify exact structures.
One method that could prove to be beneficial in this endeavor is selective ion 
monitoring spectroscopy (SIM-GC/MS). The advantage of this method is that it 
focuses on a selected target ion and does not monitor the rest of the spectrum, 
therefore being less time-consuming than GC-MS. The development of this 
method would also be useful, for the simultaneous detection of furosine and 
CML.
Recently, there has been a popular shift to the use of competitive ELISA 
techniques for the detection of CML. The monoclonal antibodies used for these 
assays produced controversial results, questioning their specificity. This will be 
discussed in the next chapter.
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Chapter 6.0-Production and Characterisation of Antibodies against 
Furosine and CML
6.1 Introduction
In clinical research, immunological approaches have been used to examine the 
presence of immunoreactive AGE proteins in human tissues [185:204i such as 
blood vessels, kidney tissue and skin [134] using antibodies of unknown specificity 
11851 in the competitive ELISA format i185;205i.
Immunoreactive AGEs were first developed by Makita and associates (1992)11851, 
involving the incubation of a protein (e.g. BSA) with glucose in preparation for 
immunisation. These anti-AGE antibodies recognised CML as the major 
determinant[206] as well as other minor epitopes. It has been assumed that the 
anti-AGE antibodies are equivalent to anti-CML antibodies for most ELISAs, but 
immunochemical differences emerge in situ. The main problem of the design of 
antibodies to AGE modified proteins is the affinity of the antibody for the AGE- 
protein versus the affinity of the antibody for the free compound. This is important 
as, pentosidine and CML present in serum exist as more than 95% bound to 
circulating albumin, with less than 2% in low molecular weight free formsl2071. The 
antibodies raised have a high affinity against AGE-protein or CML-protein, but 
have a 1000-fold lower affinity against free CML. This leads to the false negative 
result that CML is not the epitope recognised by the antibodyI185J. Therefore, this 
type of antibody is not suitable for the determination of free CML. Schleicher E et 
al (1997)12081 showed a 50-fold loss in affinity for free CML when KLH-CML was 
used as an immunogen. Also, the serum concentrations of CML determined by 
ELISA, using the polyclonal antibodies raised, were 50-100 times lower than by 
HPLC, thus illustrating the problem of standardising ELISAs. In contrast, anti- 
pentosidine antibodies against hapten-modified protein have a high affinity for the 
free molecule but a low affinity against the protein modified in vivo or during the 
Maillard reaction in vitro due to steric hindrance l20Sl. Immunoassays using such 
antibodies can be used when the AGE is released from the protein via acid or 
enzyme hydrolysis
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Immunological approaches have been attempted to determine the major AGE 
structures expressed in vivo. Using AGE-BSA as an antigen, a monoclonal anti- 
AGE antibody (6D12) and polyclonal anti-AGE antibodies have been raised I210]. 
Studies examining the immunoreactivity of these antibodies have demonstrated 
that both antibodies react with AGE samples obtained from proteins, peptides, 
lysine derivatives, and monoaminocarboxylic acids, suggesting the presence of a 
common AGE structure(s) in these AGE preparations. Subsequent 
immunological studies using 6D12 have disclosed the presence of AGE in 
several tissues and their potential involvement in disease processesI2061.
In spite of these immunological studies, the epitope structure recognised by 6D12 
is still not known. Determination of the structure is crucial to the uncovering of the 
chemical structure of AGEs. It is thought that the chemical structure differs from 
pyrraline and pentosidine since neither of them is recognised by 6D12 I2101. Ikeda 
et al (1996) showed that the epitope of 6D12 is a CML-protein adduct with a 
carbonyl group important for immunological recognition of AGE proteins. They 
also detected a major epitope other than the CML-protein adduct.
The development of immunoassays with the ability to quantify accurately AGE 
levels would be advantageous, primarily because other quantification techniques 
are time consuming, costly and insensitive. This chapter describes attempts to 
produce specific antibodies to furosine and CML, concentrating on achieving 
adequate affinity and a sufficient quantity of the antibodies to make the 
development of an immunoassay feasible. A number of established strategies 
were applied in the production of the antibodies to manipulate the hosts’ immune 
response with a view to optimising the antibody production.
6.1.1 The Principles of Antibody Production Techniques
Antibodies are raised by exploiting the B-cell mediated, immune response of a 
host animal. This response relies on the ability of the host to register the foreign 
material (immunogen) as non-self and raise antibodies which are complimentary 
to the molecule of interest and consequently be harvested and purified. The 
ability of the immunogen to produce a suitable immune response in the host
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animal is referred to as immunogenicity. Immunogenicity is defined by the 
chemical structure of the immunogen.
Antibodies are synthesized by specialised lymphocyte cells (plasma cells), which 
are in the terminal stage of B-cell differentiation. The production of a strong 
immune response is governed by the induction and regulation of the 
differentiation of B-cells into plasma cells. During differentiation, B-cells transform 
from immature B-cells, that bear cell surface receptors but do not secrete 
antibodies, to the activated form which secrete antibodies, but have no cellular 
surface receptors. This process is controlled by the presence of the antigen and 
the cell-cell communication between the B-cells and the helper T-cells and a 
number of cytokines.
Immunogens can be naturally occurring or synthetic substances. For an 
immunogen to be effective, it must have some key features: it must have an 
epitope recognised by the cell surface receptor on the virgin B-cell; it must have 
one site that can be recognised simultaneously by a T-cell receptor and it must 
be degradable
Even with these properties, it is often necessary to encourage the host animal to 
produce an adequate immune response. This can be achieved through 
alterations to the dosage and the form of the antigen; the use of adjuvants or the 
modification of the antigen.
It is essential that the immunogen is pure so as to prevent any inappropriate 
immune responses. Following initial exposure, there is a primary humoural 
response against the immunogen. This response is characterised by the 
presence of predominantly IgM molecules in the serum after approximately 7 
days. These rise to a peak concentration at about 12 days after exposure and 
then diminish. Subsequent booster injections result in the production of 
predominantly IgG classes of antibody. These form after a short lag phase due to 
the rearrangement of the B-cell genes. This is referred to as affinity maturation. 
The subsequent exposures to the immunogen result in an increase in the 
logarithmic phase of antibody production with expected plateau antibody titre of
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some 10-100 times higher, and with an extended decay phase, than by primary 
immunisation alone.
Failure of an animal to respond to an immunogen may be due to the elimination 
of the appropriate B and/or T-cell populations during the development of self- 
tolerance. Consequently, molecules with a high degree of similarity to the host’s 
isoform will be ignored by the immune system.
Animals are usually chosen for immunisation according to the following criteria: 
how much serum is required; from which species is the antigen isolated from and 
how much antigen is available.
Antibody production relies on two distinct methods: polyclonal antiserum and 
monoclonal antibody production.
6.1.2 Polyclonal Antibodies
Polyclonal antisera are routinely used for purification protocols such as ELISA 
and radioimmunoassay (RIA), where the aim is to capture the antigen.
Polyclonal antibodies are heterogeneous in nature. These antibodies recognise 
all possible epitopes on the surface of the immunogen. Each antibody group may 
vary with respect to affinity, titre and avidity (the force of attraction for the whole 
complement). These antibodies have their advantages, particularly if they are put 
through procedures that could potentially alter the structure of the antibody. An 
example of this is the conjugation of the antibody to enzymes or carrier proteins. 
However, there are disadvantages to this technology such as: the potential for a 
high degree of cross-reactivity with proteins sharing similar surface epitopes and 
the potential inter-batch variation in the affinity and specificity of antiserum.
During the production of polyclonal antiserum, animals which show a positive 
response to the immunogen are maintained in a state of globinaemia by repeated 
booster injections following the initial immunisation and then bled at suitable 
intervals to harvest the immunoglobulins. The choice of animal is dependent on a
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number of factors including its size, which will influence the amount of serum that 
can be harvested, and the ease of husbandry. Also, the immunogen used must 
be sufficiently disparate from the host’s endogenous isoform so as to be 
recognised as non-self and promote an immune response.
6.1.3 Monoclonal Antibody Production
In contrast to polyclonal antibodies, monoclonal antibodies are homogenous in 
nature and recognise one desired epitope on the target molecule. Fusion of B- 
cells result in the production of these antibodies and a suitable myeloma cell. 
These cells are termed hybridomas and they inherit selective characteristics from 
each of their constituent cell types; immortality from the myeloma cells and the 
ability to produce the required antibodies from the B-cells. The advantages of 
adopting this method of antibody production are: the hybridoma cell lines can be 
frozen and stored to ensure a constant supply of antibodies and the specific 
epitopic recognition sites of the antibody. Following subcutaneous injection and 
subsequent boosters, spleens are harvested from the animals that demonstrate a 
positive response, as determined by tail bleeds.
6.1.3.1 Fusion
Fusion of B-cells obtained from the spleens of immunised animals with 
constantly dividing, immortal plasmacytoma cell-lines is usually accomplished 
using polyethylene glycol (PEG). PEG causes the exchange of lipids on adjacent 
cells and in turn leads to the integrated cell membranes. Choice of plasmacytoma 
cells from the same species is preferable due to the decreased chromosome 
stability of inter-species fusions and potential loss of non-rodent genetic material 
during cell division p11]. Due to the limited number of myeloma cell lines from 
other species, rodent cell lines are favoured. Myeloma cells must be in the log 
phase of growth at the time of fusion and from a cell lineage with a proven record 
of successful fusions.
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6.1.3.2 Selection of Hybridomas
Fusion of the B-cells with the plasmacytoma results in a mixed population of 
hybridoma cells: B-cell-B-cell, plasmacytoma-plasmacytoma and B-cell- 
plasmacytoma hybrids. Additionally, the media will contain unfused 
plasmacytoma and B-cells. From this mixture of cell types, only the immortal, 
antibody producing plasmacytoma-B-cell hybrids are selected (Fig. 6.1). The 
most common selection method involves the use of hypoxanthine aminpterin 
thymidine (HAT) medium i205;212i.
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Figure 6.1. Cell Selection in HAT Medium
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6.1.3.3 Isolation of Single Cells and Colony Development
As a result of fusion and HAT selection there is a heterogeneous mixture of 
immortalised antibody secreting cells. As the cells stabilise their chromosome 
number, the ability to produce viable antibodies may be lost allowing non- 
secreting cells to predominate. Isolation and initiation of a cell line from a single 
progenitor ensures homogeneity of the antibody produced. This is achieved by 
using the limited dilution technique. This involves the sequential dilution of cells 
demonstrating a positive response, at reduced densities over a period of a few 
weeks to allow for environmental adjustment. Eventually, cell densities will reach 
1-2 cells per well allowing individual colonies to be chosen for continued 
proliferation.
6.1.3.4 Scale up of Antibody Production in vivo
The production of monoclonal antibodies on a large scale has been achieved, in 
the past, through in vivo intraperitoneal injection of hybridoma cells into a 
synergenic host. The cells proliferate in the peritoneal cavity of the animal and 
secrete the antibody in a fluid akin to plasma called ascites. This is drained from 
the animal approximately 2-3 times. However, due to the advances in in vitro 
protocols, and more stringent regulations governing the use of animals in 
scientific experiments, the in vivo approach to antibody production has been 
prohibited by the Animals Act 1984.
6.1.3.5 Scale up of Antibody Production in vitro
With this approach, cells are maintained in continuous culture, secreting the 
antibody product into the culture medium. Typical yields are within the region of 
5-25 mg antibody per litre of culture medium. The disadvantage of this procedure 
is the risk of the introduction of contaminants into the culture medium. Such 
contaminants would have to be rigorously removed before use in therapeutic
interventions and would have implications for infection in long-term cultures.
Another disadvantage of this type of antibody production is the slow growth rate 
of the animal cells.
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6.1.4 Furosine and CML as Immunogens
Furosine and CML are relatively small molecules (molecular weight 255 & 204, 
respectively), which is a disadvantage if they are to behave as effective 
immunogens. The conjugation of the furosine and CML with appropriate carrier 
molecules, is necessary before being introduced into the host. The heterogeneity 
of CML, in particular, could also be a problem when attempting to design specific 
antibodies.
6.1.5 Site of Immunisation and the Manipulation of the Immune Response
The route by which the antigen enters the host can have implications on the 
immunogenic potential of the molecule. The route of immunisation determines the 
site at which the immunogen is presented to the host animal. Generally, 
intramuscular and subcutaneous injections present the immunogen at the 
secondary lymphoid tissue immediately draining the site of the injection. 
Intravascular immunisation results in filtering in the spleen and ingestion results 
in an immune response in the mucosal lining. The route of administration and the 
distribution of the antigen will determine the microenvironment in which the 
antigen interacts with the antigen presenting cells I2131. T-and B-cells have the 
preferred microenvironments where the majority of the immune response occurs 
prior to migration to the primary lymphoid tissue. Augmentation and enrichment of 
the B-cells sensitised to the immunogen may occur at one site in preference to 
another resulting in site dependent differences in the efficacy of antibody 
production.
6.2 Aims
• Production of polyclonal antiserum against furosine in a rabbit host using 
synthetic furosine as the immunogen.
• Production of monoclonal antibodies derived from spleenic B-cells of mice 
immunised with synthetic furosine and CML.
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• Screening for the above antibodies to assess their ability to bind to 
furosine and CML in the solid phase and in the free solution phase.
6.3 Immunisation Methods
6.3.1 Antigens
Furosine was obtained commercially (Neosystem, Groupe SNPE, Strasbourg) 
and CML was synthesised in the laboratories at Essex University, Department of 
Biochemistry (Chapter 3). The purity of these antigens was essential. These were 
conjugated to both thyroglobulin (Tg) and bovine serum albumin (BSA), 
respectively ready for immunisation.
6.3.2 Conjugation of the Antigens to Carrier Molecule (Carried out by ISL, 
Paignton, Devon)
Conjugation of the antigens to BSA and thyroglobulin was carried out in a two- 
step process employing an activator to link the free amine groups of the antigens 
to the carboxyl groups on the carrier protein. Each of the respective peptides 
were incubated in the presence of BSA at a molar ratio of 1:1.5 and with the 
thyroglobulin at a molar ratio of 1:2, in the presence of 1 ml 0.8 M gluteraldehyde 
with constant agitation, at room temperature for 4 h. Excess gluteraldehyde was 
removed by a PD -10 column and peptide containing fractions were stored at - 
70°C.
The furosine and CML were conjugated to keyhole limpet haemocyanin (KLH) in 
two steps. An activator was employed to link the free amine groups of the 
furosine to carboxyl groups on the carrier protein. The target ratio was 50 
hapten: 1 carrier. Following the reaction, the conjugate was separated from any 
excess unbound hapten by use of a desalting column.
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6.3.3 Rabbit Immunisation for Polyclonal Antibody Production (Carried out 
by ISL, Paignton, Devon)
One female New Zealand white rabbit (less than 6 mth old) was immunised with 
furosine, subcutaneously in Freunds complete adjuvant (1 mg of carrier hapten 
conjugate), on two occasions. Ear bleeds were taken on the day of the first 
immunisation (prebleed, 10 ml), on day 12 after immunisation (1st test-bleed, 10 
ml) and 22 days after initial immunisation (2nd test-bleed, 10 ml). At this 22 day 
stage, the serum was tested for immune response using furosine bound to the 
solid phase. The rabbit was given a series of booster injections in Freunds 
incomplete adjuvant over the next four weeks. Further ear bleeds were taken and 
screened as before. Finally, a terminal bleed (20 ml) was taken to confirm 
antibody production and aliquots of the antiserum (0.5 ml) were stored at -70°C.
6.3.4 Mouse Immunisation for Monoclonal Antibody Production (carried 
out by T Jowett, Department of Medicine, UCL).
A total of two mice, aged 6 to 8 weeks old were used. The mice were injected 
subcutaneously with the peptide conjugate conformations (of furosine and CML). 
Each injection consisted of 50 pg conjugate in 100 pi RiBi adjuvant* (Sigma 
Chemicals, Poole, Dorset, UK). An intraperitoneal booster was administered four 
weeks later comprising 50pg of each respective conjugate in RiBi (200 pi). 
Eleven days later, earbleeds were taken for antibody response using peptide- 
BSA conjugate coated microtitre plates. The test bleed at a dilution of 1/100 was 
positive for a mixture of IgG and IgM. Therefore, a second booster of 50 pg was 
administered intraperitoneally 15 days later. Further test bleeds were taken 12 
days after the second boost and both mice sera were screened positive at 1/1000 
dilution. Both had a strong IgG component and a weak IgM component. In order 
to reduce the Tg response and enhance the furosine and CML response, an 
intravenous furosine-BSA and CML-BSA conjugate (100 pg) in saline solution 
was administered after the second boost. The following day an identical mixture 
was injected intraperitoneally in saline solution and 3 days later the spleens were
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removed. One spleen was stored at -70°C and the other was used for the fusion 
with plasmacytoma cells (Appendix X).
6.3.5 Summary
The mice injected with CML did not produce an adequate response to CML in 
vitro, even following booster injections. The mice injected with furosine produced 
a response to furosine, enough to warrant further investigations into the 
specificity of the antibodies.
6.4 Polyclonal Antibodies to Furosine - Titration of Antiserum with Furosine 
in the Solid Phase
The following series of assays were repeated, changing certain aspects of the 
experiment each time to improve the results. Therefore, the assay technique will 
be stated once (termed “template assay”) and any subsequent modifications will 
only state the changes to the assay, to avoid repetition.
6.4.1 “Template” Assay
96-well microtitre plates (Immulon 4, Dynatech, UK), were coated with intact 
furosine (2 pg/ml, 200 pi) in Tris/NaCI coating buffer (pH 9) and incubated over 
night at +4°C, in a humidity chamber. A series of wells with no furosine (control 
wells) were also prepared. Each well was washed 5 times with phosphate 
buffered saline solution with 0.05% Tween (PBST, 200 pi) and all non-specific 
sites were blocked using BSA in PBST (200 pi, pH 7.4) and incubating at +37°C 
in a humidity chamber. After the incubation the wells were washed again with 
PBST (200 pi) and dried thoroughly in between washes. Rabbit anti-serum was 
prepared in diluting buffer, BSA in PBST (200 pi), applied to the wells and 
incubated at +37°C in a humidity chamber. The plates were aspirated, washed 5 
times with PBST (200 pi) and dried thoroughly between each wash. Anti-rabbit-
x This adjuvant system is a stable oil in water emulsion which is recommended for use in mice and 
guinea pigs and is an alternative to conventional Freunds water-in-oil emulsion.
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IgG-peroxidase conjugate (Sigma Chemical Co., Poole, UK), in diluting buffer 
(200 pi) was added to the wells and incubated in a humidity chamber at +37°C for 
1 h. The plates were washed as described previously. Freshly made working 
substrate solution, containing 75 ml substrate buffer (500 ml of 2.5 g citric acid 
and 3.372 Na2HP0 4  pH 5), 40mg O-phenylenediamine (OPD) and 25 pi of 30% 
hydrogen peroxide (H202), was added to each well (150 pi). The wells were 
incubated at room temperature in the dark. After 30 min the reaction was stopped 
with 50 pi of 2 M sulphuric acid and the plate was mixed for 2 min. The optical 
density at 490 nm recorded.
6.4.2 Assay 1 - Titration of Pre-Bleed Versus Test-Bleed with Furosine in 
the Solid Phase
6.4.2.1 Reagents
Blocking buffer (1% BSA in PBST, 2hr incubation), diluting buffer (1% BSA in 
PBST), pre-bleed and test-bleed (1/10, 1/100, 1/1000, 1/1x104, 1/1x105, 1/1x10®, 
1/1x107, 1/1x10®, 5hr incubation), secondary antibody (1/10000).
6.4.2.2 Results
Results from antiserum dilutions of 1/10 to 1/100 are only shown as subsequent 
dilutions showed no visible absorbance readings.
Table 6.1. Results from assay 1
oo Test
reading
OD (490)
Control
reading
OD (490 )
Signal/background
ratio
1/10 pre-bleed 0.285 0.350 0.814
1/10 test-bleed 0.417 0.360 1.158
1/100 pre-bleed 0.103 0.125 0.824
1/100 test-bleed 0.188 0 .1 2 2 1.541
The control wells presented with high absorbance readings, suggesting a lack of 
specific binding by the antibodies in the test bleeds. A relatively small amount of
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binding to the furosine coated plates was observed. To improve these results the 
effect of a high concentration of coating of furosine on binding was tested.
6.4.3 Assay 2 - Titration of Pre-Bleed Versus Test-Bleed with Different 
Concentrations of Furosine in the Solid Phase (incubation 
overnight and for 3 nights at +4°C)
6.4.3.1 Reagents
Antigen (2, 5, 10 pg/ml, overnight and 3 night incubations at 4°C), pre-bleed and 
test-bleed (1/10,1/100, 1/1000, 1/1x104)
6.4.3.2 Results
Table 6.2. Titration of pre-bleed versus test-bleed with different concentrations of furosine in 
the solid phase (incubation overnight)
Antigen
coating
concentration
[ng/ml]
Bleed samples 
1/10dilution
Absorbance
O D (490)
Control reading
OD(490)
Signal/noise
ratio
2 Pre-bleed 0.198 0.217 0.912
Test-bleed 0.244 0.243 1.004
5 Pre-bleed 0.212 0.304 0.697
Test-bleed 0.260 0.325 0.800
10 Pre-bleed 0.207 0.258 0.802
T est-bleed 0.239 0.281 0.851
Readings from the wells coated in 2 pg/ml antigen were not similar to the results 
from assay 1, even though the conditions of the assay were identical.
Table 6.3. Titration of pre-bleed versus test-bleed with different concentrations of furosine in 
the solid phase (incubation for 3 nights at +4°C)
Antigen
coating
concentration
kg/ml]
Bleed samples 
1/10 dilution
Absorbance
OD(490)
Control reading
OD(490)
Signal/noise
ratio
2 Pre-bleed 0.225 0.248 0.907
Test-bleed 0.238 0.224 1.063
5 Pre-bleed 0.250 0.251 0.996
Test-bleed 0.256 0.253 1.012
10 Pre-bleed 0.268 0.256 1.017
Test-bleed 0.215 0.185 1.162
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The readings from the majority of the control wells were higher than the test 
readings. This made the comparison between different assay conditions difficult. 
However, the absorbance readings taken after 3 nights of coating were higher 
than those after 1 night in the case of 5 and 10 pg/ml antigen concentration.
6.4.4 Assay 3 - Titration of 1st Test-Bleed Versus 2nd Test-Bieed with 
Furosine (10 pg/ml) in the Solid Phase
6.4.4.1 Reagents
Antigen (10pg/ml, overnight incubation), coating buffer (0.1% bovine serum 
albumin in Tris/NaCI pH 9), test-bleed land 2 (1/10, 1/100, 1/1000, 1/10000, 
1/1x10s, 1/1x10®, 1/1x107, 1/1x108)
6.4.4.1 Results
Table 6.4 Results from assay 3
Dilution Absorbance
O D (490)
Control
O D (490)
reading Signal/noise 
ratio
151 test-bleed 1/10 0.590 0.579 1.019
1/100 0.158 0.112 1.411
1/1000 0.075 0.071 1.056
2nd test-bleed 1/10 0.541 0.338 1.600
1/100 0.155 0.098 1.582
1/1000 0.071 0.064 1.109
Graph comparing the absorbance readings of 1st and 
2nd test bleeds
1/100 1/1000
Serum dilutions
Figure 6.2. Results from assay 3
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There was difference between the 1st and 2nd test-bleeds at a concentration of 
1/10 (CV>10). All subsequant dilutions showed a minimal difference between the 
test bleeds. As with previous assays the control absorbance reading were high 
and there was an inconsistancy between readings taken from assay 2 and 3 
where the assay conditions were identical (assay 2: OD(490) = 0.239, S/N = 0.851, 
assay 3: OD(4go) = 0.590, S/N = 1.019).
Assays 1 to 3 indicated that there was some binding of the antibody to the 
antigen. To test for specificity and affinity, the antibody was purified before further 
titrations against furosine were carried out.
6.5 Titration of Purified Anti-Furosine Antibody with Furosine in the Solid 
Phase
The rabbit anti-serum was purified using affinity chromatography (Appendix XI 
and XII). The antibody was titrated with furosine in the solid phase, bound to 
microtitre plates. The same template assay was used as in section 6.4.1
6.5.1 Assay 1 - Titration of Purified Versus Terminal Bleed Antiserum with 
Furosine in the Solid Phase (range of concentrations of furosine 
coating)
6.5.1.1 Reagents
Antigen (0, 2, 5, 10 pg/ml, 2hr incubation at 37°C), anti-furosine antibody (0.1, 
0.01, 0.001, 0.0001 mg/ml), terminal bleed (1/10, 1/100, 1/1000, 1/10000)
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6.6.1.2 Results
Table 6.5. Results from assay 1
Cone of 
purified 
antibody 
[mg/ml]
2^g/ml
furosine
coating
mean
absorbance
OD(490)
2^g/ml
furosine
coating
signal/noise
ratio
5^g/ml
furosine
coating
mean
absorbance
OD(490)
5^g/ml
furosine
coating
signal/noise
ratio
10fig/ml 
furosine 
coating 
mean 
absorbanc 
e OD(490)
10^g/ml
furosine
coating
signal/noise
ratio
0.1 0.085 1.417 0.088 1.467 0.078 1.300
0.01 0.072 1.200 0.068 1.133 0.065 1.083
0.001 0.064 1.067 0.062 1.033 0.063 1.050
0.0001 
Cone of 
terminal 
bleed
0.066 1.100 0.066 1.100 0.066 1.100
1/10 0.142 2.784 0.153 3.000 0.137 2.686
1/100 0.077 1.510 0.075 1.471 0.073 1.422
1/1000 0.070 1.373 0.069 1.353 0.066 1.294
1/10000 0.061 1.196 0.062 1.216 0.060 1.176
Mean control OD(490) = 0.056 (± 0.006)
There was no difference between wells with different amounts of furosine coating 
(CVs<10). The absorbance readings decreased as the concentrations of the 
antibody and anti - serum decreased. The control readings were relatively lower 
than previous assays.
The control readings from all the assays decreased as the concentrations of the 
primary antibody decreased. This suggests that there is a degree of non-specific 
binding. The size of the furosine antigen coated on the wells (molecular weight 
255) may be too small for adequate in vitro binding between the antigen and 
furosine to occur. Therefore, the free furosine antigen (2.5 mg) was conjugated 
(carried out by ISL, Paignton, Devon) to bovine BSA (5 mg) and used to coat the 
wells in the next assay.
221
6.5.2 Assay 2 - Titration of Purified Antiserum with Furosine Conjugated
to BSA in the Solid Phase
6.5.2.1 Reagents
Furosine-BSA conjugate (2 pg/ml, overnight incubation at 4°C), blocking buffer 
(1% BSA in PBST), diluting buffer (1% BSA in PBST), anti-furosine antibody (0.1,
0.01, 0.001 mg/ml).
6.6.2.2 Results
Table 6.6. Results from assay 2
Concentration of 
antibody [mg/ml]
Mean absorbance
O D (490)
Control reading
O D (490)
Signal/noise
ratio
0.1 0.546 0.184 2.965
0.01 0.152 0.073 2.329
0.001 0.069 0.047 1.266
The absorbance readings are higher and the control readings lower than those 
seen with free furosine coating (CV>10). The control readings still increased with 
corresponding increases of antibody.
3.5
2.5
3oc
(Oc:gi
a>
0.1 0.01 0.001 
Concetration of Primary Antibody [mg/ml]
Figure 6.3. Graph comparing results from free furosine and conjugated 
furosine coated wells.
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This assay was repeated with the aim of duplicating the results. There was, once 
again, a difference in the absorbance readings between the assays and the 
control wells had higher readings.
6.6 Discussion
These results show minimal non-specific binding of the polyclonal antibody to the 
antigen, in vitro. In view of this, it was decided that the polyclonal antibodies 
raised were not satisfactory and that the production of monoclonal antibodies by 
hybridoma technology would prove to be advantageous. The advantages of 
monoclonal antibodies over polyclonal antibodies are that they are homogenous 
(i.e. every antibody molecule is identical in antigen binding properties) and also, 
the hybridoma cell lines secreting the antibodies are immortal, hence there is an 
inexhaustible supply of the antibody.
6.7 Screening of Monoclonal Antibodies to Furosine (Carried out by T 
Jowett, Department of Medicine, UCL).
6.7.1 Preliminary Screening Assays of 2C3 and 6B11 Antibody Substrates
The antibodies were screened against BSA-conjugate and free BSA. Out of 8 
microtitre plates, 11 wells recognised the furosine conjugate and not the free 
BSA. The cells relating to these wells were grown. Two of the cell lines were IgG 
and the others IgM types. The IgG cell lines were named 2C3 and 6B11. The 
cells lines were cloned by limiting dilution. Two clones of each cell line were 
cloned and named 2C3/C4, 2C3/C6,6B11/A7 and 6B11/H12.
The substrates for 2C3 and 6B11 were tested with different free AGEs and AGEs 
conjugated with proteins. Both substrates recognized furosine-BSA, furosine-Tg 
CML-Tg conjugates and Tg, but not CML-BSA and BSA. There antibodies 
recognize both AGEs and free Tg, suggesting lack of specificity.
Following on from these results, displacement assays were carried out, which 
involved the coating of wells (10 pg/ml, 100 pi) with the Tg and BSA conjugates
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of furosine and adding the antibody substrate (1/50 dilution, 50 |jl) with the 
conjugates (1.25 pg/ml, 50 |jl) added to that. No displacement was noted. The 
same procedure was repeated using two keratin proteins acid hydrolysates and 
the competitive agent and no displacement was observed in this case either.
6.7.2 Concentration and Purification of Immunoglobulins from Substrates 
2C3 and 6B11
6.7.2.1 Reagents
Solid ammonium sulphate, NaOH (1 M), HCI (1 M), substrates 2C3 and 6B11 (10 
ml), PBS.
6.7.2.2 Methods
The substrates (10 ml) were placed in labeled Universal containers (20 ml 
capacity). Each substrate pH was adjusted to 5.5 using HCI (1 M). This pH aided 
maximum precipitation. Solid ammonium sulphate (5.75 g) was slowly added to 
the substrates whilst stirring. This amount of ammonium sulphate in 10 ml of 
substrate formed a 75% saturated solution. When all the salt was added, each 
mixture was stirred (1 h, RT) to allow the mixture to equilibrate. The mixtures 
were then centrifuged (15 min, 3000 rpm) and the supernatant was discarded. 
The precipitate was redissolved in 1 ml of PBS and stored at +4°C in preparation 
for purification.
The immunoglobulin concentrate was purified using affinity chromatography 
(Appendix XI and XII).
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6.7.3 Titration of Antibodies 2C3/C4 and 6B11/A7 with Furosine and CML
Conjugates in the Solid Phase
6.7.3.1 Methods
96-well microtitre plates (Imrr.ulon 4, Dynatech, UK), were coated with furosine, 
furosine-BSA, furosine-Tg, BSA, CML, CML-BSA, CML-Tg, arginine and lysine (2 
pg/ml, 200 pi) in Tris/NaCI coating buffer (pH 9) and incubated for 2 h at 37°C 
and then over night at +4°C, in a humidity chamber. A series of wells with no 
furosine (control wells) were also prepared. Each well was washed 5 times with 
phosphate buffered saline solution with 0.05% Tween (PBST, 200 pi) and all non­
specific sites were blocked using bovine serum albumin (BSA) in PBST (200 pi, 
pH 7.4) and incubated at +37°C for 2 h in a humidity chamber. After the 
incubation the wells were washed 5 times with PBST (200 pi) and dried 
thoroughly in between washes. The antibody was prepared in diluting buffer, 1 % 
BSA in PBST (200 pi), applied to the wells (200 pi) and incubated at +37°C in a 
humidity chamber for 5 h. The plates were aspirated, washed 5 times with PBST 
(200 pi) and dried thoroughly between each wash. Anti-rabbit-lgG-peroxidase 
conjugate (Sigma Chemical Co., Poole, UK), in diluting buffer (200 pi) was added 
to the wells and incubated in a humidity chamber at +37°C for 1 h. The plates 
were washed as described previously. Freshly made working substrate solution, 
containing 75 ml substrate buffer (500 ml of 2.5 g citric acid and 3.372 Na2HP04 
pH 5), 40 mg OPD and 25pl of 30% H2O2, was added to each well (150 pi). The 
wells were incubated at room temperature in the dark. After 30 min the reaction 
was stopped with 50 pi of 2 M sulphuric acid and the plate was mixed for 2 
minutes. The optical density at 490 nm recorded.
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6.7.3.2 Results
The sound/noise ratios were calculated for each titration and compared 
(Appendix XIII).
Table 6.7. Table illustrating the highest absorption readings observed from the monoclonal 
antibodies.
Cone of 2C3/C4 antibody 
[mg/ml]
2 ng/ml F-BSA 
coating 
noise/sound ratio
2 fig/ml F-Tg 
coating 
noise/sound ratio
2 jig/ml CML-Tg 
coating 
noise/sound ratio
0.1 4.725 17.104 10.000
0.01 3.786 11.673 5.000
0.001 1.200 5.618 2.327
0.0001 0.926 6.098 2.805
Cone of 6B11/A7 
antibody 
[mg/ml]
0.1 6.612 7.209 9.786
0.01 3.687 14.212 7.419
0.001 2.181 8.627 3.157
0.0001 1.071 7.667 2.240
Antibody binding is noted in all of the wells by both monoclonal antibodies. 
Binding is significantly higher in the wells coated with furosine-BSA, furosine-Tg 
and CML-Tg conjugates, in particular the Tg conjugates (Fig. 6.4 & Table 6.7). 
The molecular weight of Tg and BSA is 330,000 and 67,000, respectively. This 
could explain the increased binding of the antibodies to the larger Tg conjugates. 
The antibodies bind to all the wells in varying degrees confirming, therefore, their 
non-specific binding.
6B11/A7
□  2mg/ml F-BSA coating 
noise/sound ratio
■  2mg/ml F-Tg coating 
noise/sound ratio
□  2mg/ml CML-Tg coating 
noise/sound ratio
0.1 0.01 0.001 0.0001 0.1 0.01 0.001 0.0001
Concentration of antibody [m g/m l]
Figure 6.4. Titration of Antibodies 2C3/C4 and 6B11/A7 with Furosine and 
CML Conjugates in the Solid Phase
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6.8 Discussion
These set of experiments have demonstrated the non-specific binding of 
polyclonal and monoclonal anti-furosine antibodies. Antibodies against CML were 
not raised successfully, suggesting a degree of similarity of CML to the hosts’ 
isoform, hence being ignored by the hosts’ immune system. There are several 
explanations as to why it is difficult to raise specific monoclonal antibodies to 
certain glycation adducts.
The immunogen used in this study contrasted to those used in previous studies in 
that the carrier protein was directly attached to furosine and CML prior to injection 
into the host. Other groups have shown that AGE modified KLH or BSA can be 
used as immunogens to prepare polyclonal 1210:2131 and monoclonal12101 antisera 
that recognize a spectrum of AGE epitopes in addition to CML, pentosidine and 
possibly early glycation adducts l214:215l.This use of in vitro AGE immunogens 
produced a range of AGEs, not all of which have been structurally defined i20*2101 
and including ones that may be less abundant in tissuesI2161. Thus, these types of 
antibodies might find their best use in surveys of age-dependent accumulation of 
a larger number of epitopes that might not be revealed by antibodies with 
narrower epitope reactivity, such as pentosidine and CML.
The use of pure glycation adducts conjugated with appropriate carrier proteins 
was adopted in this study in an attempt to reduce the generation of 
heterogeneous, unknown AGE compounds and therefore increase the specificity 
of the resulting antibodies. This technique was not successful and supports the 
literature further by confirming the need for further structural studies of the 
advanced glycation pathways as they occur in vivo, under native conditions.
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7.0 Chapter 7 - Investigation of the Mechanical Properties of Pedal Skin, in 
vivo, using a Vertical Negative Pressure Technique
7.1 Introduction
The anisotropic nature of the skin introduces complexities in its mechanical 
nature, mainly that it exhibits non-linear stress-strain properties, and viscoelastic 
(time-dependent) behaviourl217]. Because of this complexity, almost all significant 
work that has been earned out on the skin has been in vitro t2181. The main 
problems with in vitro studies are the deterioration of skin after it has been 
removed from the host causing marked alterations in the mechanical properties 
[219]. in vivo, the viscoelastic properties of the skin prove to be difficult to analyse 
due to the behaviour of the collagen and elastin in association with tissue fluids. 
The search for an accurate, non-invasive technique of measuring the mechanical 
behaviour of the skin, in vivo would be useful for observing the progression of 
skin pathologies and for testing the efficacy of skin treatments.
The ways in which various groups in this field have carried out their experiments 
are very different, producing indecisive and conflicting results. Some 
investigations of the mechanical properties of human skin, in vivo, use equipment 
that measures the deformation of skin after the application of uniaxial, biaxial or 
multiaxial forces [22ai. Devices that apply these forces have been developed in 
research laboratories for experimental purposes, but only a few are available 
commercially. As the skin is a three-dimensional tissue, the application of 
multiaxial forces is more realistic than uni- and bi- axial forces I2191. The vertical 
suction technique is an example of this type of method. The two types of 
commercial, vertical suction devices available are the Dermaflex® (Cortex 
Technology, Denmark) and the Cutometer® (580 MPA, Courage and Khazaka 
Electronic UK Ltd). The Cutometer® has mainly been used in the cosmetics 
industry for monitoring the effects of topical emollients on the biomechanical 
properties of facial and forearm skin [221]. It has recently been used for research 
purposes on assessing the elasticity of diabetic skin on different points on the 
body excluding the feet p221. For this study the Cutometer® was used to
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characterise and measure the viscoelastic properties of the epidermis on the feet 
of diabetic and non-diabetic individuals.
7.2 Techniques used to Measure Skin Mechanics in vivo
There are four directions of loads that can be applied to the skin: vertical 
pressure i.e. ballistrometry 12231 and indentation t224:2251 techniques; vertical suction 
[22i;223;223;22s-229r |jnear horizontal, uniaxial traction *230:2311 and torsion in the 
horizontal plane[232"2341.
7.2.1 Vacuum Suction Devices
As explained in Chapter 1, the majority of the studies investigating the flexibility of 
diabetic skin have involved qualitative clinical observations. More recently there 
has been the development of devices, which either indent or draw up the 
skin[226:228:232:233:235]. Nikkels-Tassoudji et al (1996) 12221 have shown that the 
mechanical properties of diabetic skin differ according to the type of diabetes, the 
test site and the age group. The authors identified the potential advantages of 
such techniques, correlating the physical changes in the skin to the duration of 
diabetes, the degree of metabolic control and the prevalence of complications 
related to diabetes. The relationship between these variables has been 
inconsistent from study to studyI39^ 11.
The main advantage of the vacuum suction technique is that it reduces the 
likelihood of underlying tissues interfering with the measurements. This has been 
clearly demonstrated i222:2291 by measuring skin flexibility on different body sites, 
but not plantar skin. Skin thickness and flexibility analysis, using ultrasonography 
and vacuum suction, respectively, on pedal skin would provide an insight into its 
biomechanical nature.
The decision to use the suction method for this study was influenced by the 
nature of the skin on the foot, particularly plantar skin. Although the plantar skin 
may be thicker than other sites on the body, it is in close proximity to underlying 
bones and joints. A method such as indentation would not portray properties
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unique to the skin but would also include the structures lying beneath the skin. 
The torsion method could overcome these problems, but as the relatively thick 
plantar skin is tightly tethered to subcutaneous tissues via fibrous attachments, 
these attachments would be included in the measurements. The vertical suction 
method minimises interference from tissues other than the skin. This will be 
discussed in more detail later on in this section. Only one published study has 
investigated the physical properties of plantar diabetic skin by using an 
indentation method[2341.
7.3 Physical Nature of Skin in Relation to Structure
The physical nature of skin incorporates elastic and viscous properties of 
solids12171. This viscoelastic mechanical model is different in different structural 
components of the skin. For example, the physical behaviour of the stratum 
comeum and the upper layers of the epidermis are influenced by fluctuations in 
the water content as a result of changes in the environmental humidity I221]. The 
internal portion of the epidermis, where the basement membrane, desmosomes, 
and elastic fibres are housed, anchors the epidermis to the deeper tissues. The 
papillary dermis has relatively loose connective tissue in contrast to the reticular 
dermis, where the connective tissue is packed tightly and the subcutaneous 
region attaches to the deeper fascia. Each of these tissue types have different 
viscoelastic properties, which in combination give the skin its overall flexibility.
The elastic fibres, the architecture of which is important in the dermis, are 
principally responsible for the elastic properties of the skin under minor loads. 
The elastic fibres in the immediate subepidermal area form a delicate framework 
perpendicular to the epidermal surface. These fibres are attached to the 
epidermal-dermal junction from one side, and to the layers of elastic fibres that 
run parallel to the surface of the skin from the other. Thus, the structure and the 
shape of the epidermal-dermal junction may influence the elasticity of the skin 
and any clinical conditions affecting this fibre framework of skin are likely to alter 
its biomechanical properties.
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The load extension properties of in vivo human skin are found to be dependent 
upon both static and dynamic tensions. The static tensions are the natural 
tensions existing in normal skin and vary between different anatomical sites 
[227:235] The dynamo tensions are caused by a combination of forces, which are 
associated with joint movement, voluntary muscle activity, and gravity [2361. 
Dynamic forces have an important influence on the magnitude of skin tensions,
i.e. as joints move, the magnitude and direction of tensions within the skin 
change markedlyI2301.
7.4 Mechanical Properties of Normal Skin
7.4.1 Introduction to Terminology
The mechanical properties of the skin are defined in terms of the deformation 
produced by a given force over a period of time. The following is a list of terms 
that are commonly used when referring to skin mechanics:
• Stress is a system of forces in equilibrium producing strain in a material or 
part of a material. The stresses may be regarded as the forces applied to 
deform the material or as equal or opposite forces with which the body 
resists. In all cases the stress is measured as a force per unit area.
• Strain is the change in volume (volume strain) and/ or a change in shape 
of a material, as a result of applied stresses. Linear strain is the extension 
per unit length due to an applied stress.
• An elastic material is a material that undergoes changes in the relative 
positions of its components that disappears as the deforming stress is 
removed. A purely elastic material resumes its original size and shape 
after being subjected to deforming stresses
• Elastic hysteresis is a phenomenon that occurs when a stress is applied in 
steps to an elastic body, and removed in equal steps. The strain on 
unloading is greater than at the corresponding stress when loading. This 
hysteresis is very small for materials such as steel and very large for 
imperfectly elastic materials such as rubber. On a graph of stress against
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strain, the area within the hysteresis loop represents the energy dissipation 
per unit volume in a cycle of loading and unloading.
• An elastic modulus is the ratio of stress to strain, within the limit of 
proportionality.
• Young modulus is the ratio of stress to strain for a homogenous material 
that obeys Hooke's law.
• Hooke’s law in its most general form, states that, for a certain range of 
stresses, the strain produced is proportional to the stress applied 
(independent of time), and disappears completely on removal of the stress. 
This law is the basis of the theory of elasticity.
• A \/iscoelastic material has the properties of elastic solid when a 
deforming stress is applied and continues to stretch, with time, under a 
constant stress (viscous fluid behaviour). The latter phenomenon is called 
creep.
• A plastic material deforms in response to the application of stress and 
does not return to its original shape once this stress has been removed. It 
is the opposite case when the material is purely elastic. A material can 
possess both elastic and plastic qualities, that are governed by the 
magnitude of the stress applied.
• An isotropic material possesses properties, such as elastic constants, that 
do not vary in direction.
• An anisotropic material possesses physical properties that vary with 
direction.
The skin exhibits viscoelastic behaviourI219J, and the typical properties are non­
linear stress-strain with hysteresis. The deformation of the skin is time- 
dependent, with a phenomenon of creep associated with it.
7.4.2 Factors Influencing the Mechanical Properties of the Skin
The mechanical properties of the skin depend on the anatomical site [23Sl. For 
example the skin, is more distensible, under suction, around acral areas such as
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the malleoli and forearms, in comparison to proximal areas such as the thigh, 
trunk and arm.
Female skin appears to be more distensible in acral areas in comparison to male 
skin. No correlation has been found between gender and skin elasticity [227], 
although female hormones may have a role in the modulation of skin mechanical 
properties, since skin elasticity in women changes throughout the menstrual cycle
[227;235]
Age also has an effect on the mechanical properties of the skin, although the 
evidence is confusing [2231. Scientists using the Cutometer® 580 MPA have 
demonstrated that the indices of elasticity diminish with age i223'22T>235\  jh is  could 
be due to the damage, disintegration, or changes of the structure of the elastic 
fibres that appear in both intrinsic and solar aging.
Some studies have shown that skin elasticity fluctuates during the dayI237]. This 
may be due to an adaptation to the standing position and that the accumulation of 
fluid within the dermis and the restoration of previous shape is associated with 
fluid removal. Skin elastic forces contribute to the recovery of skin shape after 
stretch and thus enhance the clearance of intercellular fluid. Hence, the evening 
increase of elasticity of acral skin is advantageous because strong recoil forces 
assist in the removal of oedematous fluid that accumulates in the extremities 
during the day. The viscoelastic properties of the skin are impaired by 
inflammatory skin conditions where oedema and interstitial fluid exists e.g. 
systemic sclerosis i228=231'238i.
Another factor, which can affect measurements, is the state of hydration of the 
stratum comeum. While it represents approximately two-thirds of the epidermal 
thickness, its influences cannot be neglected: its Young’s modulus is 1000 times 
higher than that of skin-108 N/m2 for a water content of 13%l233].
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7.5 Determination of Skin Mechanical Properties using Vertical Suction
The principle of the suction method is the measurement of skin elevation caused 
by the suction force exerted, over a defined area of skin. Measuring the skin 
elevation as a function of time enables the examiner to calculate particular 
variables reflecting the skin’s mechanical properties.
The two most popular commercial devices used for the measurement of skin 
flexibility are the Dermaflex A® (Cortex Technology, Hadsund, Denmark) and the 
Cutometer® 580 MPA (Courage and Khazaka, Cologne, Germany)[235].
7.5.1 Cutometer® 580 MPA
The Cutometer® 580 MPA consists of a generator for the vacuum; a sensor of 
skin elevation within the probe and a data software package. The suction probe 
has a steel ring, 2 mm in diameter (the Dermaflex® has an aperture diameter of 
10 mm) that demarcates the area of skin where the suction is applied. A double 
adhesive ring is placed on the metal ring so as to prevent the influence of skin 
creeping during the suction. The instrument is designed so that the vacuum 
strength, length of suction and number of suction cycles can be adjusted.
The Cutometer® 580 MPA differs from the Dermaflex A® in that the diameter of 
the aperture on the suction chamber is much smaller, making the measurements 
exclusive to the epidermis and papillary dermis and involves the deeper layers of 
the dermis and the subcutaneous tissues in part onlyI235]. As plantar epidermis is 
relatively thicker than other parts of the body, interference by the dermis should 
be even less likely.
The main difference between the two devices, that influenced the selection of the 
Cutometer® 580 MPA for this study, was the format in which the data could be 
collected. The Cutometer® 580 MPA not only provided a set of skin displacement 
readings with time, but also provided pressure readings in the time that the 
displacement data was gathered. This was not part of the original software
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package and was kindly provided by Courage and Khazaka on request. The 
relevance of this data will be explained later on in this chapter.
7.5.1.1 Description of the Measuring Probe4
The handheld measuring probe is attached to the main apparatus via an electric 
cable and air tube (Fig. 7.1). The machine is designed so that a variable vacuum 
pressure is applied to the surface of the skin, ranging from 50 to 500 mbar. The 
relative accuracy of the vacuum varies from 10% for vacuum values between 20 
and 100 mbar to 5% for higher vacuum values of 100 to 500 mbar. The vacuum 
is drawn through the aperture and pulls the surface of the skin up into the 
aperture of the probe. Inside the probe, the penetration depth is determined by an 
optical system, which consists of a light source and a light receptor, a long with 
two prisms facing each other, which project the light from the transmitter to the 
receptor. The light intensity varies according to the penetration depth of the skin. 
This information is then converted to the time-displacement curves outputted by 
the computer software. The skin adjacent to the probe aperture is maintained in 
position by an external guard ring attached to the probe shield (external diameter 
of 2.5cm). The measuring probe weighs approximately 90g. The function of the 
springs, inside the probe, is to maintain a constant force of 2x103 N/m2 when it is 
applied vertically on the skin surface. The absolute accuracy of the skin 
deformation measurement is 0.010 mm. The diameter of the probe aperture is 2 
mm.
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Aperture of 
the probe
Spring
External part of 
*  probe
Movable part of the 
probe
Vacuum tube 
Optical sensors
Cutometer 
hardware and 
computer
Guard ring
Figure 7.1. Schematic diagram of the measuring probe of the Cutometer® 580 MPA Aperture 
size 2mm.
* Courage and Khazaka provided all information in this section.
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Figure 7.2. Schematic diagram illustrating the optical detection system within the probe
The head of the probe houses two prisms (Fig. 7.2). One prism emits green light 
(565 nm) of constant intensity along its entire length. The second prism receives 
the light, therefore as the skin moves up into the aperture the intensity of the light 
received by the second prism is decreased. The mathematical function between 
the decreasing light intensity and the position of the skin entering the aperture is 
linear when measuring displacements between 0 and 900 pm, but is not linear at 
displacement distances between 900 and 1700 pm (Fig. 7.3). As a result of this 
curved data, the probe is calibrated by a tool designed by the company that 
allows for a pin to enter the aperture step by step at known intervals and the light 
intensity readings as a result of these different distances are stored. As the 
prisms are not identical for every probe that is made, the calibration procedures 
must be carried out for each probe. The results of the calibration are stored in the 
fixed memory of the probe and also on the factory calibration database.
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Figure 7.3. Curve of light intensity absorbed by prism two as the emitted light from prism one
is blocked at different depths. Graph supplied by Courage and Khazaka.
The device was linked to an IBM compatible personal computer. Standard control 
software, directing the Cutometer® 580 MPA, was provided by the company. The 
software allowed the storage of data such as date and time of the experiment, 
skin site, external temperature, relative humidity and the mode of measuring 
technique. In addition, the graphic display provided a curve of displacement and 
pressure versus time, along with the numerical data.
7.5.1.2 Handling the Measuring Probe
The correct handling of the probe is essential for exact and reproducible 
measurements. The measurements should always be made under the same 
room conditions i.e. the relative humidity and external temperature have to be 
constant. Only in this case can measurements over a long period of time be 
compared. The ideal conditions are an external temperature of 20°C and a 
relative humidity of 40-60%. The test subjects need at least 10 minutes to 
acclimatise. Blood circulation has to return to normal after possible physical 
strain. The probe must be applied at right angles to the skin and pressed down 
until the guard ring is level with the external casing of the probe, and maintained 
in this position to ensure a constant application of pressure. If the skin site has 
hair it is advisable to shave the area as it may touch the optical sensors when the
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suction is applied. The probe must be held as steady as possible during the 
measurement time. This is achieved by applying a double-sided tape to the probe 
and the skin surface to avoid slipping.
7.5.1.3 Description of the Measuring Modes
The Cutometer® 580 MPA offers 4 different measuring modes for different 
scientific requirements (Table 7.1).
Table 7.1. Description of the different modes provided by the Cutometer® 580 MPA
Mode Description Illustration of Description
1 Measurement with constant 
negative pressure
2 Measurement with linear rising 
and falling negative pressure
■ i i i 
1 1
w1 1 1 1 1 1
3 Measurement with first 
constant then linear falling 
negative pressure
1
4 Measurement with linear rising 
negative pressure and then 
abrupt cessation of the 
negative pressure <------► Run time [s]
Mode 1 was used in this study, where the skin was drawn into the aperture of the 
probe during an allotted measuring time with a constant negative pressure, after 
which the pressure was abruptly switched off and the skin released.
7.5.2 Variables and Prerequisites to be Considered when Taking
Skin Elasticity Measurements
7.5.2.1 Biological and Environmental Variables
The biological variables that need to be considered before taking skin elasticity 
measurements are: sex, age, race, anatomical site, endocrine factors (e.g. 
hormonal cycle, hormonal treatment); water balance (including treatment with 
diuretics), general and localised diseases and diurnal variation of water
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accumulation in the dependent parts of the body. The environmental factors 
include: sun exposure (e.g. photodamage, psoralens ultraviolet A (PUVA) 
photosclerosis); seasonal variations in the humidity of the stratum comeum; 
previous physical stress to the skin (the skin has a “stress memory” that can last 
for at least 1 h) and topical treatments.
7.5.2.2 Standardisation for Measurements
The probe is very sensitive to movement 12361 therefore both the probe and the 
skin should be static when the readings are taken. The body and foot should be 
in a standard position. This is crucial, as the pronation or supination of the foot 
could have a significant effect on the movement of skin over the joints. The site to 
be measured should be carefully marked and adjacent sites should be measured 
and a mean value calculated. The placement of the probe should be 
perpendicular to the skin surface throughout the process of data collection. 
Repeated measurements in the same area should be avoided for at least 1 h, as 
the initial recording will temporarily modify the viscoelastic behaviour of the tissue 
within that region.
7.5.2.3 Pretension of the Skin
As described previously, the skin immediately adjacent to the aperture of the 
measuring probe is held in position by a guard ring. However, even with this in 
place there is a degree of lateral displacement of the skin next to the opening 
when the suction is applied. The purpose of this instrument is to only measure 
the vertical displacement of the skin during suction and not any lateral 
displacement. In order to minimise the lateral skin displacement the skin should 
undergo pretension before the measurement is carried out. Pretension of the skin 
is achieved by applying a preliminary suction on the surface of the skin for a short 
period of time (0.1 s). With this implemented the maximum skin deformation 
readings taken show minimal variability p211.
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7.5.3 Viscoelastic Qualities of the Skin
Because of the viscoelastic nature of human skin, a simple stress strain 
relationship is an insufficient description of the tissue, i.e. Young’s Modulus is not 
applicable.
The viscoelastic components of skin are highlighted in Fig. 7.4. The curve is 
described in two parts in the suction phase, and two in the relaxation phase. In 
the first half of the suction phase the slope of the curve is almost perpendicular, 
this is the series elastic component or immediate stretch (Ue). The second part of 
the curve flattens more and more until it reaches a maximum at the end of the 
suction phase. This is the viscoelastic component or delayed stretch (Uv^. After 
the suction phase (e.g. 60s at 500 mbar) the suction is switched off. In a highly 
elastic material the curve returns to the starting point immediately and 
perpendicularly after removal of suction. In a viscoelastic material, such as the 
skin, there are two parts to the curve: the falling perpendicular, series elastic 
component (Ur) and the viscoelastic component (Uv2), which flattens out to zero.
Displacement
[nm] Ue:
U vv
Ur:
Uv2
Uf:
Immediate stretch [jim]
Delayed stretch or time 
constant on stretching [s]
Immediate retraction of skin 
after the removal of the 
vacuum [jim]
Delayed retraction or time 
constant on retraction [s]
Maximum stretch [pm]. 
Increases linearly in function 
of diameter of the apertureTime [s]
Figure 7.4. Curve illustrating the viscoelastic properties of the skin using vertical suction
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This curve is characteristic of skin as a whole, therefore suggesting that the 
epidermis has a role in this viscoelastic behaviour, but what significance does the 
epidermis alone have on the overall mechanics of the skin? This may be 
explained by the knowledge that palmar tissue exhibits parameters of 
viscoelasticityl223]. Palmar skin has a similar structure to plantar skin in terms of 
the preponderance of the stratum comeum; therefore, it could be possible that a 
viscoelastic model may describe mechanics of plantar epidermis. Keratin fibres in 
the epidermis may follow similar mechanics as collagen fibres in the dermis that 
of reorientation of the fibre network, allowing the extension of the epidermis as a 
non-linear stress-strain curve. This study attempts to concentrate on the possible 
viscoelastic components of the epidermis on three sites on the foot (see section 
7.7.1).
7.5.4 Mechanical Models of Viscoelastic Behaviour
Based on Hooke’s law, models of viscoelastic behaviour are a combination of a 
linear spring with a Young’s modulus (E) and a dashpot with a viscosity (g). The 
elastic spring produces a deformation directly proportional to the load; the 
dashpot (likened to a shock-absorber) produces a velocity of deformation 
proportional to the load. These two components may be combined in different 
ways to describe the viscoelastic behaviour of materials I219]. The two simplest 
combinations are the Maxwell and Voight models (Fig. 7.5 & 7.6).
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Elastic Viscous Maxwell Voight Kelvin
Figure 7.5. Diagrams illustrating viscoelastic models of behaviour of materials.
Maxwell Voight Kelvin
Displacement Displacement Displacement
Force Force Force
Time Time
Figure 7.6. Graphs of viscoelastic models of behaviour of materials.
Time
7.6 Summary
The Cutometer® 580 MPA, has the ability to measure the viscoelastic properties 
of the skin in vivo. Under well-controlled experimental conditions, reproducible, 
accurate stress-strain and strain-time curves can be obtained, which give 
quantitative information concerning the elastic and viscoelastic properties of the 
skin.
In this study similar conditions were adopted to study the viscoelastic properties 
of the epidermis on three different sites on the feet using a 2mm diameter 
aperture. The reproducibility and accuracy of the measurements were confirmed. 
The influence of physiological parameters such as age, sex and race were 
analysed. Data collected from non-diabetic subjects were compared to that of 
diabetic subjects in Chapter 9.
7.7 The Suitability of the Cutometer® 580 MPA for Measurement of the 
Physical Properties of Pedal Epidermis
7.7.1 Sites of Measurement
Measurements were taken from three sites on the left foot of each volunteer: the 
medial longitudinal arch (MLA); the plantar aspect of the 3rd metatarsophalangeal 
joint (MTPJ) and the dorsal aspect of the 3rd MTPJ (Fig. 7.7).
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Figure 7.7. Diagram illustrating the sites used for collecting data, a: Plantar view of the foot b: 
Dorsal view of the foot. 1 -  PM A, 2 -  MLA, 3 - dorsum
7.7.2 Assessment of Equipment for a Square Wave Pressure Application
7.7.2.1 Methods
The accuracy of the epidermal displacement readings depends on the 
consistency of the vacuum suction pressure (square wave form). Any delays in 
achieving an immediate, maximum, vacuum suction will also cause a delay in the 
displacement readings. Pressure and displacement readings were observed on 
each of the three sites on 10 diabetic subjects and 10 age and sex matched 
controls.
Cutometer® 580 MPA settings, Mode 1: Pressure 500 mbar
Rate 20 mbar/s 
On-time 60s 
Off-time 60s
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7.7.2.2 Results
Two types of pressure curves were obtained. The pressure showed either an 
increasing or decreasing exponential ‘creep’ after an instantaneous change, until 
a new steady state of approximately 500 mbar was achieved (Fig. 7.8).
Pressure
Time
Pressure
Time
Figure 7.8: Illustration of the pressure curves, a: Ascending pressure curve, b: Descending 
pressure curve
Although these anomalies in the applied pressures seemed minimal it was 
necessary, to confirm whether they influenced significantly the displacement 
readings. The pressure curves were analysed as follows:
7.7.2.2.1 Ascending Pressure Curve Analysis
In this case there was an increasing creep of pressure, which would have 
increased the displacement values over that expected from an instantaneous 
extension, Ai. The pressure curve was described as:
P = Ai + A2 *(1 -  exp(-t/x)) 1
Where:
P = Pressure
Ai = Initial pressure reading
A2 = Pressure difference from initial reading to 60s reading 
t = time
x = time constant
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A i
fc Measured curve
Estimated curve
Figure 7.9. Ascending pressure curve correction
In this case displacement curve data were reduced by a factor: 
(A2*(1-exp(-t/x)))/A2 2
to a square wave of pressure, Ai.
7.7.2.2.2 Descending Pressure Curve
In this case there was a decreasing creep of pressure which would have 
decreased the displacement values over that expected from an instantaneous 
extension, Ai + A2. The pressure curve was described as (Fig. 7.10).
P  =  A i  +  A 2 *(exp(-t/x)) 3
Where:
P  = Pressure
Ai = Initial pressure reading
A 2 = Pressure difference from initial reading to 60s reading 
t = time
x = time constant
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Estimated curve
Measured curve
Figure 7.10. Descending pressure curve correction
In this case displacement curve data were increased by a factor: 
(A2‘ (exp(-t/x)))/( A1+ A2) 4
to a square wave of pressure (Ai + A2).
7.7.2.2.3 Calculations and Results
Table 7.2. Percentage error for the corrected displacement curve data from the dorsal site
Measured Displacement 
(pm)
Corrected Displacement 
(pm)
% Error
Non-diabetic
subjects
1 171 167 -2.34
2 176 173 -1.71
3 80 77 -3.75
4 152 150 -1.32
5 200 196 -2.00
6 154 153 -0.65
7 82 79 -3.66
8 109 107 -1.84
9 146 144 -1.37
10 114 111 -2.63
Diabetic subjects
1 152 149 -1.98
2 136 132 -2.94
3 104 104 0.00
4 253 250 -1.19
5 128 126 -1.57
6 162 160 -1.24
7 270 269 -0.37
8 320 317 -0.94
9 211 207 -1.90
10 245 243 -0.82
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Table 7.3. Percentage error for the corrected displacement curve data from the MLA
Measured Displacement 
(pm)
Corrected Displacement 
(pm)
% Error
Non-diabetic 
subjects
1 94 92 -2.13
2 90 87 -3.35
3 80 75 -6.25
4 16 14 -12.4
5 71 69 -2.88
6 91 87 -4.4
7 83 80 -3.61
8 95 93 -2.11
9 94 91 -3.19
10 101 99 -1.98
Diabetic subjects
1 52 53 +1.98
2 99 97 -2.02
3 104 104 0.00
4 104 103 -0.96
5 76 74 -2.63
6 160 158 -1.25
7 200 198 -1.00
8 310 309 -0.33
9 162 162 0.00
10 213 211 -0.94
Table 7.4. Percentage error for the corrected displacement curve data from the PMA
Measured Displacement 
(pm)
Corrected Displacement 
(pm)
% Error
Non-diabetic
subjects
1 99 96 -3.03
2 96 95 -1.04
3 132 129 -2.27
4 2 2 0.00
5 94 92 -2.13
6 25 24 -4.00
7 38 36 -5.26
8 27 25 -7.41
9 5 3 -40.00
10 39 38 -2.56
Diabetic subjects
1 4 4 0.00
2 1 1 0.00
3 81 86 +6.17
4 4 4 0.00
5 28 31 +9.68
6 63 62 -1.59
7 80 78 -2.5
8 270 268 -0.74
9 167 166 -0.60
10 142 142 0.00
249
In general the magnitudes of the creeps were proportionately small compared to 
the instantaneous changes in pressure. Of the 60 pressure curves, 57 
demonstrated ascending creeps and 3 had descending creeps after the 
instantaneous pressure changes. In the determinations of the ascending creeps 
the proportion of A1/A2 was 0.03 ± 0.06 (n=57) and for descending creeps was
0.06 ± 0.04 (n=3). The percentage error between the measured displacement 
data and the corrected data were calculated as being 1.71 ± 1.00 for the dorsal
site; 2.47 ± 2.95 for the MLA and 2.86 ± 3.73 for the PMA (Tables 7.2-7.4).
7.7.3 Assessment of the Elastic Behaviour of the Epidermis
A Hookian elastic solid is a solid that obeys Hooke’s Law, which states that the 
stress is linearly proportional to the strain. The following experiments examined 
the elastic behaviour of the epidermis on the foot. Stress-strain curves were 
compiled to confirm or refute the tissues elastic behaviour.
7.7.3.1 Methods
Data were collected from each of the three sites from 10 subjects. At each site a 
series of displacement curves were generated at pressures of 100, 200, 300, 400 
and 500 mbar.
Stress-strain curves were generated by plotting the maximum displacement 
readings against pressure.
7.7.3.2 Results
The stress-strain curves for all 10 subjects were linear (Tables 7.5-77, Figs. 7.11- 
7.13), with rvalues between 0.29 and 0.98, mean r=0.85 0.15. The values for the 
displacement at 500 mbar were calculated from the slope of the graphs and 
compared to the measured displacement readings at 500 mbar (Tables 7.7-7.10).
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Table 7.5. Displacement readings from the dorsum of the foot at different pressure settings.
Subject Displacement 
@ 100 m bar 
(pm)
Displacement 
@ 200mbar 
(pm)
Displacement 
@ 300m bar 
(pm)
Displacement 
@ 400m bar 
(pm)
Displacement 
@ 500m bar 
(pm)
1 31 30 69 62 90
2 46 55 103 95 90
3 10 30 40 60 142
4 20 40 60 90 86
5 20 40 60 90 86
6 30 70 90 120 113
7 32 79 122 102 104
8 100 175 198 205 254
9 25 50 60 120 150
10 46 50 78 100 201
Table 7.6. Displacement readings from the MLA of the foot at different pressure settings.
Subject Displacement 
@ 100 m bar 
(pm)
Displacement 
@ 200mbar 
(pm)
Displacement 
@ 300m bar 
(pm)
Displacement 
@ 400m bar 
(pm)
Displacement 
@ 500m bar 
(pm)
1 25 31 64 48 50
2 20 30 30 30 58
3 10 0 10 20 27
4 10 20 40 40 39
5 10 20 40 40 39
6 10 20 90 90 70
7 50 20 40 40 88
8 75 100 150 220 240
9 43 60 76 80 110
10 41 72 70 72 85
Table 7.7. Displacement readings from the PMA of the foot at different pressure settings.
Subject Displacement 
@ 100mbar 
(pm)
Displacement 
@ 200mbar 
(pm)
Displacement 
@ 300mbar 
(pm)
Displacement 
@ 400m bar 
(pm)
Displacement 
@ 500m bar 
(pm)
1 10 45 87 89 93
2 20 50 90 90 81
3 7 13 14 29 13
4 10 47 60 41 59
5 10 47 60 41 59
6 10 47 60 41 59
7 20 40 40 60 81
8 53 55 60 80 82
9 18 32 30 60 70
10 0 0 10 10 20
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Figure 7.11. Maximum displacement readings from the dorsum of the foot at different pressure settings.
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Figure 7.12. Maximum displacement readings from the PMA of the foot at different pressure settings.
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Figure 7.13. Maximum displacement readings from the PMA of the foot at 
different Dressure settinas.
These single values calculated at 500 mbar were representative of the stress- 
strain portion of the curves, therefore any deviation of the measured reading at 
500 mbar from the line curve, is representative of the deviation from elastic 
behaviour. The difference between the measured reading and estimated 
displacement at 500 mbar was minimal (Tables 7.8-7.10).
Table 7.8. Values calculated for the gradient of the slope taken from the dorsum of the foot.
Subject Estimated 
displacement reading 
at 500 mbar
R value Displacement reading 
at 500 mbar
1 0.09 0.92 0.09
2 0.12 0.86 0.09
3 0.10 0.91 0.14
4 0.10 0.96 0.09
5 0.10 0.97 0.09
6 0.14 0.96 0.11
7 0.14 0.89 0.10
8 0.29 0.94 0.25
9 0.14 0.97 0.15
10 0.16 0.91 0.20
Mean±SD = 0.14+0.06 Mean±SD = 0.13±0.06
Table 7.9. Values calculated for the gradient of the slope taken from the MLA of the foot.
Subject Estimated 
displacement reading 
at 500 mbar
R value Displacement reading 
at 500 mbar
1 0.05 0.96 0.06
2 0.07 0.84 0.05
3 0.09 0.97 0.08
4 0.05 0.88 0.04
5 0.05 0.88 0.04
6 0.09 0.87 0.07
7 0.07 0.61 0.09
8 0.26 0.98 0.24
9 0.11 0.98 0.11
10 0.10 0.88 0.09
Mean±SD = 0.09±0.06 Mean±SD = 0.09+0.06
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Table 7.10 Values calculated for the gradient of the slope taken from the PMA of the foot.
Subject Estimated 
displacement reading 
at 500 mbar
R value Displacement reading 
at 500 mbar
1 0.05 0.77 0.06
2 0.04 0.54 0.06
3 0.02 0.72 0.01
4 0.07 0.72 0.06
5 0.07 0.72 0.06
6 0.07 0.97 0.06
7 0.08 0.93 0.08
8 0.10 0.29 0.24
9 0.07 0.94 0.07
10 0.002 0.89 0.002
Mean±SD = 0.06±0.03 Mean±SD =0.07±0.06
7.7.4 Standardisation of Methods
7.7.4.1 Aims
• To determine the appropriate body and foot position that the volunteer should 
be placed in with minimal variation in readings.
• To test the machine for repeatability of data collection at the same site of skin.
• To test the effects of pretension on the epidermis on the data.
7.7.4.2 Methods
Three healthy (non-diabetic) volunteers with no foot or skin pathologies were 
used for this set of experiments. The three sites on the foot were marked 
carefully and the volunteer lay in a supine position on the bed for 15 min before 
readings were taken. The probe was applied perpendicular to the skin for every 
reading and care was taken not to apply any external pressure. Double-sided 
tape was used to keep the probe in position. The room temperature and humidity 
was noted at the time the readings were taken.
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7.7.4.2.1 Standardisation of Body and Foot Position
Ranges of different body and foot positions, in different combinations, were 
selected (Table 7.11) and readings were taken from the three sites in each 
position.
Table 7.11. Description of the body positions when taking measurements.
Body Position  Foot Position
Sitting Relaxed position
Sub-talar joint neutral 
Lying supine Relaxed position
Sub-talar joint neutral 
Lying prone knee extended Relaxed position
__________________________ Sub-talar joint neutral
7.7.4.2.1.1 Results
Table 7.12. Relationship between body position and skin displacement in specific sites on the 
foot. Subject 1._____________________________________________________________________
Maximum Displacement of 
Epidermis (pm) using negative 
pressure of 500 mbar
Body Position Foot Position PMA MLA Dorsum
Sitting Relaxed position 40 90 230
Sub-talar joint neutral 40 80 200
Lying supine Relaxed position 20 80 260
Sub-talar joint neutral 20 70 190
Lying prone knee extended Relaxed position 10 70 100
Sub-talar joint neutral 10 60 720
Mean ±SD 23.3 ±13.7 75+10.5 283.3 ± 
220.6
Table 7.13. Relationship between body position and skin displacement in specific sites on the
foot. Subject 2.
Maximum Displacement of
Epidermis (pm) using negative
pressure of 500 mbar
Body Position Foot Position PMA MLA Dorsum
Sitting Relaxed position 12 24 52
Sub-talar joint neutral 10 23 41
Lying supine Relaxed position 10 21 70
Sub-talar joint neutral 10 20 40
Lying prone knee extended Relaxed position 10 25 30
Sub-talar joint neutral 10 20 80
Mean ±SD 10.3±0.8 22.2 ±2.1 52.2±
19.3
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Table 7.14. Relationship between body position and skin displacement in specific sites on the
foot. Subject 3_______________________ __________________________________________
Maximum Displacement of 
Epidermis (pm) using a negative 
pressure of 500 mbar
Body Position Foot Position PMA MLA Dorsum
Sitting Relaxed position 130 80 60
Sub-talar joint neutrai 120 80 80
Lying supine Relaxed position 120 85 120
Sub-talar joint neutral 110 70 75
Lying prone knee extended Relaxed position 100 70 50
Sub-talar joint neutral 100 60 120
Mean ± SD 113.3±12.1 74.2±9.2 84.2+
29.7
Table 7.15. The comparison of data collected in different body positions using independent t-test, 
p values quoted.
Subject PMA MLA Dorsum
Sitting v lying 1 0.004 0.094 0.647
2 0.178 0.331 0.664
3 0.088 0.321 0.472
Prone v supine 1 - 0.293 0.613
2 - 0.515 -
3 0.095 0.30 0.792
STJ neutral v STJ 1 - 0.288 0.394
relaxed
2 0.374 0.210 0.872
3 0.561 0.365 0.596
There was no statistical significant difference in the data between subjects 1 and 
2 (p>0.05). However, the data from subject 3 was significantly different from 
subjects 1 and 2. Therefore, the data could not be grouped together for analysis.
To test for difference in the data as a result of different body positions, 
independent t tests were performed (Table 7.15). There was no significant 
difference between readings taken when the volunteers were sitting and lying. 
There were also no marked differences between prone and supine positions in 
each of the subjects. The sitting body position was chosen, as many of the 
potential volunteers for the main study would be elderly. This position did prove to 
be the most comfortable for the patients. There was no statistically significant 
difference between the relaxed and sub-talar joint neutral positions when the 
subjects were lying or sitting. However, the standard deviation from the mean of
256
the data from the dorsal site when the two different positions were adopted was 
high (Tables 7.12 -  7.14). Clinical biomechanical observations show that, when 
the foot is placed in a relaxed position on a surface, the shape and positioning of 
the foot differs greatly from person to person. When the foot is placed in a 
standard sub-talar joint neutral position, this variation is minimal. Therefore, a 
standard, neutral foot position for all volunteers was chosen.
7.7.4.2.2 Assessing the Variability in Readings between Sites
Once standard body and foot positions were identified, the next step was to test 
the variation in readings from different sections of skin on the same site. Three 
readings were taking on different sections of skin and compared (Fig. 7.14).
Figure 7.14. Illustration of the points measured on each site of the foot.
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7.7.4.2.2.1 Results
The results showed minimal differences between adjacent regions on a particular 
site of the skin (Table 7.16-7.18). In the main study the three sites were marked 
according to specific anatomical positions. These results allow the measurements 
to be taken with confidence even if the probe deviates slightly from the marked 
position.
Table 7.16. Variability between sites when subject is in the sitting position with the foot in STJ 
neutral position. Subject 1__________________________________________________________
Displacement of 
Epidermis (pm)
Coefficient of 
Variation (%)
PMA Site 1 15 6.3
Site 2 20
Site 3 18
MLA Site 1 98 12.3
Site 2 102
Site 3 105
Dorsum Site 1 200 33.3
Site 2 200
Site 3 210
Table 7.17. Variability between sites when subject is in the sitting position with the foot in STJ 
neutral position. Subject 2__________________________________________________________
Displacement of 
Epidermis (pm)
Coefficient of 
Variation (%)
PMA Site 1 10 0
Site 2 10
Site 3 10
MLA Site 1 23 0.3
Site 2 24
Site 3 23
Dorsum Site 1 42 1.3
Site 2 44
Site 3 44
Table 7.18. Variability between sites when subject is in the sitting position with the foot in STJ 
neutral position. Subject 3__________________________________________________________
Displacement of 
Epidermis (pm)
Coefficient of 
Variation (%)
PMA Site 1 117 6.3
Site 2 120
Site 3 115
MLA Site 1 98 6.3
Site 2 100
Site 3 95
Dorsum Site 1 83 6.3
Site 2 85
Site 3 80
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7.7.4.2.3 Testing the Effect of Pretension of Skin
In this case two points adjacent to each other were marked on the measurement 
site. The first area was not subjected to skin pretension and the second was 
(0.1s). Three consecutive readings were taken from each point and the results 
were compared.
7.7.4.2.3.1 Resuit
These results showed that pretension did not have a significant effect on the data 
collection, therefore in future experiments pretension was not used (Table 7.9- 
7.11).
Table 7.19. Comparing epidermal displacement with and without pretension. Subject 1
Displacement of 
Epidermis without 
pretension (pm)
Displacement of 
Epidermis with 
pretension (pm)
Paired t-test 
p value
PMA Site 1 15 15 0.423
Site 2 20 21
Site 3 18 18
MLA Site 1 98 98 0.423
Site 2 102 105
Site 3 105 105
Dorsum Site 1 200 200 -
Site 2 200 200
Site 3 210 210
Table 7.20. Comparing epidermal displacement with and without pretension. Subject 2
Displacement of 
Epidermis 
without 
pretension(pm)
Displacement of 
Epidermis with 
pretension(pm)
Paired t-test 
p value
PMA Site 1 10 10 -
Site 2 10 10
Site 3 10 10
MLA Site 1 23 20 0.184
Site 2 24 21
Site 3 23 23
Dorsum Site 1 42 42 0.423
Site 2 44 40
Site 3 44 44
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Table 7.21. Comparing epidermal displacement with and without pretension. Subject 3
Displacement of 
Epidermis 
without 
pretension(pm)
Displacement of 
Epidermis with 
pretension(pm)
Paired t-test 
p value
PMA Site 1 117 110 0.423
Site 2 120 120
Site 3 115 115
MLA Site 1 98 98 0.423
Site 2 100 99
Site 3 95 95
Dorsum Site 1 83 84 0.225
Site 2 85 87
Site 3 80 80
7.7.4.2.4 Testing whether 1hr is enough for the Skin to lose its “ Elastic
Memory”
This was carried out on each of the three sites on the foot. Three consecutive 
readings were taken from each site and then the subject was asked to lie in a 
resting position (prone). After 1 hr readings were taken from each site and the 
data was compared to that of the initial data set.
7.7.4.2.4.1 Results
Table 7.22. Subject 1
Initial 
Displacement of 
Epidermis (pm)
Displacement of 
Epidermis after 
1hr (pm)
p value
PMA Site 1 16 16 0.423
Site 2 19 18
Site 3 18 18
MLA Site 1 98 97 0.074
Site 2 102 100
Site 3 103 100
Dorsum Site 1 200 200
Site 2 200 200
Site 3 210 210
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Table 7.23. Subject 2
Initial 
Displacement of 
Epidermis (pm)
Displacement of 
Epidermis after 
1hr (pm)
p value
PMA Site 1 10 10 0.423
Site 2 9 10
Site 3 10 10
MLA Site 1 23 20 0.423
Site 2 24 24
Site 3 23 23
Dorsum Site 1 42 42 0.184
Site 2 44 40
Site 3 44 40
Table 7.24. Subject 3
Initial 
Displacement of 
Epidermis (pm)
Displacement of 
Epidermis after 
1hr (pm)
p value
PMA Site 1 117 110 0.195
Site 2 120 120
Site 3 115 110
MLA Site 1 98 90 0.204
Site 2 100 100
Site 3 95 90
Dorsum Site 1 83 80 0.208
Site 2 85 80
Site 3 80 80
These results confirm that the skin on the foot did not remain distended 1 h after 
measurements were taken. When repeated measurements were to be taken in 
the main experiment, 1 h was left between taking the readings.
7.8 Analysis of the Viscoelastic Properties of Pedal Epidermis
Graphical representation of all the data favoured the Kelvin model of 
viscoelasticity (Fig. 7.15). The first section of each graph describes the series 
elastic component (a instantaneous function) on stretching of the tissue. The 
second section depicts an exponential function, which describes the viscous 
properties and the parallel elastic element. The time constant of this curve 
describes the viscoelasticity properties. The third section describes the series 
elastic component on retraction and the final portion of the graph the exponential 
viscoelastic component of retraction. The tissue studied also exhibited plasticity,
i.e. the displacement did not return to zero when the displacing force is removed.
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To test that the curves fitted the Kelvin model, a sub group of data were selected, 
from 15 subjects, and the curves fitted to an exponential curve only (Voight 
model) and a step plus exponential (Kelvin model) and the curves were 
compared (Equation 5 and 6).
y = Ai + A2*(1 -  exp -t/x) 5
Kelvin Model
y = A2*(1 -  exp - t h)  6
Voight Model
Ai = Instantaneous displacement reading
A2 = Amplitude of the time-dependent (viscoelastic) component
t = time
t = time constant
All the curves that were fitted using equation 5 (Kelvin model) demonstrated a 
better fit. Therefore, the Kelvin model of analysis was appropriate for the analysis 
of epidermal viscoelasticity for all future data analyses.
The series elastic element of the rising and declining portion of the displacement­
time curves was expressed as magnitude of the stretch (pm). At the end of the 
series elastic phase, the time constants of the viscoelastic components of the 
curves were calculated (Fig. 7.16 & 7.17). The majority of the curves did not 
return to zero by the end of the run time, suggesting plastic behaviour of the skin. 
The plasticity was expressed as the ratio of final displacement at 120s to 
maximum displacement at 60s (Fig. 718).
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Figure 7.15. a. Examples of the curves obtained from the dorsum, MLA and PMA sites of the 
foot from a non-diabetic subject, b. Illustration of the Kelvin model of viscoelasticity
 ►
Time
Series elastic element
Displacement ^
Viscoelastic component
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Displacement [pm]
Time [s]
Figure 7.16. Diagram explaining the calculation of the series elastic element and the time 
constant on the rising portion of the displacement-time curves.
Series elastic element for the rising phase of the curve: Ai 
Time constant calculation for the rising phase of the curve:
y= A2 (1 -  (exp - t It)) 6
Where: A2=distance between the end of the elastic stretch and the displacement 
at 60s, t=time and x=time constant.
Displacement [pm]
Time [s]
Figure 7.17. Diagram explaining the calculation of the series elastic element and the time 
constant on the falling portion of the displacement-time curves.
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Series elastic element for the rising phase of the curve: Ai
Time constant for the declining phase of the curve:
y = A2 *(exp(-t/T)) 7
Where: A2=distance between the end of the elastic stretch and the displacement 
at 60s, t=time and x=time constant).
Displacement
[ p m ]
Plasticity=a/b
Time [s]
Figure 7.18. Diagram explaining the plasticity calculation. The higher the ratio, the more plastic the tissue. 
Plasticity: = a/b
Where a = displacement at 120s 
b = displacement at 60s
7.8.1 Closer Analysis of the Descending Portion of the Displacement -Time 
Curves
There were two possible explanations for the difference in appearance of the first 
and second portions of the graphs: (1) the tissue was permanently deformed as a 
direct result of the application of pressure, or (2) the tissue exhibited plastic 
behaviour. The former is not the case. The plasticity of the tissue is demonstrated
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by the gradual return to its original position. The energy required for stretching 
the tissue (kinetic energy) is stored in the elastic elements (potential energy) and 
released (kinetic energy) gradually during retraction, as the structural 
components of the tissue realign with each other. The device had its limitations, 
as the maximum time for data collection was 120 s, which was not sufficient for 
monitoring the return of the tissue to its original state.
There was no significant difference between the magnitudes of immediate stretch 
and immediate retraction (Table 7.25).
Table 7.25. Comparisons between the immediate stretch and immediate retraction data from the 
three sites on the foot (n=10).
Dorsum Elastic Portion (pm) MLA Elastic Portion (pm) PMA Elastic Portion (pm)
Rising Falling p value Rising Falling p value Rising Falling p value
52.5±21.5 49.0+ 15.2 0.578 43.0± 39.5 4.0 ± 25.4 0.616 2 6 0 ±  17.8 24.5+ 20.6 0.678
7.8 Summary
This set of experiments have shown that the Cutometer® 580 MPA is an 
appropriate device for the initial investigation of the elastic and the viscoelastic 
properties of pedal epidermis, in v/Vo‘s‘. The device is not free of error, however, 
when taking displacement readings. These errors in the pressure application and 
subsequent displacement readings, although minimal, were acknowledged when 
analysing the data in the main study (section 7.11 and chapter 10). This resulted 
in the delay in the suction readings by a fraction of a second. The environmental 
conditions, the positioning of the skin site and the use of the measuring probe 
were all essential features that were standardised.
The following is a presentation of data collected from the three foot sites of 87 
healthy volunteers. The time-displacement curves were generated and the elastic 
and viscoelastic qualities of the epidermis were analysed.
N In vitro two-dimensional analysis of the mechanical properties plantar callus tissue was 
attempted, but was not successful (Appendix X).
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7.10 Analysis of the Elastic and Viscoelastic Properties of the Epidermis 
from Different Sites of the Foot in Healthy Volunteers
7.10.1 Aims
• To generate and compare data from a!! three sites of the feet of 87 healthy 
volunteers.
• To compare the data between different sites, sexes, ages and races
7.10.2 Methods
The data were collected from the left foot of each of 87 healthy volunteers, in a 
sitting position, with the foot in subtalar joint neutral (the recruitment process is 
described in detail in Chapter 9). Before the readings were taken the volunteer 
lay in a supine position on the bed for approximately 15min. All volunteers were 
seen in the morning between 9am and 12noon. Readings were collected from the 
three sites, already identified. The probe was applied perpendicular to the skin for 
every reading and care was taken not to apply any external pressure. The room 
temperature and humidity was noted for every set of readings taken.
7.10.3 Results
The room temperature ranged between 21-25°C and the humidity of the 
environment was between 31-50%. The elasticity of the series elastic element; 
the time constant and plasticity (explained in section 7.8) were calculated for the 
three foot sites from all the volunteers.
7.10.4 Statistical Analysis of Data Collected from 87 Non-Diabetic Subjects
A full explanation of the recruitment of patients is described in detail in Chapter 9, 
along with the comparison of data between the diabetic and non-diabetic groups.
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7.10.4.1 Distribution of Data
The distribution of the data was skewed and covered a broad range of readings 
(Appendix XIV). All the data was analysed using non-parametric statistical 
analyses, mainly the Mann-Whitney test and the Spearman correlation.
7.10.4.2 Data Analysis
7.10.4.2.1 The Series Elastic Element and the Time Constant (Viscoelastic 
Component) on Stretching and Retraction of the Epidermis on all 
Three Sites of the Foot.
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Figure 7.19. A comparison between the series elastic element data on stretching and on 
retraction, a. Dorsum b. MLAc. PMA
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Figure 7.20. A comparison between the time constant data on stretching and on retraction, 
a. Dorsum b. MLA c. PMA
There was a significant difference between the series elastic element of 
stretching and on retraction of the epidermis on all sites on the foot (p=0.001). 
There was a significant difference in the time constants on stretching and 
retraction on the dorsal epidermis (p=0.001) only and not on the MLA and PMA 
skin sites.
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Table 7.26. Descriptive data for the Series elastic element and time constant data collected from 
three sites on the feet.
Dorsum MLA PMA
Series Elastic Element on Stretching [^m] Median 67 47 26
Interquartile Range 121 489 89
Minimum 31 2 0
Maximum 671 671 607
Series Elastic Element of Retraction frim] Median 38 27 17
Interquartile Range 22 20 24
Minimum 10 4 0
Maximum 120 61 319
Time constant on Stretching [s] Median 18.1 12.5 5.3
Interquartile Range 8.1 8.4 10.9
Minimum 3.3 0.2 0.0
Maximum 47.3 77.5 45.4
Time Constant on Retraction [s] Median 24.9 15.6 7.9
Interquartile Range 11.1 13.1 13.1
Minimum 0.0 0.0 0.0
Maximum 43.4 53.0 32.2
All the indices of elasticity were significantly different from site to site on the feet 
(p=0.01). The series elastic components, time constants and plasticity (Fig. 7.21) 
were the greatest on the dorsal site, followed by the MLA and then the PMA.
Median: 0.374 
Interquartile range: 0.264 
Minimum: 0.012 
Maximum: 0.979
MLA
Median: 0.191 
Interquartile range: 0.282 
Minimum: 0.000 
Maximum: 0.94
PMA
Median: 0.031 
Interquartile range: 0.500 
Minimum: 0.000 
Maximum: 1.000
Mann-Whitney Test
Dorsum v MLA: p = 0.001
Dorsum V PMA: p = 0.001
MLA v PMA: p=  0.001
Figure 7.21. The relationship between the three sites of the foot and the plasticity of the epidermis.
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7.10.4.2.2 The Relationship between Age and the Mechanical Properties
of the Pedal Epidermis.
7.10.4.2.2.1.1 The Series Elastic Element on Stretching
There was no correlation between the age of the subjects and the elasticity. No 
significant difference was noted between the 2 age groups on all three sites 
(Figs. 7.22-7.24).
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0
50 60 70 80 9030 40
Age [yrs]
Spearman Correlation
r=0.124
Age group <65 years n=67
Median: 64.0 pm 
Interquartile range: 64.0 pm 
Minimum: 31.0 pm 
Maximum: 671.0 pm
Age group >65 years n=20
Median: 89.5 pm 
Interquartile range: 523.8 pm 
Minimum: 31.0 pm 
Maximum: 620 pm
N* 67 20
Mann-Whitney Test
p = 0 . 4 1 4
Figure 7.22. The relationship between age and the series elastic element on stretching of the epidermis 
on the dorsum.
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Age [yrs]
Spearman Correlation
r—0.042
Age group <65 years n=67
Median: 48.0 pm 
Interquartile range: 499.0 pm 
Minimum: 2.0 pm 
Maximum: 671.0 pm
Age group >65 years n=20
Median: 43.0 pm 
Interquartile range: 338.5 pm 
Minimum: 4.0 pm 
Maximum: 580.0 pm
Mann-Whitney Test
p=0.315
<65ye irs >66years
Figure 7.23. The relationship between age and the series elastic element on stretching of the epidermis 
of the MLA.
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Age [yrs]
Spearman Correlation
r=-0.114
Age group <65 years n=67
Median: 30.0 pm 
Interquartile range: 493.0 pm 
Minimum: 0.0 pm 
Maximum: 607.0 pm
Age group >65 years n=20
Median: 20.0 pm 
Interquartile range: 59.8 pm 
Minimum: 4.0 pm 
Maximum: 597.0 pm
Mann-Whitney Test
p=0.440
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Figure 7.24. The relationship between age and the series elastic element on stretching of the epidermis 
on the PMA.
7.10.4.2.2.2 Series Elastic Element on Retraction
There was a correlation between age and the rate of retraction on the dorsal site. 
No such correlation was noted with the MLA and PMA sites, however, a 
significant difference was noted between the two age groups and the epidermal 
retraction on the dorsum and MLA. Subjects aged 65 and over had smaller 
magnitudes of epidermal retraction than compared to the younger age group.
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Spearman Correlation
r=-0.274
This correlation is significant at the 0.05 
level (2-tailed)
Age group <65 years n=67
Median: 41.0 pm 
Interquartile range: 19.0 pm 
Minimum: 10.0 pm 
Maximum: 120.0 pm
Age group >65 years n=20
Median: 28.0 pm 
Interquartile range: 16.5 pm 
Minimum: 10.0 pm 
Maximum: 68.0 pm
Mann-Whitney Test
p=0.002
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Figure 7.25. The relationship between age and the series elastic element on retraction of the epidermis 
on the dorsum.
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Age [yrs]
Spearman Correlation
r=-0.265
This correlation is significant at the 0.05 
level (2-tailed)
Age group <65 years n=67
Median: 29.0pm 
Interquartile range: 16.0pm 
Minimum: 5.0pm 
Maximum: 61.0pm
Age group >65 years n=20
Median: 17.5pm 
Interquartile range: 13.8pm 
Minimum: 4.0pm 
Maximum: 55.0pm
Mann-Whitney Test
p=0.006
< 65 ye ars >65 ye ars
Figure 7.26. The relationship between age and the series elastic element on retraction of the 
epidermis on the MLA.
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Age [yrs]
< 65ycars  >65years
Spearman Correlation
r—0.090
Age group <65 years n=67
Median: 17.0 (jm 
Interquartile range: 25.0 |jm 
Minimum: 0.0 pm 
Maximum: 319.0 pm
Age group >65 years n=20
Median: 12.5 pm 
Interquartile range: 24.25 pm 
Minimum: 1.0 pm 
Maximum: 50.0 pm
Mann-Whitney Test
p=0.586
Figure 7.27. The relationship between age and the series elastic element on retraction of the epidermis 
on the PMA.
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7.11.4.2.1.3 Time Constants on Stretching
There was no correlation between age and
50  
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30 
20 
10 
0
N = 67 20
<65years >65years
viscoelasticity (time constant).
Spearman Correlation
r=-0.131
Age group <65 years n=67
Median: 18.2 s 
Interquartile range: 8.1 s 
Minimum: 6.3 s 
Maximum: 47.3 s
Age group >65 years n=20
Median: 16.3 s 
Interquartile range: 8 0 s  
Minimum: 3.3 s 
Maximum: 30.5 s
Mann-Whitney Test
p=0.348
Figure 7.28. The relationship between age and the time constants on stretching of the dorsal epidermis.
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Spearman Correlation
r=-0.023
Age group <65 years n=67
Median: 13.7 s 
Interquartile range: 8.4 s 
Minimum: 0.2 s 
Maximum: 32.4 s
Age group >65 years n=20
Median: 11.4 s 
Interquartile range: 11.0 s 
Minimum: 6.5 s 
Maximum: 77.5 s
Mann-Whitney Test
p=0.539
Figure 7.29. The relationship between age and the time constants on stretching the epidermis 
on the MLA.
30 40  50 60 70 80 90
Age [yrs]
Spearman Correlation
r=-0.069
Age group <65 years n=67
Median: 5.3 s 
Interquartile range: 10.4 s 
Minimum: 0.0 s 
Maximum: 45.4 s
Age group >65 years n=20
Median: 5.6 s 
Interquartile range: 14.5 s 
Minimum: 0.2 s 
Maximum: 29.9 s
Mann-Whitney Test
p=0.380
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Figure 7.30. The relationship between age and the time constants on stretching of the epidermis 
on PMA.
7.10.4.2.2.5 Time Constants on Retraction
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Spearman Correlation
r=0.027
Age group <65 years n=67
Median: 24.9 s 
Interquartile range: 10.9 s 
Minimum: 0.0 s 
Maximum: 43.4 s
Age group >65 years n=20
Median: 24.2 s 
Interquartile range: 12.0 s 
Minimum: 0.0 s 
Maximum: 37.8 s
Mann-Whitney Test
p=0.661
Figure 7.31. The relationship between age and the time constants on retraction of the dorsal epidermis.
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Age group <65 years n=67
Median: 15.6 s 
Interquartile range: 13.5 s 
Minimum: 0.0 s 
Maximum: 53.1 s
Age group >65 years n=20
Median: 14.6 s 
Interquartile range: 13.5 s 
Minimum: 0.0 s 
Maximum: 38.2 s
Mann-Whitney Test
p=0.976
Figure 7.32. The relationship between age and the time constants on retraction of the epidermis on 
the MLA
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Spearman Correlation
r=-0.200
Age group <65 years n=67
Median: 8.5 s 
Interquartile range: 13.5 s 
Minimum: 0.0 s 
Maximum: 32.2 s
Age group >65 years n=20
Median: 5.9 s 
Interquartile range: 11.5s 
Minimum: 0.0 s 
Maximum: 25.4 s
Mann-Whitney Test
p=0.418
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Figure 7.33. The relationship between age and the time constants on retraction of the epidermis 
on the PM A.
7.10.4.2.2.5 Epidermal Plasticity
°  °  n _ °D °a q°oO D
□ a
Age [yrs]
Spearman Correlation
r=-0.261
Age group <65 years n=67
Median: 0.387 
Interquartile range: 0.411 
Minimum: 0.020 
Maximum: 0.979
Age group >65 years n=20
Median: 312
Interquartile range: 0.355 
Minimum: 0.012 
Maximum: 0.890
Mann-Whitney Test
p=0.164
Age Groups [yrs]
Figure 7.34. The relationship between age and plasticity of dorsal epidermis.
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r=-0.294
Age group <65 years n=67
Median: 0.184 
Interquartile range: 0.634 
Minimum: 0.000 
Maximum: 0.940
Age group >65 years n=20
Median: 0.111 
Interquartile range: 0.284 
Minimum: 0.000 
Maximum: 0.839
Mann-Whitney Test
p=0.116
Age Group [yrs]
Figure 7.35. The relationship between age and epidermal plasticity on the MLA.
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Interquartile range: 0.781 
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Maximum: 1.000
Age group >65 years n=20
Median: 0.072 
Interquartile range: 0.397 
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Maximum: 1.000
Mann-Whitney Test
p=0.557
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Figure 7.36. The relationship between age and epidermal plasticity on the PMA.
7.10.4.2.3 The Relationship between the Sexes and the Mechanical 
Properties of Pedal Epidermis
There was a marked difference in the series elastic element between the males 
and the females (males: n=38, females: n=49) on all foot sites (p<0.05). There 
was a significant difference between the sexes with regards to the time constants 
on the MLA and dorsal sites (p<0.05), but not the PMA site.
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Age Groups fyrsl
N* 38 49
male female
Male n=38
Median: 59.50 pm 
Interquartile range: 39.0 pm 
Minimum: 31.0 pm 
Maximum: 578.0 pm
Female n=49
Median: 87.0 pm 
Interquartile range: 546.5 pm 
Minimum: 37 pm 
Maximum: 671 pm
Mann-Whitney Test
p=0.001
Figure 7.37. The relationship between the sexes and the series elastic element on stretching of the 
dorsal epidermis.
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N* 38 49
mate female
Male n=38
Median: 43.0 pm 
Interquartile range: 22.5 pm 
Minimum: 6.0 pm 
Maximum: 630.0 pm
Female n=49
Median: 59.0 pm 
Interquartile range: 538 0 pm 
Minimum: 2.0 pm 
Maximum: 671.0 pm
Mann-Whitney Test
p=0.028
Figure 7.38. The relationship between the sexes and the series elastic element on stretching of 
the epidermis on the MLA.
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N= 38 46
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Male n=38
Median: 22.0 pm 
Interquartile range: 49.3 pm 
Minimum: 0.0 pm 
Maximum: 590.0 pm
Female n=49
Median: 28.0 pm 
Interquartile range: 517.5 pm 
Minimum: 4.0 pm 
Maximum: 607.0 pm
Mann-Whitney Test
p=0.039
Figure 7.39. The relationship between the sexes and the series elastic element on stretching of 
the epidermis on PMA.
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Male n=38
Median: 41.5 pm 
Interquartile range: 18.25 pm 
Minimum: 10.0 pm 
Maximum: 120.0 pm
Female n=49
Median: 35.0 pm 
Interquartile range 25.5 pm 
Minimum: 10.0 pm 
Maximum: 80.0 pm
Mann-Whitney Test
p=0.084
Figure 7.40. The relationship between the sexes and the series elastic element on retraction of 
the dorsal epidermis.
Male n=38
Median: 31.0 pm 
Interquartile range: 20.3 pm 
Minimum: 11.0 pm 
Maximum: 61.0 pm
Female n=49
Median: 24.0 pm 
Interquartile range: 17.5 pm 
Minimum: 4.0 pm 
Maximum: 55.0 pm
Mann-Whitney Test
p=0.006
Figure 7.41. The relationship between the sexes and the series elastic element on retraction of 
the epidermis on the MLA.
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Male n=38
Median: 17.0 pm 
Interquartile range: 31.5 pm 
Minimum: 0.0 pm 
Maximum: 319.0 pm
Female n=49
Median: 15.0 pm 
Interquartile range: 21.5 pm 
Minimum: 1.0 pm 
Maximum: 77.0 pm
Mann-Whitney Test
p=0.006
Figure 7.42. The relationship between the sexes and the series elastic element on retraction of 
the epidermis on the PMA.
Male n=38
Median: 19.1 s 
Interquartile range: 6.6 s 
Minimum: 12.0 s 
Maximum: 37.9 s
Female n=49
Median: 17.1 s 
Interquartile range: 7.4 s 
Minimum: 3.3 s 
Maximum: 47.3 s
Male Female Mann-Whitney Test
p=0.050
Figure 7.43. The relationship between the sexes and the time constant stretching of the dorsal 
epidermis.
Male n=38
Median: 15.4 s 
Interquartile range: 7.2 s 
Minimum: 6.2 s 
Maximum: 26.1 s
Female n=49
Median: 11.6 s 
Interquartile range: 8.9 s 
Minimum: 0.2 s 
Maximum: 77.5 s
Mann-Whitney Test
p=0.050
Figure 7.44. The relationship between the sexes and the time constants on stretching of the epidermis 
on the MLA.
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Male n=38
Median: 6.3 s 
Interquartile range: 14.0 s 
Minimum: 0.0 s 
Maximum: 45.4 s
Female n=49
Median: 4.5 s 
Interquartile range: 9.1 s 
Minimum: 0.1 s 
Maximum: 32.2 s
Mann-Whitney Test
p=0.457
Figure 7.45 The relationship between the sexes and the time constants on stretching of the 
epidermis on the PMA.
Male n=38
Median: 24.4 s 
Interquartile range: 10.5 s 
Minimum: 3.3 s 
Maximum: 43.4 s
Female n=49
Median: 25.4 s 
Interquartile range: 12.1 s 
Minimum: 0.0 s 
Maximum. 37.8 s
Mann-Whitney Test
» sr p=0.001
Figure 7.46 The relationship between the sexes and the time constants on retraction of the dorsal 
epidermis.
Male n=38
Median: 14.4 s 
Interquartile range: 19.3 s 
Minimum: 1.7 s 
Maximum: 53.0 s
Female n=49
Median: 16.7 s 
Interquartile range: 12.3 s 
Minimum: 0.0 s 
Maximum: 50.5 s
Mann-Whitney Test
p=0. 006
Figure 7.47. The relationship between sexes the time constants on retraction of the epidermis 
on the MLA.
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Male n=38
Median: 7.9 s 
Interquartile range: 11.7 s 
Minimum: 0.0 s 
Maximum: 31.5 s
Female n=49
Median: 9.1 s 
Interquartile range: 14.8 s 
Minimum: 0.0 s 
Maximum: 32.2 s
Mann-Whitney Test
p=0.415
Figure 7.48. The relationship between the sexes and the time constants on retraction of the epidermis 
on the PMA
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Male n=38
Median: 0.323 
Interquartile range: 0.600 
Minimum: 0.380 
Maximum: 0.979
Female n=49
Median: 0.462 
Interquartile range: 0.542 
Minimum: 0.012 
Maximum: 0.897
Mann-Whitney Test
p=0.013
Figure 7.49. The relationship between the sexes and dorsal epidermal plasticity
Male n=38
Median: 0.142 
Interquartile range: 0.207 
Minimum: 0.000 
Maximum: 0.926
Female n=49
Median: 0.218 
Interquartile range: 0.746 
Minimum: 0.000 
Maximum: 0.940
Mann-Whitney Test
p=0.054
Figure 7.50. The relationship between the sexes and epidermal plasticity on the MLA.
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Male n=38
Median: 0.016 
Interquartile range: 0.076 
Minimum: 0.000 
Maximum: 0.951
Female n=49
Median: 0.087 
Interquartile range: 0.848 
Minimum: 0.000 
Maximum: 1.000
Mann-Whitney Test
p=0.001
Figure 7.51. The relationship between the sexes and epidermal plasticity on the PMA.
7.10.4.2.4 The Relationship between Ethnicity and the Mechanical 
Properties of the Epidermis on the Foot
The subjects were divided into two groups (Caucasian: n=69 and non-caucasian: 
n=18). The numbers in the groups differed greatly; therefore further investigations 
should be carried out to gain a more realistic association.
Caucasian Ntxvcaucasian
Caucasian n=69
Median: 61.0 pm 
Interquartile range: 55.5 pm 
Minimum: 31.0 pm 
Maximum: 671.0 pm
Non-caucasian n=18
Median: 538.5 pm 
Interquartile range: 508.0 pm 
Minimum: 44.0 pm 
Maximum: 611.0 pm
Mann-Whitney Test
p=0.003
Figure 7.52. The relationship between ethnicity and the series elastic element on stretching of 
the dorsal epidermis.
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C aucas ian  Non-caucasian
Caucasian n=69
Median: 46.0 pm 
Interquartile range: 32.0 pm 
Minimum: 2.0 pm 
Maximum: 671.0 pm
Non-caucasian n=18
Median: 516.5 pm 
Interquartile range: 520.3 pm 
Minimum: 9.0 pm 
Maximum: 630.0 pm
Mann-Whitney Test
p=0.438
Figure 7.53. The relationship between ethnicity and the series elastic element on stretching of the 
epidermis of the MLA.
N= 69 18
C aucasian  N on-caucasian
Caucasian n=69
Median: 26.0 pm 
Interquartile range: 57.0 pm 
Minimum: 0.0 pm 
Maximum: 607.0 pm
Non-caucasian n=18
Median: 30.0 pm 
Interquartile range: 514.0 pm 
Minimum: 7.0 pm 
Maximum: 590.0 pm
Mann-Whitney Test
p=0.393
Figure 7.54. The relationship between ethnicity and the series elastic element on stretching of 
the epidermis of the PMA.
Caucasian n=69
Median: 41.0 pm 
Interquartile range: 18.5 pm 
Minimum: 10.0 pm 
Maximum: 120.0 pm
Non-caucasian n=18
Median: 27.0 pm 
Interquartile range: 18.0 pm 
Minimum: 10.0 pm 
Maximum: 80.0 pm
Mann-Whitney Test
p=0.001
N= 69 18
C aucas ian  N on-caucasian
Figure 7.55. The relationship between ethnicity and the series elastic element on retraction of
the dorsal epidermis.
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Caucasian n=69
Median: 29.0 pm 
Interquartile range: 17.5 pm 
Minimum: 4.0 pm 
Maximum: 61.0 pm
Non-caucasian n=18
Median: 18.5 pm 
Interquartile range: 14.25 pm 
Minimum: 9.0 pm 
Maximum: 51.0 pm
Mann-Whitney Test
p=0.024
N on-caucasian
Figure 7.56. The relationship between ethnicity and the series elastic element on retraction of 
the epidermis of the MLA.
N on-caucasian
Caucasian n=69
Median: 17.0 pm 
Interquartile range: 25.0 pm 
Minimum: 0.0 pm 
Maximum: 319.0 pm
Non-caucasian n=18
Median: 10.0 pm 
Interquartile range: 26.0 pm 
Minimum: 1.0 pm 
Maximum: 67.0 pm
Mann-Whitney Test
p=0.160
Figure 7.57. The relationship between ethnicity and the series elastic element on retraction of 
the epidermis of the PMA.
Caucasian n=69
Median: 18.2 s 
Interquartile range: 7.3 s 
Minimum: 6.3 s 
Maximum: 47.3 s
Non-caucasian n=18
Median: 16.3 s 
Interquartile range: 9.4 s 
Minimum: 3.3 s 
Maximum: 32.3 s
Mann-Whitney Test
p= 0.224
N = 69 18
C aucas ian  N on-caucasian
Figure 7.58. The relationship between ethnicity and the time constants on stretching of the
dorsal epidermis.
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Caucasian n=69
Median: 13.5 s 
Interquartile range: 8.3 s 
Minimum: 0.2 s 
Maximum: 77.5 s
Non-caucasian n=18
Median: 11.4 s 
Interquartile range: 9.3 s 
Minimum: 6.4 s 
Maximum: 28.4 s
Mann-Whitney Test
p=0.438
Non-caucasian
Figure 7.59. The relationship between ethnicity and the time constants on stretching of the 
epidermis of the MLA
Caucasian n=69
Median: 6.5 s 
Interquartile range: 12.1 s 
Minimum: 0.0 s 
Maximum: 45.4 s
Non-caucasian n=19
Median: 1.6 s 
Interquartile range: 4.1 s 
Minimum. 0.1 s 
Maximum: 25.1 s
Mann-Whitney Test
p=0.003
Figure 7.60. The relationship between ethnicity and the time constants on stretching of the 
epidermis of the PMA.
Non-caucasian
Caucasian n=69
Median: 24.9 s 
Interquartile range: 10.6 s 
Minimum: 0.0 s 
Maximum: 43.4 s
Non-caucasian n=19
Median: 25.4 s 
Interquartile range: 13.5 s 
Minimum: 0.0 s 
Maximum: 37.8 s
Mann-Whitney Test
p=0.001
Figure 7.61. The relationship between ethnicity and the time constants on retraction of the
dorsal epidermis.
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Caucasian n=69
Median: 15.6 s 
Interquartile range: 14.4 s 
Minimum: 0.0 s 
Maximum: 53.0 s
Non-caucasian n=19
Median: 15.2 s 
Interquartile range. 11.7 s 
Minimum: 0.0 s 
Maximum: 37.0 s
Mann-Whitney Test
p=0.081
Figure 7.62. The relationship between ethnicity and the time constants on retraction of the 
epidermis of the MLA.
Caucasian n=69
Median: 8.9 s 
Interquartile range: 12.6 s 
Minimum: 0.0 s 
Maximum: 32.2 s
Non-caucasian n=19
Median: 0.0 s 
Interquartile range: 11.0 s 
Minimum: 0.0 s 
Maximum: 19.7 s
Mann-Whitney Test
p=0.159
Figure 7.63. The relationship between ethnicity and the time constants on retraction of the 
epidermis of the PMA.
0.6
Caucasian n=69
Median: 0.362 
Interquartile range: 0.187 
Minimum: 0.012 
Maximum: 0.897
Non-caucasian n=19
Median: 0.503 
Interquartile range: 0.644 
Minimum: 0.083 
Maximum: 0.979
Mann-Whitney Test
p=0.197
Figure 7.64. The relationship between ethnicity and dorsal epidermal plasticity
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Caucasian n=69
Median: 0.161 
Interquartile range: 0.251 
Minimum: 0.000 
Maximum: 0.926
Non-caucasian n=19
Median: 0.483 
Interquartile range: 0.806 
Minimum: 0.000 
Maximum: 0.940
Mann-Whitney Test
p=0 224
N = 69 10
C aucasian  N on-caucasian
Figure 7.65. The relationship between ethnicity and epidermal plasticity on the MLA.
Caucasian n=69
Median: 0.024 
Interquartile range: 0.146 
Minimum: 0.000 
Maximum: 1.000
Non-caucasian n=19
Median: 0.657 
Interquartile range: 0.877 
Minimum: 0.000 
Maximum: 1.000
Mann-Whitney Test
p=0.003
N= 69 18 '
C aucasian  Non-caucasian
Figure 7.66. The relationship between ethnicity and epidermal plasticity on the PMA.
7.11 Summary
The series elastic element on stretching was significantly higher than on 
retraction of the epidermis, on all sites of the foot (Fig. 7.19, p=0.001). There was 
a correlation between the age of the volunteers and the series elastic element on 
retraction of the dorsal epidermis (Fig. 7.25, r= -0.274), suggesting that as age 
increases, the epidermal dorsal elasticity decreases. This was not noted on the 
MLA and PMA sites. The viscoelasticity on stretching of the tissue was 
significantly lower than the viscoelasticity when the displacing force was removed
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on the dorsal site only (Fig. 7.20, p=0.001). The viscoelasticity and plasticity on 
all three sites did not relate to age.
When comparing the mechanical properties between genders and ethnicity the 
linear elasticity elements on stretching were significantly higher in females than 
males. The time constants on stretching were lower in females than males, but 
they were higher on retraction of the skin on the dorsal and MLA sites only. 
Plasticity was significantly greater on all sites in the female group.
7.12 Discussion
The evaluation of the mechanical properties of the epidermis of the foot has been 
successfully conducted with a vertical suction device. In the past, one of the 
limitations of such devices has been a lack of detail in the data collected, hence 
imposing limitations on the analysis. An additional hindrance has been the 
inability of devices to make sufficient measurements of rigid areas of skin I2391.
In this study the suppliers of the Cutometer® 580 MPA adapted the software to 
provide pressure-time and displacement-time profiles, simultaneously. With these 
data, the machine was successfully tested for accuracy and repeatability. The 
time taken for the pressure to rise from the initial Ombar reading to 500mbar was 
a fraction of a second (~0.1 s). The pressure theoretically should have remained 
constant (500 mbar) throughout the 120 s of data collection as the force 
application in the Kelvin model must follow a square wave pattern. In practice, the 
pressure was seen to deviate above or below 500 mbar. This error was 
measured and all the displacement data were adjusted to fit the corrected 
(square wave) pressure.
In order to minimise variations in data between individuals, the position of the 
body and feet of each volunteer were standardised. The environmental conditions 
were maintained as constant as possible and the readings were taken at the 
same time of day for each volunteer. The room temperature (21-25°C) and 
humidity (31-50%) did not deviate from the recommended levels.
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Although the measurements were referred to in terms of the elastic and 
viscoelastic components of the epidermis, the influence of the underlying dermal 
tissues cannot be ignored. Because of the size of the aperture in the probe, the 
dermal involvement was probably minimal. A possible way of testing for the 
extent of dermal involvement would be to take an ultrasound image of the skin 
during the application of the displacing force. The development of such a device 
would not only identify the structures involved during deformation, but could also 
provide details of the accumulation of fluids in the area and any other underlying 
anomalies in the skin structure. The two techniques when used in synchrony, 
may be useful in monitoring the change in the physical properties of skin during 
the progression of disease and also in assessing the local beneficial effects of 
particular treatments. The next chapter investigates ultrasound images of normal 
pedal skin and the appearance of different structures (e.g. collagen, fat and 
fluids) within the skin expressed in terms of echogenicity.
Application of fixed stress induced a tissue change that followed a viscoelastic 
path. That the instrument is known to sample the epidermis disproportionately to 
the dermis supports the view that the epidermis is a viscoelastic tissue, just as 
the same properties are exhibited by the dermis.
The linear elastic constant of the epidermis on stretching was higher than on 
retraction on all three sites on the foot, i.e. the rate of stretch exceeded the rate of 
retraction. This was expected, as an external energy force fuels the process of 
stretching the tissue. Once the displacing force is released, the speed with which 
the skin retracts is energised by the recoil of the tissue and not aided by an 
external source of energy (Fig. 7.67).
Due to the limited work conducted on pedal skin, there is no standard to compare 
any changes in the mechanical properties of this area of skin in response to 
disease. Before speculating on the pathological changes in the epidermis on the 
feet, the need to understand the mechanical behaviour of this type of skin in the 
absence of disease is fundamental. The three different sites on the foot in this 
study were chosen in relation to the compression, shear and torsion pressures 
that they are subjected to during gait. The dorsal skin is least involved with
295
mechanical trauma of this kind (although footwear is a common source of friction) 
and the PMA is subjected to relatively high pressures. The common protective 
physiological response of skin, particularly that of the PMA is the development of 
hyperkeratosis, which may lead to the formation of pathological callus.
Other factors that should be considered when looking at these different sites are 
what relationship they have with the underlying structures, such as bones and 
joints. The movement of these structures may impose an intrinsic adaptive 
response by the dermal and epidermal tissues, i.e. just as the skin adapts to 
external forces by thickening, it must be flexible enough to accommodate the 
movement of joints such as the metatarsophalangeal joints, during gait. The 
blood and nerve supplies to these areas may also have an input, more so in 
peripheral vascular disease and peripheral neuropathy. The mechanical 
behaviour at a cellular level in relation to the glycation of the epidermal proteins 
and cell-cell adherence proteins, as well as the physical behaviour of the skin on 
a macro level are discussed in the final chapter when the data from the diabetic 
population is considered.
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Figure 7.67. Diagram illustrating the viscoelastic behaviour of the skin when subjected to
vertical suction pressure.
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The dorsal skin had the greatest plasticity, linear elasticity constant and time 
constant of viscoelasticity both on stretching and retraction. The lowest values of 
all the indices of elasticity were measured on the PMA. Therefore, the epidermal 
tissue on the PMA area is less elastic, viscous and plastic than the skin on other, 
less weight bearing areas. This sets a standard to which the data collected from 
the diabetic subjects can be compared.
An interesting result was the decrease in the linear elasticity element, on 
retraction, with an increase in age on dorsal site only. This suggests that, effects 
of aging limit the ability for the elastic recoil of dorsal skin. This correlation was 
not seen on the MLA and PMA sites. It could be reasoned that the equilibrium 
state of the epidermis (before any displacing force is applied) on all three sites 
possesses different quantities of internal bonding (and therefore energy) between 
the cells and between the cell constituents. Therefore, when the suction force is 
applied to the surface of the skin, the adhesion between the cells and the 
intermolecular bonds that maintain the structure of the epidermis, are challenged 
and the tissue stretches. If the bonds are stronger or more abundant in the PMA 
site than the dorsal epidermis, then higher forces would be needed to stretch the 
tissue to the extent of the dorsal epidermis. It follows that these high/ abundant 
energies holding the tissue together remain within the tissue when under stress 
and not released during the viscoelastic and eventually the series elastic element 
on retraction. In brief, the skin is less flexible on the PMA than the dorsum of the 
foot. Ishikawa T et al (1995) 12271 found that the elastic properties of palmar skin 
(the finger) were not correlated with ageing. It is possible that fingers are exposed 
to various exogenous stimuli that profoundly affect the nature of the skin, this 
masking of chronological changes may also be occurring in plantar skin.
The next chapter focuses on the application of high frequency ultrasound imaging 
for the measurement of epidermal thickness. One of the observations made in 
Chapter 8, is the epidermis is thinner on the dorsum than the PMA. Therefore, 
under suction pressure, it is likely that a higher proportion of the highly elastic 
dermis on the dorsum will be drawn up into the aperture than on the PMA and will 
contribute to the elasticity readings.
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8.0 Chapter 8 -  The Investigation of Pedal Skin, in vivo, using High 
Frequency Ultrasound Imaging
8.1 Introduction
Until the advent of high-resolution ultrasound imaging of skin, methods such as 
skin pinching and weighing of skin biopsies t37:24°] had attempted to describe 
semi-quantitatively the consequences of disease on dermal tissues. High- 
frequency B-mode ultrasonography provides a method for two-dimensional in 
vivo imaging of the skin. Although examination of this kind does not have the 
resolution of histology, the advantages of ultrasound are that it is non-invasive 
and the results are immediate [220]. Reflected ultrasound waves are detected and 
processed by the instrument to produce a real-time image, as a one-dimensional 
amplitude modulated display (A scan) or a 2-dimensional brightness modulated 
display (B scan). Ultrasound has been used in a variety of dermal applications, 
such as measuring full skin thickness I241,I dermal odema P42;243it skin tumours 
12441 and wounds I245]. This is especially relevant to skin sites such as the sole of 
the foot, where full skin thickness removal for histological analysis, particularly 
from neuroischaemic diabetic patients, is not feasible.
The preferred instrument for skin imaging is the Dermascan C®, 20 MHz 
ultrasound scanner (Cortex Technology, Hadsund, Denmark). The majority of the 
studies carried out using the Dermascan C® have concentrated only on the skin 
of the arms and legs. The authors described thick skin on the palms and the 
soles, but did not discuss the results in detail, and no quantitative data were 
reported t22°;24i:24*247]
8.2 Techniques used to Measure Skin Mechanics in vivo
Over the past 30 years there has been extensive development and refinement of 
equipment and techniques involved with high-frequency ultrasonography. This 
has led to three types of scanning techniques: A-mode scanners (unidirectional in 
principle and suitable for measuring the skin thickness and the distances
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between easily identifiable interfaces); B-mode scanners (bi-directional and 
allowing cross-sectional imaging of the skin); C-mode scanners (depicting a 
number of automatic and parallel B-scans forming a three-dimensional image of 
skin); M-mode scanners (recording moving interfaces such as the wall of a large 
artery) and Doppler (measuring fluid flow such as blood). At the moment A - B- 
and C-mode ultrasonography are directly relevant to skin research.
8.3 Ultrasound Examination of Normal Skin
Although the basic organisation of the skin is the same throughout the body, the 
skin on the plantar aspect of the foot is unique [241], in that it is thick 
(approximately 10 times thicker than epidermis on other parts of the body) and 
hairless. The stratum comeum is the thickest layer in plantar epidermis. Even in 
the foetus it is appreciably thicker than the skin over other areas. During life, the 
plantar skin adapts to continuous pressure and friction by further thickening. The 
dermis in the sole is about 3mm or more thick and is composed of vascular, 
dense connective tissue.
The acoustic density of components of the skin, determines the clarity of an 
ultrasound image. The ultrasonic wave penetrating through the skin is partially 
reflected at the boundaries of the adjacent structures, and echoes of various 
amplitudes are generated. The average amplitude of the echoes in a defined 
area of the image is termed “echogenicity”. The epidermis and dermis reflect 
ultrasound variably, but both have well-defined interface echoes, excluding the 
interface between the dermis the subcutaneous fat, which is far from smooth due 
to the attachments of the subcutaneous retinacula. These factors are subject to 
regional variation, with thinner skin on the arms and legs in comparison to the 
acoustically dense truncal skin I24il. A well-organised fibre network in the dermis 
allows for high reflectance of ultrasound, consequently producing clear images. A 
disturbance of this network, such as odema causing a subepidermal increase in 
interstitial fluid, results in low reflectance. Echoes may be disturbed by air 
contained within epidermal scales, which cause heavy reflections and shadows 
on the images, thus making the epidermis a low-reflectant. Dermal echoes are 
also influenced by the distensibility state of the skin, which can alter according to
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the positioning of the joints. In the palms and the soles the fibre orientation is 
variable, and the ultrasound reflectancy is consequently disturbed. However, the 
epidermal thickness is easily measured on palms and soles, where the interface 
to the low-reflectant dermis of these regions can be reliably defined.
8.4 Ultrasound Versus Histology as Comparative Techniques
Histological examination, with its long tradition, is regarded as a gold standard for 
the investigation of skin. This makes the use of ultrasonography, as a new 
alternative, difficult. The main limitation of the histological technique, in terms of 
comparative studies, is the skin undergoes retraction and gross change of 
dimensions on cutting and removal.
Although, in vivo 20 MHz ultrasound examination does not have the resolution of 
histology, the layers of the skin are identifiable (Table 8.1).
Table 8.1. Ultrasound characteristics of normal human skin
Skin components Ultrasound (20MHz) characteristics
Epidermis Stratum Corneum 
Cellular layer
Strong entry echo, dependent upon the thickness of 
the stratum corneum.
Thin echolucent band, not usually possible to 
measure, unless from an area that has a 
characteristically thick epidermis.
Dermis Papillary dermis 
Reticular dermis
Hypodermis
Generally an echo-poor region, but interspersed with 
areas of high echogenicity.
An echo-rich region, the majority of the echogenicity 
originating from collagen fibres within the tissue. 
Collagen is identified as bundles aligned parallel to 
the surface of the skin on the scans.
Generally an echo poor region, but the fine collagen 
network that lies within the tissue can also be 
identified as bands of higher echogenicity.
Muscle layer Muscle tissue 
Connective tissue
These areas can be identified as echo-rich bands, 
with a regular alignment of fibres within the bands 
themselves, although it is thought that the muscle 
tissue itself is echo-poor.
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8.5 Ultrasound Technology and Ultrasound Equipment
Acoustic impedance is defined as the product of the density of the tissue and the 
velocity of sound in the tissue. The elasticity and density of the tissue determine 
the velocity of longitudinal sound waves in a tissue. It is the difference in acoustic 
impedance between two adjacent media, which determines echogenicity. 
Ultrasound follows optical laws where the character of a tissue interface and the 
incident angle of the ultrasound beam are prerequisites for an echo to be 
apparent.
The centre of frequency of any ultrasound equipment gives only limited 
information about the resolution of the system. There is a popular but incorrect 
idea that high frequency is automatically followed by high resolution, and it is 
often forgotten that, with high frequency, the viewing field in depth becomes 
smaller. General experience has confirmed that 20 MHz provides a good 
compromise between resolution and viewing depth.
8.5.1 Technical Specifications for Good Resolution
Resolution and appropriateness of an ultrasound system can be deduced only 
partly from certain technical specifications, and the skill of the operator. To avoid 
biased evaluations, the principles of objective and blinded comparison should be 
employed whenever possible. Some main variables to consider are: bandwidth 
and centre frequency; resolution (axial and lateral); scan speed; swept gain (fixed 
or adjustable); viewing field in depth (fixed and adjustable); scan modes 
(A/B/C/M); measuring and storage facilities and image analysis; and a selection 
of probes.
8.6 Skin Ultrasonography using the Dermascan® C
For this study the images of skin were obtained by the Dermascan® C Ver, 3, 
ultrasound scanner (Dermascan C®, Cortex Technology, Hadsund, Denmark). 
The instrument comprises of 3 main parts: the ceramic transducer (centre 
frequency 20MHz), the visualisation and analysis system and the data storage
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facility. The probe is housed in water bath, and sealed at the point of contact with 
a thin plastic membrane. The scanning field is 22.4 x 2.4 mm. The maximum 
width of the field of view is 13mm and may be scrolled down to 30 mm in depth. A 
minimal amount of conventional coupling gel is used on the surface of the skin.
Each B-mode picture is composed of 224 A-scans (12 images per second). 
Swept gain is fully operator adjustable with respect to slope, level and profile and 
can be saved for standardisation of the method. The gain and viewing fields can 
also be adjusted on the live image.
With computer assisted image analysis systems (IBM-compatible), it is possible 
to quantify the amplitude of single echoes, and thus to measure echogenicity. 
The density of the tissue determines the velocity of the longitudinal waves in a 
tissue. The intensity of the reflected echoes is evaluated by the microprocessor, 
and visualised as a coloured two-dimensional image. Care must be taken to 
maintain the probe perpendicular to the skin surface during scanning and to 
minimise the pressure of the transducer on the skin surface to ensure a 
satisfactory scan 12461.
8.6.1 Validation of the Dermascan C® - Carried out by Cortex Technology
Protocols documenting the accurate capture of images and measurements were 
validated by the makers of the device.
8.6.1.1 Image Capture Validation Procedures
A plastic test specimen with a known thickness and sound velocity is scanned. As 
the material used is homogenous, two distinct echoes are achieved from which 
the thickness can be measured using the predetermined sound velocity of the 
material. The thickness measurement procedure follows an in-depth 
measurement along the horizontal axis. The accuracy of the horizontal scaling of 
the captured images was also documented. Similarly the accuracy of the vertical
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scaling was documented by scanning a wire set-up within the material with a 
known inter-wire distances.
8.6.1.2 Measurement Functions Validation Procedures
Once the scaling is found to be correct, measurements of distances are validated 
by drawing triangles, with predefined comer co-ordinates, on the captured image 
and measuring the length of the sides. This process ensures that the captured 
image is correctly scaled both in the horizontal and vertical axes. Once the image 
is shown to be correct, the next stage is to show that any (software) calculations, 
which derive results from the image, are also correct, i.e. the sides, areas and 
line lengths drawn on the B-scan images are calculated theoretically and 
compared to the results obtained from the scanner. This is then compared with 
the results on the Dermascan C® software and the measurement functions. In 
short, the validation procedure confirms the accuracy of the image and the 
accuracy of the derived results.
All measurements were repeated for the three different zoom levels and an error 
of +/- 1% was accepted. The validation procedure was checked and accepted by 
the American Food and Drug Administration (USA).
8.7 Ultrasound Velocity of Skin
Ultrasound velocity in skin can depend on the body region. Estimates of 
ultrasound velocity are: 1550 m/s in the stratum corneum; 1540 m/s in the 
epidermis p461; 1580 m/s in the dermis and 1440 m/s in subcutaneous fat. 
Ultrasound velocity 1580 m/s is commonly used for the imaging and 
measurement of total skin thickness. However, in the stratum corneum the 
velocity is higher and will probably approach the velocity of ultrasound in the nail 
plate, 2459 m/s. From a practical point of view, a minor deviation of ultrasound 
velocity from the true value of a particular location will not influence significantly 
the full skin thickness measurement, but may influence measurements of the 
epidermis.
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8.8 Ultrasound Examination of Skin Pathologies
8.8.1 A-Mode Scanning
A-mode scanning is useful for measuring nail-plate and epidermal thickness and 
has also been used in the past for the quantification of different skin diseases, 
e.g. psoriasis, sclerotic lesions, tumours and inflammatory odema in contact and 
atopic dermatitis. A-mode skin thickness measurements can contribute to 
diagnosis, and it is a useful tool to follow-up and assess the effect of treatments, 
e.g. corticosteroids. It is common to find that skin thickening and thinning, as a 
result of the pathological conditions, including endocrine disorders, is more 
pronounced in the extremities than on the trunk. Thus, as a quantitative tool, A- 
mode ultrasound measurements of skin thickness have a wide field of application 
in experimental as well as clinical dermatology. A-mode measurements do not 
bear the obvious risk of bias of B-mode measurements, when the scan line can 
be selected from the image. In measurement of skin thickness with A-mode it is 
recommended that the mean of 3 readings be taken in order to minimise 
biological local site variation and selection of a less appropriate echo. However, 
with the Dermascan C® scanner, used in this study, an average skin thickness 
measurement is made based on 224 A-mode scans and a 22.3 mm piece of skin 
can be measured relatively quickly.
8.8.2 B-Mode and C-Mode
These types of scanning can be used when the images do not necessarily have 
to provide quantitative data. The natural field of study using these modes is that 
of analysis of tumours. Other areas of qualitative analysis using this type of 
scanning are: wounds i245:247=248] inflammatory lesions; subepidermal odema, 
scleroderma and psoriasis p491. Recent data suggests that B mode assessment 
is more reproducible, although its execution requires more time and attentionl250]. 
Different results are obtained by performing these measurements at the same 
skin site employing different swept gain curves. By using a gain curve at a higher 
level a higher measurement is recorded. This explains why a fixed gain curve 
must be adopted when taking measurements from different subjects.
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8.9 Ultrasound Imaging of Skin from the Foot
The echographic images of thick, ridged skin are very different from images taken 
from thin skin. The epidermis in the images of the very thick ridged skin (at least 
100 pm) is very well defined, whereas in the thin skin it is too thin to be resolved 
[246;249] However, the separation between the dermis and the subcutaneous layer 
in thick, ridged skin is ill defined, in contrast to thin skin. This could be due to the 
fact that in the palms and soles the fibre orientation in the dermis is variable and 
therefore the ultrasound reflectancy is less. Also, some of the ultrasound waves 
will not penetrate through the thick epidermis and papillary dermis. In some of the 
images there is a low echogenic layer just deep to the epidermis. This 
subepidermal low echogenic band has been described in aged skin on sun- 
exposed sites, in the legs of persons with venous disease, and is a frequent 
finding in ultrasonic images.
The most striking characteristics of images of plantar and palmar skin are the 
very echogenic structures within the epidermis, parallel to the entrance echo. 
These structures are visible in images of the skin on the heel, the metatarsal 
heads and the fingertips, although in images of older persons they are less 
pronounced.
The histopathological pattern of the sole of the foot confirms the thick epidermis 
measured by ultrasonography along with clearly visible layers of the epidermis. 
When methylene blue stain is used, the thickening of the epidermis is seen at the 
sites where the eccrine sweat glands penetrate through the epidermis into the 
dermis. This thickening of the epidermis could explain the echogenic structures in 
the images made by the ultrasound scanner. The thickening of the epidermis 
around the eccrine gland at the point where they penetrate through the epidermis 
into the dermis is probably a mechanism to protect the eccrine sweat glands from 
shearing stresses. Alternatively this low echogenic internal epidermal echo may 
represent the stratum corneum of the epidermis, the water barrier zone of the 
skin. It has been suggested that the skin on the sole of the foot needs water to 
preserve its resilience [53]. There is some evidence that water content of the skin 
will increase after the application of pressureI2511.
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8.9.1 Plantar Pressures and Ultrasound Imaging
The pathophysiology of pressure ulcers on the foot is not completely understood. 
In recent years it has been realised that simple ischaemia alone is an inadequate 
explanation of pressure ulcer pathogenesis. It is suggested that the skin needs 
water to maintain its resilience and its resistance to external injury and will 
therefore increase in its water content after being subjected to increased 
pressure£2511.
The plantar surface of the foot is frequently exposed to external pressures, the 
magnitude of which depends on the type of activity and peak pressure values 
under the calcaneus and the metatarsal heads. These pressures result in the 
compression of the skin and the underlying tissue and the skin blood supply. 
Thoolen (1999)12511 reported that ultrasound images of the plantar aspect of the 
foot after a period of application of external pressure showed a reduction in the 
echogenicity of the skin. This could correlate with an increase in water content, 
but could also correlate with the alteration in the organisation of the collagen 
fibres.
8.10 Summary
This study aimed to define the characteristics of normal plantar skin using high 
frequency, diagnostic ultrasound A&B-mode scanning. Measurements of 
epidermal thickness at specific sites on the foot were made and compared. The 
effects of capturing images at different acoustic velocities, on the measurement 
of epidermal thickness, were also tested.
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8.11 Measurement of Epidermal Thickness on the Feet
8.11.1 Aims
• Examining ultrasound images taken from different sites on the foot and 
identifying relevant skin structures.
• To compare the thickness of the epidermis from different sites on the foot.
8.11.2 Methods
Images of the skin were taken from each volunteer, from the same sites as 
described in Chapter 7: PMA, MLA and dorsal aspect of the left foot. Each 
volunteer was sitting with the foot in a subtalar joint neutral position. Images were 
captured with the ultrasound machine set at an acoustic velocity 1580 m/s 
(recommended value for full skin thickness imaging). The epidermal thickness 
was measured using the A- and B-scan images. The outer and inner boundary 
lines, representing the epidermis, were used to take measurements. The 
software generated an average reading in mm. The same swept gain setting was 
used for every image taken (Fig. 8.1). Care was taken to maintain the ultrasound 
beam perpendicular to the skin surface and to minimise the pressure of the 
transducer on the skin surface to ensure a satisfactory scan.
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Figure 8.1. Illustration of the swept gain setting used for ultrasound images
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The images were taken from all the volunteers recruited for the study: 103 
diabetic and 87 non-diabetic individuals. The data collected from the non-diabetic 
subjects were analysed in this section and the data taken from diabetic 
individuals was analysed and discussed in Chapter 9 and 10.
8.11.3 Results
8.11.3.1 Examination of the Ultrasound images
The ultrasound scans were presented in a linear rainbow scale such that areas of 
tissue that had a high acoustic impedance (e.g. collagen) appeared as white, red 
or yellow areas. Tissue areas with low acoustic impedance (e.g. cellular or fluid 
filled) were represented as blue or black areas (Fig. 8.2).
The ultrasound scan (Fig. 8.2) demonstrates an echogenic (high acoustic 
impedance) entry echo in the surface of the tissue (yellow and white band) below 
which a thin area of echolucency was poorly defined and difficult to measure 
accurately. This measuring difficulty may have been due to the undulating nature 
of the rete ridges and papillae of the epidermal-dermal junction causing refraction 
of the ultrasound signal, thus complicating the signal reflection. Alternatively, 
there may have been partial masking of the epidermis entry echo by the 
echogenic characteristics of the stratum corneum, thus attenuating the ultrasound 
signal. This was supported by data showing that areas with very hyperkeratotic 
homy plaques cause a marked reflectance of signal, whereas with thin or 
hydrated epidermis virtually no entry echo signal is identifiablel249].
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Figure 8.2. A typical ultrasound image of skin taken from the dorsum of the foot.
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The dermis is divided into 3 regions, the papillary dermis that contains hillock like 
projections of fine collagen, reticulin and elastin fibres, blood vessels, terminal 
nerves and fibrils that anchor the epidermis to the dermis. The deeper reticular 
dermis is composed of thicker and coarser bundles of type I and type III collagen 
interwoven with elastin fibres. Below this lies the hypodermis, a thin layer of loose 
connective tissue and adipose cells. Collagen fibres are orientated in a criss­
cross network, the long axis of the fibres tending to lie parallel to the skin's 
surface. Subcutaneous fat may extend into parts if the reticular dermis where 
coils of the sweat glands are often found.
The ultrasound scan of the dermis could be divided into an upper band consisting 
of echolucent areas, interspersed with echo-rich areas. This latter feature found 
throughout the tissue corresponded to areas of the papillary dermis containing 
adipose tissue, which could be identified as specific nodular echolucent areas on 
the scans. Deeper in the tissue highly regular echo-dense regions (yellow and 
red) were attributed to collagen fibres orientated parallel to the skin surface within 
the reticular dermis.
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8.11.3.2 Comparison between Different Skin Sites
a.
b.
c.
Figure 8.3. Examples of ultrasound images taken from the a. dorsum, b. medial 
longitudinal arch and c. plantar metatarsal area on the feet.
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All the images of dorsal skin presented with the characteristics of skin found 
elsewhere on the body, that of clearly defined identifiable regions in dermis, 
represented by orange and red areas and the epidermis, represented by the 
bright yellow regions (Fig. 8.3a). All the images generated from the three different 
foot sites clearly illustrated the yellow epidermal bands in varying degrees of 
thickness. The PMA and MLA images, particularly the latter, often had a band of 
low echolucency immediately beneath the yellow epidermal band (Fig. 8.3b), 
which could be as a result of the high echolucency of the stratum corneum 
portion of the epidermis. Therefore, the measurements of the yellow bands were 
representative of the epidermal stratum corneum. There were also observed 
differences in the dermal images between the different sites. The plantar arch 
and metatarsal images had a higher distribution of black and blue areas. The 
PMA site, almost always, had no visible dermal structures in the images (Fig. 8.3 
c). This can be explained by the presence of a higher amount of stratum corneum 
tissue on the PMA sites in relation to the other two sites. Hence, the relatively 
thick epidermis may mask parts of the entry echo and attenuate the ultrasound 
signal.
The quantitative analyses of epidermal (stratum corneum) thickness on the three 
sites on the foot are examined in detail in the following sections.
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8.11.3.3 Measurements of the Epidermis taken at an Acoustic Velocity of 
1580m/s
8.11.3.3.1 Distribution of Data
This section concentrates on the data collected from non-diabetic subjects. A full 
explanation of the recruitment of patients is described in detail in Chapter 9, 
along with the comparison of data between the diabetic and non-diabetic groups.
The distribution of the data was skewed; therefore non-parametric statistical 
analyses were used (Appendix XV).
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Velocity 1580 m/s
Median: 0.18 mm 
Interquartile range: 0.02 mm 
Minimum: 0.14 mm 
Maximum: 0.22 mm
Figure 8.4. Epidermal thickness measurements taken from the dorsum of the foot at a velocity of 
1580 m/s.
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Velocity 1580 m/s
Median: 0.18 mm 
Interquartile range: 0.05 mm 
Minimum: 0.12 mm 
Maximum: 0.30 mm
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Figure 8.5. Epidermal thickness measurements taken from the MLA of the foot at a velocity of 
1580 m/s.
Velocity 1580 m/s
Median: 0.18 mm 
Interquartile range: 0.04 mm 
Minimum: 0.09 mm 
Maximum: 0.27 mm
Figure 8.6. Epidermal thickness measurements taken from the PMA of the foot at velocity of 
1580 m/s.
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8.11.3.4 The Difference in Epidermal Thickness between the Three 
Different Sites on the Foot
No statistically significant difference was noted in the thickness of the epidermis 
between the three different sites on the foot. The range of values were greater 
from the data collected from the PMA and MLA sites, in comparison to the dorsal 
skin (Fig. 8.7).
N * 87 87 87)78
Dorsum MLA PMA
Dorsum
Median: 0.18 mm 
Interquartile range: 0.02 mm 
Minimum: 0.14 mm 
Maximum: 0.22 mm
MLA
Median: 0.18 mm 
Interquartile range: 0.05 mm 
Minimum: 0.12 mm 
Maximum: 0.30 mm
PMA
Median: 0.18 mm 
Interquartile range: 0.04 mm 
Minimum. 0.09 mm 
Maximum: 0.26 mm
Mann-Whitney Test 
Dorsum v MLA p = 0.409
Dorsum v PMA p = 0.523
MLA v PMA p = 0.241
Figure 8.7. The relationship between epidermal thickness measurements taken from the dorsum, 
MLA and PMA regions of the foot at a velocity of 1580 m/s.
8.11.3.5 The Relationship between Age and Thickness of Pedal 
Epidermis.
The epidermal thickness data from all three foot sites did not correlate with the 
age of the subjects (Figs. 8.8-8.10).
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Figure 8.8. The relationship between age and epidermal thickness measurements taken from the 
dorsum of the foot at a velocity of 1580 m/s.
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Median: 0.19 mm 
Interquartile range: 0.03 mm 
Minimum: 0.15 mm 
Maximum: 0.30 mm
Mann-Whitney Test
p=0.091
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Figure 8.9. The relationship between age and epidermal thickness measurements taken from the 
MLA of the foot at a velocity of 1580m/s.
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Age group <65 years n=67
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Maximum: 0.26 mm
Age group >65 years n=20
Median: 0.18 mm 
Interquartile range: 0.32 mm 
Minimum: 0.15 mm 
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Mann-Whitney Test
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Figure 8.10. The relationship between age and epidermal thickness measurements taken from the
PMA of the foot at a velocity of 1580m/s.
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8.11.3.6 The Relationship between the Sexes and the Thickness of Pedal
Epidermis
There was a significant difference in the epidermal thickness data, collected from 
all three foot sites, between males and the females (dorsum: p=0.042, MLA: 
p=0.036, and PMA: p=0.002). Women demonstrated greater epidermal 
thickness.
LU 0 '6
Male n=38
Median: 0.18 mm 
Interquartile range: 0.02 mm 
Minimum: 0.14 mm 
Maximum: 0.21 mm
Female n=49
Median: 0.19 mm 
Interquartile range: 0.02 mm 
Minimum: 0.16 mm 
Maximum: 0.22 mm
Mann-Whitney Test
p=0.042
Figure 8.11. The relationship between the sexes and epidermal thickness measurements taken 
from the dorsum of the foot at a velocity of 1580 m/s.
Male n=38
Median: 0.17 mm 
Interquartile range: 0.05 mm 
Minimum: 0.13 mm 
Maximum: 0.30 mm
Female n=49
Median: 0.19 mm 
Interquartile range: 0.05 mm 
Minimum: 0.12 mm 
Maximum: 0.30 mm
Mann-Whitney Test
p=0.036
Figure 8.12. The relationship between the sexes and epidermal thickness measurements taken 
from the MLA of the foot at a velocity of 1580 m/s.
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Male n=38
Median: 0.18 mm 
Interquartile range: 0.04 mm 
Minimum: 0.09 mm 
Maximum: 0.24 mm
Female n=49
Median: 0.19 mm 
Interquartile range: 0.04 mm 
Minimum: 0.15 mm 
Maximum: 0.26 mm
Mann-Whitney Test
p=0.002
Figure 8.13. The relationship between the sexes and epidermal thickness measurements from the 
PMA of the foot at a velocity of 1580 m/s.
8.11.3.7 The Relationship between Ethnicity and the Epidermal 
Thickness on the Foot
The subjects were divided into two groups (Caucasian: n=69 and non-caucasian: 
n=18) and the two variables compared. No difference was noted between the two 
groups. The numbers in the groups differed greatly; therefore further 
investigations should be carried out if a more realistic association is to be made.
Caucasian n = 69
Median: 0.18 mm 
Interquartile range: 0.02 mm 
Minimum: 0.14 mm 
Maximum: 0.22 mm
Non-caucasian n = 18
Median: 0.19 mm 
Interquartile range: 0.01 mm 
Minimum: 0.16 mm 
Maximum: 0.21 mm
Mann-Whitney Test
p=0.222
N = 69 IB
C aucas ian  Non-caucasian
Figure 8.14. The relationship between ethnicity and epidermal thickness measurements taken from 
the dorsum of the foot at a velocity of 1580 m/s.
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Caucasian n = 69
Median: 0.18 mm 
Interquartile range: 0.06 mm 
Minimum: 0.12 mm 
Maximum: 0.30 mm
Non-caucasian n= =19
Median: 0.19 mm 
Interquartile range: 0.02 mm 
Minimum: 0.16 mm 
Maximum: 0.26 mm
Mann-Whitney Test
Figure 8.15. The relationship between ethnicity and epidermal thickness measurements taken from 
the MLA of the foot at a velocity of 1580 m/s.
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Figure 8.16. The comparison between ethnicity 
the PMA of the foot at a velocity of 1580m/s.
Caucasian n = 69
Median: 0.18 mm 
Interquartile range: 0.39 mm 
Minimum: 0.09 mm 
Maximum: 0.26 mm
Non-caucasian
Median: 0.19 mm 
Interquartile range: 0.04 mm 
Minimum: 0.15 mm 
Maximum: 0.24 mm
Mann-Whitney Test
p=0.597
and epidermal thickness measurements taken from
8.11.4 Summary of Results
The measurements of epidermal thickness, taken from 87 healthy volunteers, 
showed no differences from site to site. There was a statistically significant 
difference between the thickness of epidermis on all sites on the foot between the 
sexes. Female epidermis was thicker than male epidermis.
This study has allowed for the comprehensive analysis of skin images on the 
foot, leading to the measurement of the epidermis on elected areas on the foot. 
The accuracy of the measurement technique and the relationship between the 
different areas will be discussed in more detail in the final chapter, after a 
comparison of this data is made with the diabetic patient data.
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9.0 Chapter 9 -  Patient Recruitment, Data Collection and Data Analysis
9.1 Introduction
This section outlines the patient recruitment process for the study, followed by a 
systematic collection of information from the volunteers regarding their diabetes 
status, therapy, secondary complications and general health. The health of the 
lower limbs was determined by extensive examination, enabling the investigator 
to categorise their physiological and structural condition e.g. peripheral 
ischaemia, peripheral sensory polyneuropathy, pes cavus, pes planus etc. Such 
categorisation enabled the ease of data assessment, particularly in the 
correlation analysis between data sets.
9.2 Patient Recruitment
9.2.1 Inclusion Criteria
• Test group - diabetic patients with plantar callus: All adults diagnosed 
with Type II diabetes, according to the WHO criteria [252] (Appendix XVI), 
were targeted in one health care district of North London (Bamet, Enfield, 
Harringay and Camden and Islington). Patients over the age of 18 years 
were invited to take part in the study from two main groups: the podiatry 
department and the Diabetic Eye Screening Service, Whittington hospital. 
Of the individuals that showed an interest in the study, the volunteers with 
callus on PMA were accepted.
• Control group - non-diabetic subjects with plantar callus: This group 
consisted of non-diabetic individuals age and sex matched to the diabetic 
test group. These patients were recruited from a poster and leaflet 
campaign in a number of Whittington Hospital Outpatient units.
• Subjects able to understand the research question.
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9.2.2 Exclusion Criteria
• The presence of diffuse peripheral neuropathy other than diabetic 
neuropathy e.g. malignancy, alcohol abuse, drug abuse, anaemia, vitamin 
B12 deficiency or untreated hypothyroidism.
• Significant neurological disorders other than diabetic polyneuropathy e.g. 
stroke with significant neurological deficit, transient ischaemic attacks, 
multiple sclerosis, epilepsy, dementia and paraplegia.
• Previous or present treatment with cytotoxic drugs and/;or radiotherapy.
• Drug medications that may affect the autonomic nervous system and 
epidermal keratin metabolism.
• Individuals with systemic disorders likely to effect epidermal cell kinetics 
e.g. eczema, psoriasis and scleroderma.
The local hospital advisory ethical committee approved the protocol and ethics 
committees from all other participating centres approved the study. Written and 
verbal informed consent was obtained from every subject studied. One 
investigator carried out all the physical examinations. Examinations of the lower 
limb extremity were carried out on both legs.
9.2.3 Medical History
9.2.3.1 General Medical History
Details of medical conditions, drug therapies, skin and connective tissue 
disorders, social factors and ethnicity were noted. Duration and treatment of 
diabetes, blood or urine sugar levels and patients’ social history, including details 
of smoking history were also collected. It was determined whether patients were 
registered blind or had impaired vision by questioning them. They were also 
asked if they had ever been treated for protein in their urine, were having ongoing 
haemodialysis, continuous ambulatory peritoneal dialysis, or previous kidney 
transplant.
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9.2.3.2 Podiatric History
Patients were questioned as to whether they had previously attended a podiatrist 
for a routine visit for treatment and/or for foot care advice. Details of past foot 
ulceration were documented via questioning and/or accessing the podiatry/ 
medical notes. All diabetic patients were given diabetic foot care advice.
Patients were assigned a footwear risk category, dependent on which type of 
shoe and/or insole was worn by the patient when attending the research clinic: 
low risk e.g. trainers, lace-ups, boots (with a low heel), extra depth (bespoke and 
semi-bespoke) shoes, and high risk e.g. ‘slip-ons’, slippers; sandals, high-heeled 
shoes and flip-flops. The style of orthoses worn by the patient was also recorded.
9.2.4 Sample Collection
9.2.4.1 Venous Blood
Aliquots of venous blood (2 x 5 ml and 1 x 2 ml) were collected in heparinised 
tubes for HbA1c, glycation adduct and random glucose analysis, respectively. 
The HbA1c and random glucose were conducted at the haematology laboratories 
in the hospital. The glycation adducts in the serum were prepared and analysed 
in the research laboratory by the investigator, according to the protocols already 
described in Chapter 4 (section 4.4.3.2).
9.2.4.2 Plantar Callus
The site, approximate size and aesthetic nature of the callus were recorded. For 
the quantification of glycation adducts (furosine and pentosidine) in the callus, 
tissue specimens were collected from the PMA, immediately weighed and stored 
at -70°C. Before HPLC analysis, keratins were extracted from the callus tissue 
according to the protocol described in Chapter 2 (section 2.6) and acid 
hydrolysed as described in Chapter 4 (section 4.2.10).
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9.2.5 Lower Limb Examinations
9.2.5.1 Assessment of Foot and Hand Structure
Structural deformities in the feet were assessed by noting: small muscle 
wasting*, hammer and claw toes, 1st MTPJ deformities (hallux valgus and hallux 
limitus), prominent metatarsal heads, Charcot arthropathy and the range of 
motion of the STJ, MTJ and 1st MTPJs. Excessive subtalar joint pronation and 
supination (i.e. pes cavus and pes planus) were determined during stance and 
gait Limited range of motion in the hands was examined by noting if there was 
lack of contact between any of the metacarpalphalangeal joints whilst attempting 
the ‘prayer position’ I47]. The presence of yellow nails* and skin* were also noted 
on both the hands and the feet along with any other nail pathologies were noted.
9.2.5.2 Assessment for Peripheral Neuropathy
Prior to the physical examination, patients were asked “Do you think you have 
good sensation or feeling in your feet?”. After responding, they were asked if they 
had symptoms of burning, tingling, or shooting pains in their feet, including the 
duration of the symptoms, indicating positive clinical symptoms of neuropathy.
Peripheral neuropathy was assessed by a number of well-established clinical 
techniques i22:253i. Abnormalities of pain sensation were determined using a 
Neurotip™; vibration sensation was tested on the tip of the hallux, malleoli and 
tibial tuberosities, using a 128-Hz tuning fork; dorsal temperature sensation was 
carried out using warm and cool rods; and Achilles tendon and patella tendon 
reflexes were also assessed. Cutaneous pressure perception was tested using a 
1 g, 10 g and 75 g Semmes Weinstein monofilament at six sites (1st and 5th 
plantar metatarsal area, heel, arch, apices of toes and dorsum) on each foot.
* Wasting of the inerossi results in ‘troughing’ between the dorsal tendons ^
* Yellow nails were defined as smooth, slightly thickened nails of a yellow of yellowish green hue. 
They were often noted on the hallux nail only and in general on the proximal edge of the nails.
*  The palms of the hands and soles of the feet were checked for a yellow hue in the skin.
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With the eyes closed, the patients were required to elicit a ‘yes/ no’ response to 
monofilament pressure and correctly identify the site of contact. The filament was 
placed on the foot perpendicular to the surface of the skin to ensure that the 
filament flexed with a constant force, commencing with the 1 g filament. If the 1 g 
filament was not felt at any one site the 10 g filament was then tested at that 
position. Furthermore, if the 10 g filament was not felt, the 75 g monofilament was 
similarly applied. For statistical analysis, insensitivity to at least the 10 g filament 
at any one site on either foot was indicated as abnormal sensation.
Each sensory test was scored (Appendix XVII). According to this system a score 
of up to 19 represented people with no peripheral neuropathy; a score of 20-22 
represented moderate neuropathy and a score of between 23-37 represented 
severe neuropathy.
9.2.5.3 Assessment of Peripheral Circulation
Peripheral vascular status was assessed by palpation of the dorsalis pedis and 
posterior tibial pulses on both feet. Presence of two or less of the four pedal 
pulses, either with or without the presence of odema, and/ or an ankle-brachial 
index (ABI) of < 0.9 [254]\  indicated PVD I2551. In the case of arteriosclerosis and 
atheroma the ABI is less than 0.9. However, in cases where there is median 
arterial calcification, there is as an artificially elevated systolic pressure in the 
ankle, giving an ABI reading of above 0.9. Doppler analysis was used to clarify 
the type of blood flow in the periphery e.g. triphasic, biphasic or monophasic. 
Patients were classified as having intermittent claudication (1C) if they 
experienced calf pain on exertion within 100 yards or less. Claudication is often 
absent because of concomitant neuropathy. In addition the patients were 
questioned about any previous peripheral angioplasty or peripheral bypass 
surgery they had undergone to determine a comprehensive peripheral vascular 
history.
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9.2.6 Physical Measurements if Pedal Skin
9.2.6.1 Ultrasonography
Ultrasound images (frequency 1580 m/s) were taken of the skin from the three 
sites: plantar metatarsal area immediately adjacent to the callus, media! 
longitudinal arch and the dorsal aspect of the foot, avoiding areas with prominent 
tendons and bony protuberances.
The images were all taken with the same gain parameters and saved for 
measurement of epidermal thickness using A-mode, as detailed in Chapter 8 
(section 8.11.2).
9.2.6.2 Epidermal Mechanics
The epidermal mechanics were measured on the same three sites used for the 
ultrasound imaging. The humidity and temperature within the room was noted.
9.2.7 Outcomes Measures
The following data were recorded from each diabetic (n=103) and non-diabetic 
(n=87) subject.
• Concentration of furosine and pentosidine (ng/mg of protein) in plantar 
callus.
• Concentration of furosine and pentosidine (ng/mg of protein) in blood 
serum.
• HbA1c
• Random glucose
• Epidermal thickness on the PMA, MLA and dorsum of the left foot.
• Epidermal viscoelasticity on the PMA, MLA and dorsum of the left foot.
* Ankle-Brachial index is calculated as the higher of the DP or PT arterial systolic Doppler blood
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9.3 Results
9.3.1 Patient Details
A total of 103 Types II diabetic patients and 87 non-diabetic subjects were invited 
to take part in the study (Table 9.1).
Table 9.1. Patient groups used in the study.
Subject
Group
Total
Number
Number 
of Males
Mean Age 
[yrs]
Age
Range
[yrs]
Number
of
Females
Mean Age 
[yrs]
Age
Range
[yrs]
Type II 
Diabetics
103 58 64.9 ±11.0 37 -8 6 45 62.0 ± 8.9 36 -82
Non-
Diabetics
87 38 55.6 ± 6.8 43 -6 9 49 58.1 ± 13.1 35-81
9.3.1.1 Diabetic Patient Details
The duration of diabetes was calculated from the date of diagnosis, and ranged 
from 0.1 to 32.0 yrs (mean: 6.4 ± 7.0 yrs).
The Body Mass Index (BMI)00 ranged from 20.0 to 61.3. On average, the subjects 
were overweight (mean BMI: 25.0 ± 1.7).
The majority of the volunteers (65%) were taking regular oral hypoglycaemic 
drugs; 27% were controlling their diabetes through diet; 6% were on insulin 
therapy alone and 2% were on a combination of oral hypoglycaemic and insulin 
therapies.
Only 28% of patients reported the presence of complications secondary to 
diabetes. Retinopathy was reported by 16% of the subjects; 8% had renal 
problems and 4% reported peripheral neuropathy. The incidence of vascular 
complications was: poor peripheral circulation (3%); hypertension (49%); 
myocardial infarction (7%) and angina (19%).
pressure divided by the higher brachial arterial Doppler blood pressure in both arms 
00 BMI - <18.5: underweight; 18.5-24.9: normal; 25.0-29.9: overweight and >30.0: obese.
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Generally, 6% of subjects reported foot pathologies, 7% had Tinea Pedis and 
only 3% reported poor peripheral circulation problems.
A positive smoking history was elicited from 16% of the patients.
9.3.1.2 Non-Diabetic Subject Details
The BMI of the non-diabetic group ranged from 19.8 to 39.3. On average the 
volunteers were overweight, with a mean BMI of 27.0 ± 4.3.
Reports of problems with the feet came from 43% of the volunteers, 16% of 
which presented with Tinea Pedis as a skin complaint. Only one person 
complained of problems with peripheral circulation (Raynauds syndrome). Other 
vascular pathologies included: hypertension (23%), myocardial infarction (3%) 
and angina (2%).
A positive history of smoking was elicited from 23% of the patients.
9.3.2 Questioning and Examinations
All the volunteers (diabetics and non-diabetics) were asked the same questions 
and subjected to the same examinations.
9.3.2.1 Description of Callus
Pathological callus formation was present in 52% and 77% of the diabetic and 
non-diabetic volunteers, respectively.
A majority of the diabetic group presented with minimal stratum comeum 
thickening, whereas the non-diabetic group had an almost equal presentation of 
the three callus groups (Table 9.2). Both groups presented with predominantly 
diffuse callus covering an area of less than 1 cm2 of plantar skin, with a texture 
that was either glassy or flaky. Only a small portion of the patients had discrete
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round or oval callus plaques. The association of the callus with corns was 15% 
and 25% in the diabetic and non-diabetic groups, respectively.
Close examination of the footwear revealed an approximate ratio of 1:2 of high 
risk to low risk categories (Table 9.3).
Table 9.2. Description of plantar callus in diabetic and control volunteers
Description of Callus Diabetics (%) Non-Diabetics (%)
Thickness Discrete area with 64 39
minimal thickening of 
keratin layer 
Moderate Thickening 26 37
Marked Thickening 10 24
Shape Diffuse 55 69
Oval 37 22
Round 8 5
Texture Spongy 1 2
Glassy 48 49
Flaky 51 48
Associated with Yes 15 26
Corns
No 85 62
Area < 1cm 68 68
1 -  3cm 24 31
3 -  5 cm 8 1
Chiropody 1 - 3  mths 38 5
Treatment/ Callus 
Removal
3 - 6  mths 8 0
6 - 9  mths 0 0
9 - 1 2  mths 12 0
No treatment 43 95
Table 9.3. Description footwear.
Diabetic
(%)
Non-diabetic
(%)
Low risk footwear Bespoke 3 0
Semis-bespoke 1 1
Wei I-fitted 
shoes
62 67
High risk 
footwear
Ill-fitted shoes 34 32
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Table 9.4. Description of insoles and orthoses.
Diabetic
(%)
Non-diabetic
(%)
Simple insole 6 3
Casted 2 3
orthotic
Diabetic insole 2 0
No orthoses 9 0 9 3
Diabetic volunteers with moderate and marked peripheral neuropathy had corns 
associated with callus (Table 9.5).
Table 9.5. The incidence of callus formation in neuropathic patients
Type of 
Neuropathy
Number of 
Patients 
with Thick 
Plantar 
Callus
Incidence 
of Thick 
Plantar 
Callus (%)
Number of
Patients
with
Discrete
Plantar
Callus
Lesions
Incidence
of Discrete
Plantar
Callus
Lesions
(%)
Number of 
Patient 
with Corns 
Associated 
with Callus
Incidence 
of Corns 
Associated 
with Callus 
(%)
None
(n=19)
4 4 9 0 1 9 3 9 1 11
Moderate
(n=35)
2 9 8 3 1 8 5 1 7 20
Severe
(n=19)
1 8 9 5 5 2 6 7 3 7
9.3.2.2 Structure of the Foot and Cutaneous Pathologies
Diabetics had a higher incidence of anhydrosis than non-diabetics, as well as a 
large percentage of yellow nails in both the feet and the hands (Table 9.6). The 
structures of the toes were similar in both groups. Diabetics presented with a 
higher occurrence of pronated foot than the controls. A cavoid type foot 
presented in the diabetic group was of the same incidence as non-diabetic pes 
cavus. The presentation of one pes cavus foot and one pes planus foot was only 
seen in the non-diabetics group.
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Table 9.6. Results from the physical examination of the feet of 190 patient.
Structural Pathology Diabetics Non-Diabetics
Skin Fissures 4 2
Pathologies
Tinea Pedis 7 7
Anhydrosis 72 48
Hyperhydrosis 9 14
Absence of Hair 27 22
Nail Pathologies O/C 0 0
O/M 14 16
O/X 5 0
Yellow Nail 63 39
Normal 22 43
Lesser Toe Hammertoes 8 3
Structure
Claw 27 32
Mallet 0 2
Normal 65 66
Hallux Structure HAV 21 34
Trigger 4 6
Hyperextended 1 1
Normal 46 56
General Foot Pes Planus 61 48
Structure
Pes Cavus 17 18
Pes Cavus & Pes Planus 0 6
Normal 21 28
Limited ROM in STJ 23 15
Feet
MTJ 7 2
1st MTPJ 27 23
Charcot Foot 0 0
Normal ROM 46 62
History of Yes 7 0
Ulceration
No 93 0
Hands Limited ROM 47 22
Normal ROM 53 97
Yellow skin 18 2
Yellow nail 7 1
Of the marked neuropathy group, 63% (12 out of 19) presented with limited range 
of motion (ROM) in the feet. Patients with moderate no signs of peripheral 
neuropathy also had a high incidence of limited ROM in the joints of the foot, of 
51% (25 out of 49). The same incidence of limited ROM was noted in volunteers 
with moderate neuropathy. The limited ROM was noted to be significantly higher 
in the older age group (p=0.003). Cheiroarthropathy in conjunction with limited 
ROM in the feet was noted in 33% (34 out of 103) of the diabetic subjects.
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9.3.2.3 Peripheral Neurological Examination
The prevalence of symptomatic neuropathy was 33%, of which 52% was of a 
chronic nature; 25% of patients had symptoms of chronic pain and 15% had 
acute pain. A history of foot ulceration was described by 7% of the patients; 72% 
presented with autonomic symptoms (Table 9.7).
Table 9.7. Information regarding the symptoms of neuropathy
Number
of
Subjects
Symptoms Present 33
Absent 70
Nature of Positive symptoms 34
Symptoms
Negative
symptoms
69
Duration of <1 yr 17
symptoms
1-3yrs 5
>3yrs 12
Chronic pain Yes 26
No 77
Acute pain Neuropathic pain 15
Contact
hyperaesthesia
2
No 86
History of Yes 7
ulceration
No 96
Autonomic Yes 74
symptoms
No 29
According to the scoring system 48% of the patients had no neuropathy, 33% 
presented with mild neuropathy and 19% showed signs of severe neuropathy. All 
the non-diabetics subjects scored 19 (Table 9.8).
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Figure 9.8. Neuropathic examinations and scoring system.
Neurological Examination Score Number of 
Subjects
Pin Prick Painful 1 73
Unclear 2 6
Not painful 3 24
Light touch Yes 1 86
Unclear 2 9
No 3 8
Vibration Yes 1 16
No 2 87
Pressure perception Yes 1 90
Unclear 2 5
No 3 8
Ankle reflex L/F yes 1 97
R/F yes 2 97
L/F no 3 6
R/F no 4 6
Knee reflex L/F yes 1 103
R/F yes 2 103
L/F no 3 0
R/F no 4 0
Muscular atrophy No bilateral 1 2 0
Yes unilateral 2 3 6
Yes bilateral 3 4 97
Proprioception Yes 1 103
No 2 0
Two point discrimination Yes 1 93
No 2 10
9.3.2.4 Peripheral Vascular Examination
Measurement of the ankle brachial index revealed 24% of diabetics and 2% of 
non-diabetics to have an index of less than 0.9. Diabetic patients (22%) and non­
diabetic patients (2%) complained of intermittent claudication 1C. Of the diabetic 
patients with 1C: 75% had an ABI greater than 0.9 and the remaining 25% had an 
ABI of less than or equal to 0.9. There were no patients with an ABI of less than 
0.5.
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Therefore, there was a higher incidence of PVD in the diabetics than the non­
diabetics. Only 10% (2 out of 19) of diabetics with severe neuropathy had PVD. 
Out of the patients with no peripheral neuropathy 47% (23 out of 49) had PVD 
and of the moderate neuropaths 37% (13 Out of 35) had peripheral ischaemia 
(Table 9.9).
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Table 9.9. Results of the peripheral vascular examinations.
_____________ Vascular Examination
Skin colour Normal
Hyperaemic
Pallor
Skin texture
Skin temperature
Varicose veins 
Odema
History of DVT 
Vascular surgery 
Intermittent claudication 
Heart conditions
Capillary refill time 
Palpable pedal pulses
Doppler analysis
Hyperhydrotic 
Anhydrotic 
Trophic changes 
Normal
Normal
Cold
Warm
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Myocardial infarction
Angina
Hypertension
Immediate
1sec
2sec
3sec
>3sec
R/F Dorsalis Pedis only 
L/F Dorsalis Pedis only 
R/F Posterior Tibial only 
L/F Posterior Tibial only 
All pedal pulses 
No
Triphasic 
Bi phasic 
Monophasic
Diabetic Non-diabetic
65 92
28 7
7 1
7 17
79 46
18 2
13 34
55 80
35 18
10 1
21 14
79 86
23 7
77 93
3 3
97 97
11 5
89 95
22 2
78 98
7 2
17 2
49 23
14 57
29 22
30 14
21 7
6 0
25 24
25 24
3 0
3 0
71 76
1 0
50 86
45 11
24 2
24 2
76 98
AB index <0.9
>0.9
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9.4 Statistical Analysis of Data
9.4.1 Distribution of Data
The data was not normally distributed (Appendix XVIII). Non-parametric methods 
of analysis were used.
9.4.2 Analysis of Furosine Data
DIABETIC NON-DIABETIC
Diabetics n=103
Median. 507.3 ng/mg of protein 
Interquartile range: 589.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 1590.5 ng/mg of protein
Non-diabetics n=87
Median: 471.2 ng/mg of protein 
Interquartile range: 903.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 6331.6 ng/mg of protein
Mann-Whitney Test
p=0.503
s
NO ID IM ETC
Figure 9.1. The comparison of furosine concentrations in the plantar callus of diabetic and non­
diabetic individuals
There was no significant difference in the concentration of furosine between the 
diabetic and non-diabetic individuals.
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Spearman’s Correlation
r=-0.115
Furosine in Keratin Extracts n=103
Median: 507.3 ng/mg of protein 
interquartile range: 589.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 1590.5 ng/mg of protein
Furosine in Blood Serum n=80
Median: 99.2 ng/mg of protein 
Interquartile range: 268.6 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 2526.1 ng/mg of protein
Mann-Whitney Test
p=0.001
f t *  IU  «*
K fe n ln  e x ta c lc  B lood 5 c n jn
0 200 400 600 800 1000
Concentration of furosine in blood serum [ng/mg of protein]
o“
©*♦
Figure 9.2. The comparison of furosine concentrations in diabetic plantar callus and blood serum.
There was no correlation between the concentration of furosine in plantar callus 
and furosine in the blood serum of diabetic individuals (Fig. 9.2). A significant 
difference was noted between the two groups.
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Age [yrs]
Spearman Correlation
r=0.088
Age group <65 years n=50
Median: 621.9 ng/mg of protein. 
Interquartile range: 535.3 ng/mg of protein. 
Minimum: 0.0 ng/mg of protein 
Maximum: 4757.8 ng/mg of protein
Age group >65 years n=53
Median: 452.5 ng/mg of protein. 
Interquartile range: 728.2 ng/mg of protein. 
Minimum: 0.0 ng/mg of protein 
Maximum: 1590.5 ng/mg of protein
Mann-Whitney Test
p=0.180
Figure 9.3. The comparison of furosine concentrations in diabetic plantar callus and the age of the 
subjects.
There was no correlation between the concentration of furosine in diabetic plantar 
callus and the age of the volunteers (Fig. 9.3). There was no significant difference 
found between the two age groups in terms of furosine concentration (Fig. 9.3).
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Male n=59
Median: 447.2 ng/mg of protein 
Interquartile range: 502.6 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 3368.7 ng/mg of protein 
Mean: 615.2 ng/mg of protein
Female n=44
Median: 729.9 ng/mg of protein 
Interquartile range: 825.7 ng/mg of protein 
Minimum: 26.6 ng/mg of protein 
Maximum: 1590.5 ng/mg of protein 
Mean: 1549.7 ng/mg of protein
Mann-Whitney Test
p=0.01
Figure 9.4. The comparison of furosine concentrations in diabetic plantar callus in males and 
females.
There was a significant difference in the concentration of furosine in diabetic 
plantar callus between males and females (p=0.01). The concentration of 
furosine in the female diabetic callus samples was significantly higher than that 
measured in male diabetic callus.
9.4.3 Analysis of Pentosidine Data
DIABETIC NON-DIABETIC
Diabetics n=103
Median: 72.8 ng/mg of protein 
Interquartile range: 171.3 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 848.3 ng/mg of protein 
Mean: 136.9 ng/mg of protein
Non-diabetics n=87
Median: 10.5 ng/mg of protein 
Interquartile range: 54.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 485.4 ng/mg of protein 
Mean: 49.8 ng/mg of protein
Mann-Whitney Test
p=0.001
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Figure 9.5. The comparison of the concentrations of pentosidine in the plantar callus of diabetic and 
non-diabetic individuals.
A significant difference was found between the test and control groups when 
comparing the concentration of pentosidine in plantar callus tissue (p=0.001). The 
power of this result was 99% (where; n = 190 and positive proportion = 35%).
Spearman’s Correlation
r=-0.023
Pentosidine in Keratin Extracts n=103
Median: 72.3 ng/mg of protein 
Interquartile range: 171.3 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 848.3 ng/mg of protein
Pentosidine in Blood Serum n=90
Median: 119.6 ng/mg of protein 
Interquartile range: 260.2 ng/mg of protein 
200 400 800 800 1000 Minimum: 0.0 ng/mg of protein
Pentosidine in blood serum [ng/mg of protein] Maximum: 1780.2 ng/mg of protein
Mann-Whitney Test
p=0.149
Figure 9.6. The comparison of pentosidine concentrations in diabetic plantar callus and blood 
serum.
There was no correlation between the concentration of pentosidine in diabetic 
plantar callus and the blood serum concentration of pentosidine (Fig. 9.6).
&  500
Age [yrs]
Spearman Correlation
r=0.095
Age group <65 years n=50
Median: 71.0 ng/mg of protein.
Interquartile range: 119.5 ng/mg of protein. 
Minimum: 0.0 ng/mg of protein 
Maximum: 848.3 ng/mg of protein
Age group >65 years n=53
Median: 72.8 ng/mg of protein.
Interquartile range: 266.3 ng/mg of protein. 
Minimum: 0.0 ng/mg of protein 
Maximum: 558.2 ng/mg of protein
Mann-Whitney Test
p=0.456
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Figure 9.7. The comparison of pentosidine concentrations in diabetic plantar callus and the age of
the subjects.
No positive correlation was found between the concentration of pentosidine in 
diabetic plantar callus and the age of the volunteers (Fig. 9.7). There was no 
significant difference found between the two age groups.
Spearman’s Correlation
r=0.144
Furosine in Keratin Extracts n=103
Median: 507.3 ng/mg of protein 
Interquartile range: 589.1 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 15904.9 ng/mg of protein
Pentosidine in Keratin Extracts n=103
Median: 73.9 ng/mg of protein 
Interquartile range: 170.0 ng/mg of protein 
Minimum: 0.0 ng/mg of protein 
Maximum: 848.3 ng/mg of protein
Mann-Whitney Test
p=0.001
Figure 9.8. The comparison of pentosidine and furosine concentrations in the plantar diabetic callus 
samples. 343
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There was no correlation between the concentration of furosine and pentosidine 
in the diabetic plantar callus samples (Fig. 9.8). The amount of furosine 
measured in the samples was significantly higher (~ 7-times) than pentosidine in 
the same set of callus samples.
9.4.4 Mechanical Properties of the Epidermis
9.4.4.1 The Series Elastic Elements and the I ime Constants on Stretching 
and on Retraction of the Epidermis on all Three Sites of the Foot
a. b.
© 100 aj 100
On stretching On retraction
c.
On 3 Ichiro
Fig. 9.9. A comparison between the series elastic element data in stretching and on 
retraction, a. Dorsum b. MLAc. PMA
There was a significant difference between the series elastic element data on 
stretching and retraction on all sites on the foot (p<0.01).
344
a. b.
# 0 3
0 8 3
m _______________
§r
i  ■
On ? re tN r f l Onretaclon
Fig. 9.10. A comparison between the time constant data in stretching and on retraction, a. 
Dorsum b. MLAc. PMA
There was a significant difference between the time constants on stretching and 
retraction of the dorsal skin (p<0.01), but not on the MLA and PMA (p>0.05).
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Table 9.10: Descriptive data for the series elastic element and time constant data collected from 
three sites on diabetic feet.
Dorsum MLA PMA
Series Elastic Element on Stretching frim] Median 87 60 34
Interquartile Range 90 85 59
Minimum 13 9 0
Maximum 300 270 280
Series Elastic Element of Retraction [^m] Median 50 41 21
Interquartile Range 36 40 48
Minimum 5 8 0
Maximum 192 220 250
Time constant on Stretching [s] Median 17.1 12.4 6.2
Interquartile Range 6.3 8.7 10.4
Minimum 9.4 0.0 0.0
Maximum 6307 65.0 61.3
Time Constant on Retraction [s] Median 25.8 18.3 7.3
Interquartile Range 12.5 18.5 12.0
Minimum 0.5 0.0 0.0
Maximum 55.8 55.6 41.3
Dorsum
Median: 0.38 
Interquartile range: 0.19 
Minimum: 0.00 
Maximum: 0.98
MLA
Median: 0.19 
Interquartile range: 0.21 
Minimum: 0.00 
Maximum: 0.97
PMA
Median: 0.02 
Interquartile range: 0.07 
Minimum: 0.00 
Maximum: 1.00
Mann-Whitney Test
Dorsum v MLA: p = 0.001
Dorsum V PMA: p = 0.001
MLA v PMA: p = 0.001
Fig. 9.11. A comparison of plasticity data between the three sites on the foot.
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9.4.4.2 The Series Elastic Element Data
Diabetics n=103
Median: 87.0 pm 
Interquartile range: 90.0 pm 
Minimum: 13.0 pm 
Maximum: 300.0 pm
Non-diabetic n=87
Median: 67.0 pm 
Interquartile range: 121.0 pm 
Minimum: 31.0 pm 
Maximum: 671.0 pm
Mann-Whitney Test
DIABETIC NON-DAIBETIC P=0.756
300
E3
“  200 
c
<S 100
I
DIABETIC NONDIABETIC
Figure 9.12. Diabetic and non-diabetic series elastic elements on stretching of the dorsal 
epidermis.
E1
DIABETIC NON-DIABETIC
Diabetics n=103
Median: 50.0 pm 
Interquartile range: 36.0 pm 
Minimum: 5.0 pm 
Maximum: 192.0 pm
Non-diabetic n=87
Median: 38.0 pm 
Interquartile range: 22.0 pm 
Minimum: 10.0 pm 
Maximum: 120.0 pm
Mann-Whitney Test
p=0.001
Sample Power
99% 
n=  190
Positive proportion = 35%
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Figure 9.13. Diabetic and non-diabetic series elastic elements on retraction of the dorsal 
epidermis.
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Diabetics n=103
Median: 60.0 pm 
Interquartile range: 85.0 pm 
Minimum: 9.0 pm 
Maximum: 270.0 pm
Non-diabetic n=87
Median: 47.0 pm 
Interquartile range: 489.0 pm 
Minimum: 2.0 pm 
Maximum: 671.0 pm
Mann-Whitney Test
p=0.497
DIABETIC NON-DIABETIC
NONDIABETIC
Figure 9.14. Diabetic and non-diabetic series elastic elements on stretching of the epidermis on
the MLA.
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DIABETIC NON-DIABETIC
Diabetics n=103
Median: 41.0 pm 
Interquartile range: 40.0 pm 
Minimum: 8.0 pm 
Maximum: 220.0 pm
Non-diabetic n=87
Median: 27.0 pm 
Interquartile range: 20.0 pm 
Minimum: 4.0 pm 
Maximum: 61.0 pm
Mann-Whitney Test
p=0.001
Sample Power
97% 
n = 190
Positive proportion = 36%
NO N D IA BETIC
Figure 9.15. Diabetic and non-diabetic series elastic elements on retraction of the epidermis on 
the MLA.
700 Diabetics n=103
Median: 34.0 pm
800 IIo Interquartile range: 59.0 pm|  500 Minimum: 0.0 pm
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Figure 9.16. Diabetic and non-diabetic series elastic elements on stretching of the epidermis on 
the PMA.
Diabetics n=103
Median: 21.0 pm 
Interquartile range: 48.0 pm 
Minimum: 0.0 pm 
Maximum: 250.0 pm
Non-diabetic n=87
Median: 17.0 pm 
Interquartile range: 24.0 pm 
Minimum: 0.0 pm 
Maximum: 3197.0 pm
Mann-Whitney Test
DIABETIC NON-DIABETIC P=0.004
Sample Power
100% 
n = 190
Positive proportion = 19%
d* i«J <▼
DIABETIC NON DIABETIC
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Figure 9.17. Diabetic and non-diabetic series elastic element on retraction of the epidermis on 
the PMA.
For all three foot sites, there was a significant difference in the series elastic 
elements on retraction of the epidermis between the diabetic and non-diabetic 
groups (Fig. 9.12-9.17). 
There was no difference in the series elastic elements between males and 
females, on all sites on the foot (Fig. 9.18-9.23).
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Male n=59
Median: 75.0 pm 
Interquartile range: 93.0 pm 
Minimum: 13.0 pm 
Maximum: 300.0 pm
Female n=44
Median: 96.5 pm 
Interquartile range: 86.5 pm 
Minimum: 23.0pm 
Maximum: 260.0 pm
Mann-Whitney Test
p=0.271
Figure 9.18. The relationship between the sexes and the series elastic element on stretching of 
the dorsal epidermis.
Male n=59
Median. 49.0 pm 
Interquartile range: 45.0 pm 
Minimum: 8.0 pm 
Maximum: 192.0 pm
Female n=44
Median: 50.0 pm 
Interquartile range: 25.0 pm 
Minimum: 5.0 pm 
Maximum: 170.0 pm
Mann-Whitney Test
p=0.997
Figure 9.19. The relationship between the sexes and the series elastics element on retraction of 
the dorsal epidermis.
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Male n-59
Median: 59.0 pm 
Interquartile range: 65.0 pm 
Minimum: 9 pm 
Maximum. 230 pm
Female n=44
Median: 66.0 pm 
Interquartile range: 94.5 pm 
Minimum: 14.0 pm 
Maximum: 270.0 pm
Mann-Whitney Test
p=0.535
The level of significance is 0.05 (2-tailed)
Figure 9.20. The relationship between the sexes and the series elastic elements on the 
stretching of the epidermis on the MLA
Male n=59
Median: 40.0 pm 
Interquartile range: 37.0 pm 
Minimum: 8.0 pm 
Maximum: 220 pm
Female n=44
Median: 51.0 pm 
Interquartile range: 44.75 pm 
Minimum: 10.0 pm 
Maximum: 190.0 pm
Mann-Whitney Test
p=0.577
Figure 9.21. The relationship between the sexes and the series elastic elements on the 
retraction of the epidermis on the MLA
Male n=59
Median: 31.0 pm 
Interquartile range: 60.0pm 
Minimum: 0.0 pm 
Maximum: 260.0 pm
Female n=44
Median: 40.0pm 
Interquartile range: 57.5pm 
Minimum: 0.0pm 
Maximum: 280.0 pm
Mann-Whitney Test
p=0.356
Figure 9.22. The relationship between the sexes and the series elastic elements on stretching
of the epidermis on the PMA
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Male n=59
Median: 20.0 (jm 
Interquartile range: 39.0 pm 
Minimum: 0.0pm 
Maximum: 250.0 pm
Female n=44
Median: 29.5 pm 
Interquartile range: 49.75 pm 
Minimum: 0.0 pm 
Maximum: 130.0 pm
Mann-Whitney Test
p=0.518
Figure 9.23. The relationship between the sexes and the series elastic elements on retraction of 
the epidermis on the PMA.
The same set of readings was divided into different ethnic origins, Caucasian and 
non-caucasian and the indices of elasticity compared (Fig. 9.24-9.29). No 
significant difference between the two groups was recorded, in terms of elasticity 
of the skin.
Caucasian n=73
Median: 94.0 pm 
Interquartile range: 89.5 pm 
Minimum: 17.0 pm 
Maximum. 300.0 pm
Non-caucasian n=30
Median: 54.0 pm 
Interquartile range: 60.5 pm 
Minimum: 13.0 pm 
Maximum: 260.0 pm
Mann-Whitney Test
p=0.271
Figure 9.24. The relationship between ethnicity and the series elastic element on stretching of 
dorsal epidermis.
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Caucasian n=73
Median: 54.0 pm 
Interquartile range: 38.0 pm 
Minimum: 5.0 pm 
Maximum: 192.0 pm
Non-caucasian n=30
Median: 35.0 pm 
Interquartile range: 27.3 pm 
Minimum: 8.0 pm 
Maximum: 180.0 pm
Mann-Whitney Test
N » 73 30 *
Caucasian Non-caucasian p=0.997
Figure 9.25. The relationship between ethnicity and the series elastic elements on retraction of 
dorsal epidermis.
Non-caucasian
Caucasian n=73
Median: 65.0 pm 
Interquartile range: 80.5 pm 
Minimum: 18.0 pm 
Maximum: 250.0 pm
Non-caucasian n=30
Median: 37.0 pm 
Interquartile range: 62.25 pm 
Minimum. 9.0 pm 
Maximum: 270.0 pm
Mann-Whitney Test
p=0.535
Figure 9.26. The relationship between the ethnicity and the series elastic element on stretching 
of the epidermis of the MLA.
Caucasian n=73
Median: 52.0 pm 
Interquartile range: 38.0 pm 
Minimum: 10.0 pm 
Maximum: 220.0 pm
Non-caucasian n=30
Median: 52.0 pm 
Interquartile range: 38.0 pm 
Minimum: 10.0 pm 
Maximum: 220 pm
Mann-Whitney Test
p=0.577
Non-caucasian
Figure 9.27. The relationship between the ethnicity and the series elastic elements on retraction
of the epidermis of the MLA.
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8' Caucasian n=73
Median: 40.0 |jm 
Interquartile range: 57.5 pm 
Minimum: 0.0 (jm 
Maximum: 280.0 pm
Non-caucasian n=30
Median: 20.0 pm 
Interquartile range: 30.0 pm 
Minimum: 0.0 pm 
Maximum: 190.0 pm
Mann-Whitney Test
p=0.356
Figure 9.28. The relationship between ethnicity and the series elastic elements on stretching of 
the epidermis of the PMA
Caucasian n=73
Median: 26.0 pm 
Interquartile range: 46.5 pm 
Minimum: 0.0pm 
Maximum: 250.0 pm
Non-caucasian n=30
Median: 26.0 pm 
Interquartile range: 46.5 pm 
Minimum: 0.0 pm 
Maximum: 250.0 pm
Mann-Whitney Test
p=0.518
Figure 9.29. The relationship between ethnicity and the series elastic elements on retraction of 
the epidermis of the PMA.
9.4.4.3 The Time Constant Data
There was no difference in the viscoelastic time constants of the epidermis 
between the two groups of patients on all three sites on the feet (Fig. 9.30-9.35).
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Diabetics n=103
Median: 17.1s 
Interquartile range: 6.3s 
Minimum. 9.4s 
Maximum: 63.7s
Non-diabetics n=87
Median: 18.1s 
Interquartile range: 8.1s 
Minimum: 3.3s 
Maximum: 47.3s
Mann-Whitney Test
DIABETIC NON-DIABETIC p-0.714
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N
re 9.30: Diabetic and non-diabetic time constants on stretching of the dorsal epidermis.
Diabetics n=103
Median: 25.8s 
Interquartile range: 12.5s 
Minimum: 0.5s 
Maximum: 55.8s
Non-diabetics n=87
Median: 24.9s 
Interquartile range: 11.1s 
Minimum: 0.0s 
Maximum: 43.4s
Mann-Whitney Test
p=0.632
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Figure 9.31. Diabetic and non-diabetic time constants on retraction of the dorsal epidermis.
Diabetics n=103
Median: 12.4s 
Interquartile range: 8.7s 
Minimum: 0.0s 
Maximum: 65.4s
B
Non-diabetics n=87
§ Median: 12.5s 
1 Interquartile range: 8.4s 
Minimum: 0.2s 
Maximum: 77.3s
Mann-Whitney Test
-*------- ■--------*------- *------- ■------- --------- p=0.353
DIABETIC NON-DIABETIC
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Figure 9.32. Diabetic and non-diabetic time constants on stretching of the epidermis on the MLA
Diabetics n=103
Median: 18.3s 
Interquartile range: 18.5s 
Minimum: 0.0s 
Maximum: 55.6s
Non-diabetics n=87
Median: 15.6s 
Interquartile range: 13.1s 
Minimum: 0.0s 
Maximum: 53.0s
Mann-Whitney Test
DIABETIC NON-DIABETIC P=0.335
Figure 9.33. Diabetic and non-diabetic time constants on retraction of the epidermis on the MLA
DIABETIC NON-DIABETIC
Diabetics n=103
Median: 98.3s 
Interquartile range: 10.4s 
Minimum: 0.0s 
Maximum: 61.3s
Non-diabetics n=87
Median: 5.4s 
Interquartile range: 10.9s 
Minimum: 0.0s 
Maximum: 45.4s
Mann-Whitney Test
p=0.800
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Figure 9.34. Diabetic and non-diabetic time constants on stretching of the epidermis on the 
PMA
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Diabetics n=103
Median: 7.3s 
Interquartile range: 12.0s 
Minimum: 0.0s 
Maximum: 41.3s
Non-diabetics n=87
Median: 7.9s 
Interquartile range: 13.1s 
Minimum: 0.0s 
Maximum: 32.2s
Mann-Whitney Test
p=0.547
no BD M  B E T C
Figure 9.35. Diabetic and non-diabetic time constants on retraction of the epidermis on the PMA
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There was a significant difference in epidermal viscoelasticity between the three 
different sites on the feet (Fig.9.36).
Mann-Whitney Test for a. and b. 
Dorsum v MLA p = 0.001
MLA v PMA 
Dorsum v PMA
p = 0.001 
p = 0.001
Figure 9.36: A comparison of the time constant data between different sites on the foot a. on 
stretching and b. retraction.
No statistical difference was noted in the time constant measurements between 
the sexes (Figs. 9.37-9.42).
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Male n=59
Median: 16.9s 
Interquartile range: 6.6s 
Minimum: 9.4s 
Maximum: 63.7s
Female n=44
Median: 17.7s 
Interquartile range: 5.8s 
Minimum: 9.4s 
Maximum: 31.1s
Mann-Whitney Test
p=0.445
Figure 9.37. The relationship between the sexes and the time constants on stretching of the 
dorsal epidermis.
Male n=59
Median: 25.5s 
Interquartile range: 13.2s 
Minimum: 0.6s 
Maximum: 55.8s
Female n=44
Median: 26.9s 
Interquartile range: 12.0s 
Minimum: 0.5s 
Maximum: 45.4s
Mann-Whitney Test
p=0.358
Figure 9.38. The relationship between the sexes and time constant on retraction of the dorsal 
epidermis.
Male n=59
Median: 14.1s 
Interquartile range: 8.6s 
Minimum: 0.0s 
Maximum: 65.4s
Female n=44
Median: 11.0s 
Interquartile range: 7.9s 
Minimum: 0.2s 
Maximum: 43.1s
Mann-Whitney Test
Fe r in e  FJWe  p=0.057
Figure 9.39. The relationship between the sexes and time constants on stretching of the
epidermis9on the MLA
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Male n=59
Median: 19.3s 
Interquartile range: 16.6s 
Minimum: 0.0s 
Maximum: 55.6s
Female n=44
Median: 6.9s 
Interquartile range: 11.4s 
Minimum: 0.0s 
Maximum: 41.3s
Mann-Whitney Test
p=0.451
Figure 9.40. The relationship between the sexes and time constant on retraction of the 
epidermis on the MLA.
Male n=59
Median: 6.5s 
Interquartile range: 10.9s 
Minimum: 0.0s 
Maximum: 61.3s
Female n=44
Median: 5.0s 
Interquartile range: 8.8s 
Minimum: 0.0s 
Maximum: 28.7s
Mann-Whitney Test
p=0.270
Figure 9.41. The relationship between the sexes and time constants on stretching of the 
epidermis on the PMA.
Male n=59
Median: 6.9s 
Interquartile range: 11.4s 
Minimum: 0.0s 
Maximum: 41.3s
Female n=44
Median: 8.8s 
Interquartile range: 13.1s 
Minimum: 0.0s 
Maximum: 37.1s
Mann-Whitney Test
p=0.708
Figure 9.42. The relationship between the sexes and time constants on retraction of the
epidermis on the PMA.
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There was a significant difference in the time constants on stretching of the 
epidermis between the two ethnic groups on the dorsal and MLA sights, but not 
on the PMA site (Figs. 9.43-9.46). These results were approached with caution 
as the patient numbers in each group differed.
Caucasian n=73
Median: 16.7s 
Interquartile range: 5.2s 
Minimum: 9.4s 
Maximum: 63.7s
Non-caucasian n=30
Median: 20.6s 
Interquartile range: 8.3s 
Minimum: 12.3s 
Maximum: 48.2s
Mann-Whitney Test
Caucasian Non-caucasian P 0.006
Figure 9.43. The relationship between ethnicity and time constants on stretching of the dorsal 
epidermis.
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Caucasian Non-caucasian
Caucasian n=73
Median: 25.0s 
Interquartile range: 12.8s 
Minimum: 0.6s 
Maximum: 45.4s
Non-caucasian n=30
Median: 27.0s 
Interquartile range: 9.1s 
Minimum: 0.5s 
Maximum: 55.8s
Mann-Whitney Test
p=0.234
Figure 9.44. The relationship between ethnicity and time constants on retraction of the dorsal 
epidermis.
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Caucasian n=73
Median: 13.8s 
Interquartile range: 7.7s 
Minimum: 0.3s 
Maximum: 65.4s
Non-caucasian n=30
Median: 9.4s 
Interquartile range: 10.6s 
Minimum: 0.0s 
Maximum: 46.9s
Mann-Whitney Test
p=0.035
Figure 9.45. The relationship between ethnicity and time constants on stretching of the 
epidermis on the MLA.
Norvcaucasla-i
Caucasian n=73
Median: 19.3s 
Interquartile range: 17.8s 
Minimum: 0.0s 
Maximum: 49.3s
Non-caucasian n=30
Median: 13.8s 
Interquartile range. 24.7s 
Minimum: 0.0s 
Maximum: 55.6s
Mann-Whitney Test
p=0.463
Figure 9.46. The relationship between ethnicity and time constants on retraction of the 
epidermis on the MLA.
Caucasian n=73
Median: 6.1s 
Interquartile range: 10.0s 
Minimum: 0.0s 
Maximum: 61.3s
Non-caucasian n=30
Median: 7.1s 
Interquartile range: 11.4s 
Minimum: 0.0s 
Maximum: 28.7s
Mann-Whitney Test
Caucasian Kccrasjcasljfi p=0.783
Figure 9.47. The relationship between ethnicity and time constants on stretching of the
epidermis on the PMA.
Caucasian n=73
Median: 7.9s 
Interquartile range: 10.1s 
Minimum: 0.0s 
Maximum: 41.3s
Non-caucasian n=30
Median: 4.5s 
Interquartile range: 18.5s 
Minimum: 0.0s 
Maximum: 32.5s
Mann-Whitney Test
Caucasian Non-caucasian D~0.329
Figure 9.48. The relationship between ethnicity and time constant on retraction of the epidermis 
on the PMA.
9.4.4.4 Epidermal Plasticity
The plasticity of the epidermis on the PMA of non-diabetics was significantly 
greater than diabetic epidermis on a similar skin site (Fig. 9.51).
Diabetics n=103
Median: 0.38 
Interquartile range: 0.19 
Minimum: 0.00 
Maximum: 0.45
Non-diabetics n=87
Median: 0.38 
Interquartile range: 0.26 
Minimum: 0.01 
Maximum: 0.98
Mann-Whitney Test
DIABETIC NON-DIABETIC P=0.436
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Figure 9.49. Diabetic and non-diabetic plasticity of dorsal epidermis.
Diabetics n=103
Median: 0.19 
Interquartile range: 0.21 
Minimum: 0.00 
Maximum: 0.97
Non-diabetics n=87
Median: 0.16 
Interquartile range. 0.28 
Minimum: 0.00 
Maximum: 0.94
Mann-Whitney Test
p=0.854
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Figure 9.50. Diabetic and non-diabetic plasticity of epidermis on the MLA
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Diabetics n=103
Median: 0.02 
Interquartile range: 0.07 
Minimum: 0.00 
Maximum: 1.00
Non-diabetics n=87
Median: 0.03 
Interquartile range: 0.050 
Minimum: 0.00 
Maximum: 1.00
Mann-Whitney Test
p=0.007
.£ • 0.6
NONDIABETIC
Figure 9.51. Diabetic and non-diabetic plasticity of epidermis on the PMA.
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Figure 9.52. The epidermal plasticity on different sites of in the foot.
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Male n=59
Median: 0.35 
Interquartile range: 0.21 
Minimum: 0.0 
Maximum: 0.95
Female n=44
Median. 0.41 
Interquartile range: 0.16 
Minimum: 0.06 
Maximum: 0.61
Mann-Whitney Test
IUC5 lcmdE5 p—0.266
Figure 9.53. The relationship between the sexes and epidermal plasticity on the dorsum.
Male n=59
Median: 0.19 
Interquartile range: 0.2 
Minimum: 0.00 
Maximum: 0.91
Female n=44
Median: 0.20 
Interquartile range: 0.24 
Minimum: 0.00 
Maximum: 0 97
Mann-Whitney Test
p=0.414
Figure 9.54. The relationship between the sexes and epidermal plasticity on the MLA.
Male n=59
Median: 0.01 
Interquartile range: 0.05 
Minimum: 0.00 
Maximum: 1.00
Female n=44
Median: 0.02 
Interquartile range: 0.08 
Minimum: 0.00 
Maximum: 0.97
Mann-Whitney Test
p=0.534
Figure 9.55. The relationship between the sexes and epidermal plasticity on the PMA.
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Caucasian n=73
Median: 0.39 
Interquartile range: 0.20 
Minimum: 0.00 
Maximum: 0.95
Non-caucasian n=30
Median: 0.35 
Interquartile range: 0.18 
Minimum: 0.10 
Maximum: 0.61
Mann-Whitney Test
p=0.084
Figure 9.56. The relationship between ethnicity and epidermal plasticity on the dorsum.
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Caucasian n=73
Median: 0.22 
Interquartile range: 0.19 
Minimum: 0.00 
Maximum: 0.91
Non-caucasian n=30
Median: 0.09 
Interquartile range: 0.23 
Minimum: 0.00 
Maximum: 0.97
Mann-Whitney Test
p=0.002
Figure 9.57. The relationship between ethnicity and epidermal plasticity on the MLA.
The plasticity of the epidermis on the MLA and PMA sites was significantly 
greater in the Caucasian group than the non-caucasian group (Figs. 9.57 & 9.58).
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Caucasian n=73
Median: 0.02 
Interquartile range: 0.08 
Minimum: 0.00 
Maximum: 1.00
Non-caucasian n=30
Median: 0.00 
Interquartile range: 0.04 
Minimum: 0.00 
Maximum: 0.59
Mann-Whitney Test
Caucasian HorKaoslai p—0.016
Figure 9.58. The relationship between ethnicity and epidermal plasticity on the PMA.
9.4.5 Epidermal Thickness Data
There was a statistical significant difference in the thickness of the epidermis 
between the diabetic and non-diabetic groups on the PMA site only (Fig. 9.61). 
The power of this result was 70% (where: n = 190 and positive proportion = 41%)
Diabetics n=103
Median: 0.18mm 
Interquartile range: 0.05mm 
Minimum: 0.09mm 
Maximum: 0.44mm
Non-diabetics n=87
Median: 0.18mm 
Interquartile range: 0.02mm 
Minimum: 0.14mm 
Maximum: 0.22mm
Mann-Whitney Test
DIABETIC NON-DIABETIC P=0.996
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Figure 9.59. Diabetic and non-diabetic dorsal epidermal thickness.
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Diabetics n=103
Median: 0.19mm 
Interquartile range: 0.08mm 
Minimum: 0.09mm 
Maximum: 0.43mm
Non-diabetics n=87
Median: 0.18mm 
Interquartile range: 0.05mm 
Minimum: 0.12mm 
Maximum: 0.30mm
Mann-Whitney Test
p=0.336
NONDIABETIC
Figure 9.60. Diabetic and non-diabetic epidermal thickness on the MLA
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Diabetics n=103
Median: 0.20mm 
Interquartile range: 0.07mm 
Minimum: 0.09mm 
Maximum: 0.26mm
Non-diabetics n=87
Median: 0.18mm 
Interquartile range' 0 04mm 
Minimum: 0.09mm 
Maximum: 0.26mm
Mann-WhitneyTest
p=0.017
Figure 9.61. Diabetic and non-diabetic epidermal thickness on the PMA.
As would be expected, the epidermal thickness was the highest on the PMA site, 
followed by the MLA and then the dorsal sites (Fig. 9.62).
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Mann-Whitney Test
Dorsum v MLA p = 0.477
MLA v PMA 
Dorsum v PMA
p = 0.147 
p = 0.009
Figure 9.62. Epidermal thickness on different sites on the foot.
The epidermal thickness data did not differ between the sexes or the ethnic 
groups on all three sites on the feet of diabetic individuals (Figs. 9.63-9.68).
Male n=59
Median: 0.18mm 
Interquartile range: 0.05mm 
Minimum: 0.11mm 
Maximum. 0.32mm
Female n=44
Median: 0.19mm 
Interquartile range: 0.05mm 
Minimum: 0.09mm 
Maximum: 0.44mm
Mann-Whitney Test
Mates Females p=0.311
Figure 9.63. The relationship between the sexes and dorsal epidermal thickness
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Male n=59
Median: 0.19mm 
Interquartile range: 0.07mm 
Minimum: 0.11mm 
Maximum: 0.43mm
Female n=44
Median: 0.20mm 
Interquartile range: 0.09mm 
Minimum: 0.09mm 
Maximum: 0.40mm
Mann-Whitney Test
p=0.963
Figure 9.64. The relationship between the sexes and epidermal thickness on the MLA.
Male n=59
Median: 0.20mm 
Interquartile range: 0.06mm 
Minimum: 0.09mm 
Maximum: 0.36mm
Female n=44
Median: 0.20mm 
Interquartile range: 0.08mm 
Minimum: 0.10mm 
Maximum: 0.34mm
Mann-Whitney Test
Figure 9.65.The relationship between the sexes and epidermal thickness on the PMA.
Caucasian n=73
Median: 0.18mm 
Interquartile range: 0.05mm 
Minimum: 0.10mm 
Maximum: 0.44mm
Non-caucasian n=44
Median: 0.18mm 
Interquartile range: 0.05mm 
Minimum: 0.09mm 
Maximum: 0.32mm
Mann-Whitney Test
p=1.000
Figure 9.66. The relationship between ethnicity and dorsal epidermal thickness.
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Caucasian n=59
Median: 0.20mm 
Interquartile range: 0.09mm 
Minimum: 0.09mm 
Maximum: 0.43mm
Non-caucasian n=44
Median: 0.18mm 
Interquartile range: 0.06mm 
Minimum: 0.10mm 
Maximum: 0.32mm
Mann-Whitney Test
p=0.277
Caucasian Non-caucasian
Figure 9.67. The relationship between ethnicity and epidermal thickness on the MLA.
Caucasian n=59
Median: 0.20mm 
Interquartile range: 0.06mm 
Minimum: 0.10mm 
Maximum: 0.34mm
Non-caucasian n=44
Median. 0.21mm 
Interquartile range: 0.09mm 
Minimum: 0.09mm 
Maximum: 0.36mm
Mann-Whitney Test
p=0.553
Caucasian Non-caucasian
Figure 9.68. The relationship between ethnicity and epidermal thickness on the PMA.
9.5 Summary of Results
9.5.1 Callus Incidence and Distribution
Pathological callus formation was present in 52% of the diabetic patient 
population and 77% of the non-diabetic population. The majority of the diabetic 
patients presented with minimal stratum corneum thickening and the control 
group had an equal distribution of the three callus descriptions. The controls also
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had more corns associated with callus than the diabetic patients and this was 
related to an increase in age. There was no relationship between the age of 
diabetics and callus formation. The area of the callus was relatively small in both 
the groups (68% had a callus area of 1cm3).
Both groups were overweight, although the range of BMI data was greater than 
that of the non-diabetics (diabetics: 20-61.3, and non-diabetics: 29.8-39.3).
There was a high prevalence of callus formation in the sensitive and insensitive 
diabetic sub-groups. There was no association between the distribution of callus 
and the duration of diabetes. There was an association between the formation of 
corns and diabetic peripheral sensory neuropathy.
9.5.2 Foot and Hand Structures and Cutaneous Pathologies
There was a similar incidence of toes deformities in both groups. The diabetic 
group had a much higher incidence of pes planus in comparison to the controls. 
There was a difference between the diabetic patients with no neuropathy, 
moderate neuropathy and marked neuropathy presenting with limited ROM of the 
feet (51%, 63% and 63%, respectively). The limited ROM in the diabetic groups 
was greater in the older age group. The combination of cheiroarthropathy and 
limited ROM in feet was seen in 33% of the diabetic patients.
9.5.3 Glycation Adducts
The significant finding in this study was the amount of pentosidine being higher in 
the diabetic plantar callus in comparison to the controls (Fig. 9.5, p=0.001). In 
contrast, the quantity of the early glycation product, furosine, was similar in each 
of the groups (Fig. 9.1, p=0.503).
There was a higher concentration of furosine in the plantar callus (Fig. 9.8) than 
pentosidine (Fig. 9.8, p=0.001). Within the diabetic group of subjects, a difference 
was observed in furosine concentrations between males and females (Fig. 9.4,
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p=0.01). The concentration of both furosine and pentosidine was not associated 
with age.
There was a marked difference between furosine in callus and furosine in blood 
serum, whereas the same difference was not observed when pentosidine was 
measured in these tissues (Fig. 9.2 & 9.6). Both compounds did not show a 
positive association with HbA1c levels.
9.5.4 Mechanical Properties of the Epidermis on the Feet
The epidermis on the three different sites on the foot displayed differences in the 
elastic, viscoelastic and plastic behaviour. These properties were quantifiably 
higher on dorsal skin than MLA and PMA skin. The epidermis on the PMA was 
the least elastic, viscoelastic and plastic of the three sites.
The series elastic element on retraction of the epidermis was significantly greater 
in diabetes, on all three foot sites (p < 0.05). There were no marked differences in 
the data between males and females. The epidermal plasticity of of diabetic 
plantar epidermis was significantly lower than non-diabetic plantar epidermis (p =
0.77).
9.5.5 Epidermal Thickness
The epidermal thickness on the PMA of the foot was significantly higher in the 
diabetics than the controls (Fig. 9.61, p=0.017). The range of thickness readings, 
on three sites, was broader in the diabetics than the non-diabetics (Figs. 9.59 -  
9.61). As with the elasticity data, the epidermal thickness differed between the 
sites, i.e. the epidermis was the thickest on the PMA, followed by the MLA and 
dorsal sites consecutively (Fig. 9.62). The sex and ethnic origins of the subjects 
apparently have no effect on the epidermal thickness.
There were no positive correlations between the epidermal thickness and 
elasticity, or between the quantity of glycation adducts and the physical 
properties.
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10.0 Chapter 10 -  Discussion
10.1 Introduction
In this thesis, mechanical and biochemical methods were developed and tested 
to improve the quantitative evaluation of pedal epidermis in healthy and Type II 
diabetic populations. The primary aim of this series of investigations was to test 
for an association between epidermal mechanics and the accumulation of 
glycation products, principally furosine, pentosidine and carboxy methyl lysine, 
within the superficial layers of the plantar stratum comeum.
Quantitative mechanical measurements were achieved by the use of vertical, 
negative (suction) pressure, to identify and compare specific indices of elasticity, 
between the groups. High frequency A- and B-mode ultrasound imaging (20 
MHz) was implemented for the quantitative measurement of epidermal thickness 
and to assess qualitative differences between the skin on different sites of the 
foot.
The exploration of different keratin extraction methods achieved the aim of 
designing a protocol that not only produced a broad spectrum of epidermal 
keratins but also was cost-effective and time-efficient. The latter point was 
important as the proceeding hydrolysis methods and HPLC and GC/MS analyses 
would add to the experimental time for each sample. The development of 
accurate analytical techniques for the identification and quantification of specific 
glycation adducts from acid hydrolysed keratin extracts was achieved
The need for pure synthetic AGE standards, for accurate quantification of 
glycated compounds, was highlighted. The purity of the compounds was 
essential for them to act as immunogens for raising monoclonal antibodies, with 
the appropriate specificity.
The detection of CML using GC/MS was shown to be appropriate for the 
qualitative detection of CML but lacked the sensitivity for its quantification. Recent 
publications have explored electrospray ionisation and matrix assisted laser
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desorption/ ionisation time-of-flight (MALDI-TOF) as a method of protein analysis. 
This technique analyses the protein as a whole therefore eliminating any 
interference by artefacts liable to be generated during hydrolysis. In theory 
MALDI-TOF would be advantageous in mapping the exact glycation sites along 
the keratin protein chain[25g, however evidence of this method being an effective 
tool for CML quantification has not been forthcomingI256].
The preparation and analysis of hydrolysates for CML using GC/MS was time 
consuming and produced semiquantitative results. Other methods of 
quantification were sought leading to the production of monoclonal antibodies 
against CML and furosine. These antibodies did not bind selectively to the 
glycation products. Other groups have identified the same problems discussed in 
this study and the search for anti-AGE antibodies to specific AGEs is still in 
progress in many glycation research centres around the world. In this thesis pure 
CML and furosine were attached to carrier proteins before injection into the host, 
as opposed to the injection of a mixture of AGEs formed via incubation of BSA or 
KLH in glucose prior to immunisation. This deliberate alteration was an attempt to 
encourage the development of antibodies with specific binding sites for CML and 
furosine. The injection of glycated BSA/ KLH by other researchers in this field 
was in effect injecting a mixture of AGEs some of which have not been identified 
as yet. Therefore a mixture of AGEs could encourage the production of 
antibodies with non-specific binding activities. These antibodies would have their 
uses in identifying AGEs as a collective in tissues at the expense of identifying 
specific AGEs. In view of this knowledge the need for the identification of 
individual AGEs takes priority above immunoassay development.
A series of clinical observations that are pertinent to the condition of the “diabetic 
foot” were recorded during the collection of the experimental data to support or 
refute observations made previously of the foot pathologies commonly seen in 
diabetes.
This final chapter discusses the evidence that has emerged from several 
expositions in the analysis of epidermal tissues in Type II diabetes using
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knowledge from a diverse range of disciplines particularly that of the biochemical 
and physical behaviour of the epidermis at a micro and macro level.
The published literature, reviewed in Chapter 1, in the field of diabetes and non- 
enzymatic glycation of proteins, over the past two decades has made a valid 
contribution to a clearer understanding of the origins of the secondary 
complications related to diabetes. As glycation potentially involves any protein, 
many tissues have been investigated. Blood tissue was used for pioneering 
studies in this field, for its ease of access and for the dynamic nature of its 
constituent proteins in relation to glucose during hyperglycaemic and 
normoglycaemic states. The pursuit of a therapeutic intervention, to inhibit the 
prevention of the glycation of human proteins, still exists today and is complicated 
by the multifarious nature of glycation products. The evolution of this area of 
biochemistry, aided by the acceptance of the heterogeneous nature of these 
modified proteins, has entered the 21st century with a less blinkered view of the 
singular influence that glycation adducts have on the progression of tissue 
pathology in diabetes. During the latter part of the 1990s a shift towards the 
investigation of reactive oxygen species (ROS) provided a connection between 
ROS and the four hypotheses that explain cell pathology in diabetes: increased 
polyol pathway flux; activation of protein kinase C isoforms; increased 
hexoseamine pathway and increased accumulation of AGEs [257]. This mosaic of 
interrelated processes explains pathologies not only seen in diabetes, but in 
rheumatoid arthritis, Alzheimers disease and cardiovascular disease.
For a short period of time, different investigators explored the measurement of 
furosine, in plantar callus tissue, hair and nails. These groups concentrated their 
efforts on measuring the amount of furosine in these keratin rich tissues, with a 
vision of using the concentration of furosine as an index for hyperglycaemia. 
These published works confirmed the presence of furosine in plantar callus. It 
seems surprising that further scrutiny for the presence of AGEs in these tissues 
was not attempted, as the confirmation of the presence of an early glycation 
product suggests a potential for AGE formation. However, in these studies, the 
sole aim of measuring furosine in the callus tissues was to see if it could act as 
an indication of glycaemic control. The local effects of protein glycation on the
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physical properties of the skin were not considered. Different investigators 
recognised the implications that protein glycation may have on the mechanical 
properties of tissues such as tendon and dermal collagen, but a detailed 
investigation of skin on the feet was not carried out.
The hypotheses tested in this thesis, originated from the lack of knowledge, in 
this area of medicine, in terms of diabetic foot pathologies. It attempted to confirm 
the presence of known early and late glycation products, using accurate 
analytical techniques and applied these results to the implications they may have 
on the physical behaviour of plantar skin in diabetes.
10.2 Hypothesis 1: There is an Increase in Glycation of Plantar Epidermal 
Proteins in Type II Diabetes.
The accumulation of furosine and pentosidine in plantar callus tissues was 
evident in diabetic and non-diabetic subjects. There was no significant difference 
in furosine concentration between the two groups. However, the range of 
concentrations of furosine in diabetic callus was greater than those recorded in 
the non-diabetic callus.
There was, on average, a greater concentration of furosine than pentosidine in 
callus collected from both groups.
There was a significantly higher concentration of pentosidine in diabetic callus 
than controls (p<0.001). As with the furosine results, the range of pentosidine 
concentrations was greater in the diabetic samples than controls.
The paths of non-enzymatic glycation, studied in this thesis, were the formation of 
furosine, which exclusively involves the terminal amino group of a lysine residue; 
and pentosidine involving both lysine and arginine residues. From the genesis of 
the single keratin polypeptide chain through to the complex filament network 
formation, there are lysine and arginine residues present at all points along the 
way, which are potentially susceptible to non-enzymatic glycation at all these 
levels of keratin synthesis.
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The glucose that is involved with glycation originates from the circulation, diffuses 
into the interstitial fluid spaces of the dermis and the epidermis and migrates 
across the epidermal cell membrane into the interior of the cell[7cq. It serves as a 
fuel for the synthesis of DNA, lipids and proteins. Glucose utilisation is increased 
with an increase in epidermal cell proliferation, such as in psoriasis and wound 
healing I611. Plantar epidermal tissue, as a result of mechanical stimulation has a 
high cell turnover rate, and the utilisation of glucose, by the keratinocytes is 
increased commensurately. In a hyperglycaemic environment, a surplus of 
glucose may be a substrate for glycation of all the proteins expressed by the 
keratinocyte cells.
The majority of the proteins extracted from the plantar callus specimens were 
keratins. There is a possibility that trace amounts of unknown proteins, 
unidentifiable by electrophoresis and immunoblot techniques were present in the 
extracts. According to the model of callus formation I261, immature keratinocytes 
enter the stratum comeum, and as a consequence of their lack of appropriate 
differentiation, desmosomal degradation is incomplete. This contrasts to normal 
differentiation where the structural integrity of the desmosomes decreases in the 
superficial layers of the epidermis, allowing for desquamation of the comeocytes 
[258]. Therefore, it is possible that, the intracellular attachment proteins 
(desmoplakins and plakoglobins) i62:180;259:260! that reside in the desmosomes may 
be present in the callus tissues sampled in this thesis. The desmogleins, 
desmocollins and integrin a6p4, found in hemidesmosomes would be less likely 
to be present in the superficial layers of the stratum comeum as their purpose is 
to bind the basal keratinocytes to the basement laminar p61263i.
Although there is a possibility that desmoplakins and plakoglobins may be 
present in the plantar callus tissue, it is the proteins in the stratum comeum layer 
that are of more importance. The terminal differentiation programme for human 
keratinocytes involves the formation of a cell envelope (CE) structure consisting 
of a thin layer (~15 nm thick) of insoluble, isopeptide bond cross-linked proteins 
(involucrin, cysteine, and the carboxy termini of desmoplakin and envoplakin) 
with a thin layer (-5 nm thick) of attached lipids [264]. This structure forms on the
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intracellular surface of the plasma membrane and ultimately replaces it and the 
cytoskeletal connections to the cell periphery are lost, as part of controlled death 
I265J. The bulk of the terminally differentiated epidermal comeocytes consists of 
cytoskeletal keratin intermediate filament-filaggrin complex that is retained within 
the CE structure (Fig. 10.1). The enzyme facilitated /V-(y-glutamyl) lysine cross­
links between the glutamyl of the involucrin (molecular weight 26 kDa) and the 
primary amino group of lysine residues from other proteins result in stable 
macromolecular assemblies incorporated within the CE I264]. Loricim (26 kDa) is 
rich in cysteine, serine and glycine amino acids and is characteristically insoluble 
due to disulphide bonding and is, in conjunction with proline rich elafin, subjected 
to A/-(y-glutamyl) lysine isopeptide bonding in the inner cytoplasmic layer of the 
CE late in the epidermal differentiation phase. It comprises 80% of the CE and 
provides resilience to the stratum comeum as a result of its flexible character 
[67:264] |t  js  jn v o ju c r jn  t h a t  confers rigidity and insolubility to comeocytes in the 
stratum comeum. All of the proteins that reside in the CE are linked via 
isopeptide bonds to keratin filaments (K1, K2, K5 and K6). Although these 
proteins are less abundant than the keratins within the desquamating layers of 
the epidermis, they may be present in slightly higher proportions in the deeper 
layers of the stratum comeum. The samples of plantar callus tissues collected in 
this study consisted of both the superficial and deep layers of the stratum 
comeum, therefore a fraction of the CE proteins may also have been present in 
the extracts generated. Therefore, it is possible that these proteins may also be 
subject to glycation. Further investigations of these proteins in isolation would be 
necessary.
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Figure 10.1. Schematic diagram of the cell envelope (CE).
Filaggrin (histidine rich protein) is in abundance in keratinocytes as they approach terminal differentiation in the SC. These 
are synthesised by the keratohyalin granules within the granular cells from the profilagrin protein. During the transition from 
the granular layer, the profilagrin is dephosphorylated to filaggrin. This conversion only occurs in tissues, which synthesise 
high molecular weight keratins. The intracorneocyte filaggrins are short lived in the lower stratum comeum. Filaggrin lies 
between the keratin filaments and acts by aggregating the keratin filaments. The protein involucrin (molecular weight 80- 
90kDa), is expressed in association with keratins K1 and K10 in the spinous layer. The protein loricrin is expressed in the 
granular cells, and its function is to add to the cytoarchitecture of the keratinocytes.
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The accumulation of AGEs in human tissue proteins is related to the turnover rate 
of those tissues: the longer the life span of a tissue the greater the potential of an 
increased accumulation of AGEs. The average time that keratinocytes take to 
travel from the basement membrane to the surface of the stratum comeum, in the 
non-pathological skin is approximately 40 days i69*661. This value applies to 
human volar skin and is subject to variation on different sites of the body. The 
epidermal kinetics of plantar skin are disturbed so as to adapt to the pressures of 
gait. This perturbation encourages an increased rate of cell renewal and 
decreased desquamation, hence the thickening of the stratum comeum.
The measurement of a greater concentration of furosine than pentosidine in the 
callus specimens has several explanations. If the furosine is exclusively 
converted to pentosidine then the comeocytes desquamate before this process of 
conversion is allowed to complete. Alternatively, furosine could be the 
intermediate compound for the conversion to other AGEs in addition to 
pentosidine. With the existing knowledge that the modifications of proteins into 
different AGEs originate from furosine, it is reasonable to suggest that a fraction 
of furosine generated in plantar epidermis is converted to pentosidine and the 
remainder could generate other AGEs such as CML. The identification of trace 
amounts of CML described in Chapter 5 supports this hypothesis. There is also a 
possibility that sugar attachment could be occurring at different times and 
different points along the keratin chain, therefore at the time of sampling the 
tissues there could be both furosine and pentosidine formations along the same 
keratin chain. Finally, the immaturity of the comeocytes entering the callus 
domain of the stratum comeum could reflect the higher levels of furosine in 
relation to pentosidine.
It would be pertinent to investigate the dispersion of individual keratins and 
glycated proteins within epidermal tissues as a consequence of physical damage. 
Such physical challenges include the response of the plantar epidermis to 
repetitive low grade trauma during gait, forming callus or, in more extreme cases, 
ulcers [267].
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Is there an association between the concentration of furosine and 
pentosidine in piantar epidermal proteins and circulating blood serum 
proteins?
There was no correlation between furosine in plantar callus and furosine in blood 
serum (diabetic r=-0.115, non-diabetic r=0.084). A similar observation was 
recorded for pentosidine concentrations (diabetic r=-0.023, non-diabetic r=0.136).
The half-life of haemoglobin tissue (-120 days) is approximately three times 
longer than the epidermal turnover time, therefore one would expect a greater 
potential for the accumulation of AGEs in the blood serum protein than plantar 
epidermal keratins. This was reflected by the pentosidine data, where the ratio of 
pentosidine concentration in the keratins to that measured in the blood serum 
was 1:3 and 1:2 in diabetics and controls, respectively. The reverse was recorded 
with the furosine data where its concentration in keratin was much higher than in 
blood serum (diabetics 4:1; non-diabetics 7:1).
Is there an association between the concentration of furosine and 
pentosidine in plantar epidermal proteins and glycaemic control?
There was no correlation between the HbA1c values and the accumulation of 
furosine and pentosidine in diabetic plantar keratin (furosine r=0.107, pentosidine 
r=0.158). Therefore, the measurement of furosine and pentosidine in the plantar 
callus tissues of this study did not reflect glycaemic control.
The presence of increased levels of keratin glycation independent of HbA1c 
levels, could be due to hyperglycaemic "memory”. This phenomenon has been 
seen in microvasculature, where there is a persistent progression of 
hyperglycaemia induced alterations during the subsequent periods of normal 
glucose homeostasisI268J. Animal studies have demonstrated the development of 
retinopathy long after the glucose levels were normalised and the same effect 
has been noted in humans in the DCCT, where despite intensive therapy for 
hyperglycaemia, retinopathy and nephropathy were evident four years after the 
trial, even though the HbA1c levels were maintained. However, in these studies
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the furosine and pentosidine concentrations in dermal collagen were significantly 
reduced, but the CML content and solubility of collagen increased [189]. The 
concept of hyperglycaemic memory may be explained by the production of 
superoxides, in the mitochondria, at physiological concentrations of glucose, with 
the resulting continued activation of the pathways in the absence of 
hyperglycaemia. Therefore, the interruption of AGE formation can be achieved by 
the inhibition of the production of superoxidase [2691. It would be difficult to 
accomplish this using conventional antioxidants, as their effects are selective 
according to their stiochiometry. New compounds that have a lower molecular 
weight than the conventional antioxidants behave as scavengers of superoxides 
by mimicking the behaviour of enzymes. These compounds normalise diabetes- 
induced inhibition of aortic prostacylcin synthetase in animals and significantly 
improve diabetes-induced reduction of nerve conduction and reduced blood flow
[270]
Does the concentration of furosine and pentosidine in diabetic and non- 
diabetic plantar epidermal proteins increase with age?
There was no association between furosine and pentosidine concentrations and 
age in both groups (diabetic furosine r^0.088; diabetic pentosidine r=0.095; non­
diabetic furosine r=-.0.193; non-diabetic pentosidine r=-0.143).
As already mentioned, the accumulation of the glycation products, particularly 
pentosidine, is influenced by keratinocyte turnover. It could be that this 
specialised area of skin, with its unique epidermal kinetics, needs the focus of 
glycation redirected to the age of the tissue and not the age of the person.
The next section addresses the second hypothesis by discussing the protein 
associations in epidermal tissue that provide the resilience and flexibility that is 
key to its protective function. The discussion addresses the function of 
intramolecular bonds and intercellular adhesions that are present in varying 
combinations throughout the epidermis, and adapts the knowledge obtained in 
Chapter 7 to the physical properties of plantar epidermal tissues. As these 
cellular interactions contribute to the physical behaviour of the epidermis at a
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macro level, this knowledge is adapted to plantar epidermis in its normal state 
before the effects of hyperglycaemia are considered.
10.3 Hypothesis 2: There is a Decrease in Flexibility of Pedal Epidermis in 
Type II Diabetes.
The term flexibility is used to describe the five indices of elasticity measured in 
this thesis: the series elastic element on stretching and retraction; time constants 
on stretching and retraction and plasticity.
The series elastic element, retraction of the epidermis was significantly greater in 
the diabetic group on the three sites on the foot (p<0.05) than the controls. For a 
realistic expression of elasticity these data were corrected according to the 
epidermal thickness, measured by ultrasonography, giving a time constant or the 
series elastic element reading per unit thickness of epidermis. The series elastic 
coefficient/ mm of epidermis was significantly greater in the diabetic population 
than the controls (p<0.001). No other differences were noted when the thickness 
of the skin was taken into account.
There was no significant difference in the time constants on stretching and 
retraction between the diabetic and control groups (p>0.05). The epidermal 
plasticity of non - diabetic plantar epidermis was significantly greater than that of 
diabetic plantar epidermis (p < 0.007).
Other than keratins there are specific proteins, unique to keratinocytes that 
facilitate inter- and intra-cellular adhesions of epidermal keratinocytes. The 
expression of these proteins changes throughout the keratinisation process. As a 
collective, the keratinocytes provide the plantar epidermis with the appropriate 
mechanical properties it requires to withstand mechanical trauma. Increased 
cross-linking via pentosidine AGE formation may effect the dynamics of the 
epidermis.
Between the keratin filaments there are the non-helical domains, N- and C- 
terminal groups, protruding into the cellular matrix. A suggested mechanism for
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the elasticity of the stratum comeum is through the reduction of the 
intermolecular forces between these filaments through non-helical regions, with 
the help of water extractable materials such as free amino acids (48.3% of water 
extractable materials). The properties associated with increased elasticity depend 
on increased intermolecular interaction between the water-extractable materials 
and the keratin fibres in the non-helical regions in the presence of an appropriate 
amount of water I271]. Therefore, dehyradation of the tissue would cause a 
reduction in this interaction and reduce the skins elasticity (Fig. 10.2). The 
profound change in the mechanical properties of the matrix upon dehydration is 
evident. In diabetes, autonomic neuropathy results in clinically anhydrotic skin on 
the foot (72% of diabetics in this thesis), therefore with less water in the stratum 
comeum the elastic and viscolelastic properties of the epidermai may be affected. 
To add to this model further, the protruding amino terminal domains may also be 
subject to glycation, therefore disturbing the dynamics between the keratin 
filaments even more (Fig. 10.2).
The structures within the cells, other than keratins that contribute to cell 
adhesion, have been mentioned earlier in this chapter. The mechanical 
properties of the epidermis result from its geometric form and the intrinsic 
properties of its constituent materials, mainly linearly elastic, high modulus keratin 
fibres embedded in a viscoelastic matrix of a lower modulus. The physical 
properties of keratin filaments are determined by their length (which is much 
higher than the cross-sectional area and thus provides a high level of flexibility; 
orientation (parallel arrangement); and packing (influenced by the size of the 
keratin bundles). Keratin intermediate filaments anchor to the desmoplakins 
within the desmosomes [258] providing the keratinocytes with a degree of tensile 
strength. Although the KIFs do not pass through the cell membrane, they are 
indirectly connected to each other through the desmosomes, forming a continual 
fibre network and structural continuity throughout the cell system. If glycation 
occurs at the terminal domains of the keratin filament tetramers, there is a 
possibility that the length of the filaments may be altered, thus compromising the 
flexibility.
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Figure 10.2. Diagram illustrating the possible affects of glycation and on the physical nature of 
the keratin filaments
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When subjected to a deforming force it seems that the keratin filament will 
essentially behave as a linear elastic tissue and the stress that develops within 
the filaments will occur as a result of resistance to stretching offered by the a- 
helices. At larger strains the molecular organisation of the filament is 
progressively disrupted, as shown by X-ray diffraction studies, but these strains 
lie outside the normal physiological range encounteredl272].
This synopsis of the cohesion inter and extracellular structures of keratinocytes 
has explained how the keratins in the epidermis provide the skin with the 
resilience and flexibility that is essential during natural joint and muscle 
movement. This is of particular importance on the foot, where the skin lies in 
closely associated with muscle and bone tissue. The plantar epidermis is the first 
point of contact the skin has with the ground (or shoe) during gait, and is 
designed to withstand shear, compression and torsion stresses. The function of 
keratin filaments in epidermal cells is to impart mechanical integrity to the cells, 
without which they would become fragile and prone to rupturing upon mild 
physical trauma [G2].
In a clinical environment, the measurement of in vivo skin flexibility has involved 
basic devices in the past and observations have been understandably subjective. 
The evaluation of the viscoelasticity of the epidermis, in relation to vertical 
negative pressure, on different sites on the foot has been successfully conducted 
in this thesis using the Cutometer®.
The in vitro studies confirmed the difficulties encountered when attempting to 
simulate an in vivo environment for the callus specimens. When the stratum 
comeum (consisting of live cells) is separated from the skin, mechanical 
behaviour is grossly altered as a result of the removal of the dermis I2731. The 
problem of preventing dehydration of callus, which begins immediately after the 
removal from the foot, still remains.
The macro-structure of human epidermis, it is characterised as a 3-dimensional 
arrangement of fibres, which when stretched, could eventually change to one with 
a largely 2-dimensional orientation. In an experimental diabetes model,
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Andreassen et al (1981)[158] demonstrated profound alterations in the collagen of 
diabetic rat skin, leading to an increase in the stiffness and strength. This 
stiffness is characterised by additional glycated cross-links formed between 
collagen molecules along with the whole extent of the triple helix, thus reducing 
the ability to change fibre orientation in this way i.e. reducing the ability to stretch 
under stress t56;27*275!. This experimental model could is transferable to epidermal 
tissues, in vivo. Therefore, if there is a greater degree of cross-links between 
keratin filaments, the ability to lengthen when under stress decreases. The 
results in this thesis show diabetic epidermis to exhibit greater elasticity on 
retraction of the epidermis than the non-diabetic epidermis. The elasticity on 
stretching of the epidermis did not differ between the two groups and the plantar 
epidermal plasticity was lower in the diabetic groups. Therefore, although the 
epidermis has the ability to retract in diabetes, more readily than non-diabetic 
epidermis, it is possible that the realignment of the tissues, after the deforming 
force is released, takes longer in the diabetic epidermis.
10.4 Hypothesis 3: There is an Increase in the Thickness of Pedal 
Epidermis in Type II Diabetes.
The plantar epidermal thickness was significantly higher in diabetics in 
comparison to controls (p<0.05), implying a denser plantar epidermis in diabetes. 
This fits the reasoning that the keratinocytes respond to mechanical trauma by 
increasing cell proliferation I73*76!. Therefore, the density of the tissues is 
expressed as high echogenicity in the ultrasound images.
Is there an association between the flexibility o f pedal epidermis and age, 
gender and ethnicity?
There was no association between age and epidermal flexibility, with the 
exception of the linear elastic element on retraction of non-diabetic dorsal 
epidermis (r^-0.559).
There was no difference in all five indices of elasticity between the genders in the 
diabetic group (p>0.05). Differences were noted between the ethnic groups, in
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varying degrees, on all three sites of the feet of both diabetics and controls 
(p<0.05). The Black and Asian skin types were overall less plastic and 
viscoelastic than the Caucasian skin types. The non-diabetic group only reflected 
this trend on the MLA site in terms of series linear coefficient on stretching the 
epidermis (p<0.001). These results need to be considered with caution, as the 
patient numbers in the groups were small. To gain a more realistic knowledge of 
the physical properties of skin in different skin types, further studies, recruiting 
more patients would increase the power of the results.
Is there an association between the thickness of pedal epidermis and agef 
gender and ethnicity?
There were no significant differences recorded in the epidermal thickness 
between the genders and between groups of different ethnic origin (p>0.05). In 
the diabetic population there was no correlation between age and epidermal 
thickness on all sites of the foot.
The non-diabetic females had thicker epidermis than the males on all three sites 
of the foot. Previous ultrasound studies have measured the full thickness of skin 
on other parts of the body as being thinner in the females p41]. As the acoustic 
density of the epidermis increases it can mask the echoes travelling into the 
dermis, therefore giving a false representation of the dermal layer of the skin. 
This could be an explanation for the results recorded in the Olsen study.
The low acoustic density of skin often creates problems when skin thickness 
measurements are made, as it is often difficult to convincingly identify the 
interface between the dermis and deeper structures, and there is a risk that the 
thickness of the dermis is underestimated [241]. The images taken of the pedal 
skin in this thesis, particularly the PMA, did not show the dermal structures 
clearly. This is advantageous as it makes the epidermal-dermal boundary 
definition clearer. The device does not have a sensitive enough resolution to note 
slight increases in epidermal thickness such as the swelling of the stratum 
comeum as a result of the ingress of water. This is an important point applicable 
to all studies that use this equipment for a quantitative analysis tool. However, the
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equipment provides images of skin that are the nearest possible to the in vivo 
representation of the skin on different body sites. The images still provide a far 
more accurate indication of tissue thickness than histological techniques that 
ultimately result in post-fixation deformities in the structures.
What were the clinical observations made in the feet of diabetic and non­
diabetic volunteers?
The genesis of this thesis originated from the detrimental effects that plantar 
callosities have on a foot at risk of ulceration. Clinical observations of diabetic 
callus, in particular around a chronic ulcer, question the physical nature of the 
tissues whilst the healing process is underway. Surveys analysing the distribution 
of callus in diabetic populations have reported conflicting outcomes. If the theory 
of glycation having an effect on the epidermal tissues was to be explored, it was 
imperative that the volunteers recruited for this study were examined for callus 
distribution and quality, so that an extrapolation callus formation and glycation 
accumulation could be scrutinised. It was essential that the population being 
investigated in this study was representative of the population of Type II 
diabetics. The recruitment of volunteers was based on the random sample of the 
diabetic population in North London. The overall participation rate was 
approximately 10%. The age distribution of the diabetic population was not 
normal, but slightly skewed to the right. This is this would be expected as persons 
with Type II diabetes usually, but not always, present with the disease above the 
age of 40; therefore, the occurrence of diabetes would favour the older 
population. The ages of the control group were of a normal distribution.
Calluses appear to have a mechanical etiology, although not all areas of high 
pressure develop callus, therefore the exact mechanical stimulus of callus 
formation is not clear. Calluses can act by distributing the force from an area or 
can behave in the opposite way by acting as a foreign body on the surface of the 
skin I331. In this thesis, pathological callus was present in 52% of the diabetic 
patient population and 77% of the non-diabetic group, agreeing with previously 
published data by Holewski et al (1989) I8]. The majority of the diabetics 
presented with minimal stratum comeum thickening whereas the non-diabetics
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presented with an even distribution of all three types of callus. In addition, the 
controls had more corns than the diabetic patients, which was associated with an 
increase in age.
In the diabetic group a similar prevalence of callus formation was recorded in 
both neuropathic and non-neuropathic diabetic patients of all ages. Callus 
formation was independent of duration of diabetes, which agrees with other data
[32]. Most of the diabetics with peripheral sensory neuropathy did present with 
plantar corns.
Both diabetic and non-diabetic groups were overweight (BMI=25 and 27, 
respectively). The range of BMI was greater in the diabetics (minimum=20 and 
maximum=61.3) than the non-diabetics (minimum=29.8 and maximum=39.3. 
The natural progression from this observation would be that as the body mass 
increases, there is an increase in plantar pressures. This association was tested 
by Ahroni et al (1999) [16], where there was no correlation between body mass 
and peak plantar pressures. Another study reported that patients with 
neuropathic ulceration were significantly heavier than diabetic patients without 
ulceration[277], and also had an uneven plantar pressure distribution.
The diabetic population had a greater incidence of bilateral pes planus. From a 
clinical perspective the connection with Charcot foot is brought to mind, where it 
is theorised that the arterio-venous shunting, as a consequence of postganglionic 
autonomic denervation, causes demineralisation of the bones and the resulting 
collapse of the foot. This phenomenon occurs gradually over time or can present 
as acute attacks which if not dealt with early enough, will result in gross 
deformities of the foot. These data demonstrate pes planus as a structural 
deformity of the diabetic foot. With this in mind one would expect the 
demineralisation of the skin would lead to abnormalities in the connective tissue 
metabolism and structural changes in the skin. Diabetic A-V shunting is mainly 
found in the diabetic lower limb and foot, yet the largest difference in skin 
thickness is found in the thigh and not the foot l41]. In this study, diabetic 
neuropathy did not relate to epidermal thickening, but the differences in thickness 
were present between the diabetics and controls in the plantar skin. This
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suggests that another aspect of diabetes other than neuropathy may have an 
effect on epidermal thickness.
Diabetic patients with PVD had thinner epidermis on the PMA and dorsal sites 
(p=0.018 and p=0.024, respectively) than diabetic patients without PVD. This 
agrees with the concept of poor nutrition of the skin, leading to its atrophy and of 
the associating appendages. A point of discussion with regards to glycation, 
would be that if there is a limited blood supply to the foot, the amount of glucose 
that may diffuse into the dermis followed by the epidermal tissues would also be 
reduced. Therefore, the potential for glycation of tissues is low. The amount of 
furosine noted in the keratin was far higher than that found in circulating blood, 
which suggests that free glucose from the circulating tissues may have diffused 
into tissues elsewhere in the body. Without detailed information about the blood 
in the immediate vicinity of the foot, only an assumption connecting the two can 
be made. Other studies using ultrasonography have not found a relationship 
between microvascular disease and increased thickness of skin in the extremities 
l40]. Whether changes in capillary blood flow, increase of glycation, polyol 
accumulation or other metabolic disorders are responsible for these findings 
remains to be established.
The majority of the patients with marked peripheral neuropathy (63%) and 
moderate peripheral neuropathy (63%) presented with limited range of motion 
(ROM) in the feet and 51% of the patients with no signs of neuropathy also 
presented with limited ROM in the feet. Reduced joint mobility in the feet, in 
particular the sub-talar joint disrupts the biomechanical function of the foot, 
therefore compromising plantar pressure distribution I2781. This limited ROM may 
distribute plantar pressures unevenly due to the resulting lack of shock 
absorption that the rigid foot will supply. The same phenomenon is seen to occur 
in diabetics with ulceration, more so than in diabetics without ulceration I279J. An 
increase in glycation related cross-linking of the collagen in extensor tendons of 
diabetics subjects, altering the ultrastructure of the associated tendons[125].
This thesis demonstrated no relationship between the epidermal thickness and 
HbA1c levels. The relationship between the cheiroarthropathy and peripheral
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sensory neuropathy was not clear (no neuropathy: 49%; moderate neuropathy: 
39% and marked neuropathy: 63%). The results are interesting, as the concept of 
limited digital range of motion is conventionally seen in Type I diabetes. In this 
study an association between the limited ROM in the feet and the small joints in 
the hands was made in some participants.
Although there was a higher incidence of yellow nail in the feet of diabetic 
patients than the controls, the presence of yellow nails in the controls indicates 
that the accumulation of AGEs can occur in a non-diabetic state. The non­
diabetics with yellow nails did not have PVD. In both groups the presentation of 
yellow nails on the feet was seen in patients with higher HbA1c readings. 
Examination of the palmar skin recorded 19 diabetic patients and 2 non-diabetic 
subjects with a yellow hue on the skin. Those with such a presentation had 
significantly higher levels of pentosidine in the plantar callus than those without 
yellow palmar skin (p<0.05). The majority of people with chieroarthropathy, 
limited joint motion in the feet and yellow nails were at least 65 years of age.
Is there an association between clinical pathologies of the feet in diabetes 
and the physical qualities measured in the feet?
There was no association between epidermal thickness on the feet and the 
duration of diabetes or glycaemic control.
This thesis did not find a statistical significant difference, between epidermal 
thickness and neuropathy. There was a significant difference however in 
epidermal thickness readings taken from the PMA between non-diabetic 
volunteers and diabetic patients without neuropathy. The former was greater than 
the latter, which implies that the average thickness PMA of epidermal tissue in 
diabetic patients to be considerably greater in the neuropathic patients, the PMA 
data, as a whole, in diabetics is higher than non-diabetic PMA epidermal 
thickness and therefore may be related to neuropathy. A larger patient group 
would be needed to confirm this.
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10.5 Summary of Conclusion
The following conclusions, based on the present experimental and numerical 
studies can be drawn:
1. The plantar callus tissues of diabetic and non-diabetic individuals are involved 
with non-enzymatic glycation. The amount of pentosidine measured is 
significantly greater in plantar diabetic callus than non-diabetic callus.
2. Keratin is a major determinant of epidermal dynamic stiffness. Site dependent 
variations, on the feet, in both the dynamic and time-dependent mechanical 
properties have been recorded in the normal populations. The diabetic pedal 
epidermis is more elastic on retraction than non-diabetic epidermis and less 
plastic on the PMA site only. This has allowed for the comparison of data to be 
made between the diabetic and non-diabetic population. These data can be used 
for comparative studies in the future regarding the mechanical properties of the 
epidermis on the periphery of plantar neuropathic ulcers.
3. Regional variations in epidermal thickness were noted between diabetic and 
non-diabetic populations. Plantar epidermal thickness in the diabetic population 
was significantly higher than that of the control group.
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Appendix I The Lowry Protein Assay Procedure
Reagents
Reagent A
Dc Protein Assay (Bio-Rad Laboratories). Content: 2% Na2C0 3  in 0.1N NaOH, 2% 
NaK Tartrate, 1 % CuSCVShfeO.
Reagent B
Dc Protein Assay/2N Folin reagent (Bio-Rad Laboratories).
Protein Standard
Prepared from bovine serum albumin (BSA)
Instruments
Spectrophotometer which transmits light at 630nm.
Materials
Pipettes, universal plastic vials, Immulon 4 assay wells (Dynex Ltd)
Calibration
BSA protein standards of concentrations 1, 0.75, 0.5, 0.25, 0.1 and 0.00 mg/ml 
Method
Each standard (5 jil) was placed in wells in duplicate. Aliquots (5 pi) of each sample 
were placed in adjacent wells. Reagent A (25 |iil) was placed in each of the wells and 
the mixtures allowed to incubate at room temperature on a shaker for 15 min. 
Reagent B (200 pil) was added to each well and allowed to incubate for a further 
15mins at room temperature on a shaker. The absorbance readings were taken at 
630nm.
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Appendix II One-Dimensional SDS-PAGE Protocol
Reagents and stock solutions 
Acrylamide stock (50% w/v)
Acrylamide (Sigma Chem), 23.38 g and bis-Acrylamide (Sigma Chem), 0.63 g was 
made up 50 ml in d.H20  and stored away from light at +4°C.
1M Tris, pH 8.8
Tris (Sigma Chem), 12.1 g was added to 80 ml d.H20. The pH adjusted to 8.8 and 
then made up to 100 ml.
10% Sodium Dodecyl Sulfate (SDS)
SDS (Sigma Chem), 2 g was added to 20 ml d.H20.
1% SDS
1 ml of 10% SDS was added to 9 ml d.H20.
15% Ammonium Persulphate (APS)
Ammonium persulphate (BioRad), 0.6 g was added to 4 ml d.H20. This solution was 
made up fresh each day before use.
1M Tris pH 6.8
Tris (Sigma Chem), 12.1 g added to 80 ml d.H20  The pH was adjusted to 6.8 and 
the solution is then made up to 100 m l.
0.5% Bromophenol Blue
Bromophenol Blue (Sigma Chem), 0.05 g was added to 10 ml d.H20.
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Gel Assembley
12.5% SDS Acrylamide Separating Gei (makes 2 Omi)
Acrylamide stock 5 ml
1M Tris pH 8.8 7.5 ml
d.H20  6.85 ml
10% SDS 0.2 ml
15% APS 0.45 ml
Immediately before pouring the gel, 20 pi TEMED was added.
5% SDS Acrylamide Stacking Gel (makes 5 ml)
Acrylamide stock 0.5 ml
1M Tris pH 6.8 0.62 ml
d.H20 3.57 ml
10% SDS 0.05 ml
15% APS 0.25 ml
Immediately before pouring the gel, 10 pi TEMED was added.
The separating gel was poured into the casting apparatus to approximately 1 cm 
below the bottom of the comb using a syringe and left to set for 30 min, with an 
overlay of 1% SDS. When set, the SDS was carefully poured off and the comb 
placed in the apparatus. The stacking gel was poured on top of the separating gel, 
using a syringe and left to set for approximately 10mins. Once set, the comb was 
carefully removed and the gel was placed in the electrophoresis tank.
Sample Preparation 
Sample Buffer (makes 8 ml)
d.H20  4.2 ml
1M Tris, pH 6.8 1.0 ml
Glycerol 0.8 ml
10% SDS 1.6 ml
0.5% Bromophenol Blue 0.4ml
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1 ml of this sample buffer was placed in an Eppendorf vial and 25 pi of 0- 
mercaptoethanol was added immediately prior to addition to the sample under 
investigation.
5 x  Running Buffer
Tris Base (15 g), glycine (72 g) and SDS (5 g) was made up to 1 litre in d.FfeO.
For one run, 60 ml of the stock solution was diluted in 240 ml d.H20; the upper 
buffer chamber was filled with approximately 115ml (half way between the long and 
short plates) and the power tank chamber with approximately 185 ml (enough to 
cover the anode wire).
Electrophoresis
The samples are loaded onto the gel and run at a constant 100 mV for 60 -  90 mins.
Molecular Weight Markers (Sigma Chem)
Protein Molecular Weight (Da)
Myosin 200,000
fi-galactosidase 116,250
Posphorylase 97,400
Serum Albumin 66,200
Oval Albumin 45,000
Carbonic Anhydrase 31,000
Trypsin Inhibitor 21,500
Lysozyme 144,00
Aprotinin 6500
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Staining (Coomassie Blue R-250 Staining Solution)
Methanol (Sigma Chem), 400 ml 
Glacial Acetic Acid (BDH), 100 ml 
d.H20, 500 ml
Coomassie Blue (Sigma Chem), 1 g
The gel was carefully placed into the destaining box and enough stain was poured in 
to cover the gel. This was left on the shaker for 1 to 2 hours.
Destaining (Coomassie Blue Destaining Solution)
Methanol, 400 ml 
Glacial Acetic Acid, 100 ml 
d.H20, 500 ml
The gel was carefully removed from the staining solution and placed in the destain 
box. Just enough destaining solution was added to cover the gel and this was left on 
the shaker for 1 hour. The destain was then replaced with fresh solution and left on 
the shaker over night.
Gel Imaging
An image of the gel was taken using a white light transilluminater and saved using 
Grabbit - IT® Annotating Grabber (32bit) 2.59 (Ultraviolet Products Limited). The 
gels were analysed using Gene Tools® Version 2 (Syngene. A division of Synoptics 
Ltd).
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Appendix III Western Blot Analysis Protocol
Reagents and stock solutions 
Nitrocellulose membrane
Immun - Blot™ PVDF, membrane for protein blotting 0.2 pm (Bio -  Rad, Cat 162 -  
0177)
Transfer buffer (x 10)
Tris (hydroxymethyl) aminomethane (Sigma Chem), 15.15 g, glycine (Sigma Chem), 
67.3 g and SDS (Sigma, Chem), 5 g were made up in 500 ml d.H20  (may require 
warming to aid dissolution). Methanol (BDH), 125 ml was added.
Wash buffer (x 10)
Sodium chloride (8 g), potassium chloride (0.2 g), di-sodium hydrogen 
orthophosphate (1.15 g) and potassium dihydrogen orthophosphate (0.2 g) were 
dissolved in 1 litre of d.H20  and 50 pi of Tween 20 was added.
Blocking buffer
Tris (2.4 g) and bovine serum albumin (9 g) were dissolved in 300 ml d.H20  (pH 
should be 7.4)
Primary antibody solution
Anti-keratin antibody (40 pi) was added to the blocking buffer (20 ml).
Secondary antibody
Anti-mouse/ anti-guinea pig IgG HRPO antibody (10 pi) was added to the blocking 
buffer (20 ml)
Substrate solution a
4-chloro-1-napthol (Sigma Chem), 60mg was added to 20 ml methanol in the dark.
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Substrate solution b
Tris (Sigma Chem), 1.21 g and sodium chloride (Sigma, Chem), 14.63 g was 
dissolved in 400 ml d.H20. The pH was adjusted to 7.6 and then the solution was 
made up to 500 ml.
Working substrate solution
Hydrogen peroxide (60 pi, 30%) was added to 100 ml of substrate b. All of this 
solution was then added to the substrate and then used immediately.
Protocol
Both the electrodes were soaked in water for 5 min to prevent trapping any air 
bubbles under the filter paper. The anode was placed in the gel tank and plugged 
in. Filter paper (9 sheets) were soaked in the transfer buffer and placed on the 
anode plate. The sheets were placed on the anode one by one and the air bubbles 
were smoothed out after each sheet was applied. A piece of dialysis membrane was 
soaked in water for 5 min, then in transfer buffer for 15 min and placed over the filter 
paper. The nitrocellulose membrane was soaked in methanol for 5 min followed by 
transfer buffer for 15 min and placed on top of the dialysis membrane. A small piece 
from the comer of the membrane was cut away in order to orientate the blot. The gel 
was soaked in water and then in the transfer buffer and then placed on top of the 
nitrocellulose membrane. Finally, 9 more sheets of filter paper were soaked in 
transfer buffer and placed over the gel. All air bubbles were gently smoothed away. 
The cathode plate was placed on top of the assembly and plugged in. The lid was 
placed on top of the tank and the system set at 80 V and 350 mA for approximately 
2 hours. After this time the gel was checked to see whether full transfer of the 
proteins had occurred. The nitrocellulose membrane was carefully removed from the 
apparatus and placed in a polyethene bag containing blocking buffer (50 ml). This 
was incubated at room temperature for 2 hours on a shaker.00 The membrane was 
then placed in a polyethene bag containing wash buffer (50 ml) and incubated at
°° The gel was stained and destained according to the protocol described in Appendix I To confirm that complete protein 
transfer onto the membrane had occurred
428
room temperature for 20 min on a shaker. The blot was then incubated, on a shaker 
overnight, in the primary antibody solution (20 ml). The blot was the washed in 
blocking buffer (50 ml, x 2) and then in wash buffer (50 ml). After this procedure the 
blot was incubated in the secondary antibody solution for 2 hours at room 
temperature on the shaker. The blot was finally washed 3 times in was buffer for 
15mins each time and then placed in the working substrate solution and gently 
incubated until grey/black bands were visible. The resulting blot was photographed 
using the equipment described in Appendix II.
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Appendix IV Immunoblots of Keratin Extracts from 14 Callus
Specimens using Extraction Method 3 (Chapter 2)
1 2 3 4 5 6 7 8 9 10 11 12 13 14
84kD<a —
58 k Da —
I 56 k Da
45 k Da —
36.5kD3
26.6 kDa —
Figure IV.i: Immunoblot using AE1 monoclonal antibody. The 50kDa band 
is present on the blot but too feint to be visible on this scan.
1 2 3 4 5 6 7 8 9 10 11 12 13 14
84kDa
58kDa
45 k Da
36.5kDa
26.6 k Da
Figure IV.ii: Immunoblot using AE3 monoclonal antibody.
Samples 1-7: Keratin extracts taken from non-diabetic plantar callus samples. 
Samples 8-14: Keratin extracts taken from diabetic plantar callus samples
58 -  67k Da
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Appendix V Derivatisation Procedure for GCI MS Analysis of CML
Reagents
Methanolic acid (0.5 M), dichloromethane, TFAA, methanol 
Method
The sample (2.5 mg) was placed in a glass vial and methanolic acid (0.5 ml, 0.5 
M) was added and heated for 1h at 80°C. The acid was removed by rotary 
evaporation and dichloromethane (0.5 ml) was added and mixed. Trifluoracetic 
anhydride (1 ml) was added to the solution and mixed and the reaction mixture 
was allowed to stand at room temperature for 1h. All solvent was removed under 
rotary evaporation, until the sample was dry and the vial was sealed and stored 
at 0°C, ready for GC/MS analysis (see Appendix VI for the GC/MS conditions).
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Appendix VI GC/MS Analysis Equipment and Conditions
GC/MS System
Hewlett Packard 5890 Series II Gas Chromatography 
HP 5972 Series Mass Selective Detector 
HP 7673 Controller
Temperature Program
Initial temperature 50°C for 20 min 
Level 1 Rate 15°C/min
Final Temperature 130°C 
Time 2 min 
Level 2 Rate 2°C/min
Final Temperature 230°C 
Time 5 min 
Level 3 Rate 0°C/min
Total run time = 64.3 min
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Appendix VII NMR and GC/MS Spectra from Chapter 3
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Figure Vll.i: NMR spectrum of CML synthesised according to method 1. The spectrum is a 
mixture of lysine, CML and CML salts.
433
t v .  n u  1 41 o
SKSOW^
   .
4000« E  I
aSBSMO \
-fiittfi
;O X W
\wuc
\OCttUC:
5AOC
CML peak 
35min v
Additional peaks
between
40&50min
- -  i f r w  m x  S u e  jp i p  a a e  «pod 4»qd m a s  s t i r  ic a c  « o c  ■*?«>
| —rr -v m m  j Ilf ‘ J * O t  S rmvx J . . *  Iswxna *
wmm
xuaaa
«*O0
ttoiQCV 
I400ED
liMOP ®
1 W 0 »
wod *4}
O H  1 1  [  *401»
4900G
138 *83
*WB! i f  1 ® *  HO 
mfcy < i . bp «  n i  t z  t d
Figure VII.ii: Mass spectrum confirming the presence of CML synthesised 
according to method 1, with additional impurities.
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Acetone
Standard
c-C
6-C
Y-Cp-C
5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 ppm
Figure Vll.iii: NMR spectrum of the compound formed by method 2. Spectrum 
indicates the presence of acetyllysine and CML
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aPPM
b
1:1:1
CML
PPM
Figure Vll.lv: NMR spectra of CML synthesised by method three a. protected CML. The 
product was characterised by 1H NMR (270MHz, CD3OD) where chemical shift 8H (ppm) 
and coupling constant J (Hz) values were: 1.5ppm large singlet 21.650int tBOC, 1.8- 
1.6ppm multiplet 4 x CH2) 2.9-3.1 ppm triplet 2 int CH2, 3.3ppm multiplet b. 
deprotected CML
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Figure Vll.v: Mass spectrum of pure CML synthesised from method 3. 
CML m/e=392
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Figure Vll.vi: NMR spectrum of pentosidine
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Appendix VIII HPLC Data from Chapter 4
Table Vlll.i. Furosine standard data from day one and two
0.0156 mg/ml furosine R7 [min] 
Day One
RT [min] 
Day Two
Area 
[counts 
x 103] 
Day one
Area 
[counts 
X103] 
Day Two
1 8.29 8.04 195.43 192.38
2 8.37 8.15 195.27 197.22
3 8.44 8.18 200.85 195.45
Mean 8.37 8.13 197.17 195.02
Standard Deviation 7.41 x 10'2 7 .2 2x 1  O'3 3.19 2.45
Standard Error 2.27 x 10"2 4.17 x10 '2 1.94 1.41
0.0078 mg/ml furosine
1 8.47 8.23 91.06 87.69
2 8.43 8.23 88.90 87.86
3 8.37 8.21 89.02 87.53
Mean 8.42 8.23 89.66 87.70
Standard Deviation 5.04 x 10'2 9.81 x 10'2 2.75 0.17
Standard Error 1.98 x 1 0 ‘2 5 .6 7x 1  O'3 1.59 9 .6 8x 1  O'2
0.00390 mg/ml 
furosine
1 8.35 8.20 41.25 43.57
2 8.30 8.19 43.30 43.97
3 8.28 8.19 46.69 43.64
Mean 8.31 8.20 43.75 43.73
Standard Deviation 3.43 x 10'2 6.51 x 10 2 2.75 0.21
Standard Error 2.91 x 10'2 2.76 x 10‘3 1.59 0.12
0.00195 mg/ml 
furosine
1 8.28 8.20 22.01 22.11
2 8.25 8.19 22.14 22.91
3 8.17 8.20 22.62 24.43
Mean 8.23 8.20 22.26 23.15
Standard Deviation 5 .6 6 x 1  O'2 3 .0 6 x 1  O'2 0.322 1.18
Standard Error 4 .2 8 x 1  O'2 1 .7 6 x 1 0‘3 0.19 0.68
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Table Vlll.ii. Data for day-to-day repeatability of furosine standard peaks
0.0156 mg/ml furosine RT [min] Peak Area [counts x 103]
Mean Day One 8.37 178.36
Mean Day Two 8.13 197.17
Mean 8.25 187.77
SD 0.17 13.31
CV% 2.07 7.09
0.078 mg/ml furosine RT [min] Peak Area [counts x 103]
Mean Day One 8.42 87.69
Mean Day Two 8.23 49.66
Mean 8.33 68.68
SD 0.14 26.90
CV% 1.67 39.16
0.0039 mg/ml furosine RT [min] Peak Area [counts x 103]
Mean Day One 8.31 43.73
Mean Day Two 8.20 43.75
Mean 8.26 43.74
SD 0.08 0.015
CV% 0.99 0.03
0.00195 mg/ml furosine RT [min] Peak Area [counts x 103]
Mean Day One 8.24 23.15
Mean Day Two 8.20 22.26
Mean 8.22 22.71
SD 0.02 0.63
CV% 0.28 2.77
0.000975mg/ml RT [min] Peak Area [counts x 103]
furosine
Mean Day One 8.14 10.95
Mean Day Two 8.22 10.96
Mean 8.18 10.95
SD 0.06 0.01
CV% 0.71 0.08
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Table Vlll.iii. Pentosidine standard data from day one and two
200 ng/ml pentosidine RT [min] 
Day One
RT [min] 
Day Two
Area 
[counts 
x 103] 
Day one
Area 
[counts 
X103] 
Day Two
1 10.27 10.44 87.534 88.725
2 10.31 10.42 88.664 88.153
3 10.44 10.30 88.413 88.850
Mean 10.34 10.39 88.204 88.576
Standard Deviation 8 .8 9x 1  O'2 7 .5 7x 1  O'3 0.593 0.372
CV% 0.89 0.87 0.67 0.42
100 ng/ml pentosidine
1 10.25 10.40 50.490 51.060
2 10.40 10.35 51.898 48.900
3 10.35 10.28 50.491 49.030
Mean 10.33 10.34 50.960 49.670
Standard Deviation 7.64 x 10'2 6.03 x 10'2 0.813 1.21
CV% 0.60 0.12 0.19 2.44
50 ng/ml pentosidine
1 10.26 10.35 30.260 31.250
2 10.30 10.32 31.606 33.307
3 10.28 10.38 31.837 36.698
Mean 10.28 10.35 31.234 33.752
Standard Deviation 0.02 0.300 0.852 2.751
cv% 0.41 0.08 2.73 8.51
25 ng/ml pentosidine
1 10.30 10.33 21.247 22.015
2 10.34 10.27 22.084 22.145
3 10.28 10.31 23.153 22.627
Mean 10.31 10.30 22.161 22.262
Standard Deoiation 3 .055x1  O'2 3 .0 5 5 x 1 0'2 0.955 0.322
CV% 0.03 0.03 0.96 0.32
12.5 ng/ml 
pentosidine
1 10.31 10.32 15.387 15.491
2 10.30 10.34 15.666 15.643
3 10.33 10.30 15.948 15.748
Mean 10.31 10.32 15.667 15.627
Standard Deviation 1 .5 2 x 1 0‘2 0.02 0.281 0.1292
CV% 0.22 0.18 1.79 0.83
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Table Vlll.iv. Data for day-to-day repeatability of pentosidine standard peaks
200 ng/ml pentosidine RT [min] Peak Area [counts x 103]
Mean Day One 10.34 88.204
Mean Day Two 10.39 88.576
Mean 10.37 88.390
SD 0.04 0.186
CV% 0.34 0.21
100 ng/ml pentosidine RT [min] Peak Area [counts x 103]
Mean Day One 10.33 50.960
Mean Day Two 10.34 49.670
Mean 10.34 50.315
SD 0.01 0.9122
CV% 0.07 1.81
50 ng/ml pentosidine RT [min] Peak Area [counts x 103]
Mean Day One 10.28 31.234
Mean Day Two 10.35 33.752
Mean 10.32 32.493
SD 0.05 1.780
CV% 0.48 5.48
25 ng/ml pentosidine RT [min] Peak Area [counts x 103]
Mean Day One 10.31 22.161
Mean Day Two 10.31 22.262
Mean 10.31 22.212
SD 0 0.071
CV% 0 0.32
12.5 ng/ml pentosidine RT [min] Peak Area [counts x 103]
Mean Day One 10.31 15.667
Mean Day Two 10.32 15.627
Mean 10.32 15.647
SD 0.01 0.028
CV% 6.86 x 0.18
10-5
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Table Vlll.v. Furosine data for freeze-thaw study
Freeze/Thaw Cycle Mean Peak 
Area 
[counts x 103]
0 191.7
1 182.2
2 181.5
3 181.2
4 181.8
5 184.1
6 181.8
Table Vlll.vi. Pentosidine data for freeze-thaw study
Freeze/Thaw Cycle Mean Peak 
Area 
[counts x 103]
0 87.7
1 88.9
2 90.2
3 80.0
4 66.1
5 54.1
6 56.4
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Table Vlll.vii. Hydrolysis of callus samples under hypoxic and non-hypoxic conditions-assayed
for furosine
Callus Sample Concentration of furosine 
[ng/mg protein] 
Hydrolysis under nitrogen
Concentration of furosine 
[ng/mg protein] 
Hydrolysis under oxygen
Concentration of furosine 
[ng/mg protein] 
Hydrolysis under air
1N 343.0 96.8 263.0
2N 156.1 565.9 282.0
3N 263.8 192.2 132.2
4N 141.2 195.8 70.6
SN 245.5 40.9 190.9
6N 198.2 0.0 186.5
1D 293.9 240.5 242.5
2D 801.3 154.7 435.5
3D 217.8 75.9 210.6
4D 184.6 204.0 124.8
SD 83.8 169.3 218.5
6D 545.6 551.8 267.7
Table Vlll.viii. Hydrolysis of callus samples under hypoxic and non-hypoxic conditions-assayed 
for pentosidine
Callus Sample Concentration of pentosidine 
[ng/mg protein] 
Hydrolysis under nitrogen
Concentration of pentosidine 
[ng/mg protein] 
Hydrolysis under oxygen
Concentration of pentosidine 
[ng/mg protein] 
Hydrolysis under air
1N 458.7 213.8 246.8
2N 257.9 165.2 143.8
3N 447.4 197.9 235.7
4N 285.6 160.1 166.5
5N 474.2 13.8 11.6
6N 28.5 13.8 0.0
1D 138.0 143.3 133.0
2D 18.2 172.0 166.8
3D 41.8 334.6 337.7
4D 226.6 189.4 130.5
5D 281.2 90.2 87.2
6D 217.7 0.0 10.9
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Table Vlll.ix. Keratin extracts after acid hydrolysis under hypoxic conditions and assayed for
furosine and pentosidine
Sample Concentration of furosine 
[ng per mg of protein]
Concentration pentosidine  
[nc^per m g of protein]
1N 1234.1 5.2
2N 920.9 22.7
3N 723.7 14.7
4N 279.2 9.3
5N 760.5 5.7
6N 146.9 6.8
1D 498.2 20.4
2D 320.2 34.8
3D 151.3 150.6
4D 281.0 13.0
SD 609.9 18.5
6D 481.4 16.6
Figure Vlll.viii
Table Vlll.x. Callus and keratin extracts after enzyme hydrolysis-assayed for furosine and 
pentosidine
Raw SC Concentration  
of furosine 
[ng/mgprotein]
Keratin
Extract
Concentration of 
furosine 
[ng/mg protein]
Concentration of 
pentosidine 
[ng/mg protein]
1N 169.8 1N 223.9 6.4
2N 7440.1 2N 508.8 10.3
3N 229.1 3N 683.2 5.2
4N 366.7 4N 205.5 15.2
SN 964.2 5N 86.6 11.5
6N 266.0 6N 308.6 6.8
1D 223.9 1D 213.4 140.5
2D 974.3 2D 77.4 6.6
3D 355.6 3D 109.7 25.7
4D 146.6 4D 243.0 21.7
5D 117.6 5D 388.6 5.6
6D 293.0 6D 342.3 6.2
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Table Vlll.xi. Hydrolysis of keratin extracts for different lengths of time
Hydrolysis Time 
[Hours^
Mean Concentration of Furosine 
[ng/mg per protein]
Mean Concentration of 
Pentosidine [ng/mg per protein]
2 1606.4
4 6340.2
6 10853.6 44.751
18 5171.4 163.196
24 2610.6 111.172
30 1807.2 46.926
Table Vlll.xii. Furosine recovery data for keratin extract after 6h acid hydrolysis
Samples Percentage Recovery
minus furosine
1mg/ml furosine 79.97
0.1mg/ml furosine 77.36
0.01mg/ml furosine 76.6
0.001mg/ml furosine 75.00
Table Vlll.xiii. Pentosidine recovery data for keratin extract after 18h acid hydrolysis
Samples Percentage Recovery
minus pentosidine
1mg/ml pentosidine 69.97
0.1mg/ml pentosidine 57.36
0.01mg/ml pentosidine 56.60
0.001mg/ml pentosidine 45.00
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Table Vlll.xiv. Concentration of furosine in keratin extracts hydrolysed for 6h in acid
Samples Peak Area [counts x 10s] Concentration of 
Furosine 
[ng/mg protein]
IN 9.16 1.76
2N 2.52 1.46
3N 0.27 15.29
4N 2.32 9.23
5N 4.29 2.43
6N 0.55 1.22
1D 4.31 9.40
2D 3.13 1.69
3D 2.53 2.16
4D 4.69 240.00
5D 4.32 25.88
6D 12.54 11.20
Table Vlll.xv. Concentration of pentosidine in keratin extracts hydrolysed for 18h in acid
Samples Peak Area [counts x 10s] Concentration of 
Pentosidine 
[pg/mg protein]
1N 1.311 2.56
2N 5.899 11.69
3N 28.327 57.28
4N 77.190 156.10
5N 1.628 3.29
6N 3.236 6.54
1D 1041.55 210.63
2D 82.641 167.63
3D 15.162 30.661
4D 64.938 131.321
5D 23.352 47.223
6D 20.005 40.455
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Appendix IX The Distribution of the Furosine and Pentosidine Measured in 
Keratin and Serum Proteins from Non-diabetics individuals
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Figure IX.i: The distribution of furosine measured in keratin extracts from 87 non-diabetic 
subjects
Std. Dev = 96.07 
Mean = 50 
N = 87.00
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Figure IX.ii: The distribution of pentosidine measured in keratin extracts from 87 non-diabetic 
subjects
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Normal Q-Q Plot
Concentration of furosine in serum [ng/mg of protein] Observed Value
Figure IX.iii: The distribution of furosine measured in the serum of 76 non-diabetic subjects
1 b
50
40
30
10
0
Std Dev ■  317.34  
M ean -  158 
N -  75 .00
Normal Q-Q Plot
C35
Zs
Ia
Concnetration of pentosidine in serum [ng/mg of protein] Observed Value
Figure IX.iv: The distribution of pentosidine measured in the serum of 87 non-diabetic 
subjects
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Figure IX.v: The distribution of HbA1c levels in the blood of 87 non-diabetic subjects.
The removal of the outlying data from all of these distributions did not have an 
effect on the distribution curves, i.e. they remain skewed.
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Appendix X Spleen Fusion Protocol -  Carried out by T. Jowett, Department 
of Medicine, UCL
Reagents
3 X 2 0  ml RPMI
1 X 1 ml RPMI in a Bijou
1 X 1 ml 50% PEG (Sigma, P7181)
Method
The spleen was teased apart using forceps in an aliquot of RPMI (2 ml) in a petri- 
dish. The mixture was layered onto RPMI (20 ml) in a Universal and decanted 
using a Pasteur pipette into a second Universal, leaving any clumps behind. The 
solution was centrifuged at 1000 rpm for 10 min, aspirated and tapped loose. An 
aliquot of RBCLB (1 ml) was gently mixed in the pipette for 1 min and pipetted 
into RPMI (20 ml) in a Universal and mixed well. The mixture was centrifuged at 
1000 rpm° for 10 min, aspirated and tapped loose again. Whilst swirling RPMI 
(10 ml) was slowly added to the Universal and any clumps present were removed 
using a Pasteur pipette. The amount of spleen cells at this point was counted 
(approximately 108 cells/ml). The mixture was allowed to stand until needed. A
volume equivalent to 10:1 (spleen: myeloma cells) was used for the next few
steps in the procedure.
The mixture was centrifuged for 10 min at 1000 rpm, aspirated and tapped loose. 
An aliquot of RPMI (20 ml) was added, mixed carefully and centrifuged as 
described previously. Another aliquot of RPMI (10 ml) was added, mixed 
thoroughly with a pipette, transferred to the spleen cell universal and mixed 
thoroughly. The mixture was centrifuged at 1000 rpm for 10 min, aspirated and 
tapped loose. An aliquot of PEG (1 ml, 50%) was added dropwise with gentle 
shaking over 2 min, followed by RPMI (1 ml) and shaking gently over 1 min. Over
"Whilst spinning, the number of myeloma cells were counted (0 cells/ml)
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a 4 min period RPMI (20 ml) was added under continuous shaking. The 
Universal was sealed and gently inverted 3 times and centrifuged at 800 rpm for 
8 min. The final mixture was aspirated (not tapped loose), Cell medium (CM) (10 
ml) was added and swirled gently whilst breaking up any clumps with a Pasteur 
pipette. The cells were incubated at 37°C for 3-4 h.
An aliquot of hybridoma enhancing supplement (10%, 100 \i\) was placed in each 
well of 8, 96 well plates and incubated at 37°C for a few hours. This is referred to 
as the “feeder layer”. A mixture of fusion products (10 ml), CM (30 ml), CM plus 
2 x HAT (40 ml) was place in a sterile bottle and 100pl of this was pipetted into 
each well onto the feeder layer. After, approximately 4 days the myelomas were 
mostly dead and the hybridomas were visible. After 14 days they were tested for 
specific antibodies.
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Appendix XI Purification Of Monoclonal and Polyclonal Antisera using 
Affinity Chromatography -  Protein-A- Sepheraose*
Reagents
Protein-A-sepharose CL-4B (Pharmacia, Milton Keynes), Tris/HCI (0.1 M, pH 7.0), 
glycine (0.1 M, pH 3.0), Tris (1 M, pH 9.0)
Method
The protein-A-sepharose gel (1 g) was swollen and washed with 20 ml, 0.1 M 
Tris/HCI, pH 7.0. The mixture was then centrifuged (10 min, 3000 rpm) and the 
solvent was decanted off the gel. This wash procedure was repeated 2 more 
times. An aliquot of the serum (1 ml) was diluted with the starting buffer (4 ml) 
and added to the gel. The mixture was then incubated at room temperature, 
under rotation, for 1 h. The gel was placed into a 5 ml column and the 
breakthrough was collected. It was then washed with 0.1 M Tris, pH 7.0 (20 ml) 
and the wash was collected. The gel was washed to remove any unwanted 
contaminants and they were both collected to check for and loss of IgG. The 
column was then eluted with 0.1M glycine buffer, pH 3.0 (10 ml). Since the 
elution conditions are quite harsh, it was necessary to collect the fractions in a 
few drops of 1 M Tris/HCI, pH 9.0 (50 pi), so that the final pH of the fractions was 
neutral. All fractions were measured for protein content using the Lowry 
procedure Appendix I) and those containing the antibodies were pooled and 
stored at -70°C. The pooled fractions were then applied to one dimensional SDS- 
PAGE to confirm the presence of pure antibodies (Appendix XII).
Protein A-Sepherose CL-4B (Pharmacia, Milton Keynes) is a protein A covalently bonded to a cross-linked matrix, 
Sepherose CL-4B, by the cyanogen bromide method. This matrix exhibits high chemical and mechanical stability and the 
protein A-Sepherose CL-4B is stable over the pH range 2-11. It also tolerates high concentrations of denaturants, such as 
urea and quanidine, commonly used for eluting bound molecules from immunoadsorbants.
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Appendix XII Protein A-Sepherose Purification of Polyclonal and
Monoclonal Antibodies to Furosine
Antibodies Concentration of Fractions kept [mg/ml]
Polyclonal 3.21
7.03
2.95
Monoclonal 2C3/C4 4.23
4.30
3.92
Monoclonal 6B11/A7 5.75
5.02
4.70
There are 2 main bands of molecular weights 50 and 25-30 kDa that represent the 
heavy and the light portions of the antibody. These 2 bands on their own confirm the 
presence of pure antibody in the fractions collected (Figs. XII.i.a and XII.ib). The 
breakthroughs and washes were also applied to the gels for comparison (Figs. 
XII.ii.a and Xll.ii.b).
25-30 kDa
Breakthrough Wash Pure Ab
Figure Xll.i.a: SDS-PAGE of pure polyclonal antibodies; b: SDS-PAGE of pure polyclonal 
antibodies, breakthrough and wash from purification procedure.
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v  v Wash Breakthrough Pure Ab
2C3/C4 6B11/A7
Figure Xll.ii.a: SDS-PAGE of pure monoclonal antibodies; b: SDS-PAGE of pure monoclonal 
antibodies, breakthrough and wash from purification procedure.
6B11/A7
2C3/C4
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Appendix XIII Results from Titrations using Monoclonal Antibodies
Cone of 
polyclonal 
antibody 
[mg/ml]
2 pg/ml F 
coating 
mean abs
OD(490)
2 pg/ml F-BSA 
coating 
mean abs
OO(4t0)
2 pg/ml F-Tg 
coating 
mean abs
OD(4to)
2 pg/ml BSA 
coating 
mean abs
OD(4go)
2 pg/ml CML 
coating 
mean abs
OD(490)
2 n.g/ml 
CML-BSA 
coating 
mean abs
OD(490)
2 pg/ml CML- 
Tg 
coating 
mean abs 
OD(490)
2 pg/ml Tg 
coating 
mean abs
OD(4#o)
2 pg/ml 
arginine 
coating 
mean abs 
OD(490)
2 pg/ml 
lysine coating 
mean abs
OD(49oj
0.1 0.536 0.499 0.474 0.365 0.116 0.155 0.185 0.257 0.453 0.533
0.01 0.136 0.099 0.100 0.082 0.042 0.068 0.067 0.081 0.091 0.097
0.001 0.059 0.051 0.061 0.066 0.037 0.047 0.093 0.061 0.088 0.046
0.0001 0.075 0.051 0.059 0.050 0.055 0.051 0.048 0.039 0.038 0.041
Cone of 
2C3/C4 
antibody 
[mg/ml]
0.1 0.062 0.430 0.821 0.052 0.049 0.050 0.380 0.044 0.058 0.067
0.01 0.068 0.212 0.642 0.062 0.044 0.041 0.190 0.047 0.043 0.051
0.001 0.052 0.060 0.309 0.060 0.047 0.041 0.114 0.061 0.048 0.054
0.0001 0.490 0.050 0.311 0.052 0.045 0.043 0.115 0.052 0.049 0.066
Cone of 
6B11/A7 
antibody 
[mg/ml]
0.1 0.074 0.562 0.793 0.067 0.050 0.053 0.411 0.036 0.057 0.067
0.01 0.080 0.365 0.739 0.050 0.045 0.044 0.319 0.045 0.055 0.055
0.001 0.079 0.133 0.440 0.055 0.048 0.046 0.161 0.045 0.070 0.046
0.0001 0.074 0.060 0.391 0.049 0.048 0.036 0.112 0.042 0.051 0.061
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Cone of 
polyclonal 
antibody 
[mg/ml]
2 pg/ml F 
coating 
noise/soun 
d ratio
2 pg/ml F- 
BSA coating 
noise/sound 
ratio
2 pg/ml F-Tg 
coating 
noise/sound 
ratio
2 pg/ml BSA 
coating 
noise/sound 
ratio
2 pg/ml CML 
coating 
noise/sound 
ratio
2 pg/ml 
CML-BSA 
coating 
noise/soun 
d ratio
2 pg/ml 
CML-Tg 
coating 
noise/sound 
ratio
2 pg/ml Tg 
coating 
noise/sound 
ratio
2 pg/ml 
arginine 
coating 
noise/sound 
ratio
2 pg/ml 
lysine 
coating 
noise/sound 
ratio
0.1 1.229 1.002 0.983 0.658 0.892 0.708 0.701 1.019 1.037 1.039
0.01 1.236 0.934 0.736 0.621 0.300 1.115 1.031 1.556 0.813 0.907
0.001 0.957 0.785 0.735 0.805 0.822 0.904 1.788 1.299 1.660 0.730
0.0001 1.230 0.927 0.694 1.000 1.170 1.202 0.842 0.830 0.745 0.820
Cone of 
2C3/C4 
antibody 
[mg/ml]
0.1 0.805 4.725 17.104 0.839 1.140 0.568 10.000 1.128 1.055 1.156
0.01 0.782 3.786 11.673 0.290 0.936 0.784 5.000 0.839 0.683 1.041
0.001 1.000 1.200 5.618 0.780 0.959 0.911 2.327 1.298 1.043 1.109
0.0001 0.925 0.926 6.098 0.505 0.568 0.935 2.805 0.945 0.980 1.269
Cone of 
6B11/A7 
antibody 
[mg/ml]
0.1 1.088 6.612 7.209 1.175 1.163 0.981 9.786 0.782 1.000 0.957
0.01 1.096 3.687 14.212 0.833 1.000 1.023 7.419 1.000 1.100 0.917
0.001 1.411 2.181 8.627 1.078 0.941 1.179 3.157 0.738 1.373 0.767
0.0001 0.824 1.071 7.667 0.961 1.067 0.923 2.240 2.240 0.850 1.245
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Appendix XIV Distribution of Data from Chapter 7
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Figure XlV.i: The distribution of the series elastic element data on stretching of dorsal epidermis.
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Figure XlV.ii: The distribution of the series elastic element on stretching of the epidermis 
on the M LA /.
458
Di
st
rib
ut
io
n 
D
is
tr
ib
ut
io
n
Std . D e v  =  2 2 6 .3 5  
M ea n  =  151 
N  =  8 7  0 0
0 '<b % % % \  % *<b % % % %
Displacement [um]
Normal Q-Q Plot
©
5
OZ
Observed Value
Figure XlV.iii: The distribution of the series elastic element data on stretching of the 
epidermis on the PMA.
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Figure XlV.iv: The distribution of the series elastic element data on retraction of the 
dorsal epidermis.
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Figure XIV.v: The distribution of the series elastic element data on retraction of the 
epidermis on the MLA.
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Figure XlV.vi: The distribution of the series elastic element data on retraction of the 
epidermis on the PMA.
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Figure XlV.vii: The distribution of the time constant data on stretching of the dorsal 
epidermis.
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Figure XlV.viii: The distribution of the time constant data on stretching of the epidermis 
on the MLA.
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Figure XlV.ix: The distribution of the time constant data on stretching of the epidermis on 
the PMA.
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Figure XIV.x: The distribution of the time constant data on retraction of the dorsal 
epidermis.
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Figure XlV.xi: The distribution of the time constant data on retraction of the epidermis of 
the MLA.
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Figure XlV.xii: The distribution of the time constant data on retraction of the epidermis of 
the PMA.
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Appendix XV Distribution of Data from Chapter 8
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Figure XV.i: The distribution of epidermal thickness data from the dorsal site, v=1580m/s.
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Figure XV.ii: The distribution of epidermal thickness data from the MLA, v = 1580m/s.
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Figure XV.iii: The distribution of epidermal thickness data from the PMA, v = 1580m/s.
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Figure XV.iv: The distribution of epidermal thickness data from the dorsal site, v = 2459m/s.
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Figure XV.v: The distribution of epidermal thickness data from the MLA, v = 2459m/s.
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Figure XV.vi: The distribution of epidermal thickness data from the PMA, v = 2459m/s.
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Appendix XVI Definition, Diagnosis and Classification of Diabetes 
Mellitus
In 1999 the World Health Organisation (WHO) published a comprehensive report 
discussing the definition, diagnosis and classification of diabetes mellitus (DM) 
[252]. The following reports the criteria for diagnosis according Diabetes UK, who 
have used the WHO document as their key reference.
Definition
According to the WHOs publication o f:1Definition, Diagnosis and Classification of 
Diabetes Mellitus and its Complications’, the definition of diabetes is as follows:
“ The term diabetes mellitus describes a metabolic disorder of multiple aetiology 
characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat 
and protein metabolism resulting from defects in insulin secretion, insulin action, or 
both. The effects of diabetes mellitus include long-term damage, dysfunction and 
failure of various organs. Diabetes mellitus may present with characteristic 
symptoms such as thirst, polyuria, blurring of vision, and weight loss. In its most 
severe forms, ketoacidosis or a non-ketotic hyperosmolar state may develop and 
lead to stupor, coma and, in absence of effective treatment, death. Often 
symptoms are not severe, or may be absent, and consequently hyperglycaemia 
sufficient to cause pathological and functional changes may be present for a long 
time before the diagnosis is made. The long-term effects of diabetes mellitus 
include progressive development of the specific complications of retinopathy with 
potential blindness, nephropathy that may lead to renal failure, and/or neuropathy 
with risk of foot ulcers, amputation, Charcot joints, and features of autonomic 
dysfunction, including sexual dysfunction. People with diabetes are at increased of 
cardiovascular, peripheral vascular and cerebrovascular disease.
Several pathogenetic processes are involved in the development of diabetes. 
These include processes which destroy the beta cells of the pancreas with 
consequent insulin deficiency, and others that result in resistance to insulin action. 
The abnormalities of carbohydrate, fat and protein metabolism are due to deficient 
action of insulin on target tissues resulting from insensitivity or lack of insulin.’
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Diagnostic Criteria
The criteria for diagnosis differ between patients with and without symptoms, the 
symptoms being polyuria, polydipsia and unexplained weight loss.
1) Symptoms:
• A random venous plasma glucose concentration £ 11.1mmol/l 
or
• A fasting plasma glucose concentration £ 7.0mmol/l (whole 
blood >6.1 mmol/l or
• Two hour plasma glucose concentration > 11.1 mmol/l two hours 
after 75g anhydrous glucose in an oral glucose tolerance test 
(OGTT).
2) No symptoms:
Diagnosis should not be made on one single glucose determination. An 
additional glucose test result from another day with a value in a diabetic 
range is required. This test can be any of the tests described above. If the 
fasting or random glucose tests are not diagnostic, the OGTT should be 
used.
A diagnosis should never be made on the basis of glycosuria or a stick reading of 
finger prick blood glucose alone, although these tests are useful for screening 
purpose. HbA1c measurement is also not recommended for the diagnosis of 
diabetes.
Diabetes UK recommends that diagnosis be confirmed by a glucose 
measurement performed in an accredited laboratory on a venous plasma sample. 
This should mean that there is less need to perform OGTT on the majority of the 
population. However, in the elderly and some ethnic minority groups the fasting 
glucose alone may not be a reliable indicator of diabetes. For these individuals, 
and in the absence if symptoms, the use of a glucose tolerance test would be 
necessary as a definitive test.
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Classification
• Insulin dependent (IDDM) and non-insulin dependent diabetes (NIDDM) 
are termed Type 1 and Type 2 diabetes, respectively.
• Impaired Glucose Tolerance (IGT) is a stage of impaired glucose 
regulation. It is characterised by a fasting plasma glucose < 7.0mmol/l and 
OGTT two hour value > 7.8mmol/l but < 11.1 mmol/l..
• Impaired Fasting Glycaemia (IFG) classifies individuals who have fasting 
glucose values above the normal range but below those diagnostic of 
diabetes. Fasting plasma glucose £ 6.1 mmol/ll but < 7.0mmol/l). Diabetes 
UK recommends that individuals with IFG should have an OGTT to 
exclude the diagnosis of diabetes.
Gestational diabetes encompasses groups that have formerly been classified as 
Gestational Impaired Glucose Intolerance (GIGT) and Gestational Diabetes 
Mellitus (GDM).
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Appendix XVII Patient Questionnaires
Record Sheet for diabetics
Name
Hospital number 
Patient Identification 
Date of Birth 
Age in completed years 
Weight 
Height
Serum Glucose 
Date of diagnosis 
Duration of diabetes
Therapy for diabetes
History of diabetic 
complications
Smoker
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Diet controlled = 1 Oral hypoglycaemic = 2 ..........
Insulin = 3 Insulin and oral hypoglycaemic = 4
Not known = 9
Renal = 1 Retinopathy = 2 Neuropathy = 3 ................
Vascular insufficiency =4 Skin conditions = 5 Foot pathologies = 6* 
‘Notes..................................................................................................
Yes = 1 No = 2
Record Sheet for Non-Diabetics
Name
Hospital number
Patient Identification
Date of Birth
Age in completed years
Weight
Height
History of foot problems Yes=1* No
‘ Notes....................
Smoker Yes = 1 No
Structural and Cutaneous Pathologies
Lesser to structure Hammer = 1
Normal = 4 
*Notes............
daw = 2 
Other = 5 *
Mallet = 3
Hallux structure HAV = 1 Trigger = 2 Hyperextended = 3
Unilateral = 4 
‘ Notes.............
Bilateral = 5 Normal = 6 Other
Loss of forefoot arch Slight = 1 Moderate = 2 Marked = 3
Unilateral = 4 
‘Notes............
Bilateral = 5 Normal = 6 Other
General foot structure Pes Planus = 1 Pes Cavus = 2 Unilateral =3
Bilateral =4 
‘Notes............
Normal = 3 Other = 4*
Limited range of motion Yes = 1* No = 2
In hands ‘Notes............
Limited range of motion Yes = 1* No = 2
In feet ‘Notes............
Charcot joints Yes = 1*
‘Site...............
No = 2
Skin pathologies Corns and callosities = 1 Fissures = 2 Tinea Pedis = 3
Anhydrosis = 4 
Absence of hair 
‘Notes............
Hyperhydrosis = 5 
= 6 Other = 7*
Nail pathologies O/C = 1 O/M =2 Yellow nail = 3
Normal = 5 Other = 6*
*Notes............
History of ulceration Yes = 1* No = 2
•Notes
Footwear
Wear marks on shoes
Bespoke = 1 Semi-bespoke = 2
Normal well-fitted = 3 Normal ill-fitted = 4 
Other = 5*
•Notes..........................................................
Orthoses Simple Insole = 1 Orthotic = 2 Diabetic Insole
No Orthoses = 4 Other = 5*
•Notes.....................................................................
Neurological and Vascular Assessment
Neurological Assessment
Symptoms Present = 1 Absent = 2
Nature of symptoms Positive Symptomatology = 1 Negative Symptomatology
Duration of symptoms <1year = 1 Notes......................... 1-3 years = 2
>3 years = 3 Notes.................................
Chronic pain No = 1 Insidious = 2 Intermittent = 3
Bilateral = 4 Unilateral = 5 Related to treatment = 6
Unrelated to treatment = 7 When walking = 8
When resting = 9
History of Ulceration Yes = 1 * No = 2
*Notes......................................................................
Autonomic symptoms Notes.......................................................................
Acute pain Neuropathic pain = 1 Contact hyperaesthesia = 2
No = 3
Pinprick test Painful = 1 Unclear = 2 No pain = 3
Light touch test Yes = 1 Unclear= 2 No = 3
Vibration Yes = 1 No = 2*
*Biosthesiometer reading..............
Pressure perception Yes =1 Unclear = 2 No = 3
Ankle reflex UF Yes = 1 R/F Yes = 2 UF No = 3
R/F No = 4
Knee reflex UF Yes = 1 R/F Yes = 2 UF No = 3
R/F No = 4
Muscular atrophy Yes = 1 Unilateral = 2 Bilateral = 3
No = 4
Proprioception Yes = 1 No = 2
Two point discrimination Yes = 1 No = 2
Vascular Assessment
Skin colour Normal = 1
Other = 4* 
‘Notes............
Hyperaemic = 2 Pallor = 3
Skin texture
Normal
Hyperhydrotic =
= 4 Other = 
‘ Notes............
1 Anhydrotic = 2 Trophic changes 
= 5*
Skin temperature Normal = 1 
‘ Notes............
Cold = 2 Warm = 3 Other =
Varicose veins Yes = 1 Unilateral = 2 Bilateral = 3 No = 4
Odema Yes = 1 Unilateral = 2 Bilateral = 3 No = 4
History of DVT Yes = 1 No = 2
Vascular surgery Yes = 1*
‘ Notes...........
No - 2
Claudication 100 yards or less = 1 No - 2
Heart conditions Myocardial infarction = 1 Angina = 2 Hypertension = 3
Capillary Refill Time Immediate = 1 
>3sec = 5
1sec = 2 2sec=3 3sec = 4
Pedal pulses palpable R/FDP = 1 
No = 5*
L/FDP =2 R/FPT = 3 L7FPT =
‘ Doppler analysis Triphasic = 1 
*Notes...........
Biphasic = 2 Monophasic = 3
Callus Information
Description of callus Distinct area with minimal thickening of keratin layer = 1
Moderate thickening = 2 Marked thickening = 3
Oval = 4 Diffuse = 5 Round = 6 Spongy = 7
Glassy = 8 Flaky = 9
Associated with corns = 10 Not associated with corns =11
Area ........................Cm2
Site ................................................
Chiropody treatment for 1-3mths = 1 3-6mths = 2 6-9mths = 3
callus removal 9-12mths = 4 No = 5 Other = 6*
•Notes.......................................................................
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Appendix XVIII The Distribution of all the Data Collected from the 
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Figure XVIII.i. The distribution of furosine in keratin extracts from 103 diabetic subjects
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Figure XVIII.ii. The distribution of furosine in blood serum from diabetic subjects
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Figure XVIII.iii. The distribution of pentosidine in keratin extracts from103 diabetic subjects
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Figure XVIII.iv. The distribution of pentosidine in blood serum from diabetic subjects
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Figure XVIII.v: The distribution of the series elastic element data on stretching of dorsal epidermis.
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Figure XVIII.vi: The distribution of the series elastic element data on stretching of the epidermis on
the MLA.
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Figure XVIII.vii: The distribution of the series elastic element data on stretching of the epidermis on 
the PMA.
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Figure XVIII.viii. The distribution of the series elastic element data on retraction of the dorsal 
epidermis.
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Figure XVIII.ix. The distribution of the series elastic element data on retraction of the epidermis on the
MLA.
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Figure XVIII.x. The distribution of the series elastic element data on retraction of the epidermis on 
the PMA.
30
20
10
0
Normal Q-Q Plot
Std Dev = 9.55  
Mean = 20 
N - 103.00
1 co > 
<0E
0
1
Time constant [s] Observed Value
Figure XVIII.xi. The distribution of the time constant data on stretching of the dorsal epidermis
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Figure XVIII.xii. The distribution of the time constant data on stretching of the epidermis on the MLA
480
30
20
10
Std. Dev = 9.92 
Mean = 9 
N = 103.000
Normal Q-Q Plot
©3
to>
75
Z
Time constant [s] Observed Value
Figure XVIII.xiii. The distribution of the time constant data on stretching of the epidermis on the 
PMA
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Figure XVIII.xiv. The distribution of the time constant data on retraction of the dorsal epidermis
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Figure XVIII.xv. The distribution of the time constant data on retraction of the epidermis on the MLA
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Figure XVIII.xvi. The distribution of the time constant data on retraction of the epidermis on the 
PMA
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Figure XVIII.xvii. The distribution of the epidermal plasticity data from the dorsum
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Figure XVIII.xviii. The distribution of the epidermal plasticity data from the MLA
482
o70
60
50
30
20
Std D ev  = 22  
M ean  = .10
10
0
%°e'j bbb bbbb bbbb bb %
Normal Q -Q  Plot
<D35
CD
Z
Observed ValuePlasticity
Figure XVIII.xix. The distribution of the epidermal plasticity data from the PMA
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Figure XVIII.xx. The distribution of the epidermal thickness data from the dorsum
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Figure XVIII.xxi. The distribution of the epidermal thickness data from the MLA
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Figure XVIII.xxii. The distribution of the epidermal thickness data from the MLA
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